Drug–Adverse Event Causality Assessment
Your pair not here? Sponsor an assessment from $9 — an AI research agent drafts the Bradford Hill card, every citation is machine-verified, and the page publishes for everyone. Or use the free case worksheet.
How this list was built, and how to read a card
Metoclopramide ↔ Tardive dyskinesia
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2010, 2011, 2012, 2013 — 91% of all 13,205 reports arrived in two years (2011–2012). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Dashed lines: 2009 — FDA boxed warning for tardive dyskinesia
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
This is the single largest PRR among the pairs on this page, and the underlying mechanism is textbook: metoclopramide is a dopamine D2-receptor antagonist, the same pharmacological class responsible for antipsychotic-induced tardive dyskinesia. FDA's 2009 boxed-warning decision followed continued spontaneous reports concentrated in patients who had taken the drug for more than 3 months, and published analyses since have identified metoclopramide as the single most common cause of drug-induced movement disorders overall — not just among gastric-motility agents, but across all drug classes. Risk rises sharply with treatment duration and cumulative dose, which is why the boxed warning specifically limits use beyond 12 weeks except in rare cases. This is one of the best mechanistically-understood adverse drug reactions in this dataset — a predictable, class-wide, dose/duration-dependent effect, not merely a statistical coincidence.
Regulatory basis: FDA boxed warning (2009), metoclopramide prescribing information.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset after months–years of cumulative dosing, consistent with the mechanism |
| Strength | met | PRR 335, one of the largest on this page |
| Consistency | met | Replicated across decades, same pattern as other D2 antagonists |
| Specificity | partial | Not unique to metoclopramide — shared across the D2-antagonist class |
| Biological gradient | met | Risk rises with treatment duration/cumulative dose |
| Plausibility | met | D2 receptor antagonism — same mechanism as antipsychotic-induced TD |
| Coherence | met | Fits established class pharmacology |
| Experiment | partial | 12-week duration limit (boxed warning) functions as a real-world exposure-reduction intervention; not an RCT |
| Analogy | met | Direct analogy to antipsychotic-induced tardive dyskinesia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Clozapine ↔ Agranulocytosis / severe neutropenia
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 21% of 2,047 reports), so stimulated reporting is unlikely to explain the signal.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Clozapine-induced agranulocytosis is arguably the most consequential single adverse-drug-reaction discovery in modern psychiatry: it is the reason clozapine, despite being one of the most effective antipsychotics for treatment-resistant schizophrenia, can only be dispensed in the U.S. through a mandatory REMS program requiring regular absolute neutrophil count (ANC) monitoring for the life of the prescription — weekly for the first 6 months, biweekly for the next 6, then monthly if counts stay in range. Reported incidence is 1–2% of patients, overwhelmingly concentrated in the first 6 months of therapy, which is itself a form of temporal and dose-independent specificity (the event is a sudden, often zero-count crash, not a gradual dose-related decline). The mechanism remains formally unresolved — proposed as an idiosyncratic, likely immune-mediated toxic effect on bone marrow myeloid precursors or their progenitors — but the monitoring program's mandatory, indefinite existence is itself regulators' institutional verdict that the causal link is settled, not merely a statistical association.
Regulatory basis: Clozapine REMS program (mandatory ANC monitoring); clozapine prescribing information.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Risk overwhelmingly concentrated in the first 6 months — a well-characterized window |
| Strength | met | PRR 21–27 |
| Consistency | met | Replicated across countries and registries for decades |
| Specificity | met | Risk is unusually high for clozapine among antipsychotics specifically |
| Biological gradient | partial | Idiosyncratic reaction; not clearly dose-dependent the way the TD example above is |
| Plausibility | met | Proposed immune-mediated bone-marrow toxicity mechanism |
| Coherence | met | Consistent with a myeloid-toxicity pattern |
| Experiment | met | Mandatory ANC monitoring (REMS) demonstrably reduces fatal outcomes — a real-world intervention |
| Analogy | partial | Other drugs (older antipsychotics, antithyroid agents) also cause agranulocytosis, but at lower rates |
This page's own qualitative read, not an automated/citation-gated assessment.
Ciprofloxacin (fluoroquinolones) ↔ Tendon rupture / tendinitis
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2008, 2010, 2011 — 18% of all 1,243 reports arrived in two years (2010–2011). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Dashed lines: 2008 — FDA boxed warning, tendinitis/tendon rupture; 2016 — FDA strengthens fluoroquinolone warnings
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Fluoroquinolone-associated tendinopathy, most notoriously Achilles tendon rupture, carries an FDA boxed warning since 2008 that applies class-wide, not just to ciprofloxacin. This is one of the more mechanistically dense entries on this page: at least five distinct pathways have been proposed and partly confirmed in vitro, not just one. Ciprofloxacin upregulates matrix metalloproteinase-3 in tendon-derived cells while suppressing tenocyte proliferation and migration (via reduced FAK phosphorylation), directly degrading and under-replacing collagen. Separately, fluoroquinolones chelate magnesium and iron, cofactors tendon cells need to hydroxylate proline residues during collagen maturation — chelation leaves collagen fibers under-cross-linked and mechanically weaker, the same chelation chemistry responsible for the well-known interaction with magnesium-containing antacids. A third pathway implicates fluoroquinolone-driven reactive oxygen species production in tenocyte mitochondria. Clinical risk factors are well replicated across independent studies: age over 60, concurrent corticosteroid use, and solid-organ transplant history all multiply risk. This is a case where a drug class effect was identified, mechanistically investigated from multiple independent angles, and confirmed beyond spontaneous reports alone.
Regulatory basis: FDA boxed warning for tendinitis/tendon rupture (2008); fluoroquinolone class labeling, with further systemic safety-label restrictions added in 2016. Mechanism review: PMC4080593.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset typically within days to weeks of exposure |
| Strength | met | PRR 26–38 |
| Consistency | met | Class-wide, replicated across multiple countries |
| Specificity | partial | Class effect, not unique to ciprofloxacin |
| Biological gradient | partial | Risk factors (age, steroids, transplant) modify risk; no clean dose-response shown |
| Plausibility | met | Magnesium chelation / MMP activation, with supporting in-vitro and animal evidence |
| Coherence | met | Fits the broader fluoroquinolone connective-tissue toxicity pattern |
| Experiment | not established | No RCT withdrawal/rechallenge data |
| Analogy | met | Analogous to other fluoroquinolone connective-tissue signals (e.g. aortic dissection) |
This page's own qualitative read, not an automated/citation-gated assessment.
Ranitidine (Zantac) ↔ Cancer (breast, prostate, bladder, colorectal, renal)
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2014, 2020, 2021, 2022, 2023 — 93% of all 47,105 reports arrived in two years (2021–2022). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Dashed lines: 2019 — FDA NDMA contamination alert; 2020 — FDA requests market withdrawal
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
This is the clearest "mechanism, not mystery" entry on this page. Ranitidine itself is not believed to cause cancer; the problem was contamination. In 2019–2020, independent and FDA laboratory testing found that ranitidine can degrade — especially under heat or over time in storage — into NDMA (N-nitrosodimethylamine), a compound classified as a probable human carcinogen based on animal studies. The elevated cancer signals across multiple unrelated organ systems in this dataset (breast, prostate, colorectal, bladder, renal all flagged independently) is exactly the pattern a systemic carcinogen contaminant would produce, rather than the organ-specific pattern a drug's own pharmacology usually leaves. FDA requested market withdrawal of all ranitidine products in the U.S. in April 2020. This is a textbook example of a real, serious, and ultimately regulatory-confirmed signal — but the causal agent was a manufacturing/stability impurity, not ranitidine's intended pharmacological action.
Regulatory basis: FDA market withdrawal request for all ranitidine products (April 2020), citing NDMA contamination.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Long-term use before diagnosis fits carcinogen-latency expectations |
| Strength | partial | Each organ-specific PRR (38–61) is moderate alone; the real strength is the cross-organ pattern |
| Consistency | met | Replicated across 5 independent organ sites in this dataset |
| Specificity | not established | Deliberately so: the carcinogen is a contaminant, not ranitidine's own pharmacology — a multi-organ pattern is the expected signature of a contaminant, not a specific drug effect |
| Biological gradient | met | FDA found contamination increased with storage time and heat |
| Plausibility | met | NDMA is an IARC/EPA-classified probable carcinogen; degradation chemistry independently confirmed |
| Coherence | met | Multi-organ pattern coheres with systemic contaminant exposure, not with H2-blocker pharmacology |
| Experiment | met | Market withdrawal (2020) is the real-world exposure-removal intervention |
| Analogy | met | Analogous to other nitrosamine-contamination recalls in the same period (valsartan, metformin ER) |
This page's own qualitative read, not an automated/citation-gated assessment.
Oxycodone ↔ Drug dependence / withdrawal syndrome
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2004, 2005, 2007, 2020, 2021, 2022, 2023 — 76% of all 100,307 reports arrived in two years (2021–2022). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
The largest report volume of any pair on this page, and the least scientifically contested: oxycodone is a full mu-opioid receptor agonist, and physical dependence and withdrawal on cessation are expected, dose- and duration-related pharmacological effects of that mechanism, not an idiosyncratic reaction. This pair is included less because it is surprising and more because its sheer scale in this dataset (over 100,000 co-reports) is itself a public-health data point, central to the opioid-crisis regulatory response, including REMS requirements for opioid analgesics and prescribing-guideline changes from CDC.
Regulatory basis: opioid analgesic REMS program; CDC clinical practice guideline for prescribing opioids.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Dependence develops over the course of exposure, before withdrawal is observed on cessation |
| Strength | met | PRR 158 |
| Consistency | met | Replicated across every opioid in the class |
| Specificity | partial | Opioid class effect, not specific to oxycodone |
| Biological gradient | met | Textbook dose/duration dependence |
| Plausibility | met | Mu-opioid receptor mechanism, among the best-characterized in pharmacology |
| Coherence | met | Fits the entire opioid pharmacology literature |
| Experiment | met | Reduced prescribing volume demonstrably reduces new dependence at the population level |
| Analogy | met | Direct analogy across the entire opioid class |
This page's own qualitative read, not an automated/citation-gated assessment.
Risperidone ↔ Gynaecomastia
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2014, 2015, 2016, 2017, 2018, 2019, 2020 — 51% of all 24,608 reports arrived in two years (2016–2017). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
One of the largest PRR values on this page that is not circular or a coding artifact. Risperidone raises prolactin more than most other second-generation antipsychotics because, unlike many of its peers, it does not readily cross back out of the pituitary once it blocks dopamine D2 receptors there. Elevated prolactin drives breast tissue growth in males (gynecomastia) and galactorrhea in both sexes. This dose-related, mechanistically direct, and well-replicated across independent case series and the prescribing information itself.
Regulatory basis: risperidone prescribing information (hyperprolactinemia warning).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Develops over weeks–months of exposure |
| Strength | met | PRR 614, one of the largest non-circular pairs on this page |
| Consistency | met | Replicated across many independent case series |
| Specificity | met | Notably higher than most other second-generation antipsychotics |
| Biological gradient | met | Correlates with serum prolactin level |
| Plausibility | met | Risperidone's limited blood–brain-barrier efflux keeps pituitary D2 blockade high — a well-described PK mechanism |
| Coherence | met | Fits known antipsychotic prolactin pharmacology |
| Experiment | partial | Switching to a prolactin-sparing agent reduces symptoms in practice; not a dedicated RCT |
| Analogy | met | Direct analogy to other prolactin-raising antipsychotics, at lower magnitude |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — relapse-prevention comparison trial (NCT00216476), N=711, 3 arms
| Event (precursor lab finding) | Risperidone LAI (n=329) | Quetiapine (n=337) | Aripiprazole (n=45) |
|---|---|---|---|
| Hyperprolactinaemia | 43 (13.1%) | 5 (1.5%) | 0 (0%) |
The trial term is hyperprolactinaemia (the lab/mechanistic precursor), not gynaecomastia itself (the downstream clinical consequence this card's FAERS numbers track) — but the pattern directly confirms the mechanism: risperidone raised prolactin in roughly 1 in 8 patients, nearly 9× quetiapine's rate and far above aripiprazole's. View on ClinicalTrials.gov →
TNF-inhibitors (adalimumab) ↔ Drug-induced lupus
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2024, 2025 — 27% of all 2,338 reports arrived in two years (2024–2025). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
TNF-alpha inhibitors (adalimumab, infliximab, etanercept) are well documented in the rheumatology literature to induce a lupus-like syndrome, with clinically evident cases in roughly 0.2% of treated patients across the class — strikingly close to this dataset's own trial-derived rate for adalimumab specifically (see the trial box below). Published reviews put infliximab and etanercept ahead of adalimumab in how often they trigger antinuclear/anti-dsDNA antibody formation, so adalimumab is, if anything, a conservative example of a class-wide effect rather than its worst case. Onset is typically around 11 months into therapy (joint and skin manifestations predominate: malar/annular rash, arthralgia, sometimes myositis), and symptoms resolve over three weeks to six months after the drug is stopped — a real dechallenge pattern, not instant, but documented. This is a recognized, labeled class effect, not specific to adalimumab.
Regulatory basis: TNF-inhibitor class labeling (autoimmunity/lupus-like reactions warning). Anti-TNF-α-induced lupus, review: PMC6852950.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Typically emerges after months of therapy |
| Strength | partial | PRR 18.4, moderate |
| Consistency | met | Replicated class-wide (adalimumab, infliximab, etanercept) |
| Specificity | partial | Class effect |
| Biological gradient | not established | No clear dose-response demonstrated |
| Plausibility | met | Anti-dsDNA / anti-histone antibody induction is documented |
| Coherence | met | Fits known TNF-inhibitor immunology |
| Experiment | met | Symptoms resolve after stopping the drug (dechallenge) — the most direct evidence on this page short of a trial |
| Analogy | met | Classic "drug-induced lupus" category shared with older drugs (hydralazine, procainamide) |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — long-term Humira registry (NCT00524537), N=5,025
| Event | Adalimumab (n=5,025) |
|---|---|
| Lupus-like syndrome (any) | 11 (0.22%) |
| Systemic lupus erythematosus | 9 (0.18%) |
| Cutaneous lupus erythematosus | 1 (0.02%) |
A single-arm long-term registry (no placebo comparator), but with a real denominator across 5,025 patients — direct evidence the event genuinely occurs at a low but non-zero, quantifiable rate under real-world adalimumab use, independent of FAERS's passive-report counting. View on ClinicalTrials.gov →
Erythropoiesis-stimulating agents (darbepoetin alfa) ↔ Mortality / cardiovascular risk
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2012, 2014, 2015, 2016, 2017, 2018 — 40% of all 15,865 reports arrived in two years (2014–2015). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Unlike most entries on this page, the darbepoetin/death signal is backed by dedicated randomized controlled trials, not just spontaneous reports. The CHOIR trial (hemoglobin targets in chronic kidney disease, NEJM 2006) and the TREAT trial (darbepoetin alfa specifically, NEJM 2009) both found that targeting higher hemoglobin levels with an ESA increased cardiovascular events (including stroke, in TREAT) without a clear survival benefit, and ESAs also carry a labeled warning about shortened survival and faster tumor progression when used in certain cancer patients. FDA added a boxed warning and, for a period, required participation in a dedicated REMS program (ESA APPRISE) before this evolved into label-based risk communication. The raw "Death" PT in FAERS is non-specific, but the underlying causal story here is unusually well controlled compared to most of this page.
Regulatory basis: FDA boxed warning for ESAs; Pfeffer MA, et al. (TREAT). N Engl J Med. 2009;361(21):2019–2032; Singh AK, et al. (CHOIR). N Engl J Med. 2006;355(20):2085–2098.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Established by prospective randomized-trial design, not just spontaneous-report timing |
| Strength | met | Statistically significant within randomized trials — the gold-standard strength tier |
| Consistency | met | Replicated independently across CHOIR and TREAT |
| Specificity | partial | Effect concentrated in the higher-hemoglobin-target strategy, not ESA exposure alone |
| Biological gradient | met | Risk tracked with hemoglobin target/dose achieved |
| Plausibility | met | Thrombosis/vascular mechanism proposed for higher-hemoglobin-driven events |
| Coherence | met | Fits known hematologic/vascular physiology |
| Experiment | met | This is the experiment — the strongest evidence tier on this entire page |
| Analogy | partial | Loosely analogous to other "more aggressive lab-value target = more harm" trial findings (e.g. tight glycemic control) |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — TREAT (NCT00093015), N=4,038, placebo-controlled
| Serious event | Darbepoetin alfa (n=2,004) | Placebo (n=2,019) |
|---|---|---|
| Death (all-cause) | 39 | 38 |
| Haemorrhagic stroke | 4 | 1 |
| Ischaemic stroke | 6 | 4 |
| Sudden death / sudden cardiac death | 13 | 13 |
This refines the prose above: in TREAT's own numbers, all-cause death was essentially identical between arms (39 vs. 38 of ~2,000) — the trial's real finding was concentrated in stroke risk (haemorrhagic stroke 4× more common on darbepoetin), not raw mortality. The FAERS "Death" PT at the top of this card is a blunter instrument than this trial's cause-specific breakdown. View on ClinicalTrials.gov →
Nirmatrelvir/ritonavir (Paxlovid) ↔ COVID-19 recurrence ("Paxlovid rebound")
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 78% of 20,089 reports), so stimulated reporting is unlikely to explain the signal.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
"Paxlovid rebound" — recurrence of COVID-19 symptoms or a positive test 2–8 days after finishing a 5-day nirmatrelvir/ritonavir course, sometimes after testing negative in between — became widely enough recognized that CDC issued a Health Alert Network advisory about it in May 2022. The leading mechanistic explanation is that the drug's antiviral course may be short relative to the time needed to fully clear virus in some patients, allowing a viral (and symptomatic) rebound once the drug is stopped, rather than true reinfection. It is included here as a genuinely well-publicized, real, and mechanistically plausible phenomenon, though the precise frequency and whether it differs meaningfully from the "rebound" some untreated COVID-19 cases also show is still an active area of study.
Regulatory basis: CDC Health Alert Network Advisory 467 (May 24, 2022): rebound reported 2–8 days after recovery, median duration 3 days, not attributed to reinfection or resistance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Defined 2–8 day post-course window |
| Strength | met | PRR 285.7 for "disease recurrence" |
| Consistency | met | Widely replicated; prompted an independent CDC advisory |
| Specificity | not established | The proposed mechanism isn't unique to this drug — likely reflects short antiviral-course length generally |
| Biological gradient | not established | Not clearly dose/duration related beyond the fixed 5-day course |
| Plausibility | met | Short antiviral course relative to viral clearance kinetics is a coherent, published hypothesis |
| Coherence | partial | Some rebound also occurs in untreated patients, complicating a clean causal story |
| Experiment | not established | No RCT designed specifically to test rebound causally |
| Analogy | met | Analogous to rebound phenomena described with other short-course antivirals |
This page's own qualitative read, not an automated/citation-gated assessment.
⚠ Trial evidence found, but doesn't capture rebound — EPIC-HR (NCT04960202), N=2,091
| Serious event | Nirmatrelvir/ritonavir (n=1,038) | Placebo (n=1,053) |
|---|---|---|
| COVID-19 (new/recurrent diagnosis) | 2 | 7 |
| COVID-19 pneumonia | 7 | 36 |
This is a genuine negative result for the specific rebound claim, not a confirmation. EPIC-HR, the pivotal registration trial, shows fewer COVID-19 and pneumonia events on drug than placebo, exactly as expected for an effective antiviral — it doesn't surface a rebound signal at all. That's consistent with the history: rebound was identified afterward, in real-world post-marketing use, not in this trial. It illustrates a real limit of trial AE tables: they can only surface what the trial was watching for, and nobody was specifically coding "symptom rebound 5–10 days after a negative test" as a term when EPIC-HR ran. View on ClinicalTrials.gov →
Varenicline (Chantix) ↔ Suicidal ideation / depression
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2008, 2009, 2011 — 46% of all 4,188 reports arrived in two years (2010–2011). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Dashed lines: 2009 — FDA boxed warning, neuropsychiatric events; 2016 — boxed warning removed after EAGLES trial
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
This is the most instructive case on this page precisely because the story has two acts. In 2009, after a wave of post-marketing reports of neuropsychiatric events, FDA added a boxed warning to varenicline for suicidal thoughts and behavior — the kind of signal disproportionality data like this would have supported at the time. But FDA also required the manufacturer to run a large, purpose-built randomized controlled trial (EAGLES, published in The Lancet, 2016) directly comparing varenicline, bupropion, nicotine patch, and placebo for neuropsychiatric safety. EAGLES found no statistically significant increase in moderate-to-severe neuropsychiatric events for varenicline versus placebo, and FDA removed the boxed warning in December 2016. The spontaneous-report signal was real and worth investigating; the controlled trial it motivated did not confirm a causal drug effect at the magnitude first feared. This is the clearest example in this dataset of why a disproportionality signal is a prompt for better-controlled study, not a verdict on its own.
Regulatory basis: FDA boxed warning added 2009, removed December 2016, following the EAGLES trial (Anthenelli RM, et al. Lancet. 2016;387(10037):2507–2520).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Met in the original spontaneous reports |
| Strength | partial | PRR 5.5–8.3, modest |
| Consistency | not established | The EAGLES RCT did not replicate the signal |
| Specificity | not established | — |
| Biological gradient | not established | — |
| Plausibility | partial | Nicotinic receptor/CNS mechanism proposed but not confirmed |
| Coherence | not established | Doesn't fit the larger randomized-trial picture |
| Experiment | not established | The actual experiment (EAGLES) returned a null result — the whole point of this entry |
| Analogy | not established | — |
Almost every viewpoint looked "met" from spontaneous reports alone in 2009; the actual experiment is what changed the picture. This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — EAGLES (NCT01456936), N=8,058, 4 arms
| Serious event | Varenicline (n=2,016) | Bupropion (n=2,006) | NRT patch (n=2,022) | Placebo (n=2,014) |
|---|---|---|---|---|
| Depression | 1 | 1 | 1 | 0 |
| Suicidal ideation | 2 | 1 | 0 | 3 |
| Suicide attempt | 0 | 2 | 1 | 1 |
| Completed suicide | 0 | 0 | 0 | 1 |
| Suicidal behaviour | 0 | 0 | 0 | 1 |
Varenicline's counts are not higher than placebo for any of these five terms — for several, placebo is higher. This is the primary source underneath the "EAGLES found no significant increase" claim in the prose above, not a secondary summary of it. View on ClinicalTrials.gov →
Isotretinoin (Accutane) ↔ Depression / suicidal ideation
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2011, 2012 — 38% of all 5,698 reports arrived in two years (2011–2012). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Isotretinoin carries a prominent psychiatric warning on its U.S. label, and individual case reports of depression and suicidal ideation following treatment are well documented and plausible (isotretinoin affects retinoid signaling pathways implicated in mood regulation). But the two largest cohort studies on this question directly disagree with each other, and that disagreement is the real story. Jick et al. (2000) followed 7,195 Saskatchewan isotretinoin users and 13,700 acne patients on oral antibiotics (plus a smaller UK cohort), comparing depression/psychosis diagnoses before vs. after exposure, and found relative risks around 1.0 — no detectable excess. Sundström et al., a Swedish registry cohort of 5,756 isotretinoin patients, found the opposite framing of the same question: the standardized incidence ratio for attempted suicide was already elevated in the year before treatment started (SIR 1.57 for all attempts), not just during or after it — the single clearest documented instance of the confounding-by-indication pattern this grade is built on (people with the most psychologically distressing acne are the ones referred for isotretinoin in the first place). Note also that completed suicide specifically is not a flagged signal in this dataset (PRR 1.3), which argues against the most severe form of the proposed association, even while the milder mood-symptom signals remain flagged. This page grades it as genuinely contested rather than established in either direction.
Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol. 2000;136(10):1231–1236. PMID 11030769. Sundström A, et al. Association of suicide attempts with acne and treatment with isotretinoin. BMJ. 2010;341:c5812.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Mixed — several studies find depression risk highest before treatment starts |
| Strength | partial | PRR 10–11, modest |
| Consistency | not established | Published cohort studies disagree with each other |
| Specificity | not established | Depression is also elevated in acne patients not on isotretinoin |
| Biological gradient | not established | No consistent dose-response shown |
| Plausibility | partial | Retinoid-signaling/mood hypothesis proposed, not confirmed |
| Coherence | partial | A competing hypothesis (disease severity, not drug) fits the same data equally well |
| Experiment | not established | No clean dechallenge/rechallenge trial data |
| Analogy | not established | — |
This page's own qualitative read, not an automated/citation-gated assessment.
Thalidomide ↔ Abnormal/increased blood hCG
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 35% of 113 reports), so stimulated reporting is unlikely to explain the signal.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
These are, numerically, among the single highest PRR values in this entire dataset — and they are a near-certain reporting artifact, not a drug effect, included deliberately as a counter-example. Thalidomide is the drug most responsible for the existence of modern pharmacovigilance, after causing severe birth defects (notably phocomelia) in thousands of children in the late 1950s–60s when given to pregnant women for morning sickness. Precisely because of that history, its current U.S. uses (multiple myeloma, erythema nodosum leprosum) are restricted under the mandatory THALOMID REMS program, which requires routine pregnancy testing (serum/urine hCG) for every patient of childbearing potential before and during treatment. A hCG result flagged as "abnormal" or "increased" in that monitoring context is a required-testing artifact — it reflects the surveillance protocol built around the drug, not a new finding the drug caused. Tellingly, classic teratogenicity terms (phocomelia, congenital anomaly) do not even appear as flagged signals in this dataset, precisely because the REMS program has been so effective at preventing pregnancy exposure in the first place. The historical causal link for birth defects is not in question; it simply does not show up as a modern FAERS disproportionality signal, for the same reason the HPV/Pap-smear pattern does not reflect vaccine harm on the companion vaccine signal-pairs page.
Regulatory basis: THALOMID REMS program (mandatory pregnancy testing); historical teratogenicity established independently of FAERS, pre-dating the modern FAERS system.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | n/a | Not a biological effect — a surveillance-protocol artifact |
| Strength | met | Numerically very high PRR — but this measures testing-protocol intensity, not a biological effect |
| Consistency | met | Consistent with the REMS testing requirement, not with a biological drug effect |
| Specificity | not established | hCG monitoring applies to every patient of childbearing potential regardless of other factors |
| Biological gradient | n/a | — |
| Plausibility | n/a | Thalidomide does not raise hCG biologically |
| Coherence | not established | Fails coherence with known thalidomide pharmacology (not an endocrine/hCG-active drug) |
| Experiment | n/a | — |
| Analogy | met | Directly analogous to the HPV/Pap-smear surveillance-coincidence example on the companion vaccine page |
This entry fails most Hill viewpoints despite a sky-high PRR — a clean illustration of why strength alone proves nothing. This page's own qualitative read, not an automated/citation-gated assessment.
Alendronate (bisphosphonates) ↔ Atypical femoral fracture
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2013, 2014, 2018, 2020 — 21% of all 796 reports arrived in two years (2013–2014). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Alendronate is the archetypal oral bisphosphonate and first-line therapy for postmenopausal osteoporosis, and it genuinely reduces ordinary osteoporotic fractures. But prolonged use — characteristically more than three to five years of continuous exposure — is associated with a rare, distinctive low-energy subtrochanteric and diaphyseal femoral fracture pattern ("atypical femoral fractures"), mechanically different from the ordinary hip fracture the drug prevents. The FDA added a warning to the bisphosphonate class in October 2010, and the American Society for Bone and Mineral Research convened a task force the same year to standardize the case definition, precisely because the pattern is easy to miss. The FAERS term shown here ("femur fracture") is broader than the atypical pattern, so the raw count conflates the two — a genuine reporting limitation — but the specific atypical-fracture association is well supported in longitudinal cohort data and the label.
Regulatory basis: FDA Drug Safety Communication on atypical femur fractures with bisphosphonates (October 2010); ASBMR task-force case definition (2010); alendronate prescribing information (warnings on atypical subtrochanteric/diaphyseal fractures).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Fractures occur after years of continuous exposure, not before |
| Strength | met | PRR 121 here; a large effect for the atypical-specific pattern in cohort data |
| Consistency | met | Replicated across independent bisphosphonate cohorts and countries |
| Specificity | partial | The atypical pattern is specific, but the FAERS term also captures ordinary fractures |
| Biological gradient | met | Risk rises with duration of use (roughly >3–5 years) |
| Plausibility | met | Over-suppression of bone turnover impairs micro-damage repair — a named mechanism |
| Coherence | met | Coheres with bisphosphonate pharmacology and the same pattern after denosumab |
| Experiment | partial | Risk falls after a drug holiday, though with a lag — supportive, not a clean on/off test |
| Analogy | met | The same atypical pattern occurs with other antiresorptives, including denosumab |
This page's own qualitative read, not an automated/citation-gated assessment.
Denosumab ↔ Osteonecrosis of the jaw
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 25% of 8,445 reports), so stimulated reporting is unlikely to explain the signal.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Denosumab is a RANKL inhibitor given as 60 mg every six months for osteoporosis and at 120 mg monthly in cancer/bone-metastasis settings. Osteonecrosis of the jaw (ONJ) — exposed, non-healing bone in the mouth — is a labeled risk for denosumab, just as it is for the bisphosphonates; it is best understood as a class effect of drugs that suppress bone resorption. Risk is strongly dose- and duration-dependent and is driven mainly by the oncology dosing, so ONJ is comparatively rare at osteoporosis dosing. This is a mechanistically coherent, clinically managed adverse effect, not a statistical artifact.
Regulatory basis: denosumab prescribing information (boxed warning for osteonecrosis of the jaw in oncology dosing); class effect shared with the bisphosphonates.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | ONJ appears after cumulative exposure; the bone was intact beforehand |
| Strength | met | PRR 55 in this dataset |
| Consistency | met | Consistent across the whole antiresorptive class (bisphosphonates and denosumab) |
| Specificity | partial | Not unique to denosumab; cancer patients often receive several agents |
| Biological gradient | met | Markedly higher at monthly oncology dosing than at q6mo osteoporosis dosing |
| Plausibility | met | RANKL inhibition suppresses osteoclast function; jaw bone, exposed to oral flora, is the sentinel site |
| Coherence | met | Coheres with the bisphosphonate ONJ literature and the drug's bone biology |
| Experiment | partial | Drug-holiday experience is supportive, not a randomized test |
| Analogy | met | Directly analogous to bisphosphonate-associated ONJ |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — denosumab 60 mg Q6M vs placebo, breast cancer on aromatase inhibitors (NCT00556374), N=3,399
| Term (as recorded) | Denosumab 60 mg (n=1,709) | Placebo (n=1,690) |
|---|---|---|
| Osteonecrosis (serious) | 1 | 3 |
| Abscess jaw (serious) | 1 | 0 |
Jaw-specific events appear on the denosumab arm, but at these counts the arms cannot be separated — consistent with ONJ being genuinely rare at osteoporosis dosing. The risk is established from the oncology-dosing experience and long-term data, not from a trial this size. View on ClinicalTrials.gov →
Pioglitazone ↔ Bladder cancer
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2011, 2012, 2013, 2015, 2016, 2017, 2018, 2019, 2020 — 75% of all 8,736 reports arrived in two years (2015–2016). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Pioglitazone, a thiazolidinedione for type 2 diabetes, was flagged for a possible bladder-cancer risk by a French national cohort in 2011, which led France to suspend the drug and prompted the FDA and EMA to add warnings and restrict its use (FDA label warning, 2011). Yet the picture has not resolved cleanly: several large subsequent observational studies and pooled analyses found little to no increase in bladder-cancer risk, and some of the FAERS over-reporting almost certainly reflects intensified bladder/prostate surveillance in this population plus the regulatory scare itself driving reporting. The honest grade is "contested," not "established" — a labeled caution resting on genuinely disagreeing evidence.
Regulatory basis: FDA drug safety communication and label change (2011); ANSM (France) suspension (2011); EMA review. The epidemiological evidence is mixed, with later large studies finding little to no elevated risk.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Plausible (years of exposure precede diagnosis), but cancer latency makes it hard to pin down |
| Strength | met | PRR 84 — but very likely inflated by reporting and surveillance bias |
| Consistency | not established | Large studies genuinely disagree on whether risk is elevated at all |
| Specificity | partial | Bladder is a specific organ, but this population is heavily screened for it |
| Biological gradient | partial | Some studies suggest a duration/dose trend; others find none |
| Plausibility | partial | Rodent urothelial tumors exist; human relevance is uncertain |
| Coherence | not established | Does not cohere into a decisive pattern either way |
| Experiment | not established | No randomized trial was designed to test this outcome |
| Analogy | partial | A few other drug classes carry debated bladder-cancer signals |
This page's own qualitative read, not an automated/citation-gated assessment.
Atorvastatin (statins) ↔ Type 2 diabetes mellitus
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2009, 2013, 2014, 2015, 2016, 2017 — 68% of all 11,252 reports arrived in two years (2014–2015). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Pooled randomized-trial data found a small but statistically significant increase in new-onset diabetes among statin recipients (Sattar et al., Lancet 2010, PMID 20167359), and in 2012 the FDA added a warning about increases in blood glucose and HbA1c. The effect is real but modest, appears dose-related, and is generally judged to be outweighed by statins' cardiovascular benefit; whether it reflects a true diabetogenic action or the unmasking of already-predisposed patients remains debated. The very high FAERS PRR here overstates the clinical magnitude — statin users are heavily monitored, so even a modest true effect inflates further in spontaneous reporting.
Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742 (PMID 20167359). FDA prescribing-information change on glucose/HbA1c (2012).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | New diabetes appears after starting the statin, but latency is long and variable |
| Strength | partial | PRR 42 in FAERS, but only a small absolute effect in randomized trials |
| Consistency | met | Reproduced across many statin trials in the pooled analysis |
| Specificity | not established | Diabetes is common and multifactorial; statins affect many pathways |
| Biological gradient | partial | The effect tracks with statin intensity/dose in several analyses |
| Plausibility | partial | Proposed mechanisms include effects on insulin sensitivity and glucose transport |
| Coherence | partial | Fits the modest glucose-raising seen with the class, without implying large harm |
| Experiment | met | Randomized trials are the strongest evidence here — the effect is real, just small |
| Analogy | partial | Other drugs with metabolic effects can modestly shift glucose |
This page's own qualitative read, not an automated/citation-gated assessment.
Drospirenone/ethinyl estradiol ↔ Pulmonary embolism (venous thromboembolism)
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2012, 2013, 2014 — 58% of all 9,167 reports arrived in two years (2011–2012). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Combined oral contraceptives are a well-recognized cause of venous thromboembolism, and the progestin component modifies that risk: national cohort data found drospirenone-containing combined pills carried a modestly higher VTE risk than levonorgestrel-containing pills (Lidegaard et al., BMJ 2009, PMID 19679613). The FDA revised the drospirenone labeling in 2011 to reflect this. The mechanism — an estrogen/progestin-driven procoagulant shift — is established pharmacology, and VTE is the classic serious adverse effect of combined hormonal contraception.
Lidegaard Ø, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890 (PMID 19679613). FDA prescribing-information revision for drospirenone-containing contraceptives (2011).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | VTE occurs during exposure, with the highest risk in the first months of use |
| Strength | met | PRR 51 here; a consistent, moderate odds ratio in cohort studies |
| Consistency | met | Replicated across multiple national cohorts and pharmacovigilance systems |
| Specificity | partial | A class effect of combined hormonal contraceptives, differing by progestin |
| Biological gradient | met | Risk differs by progestin type and by estrogen dose |
| Plausibility | met | Estrogen/progestin shifts clotting factors toward a procoagulant state |
| Coherence | met | Coheres with the broader hormonal-contraception VTE literature |
| Experiment | partial | Risk declines after discontinuation; no randomized exposure-removal trial exists |
| Analogy | met | Other estrogen-containing products carry the same VTE risk |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — EE 20 µg/drospirenone 3 mg, extended vs standard regimens (NCT00266032), N=1,067
| Term (as recorded) | Flexible extended (n=642) | Fixed extended (n=209) | Standard 24+4 (n=216) |
|---|---|---|---|
| Deep vein thrombosis (serious) | 1 | 0 | 0 |
One serious DVT in the extended-dosing arm — far too few events for a trial of this size to quantify VTE risk. This is why the drospirenone risk was established from large national cohorts: trials are simply underpowered for events this rare. View on ClinicalTrials.gov →
Omeprazole (proton-pump inhibitors) ↔ Chronic kidney disease
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2017, 2018, 2019, 2020, 2021, 2022, 2023 — 72% of all 13,546 reports arrived in two years (2018–2019). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Proton-pump inhibitors are among the most-prescribed drug classes, and a widely-cited cohort analysis found that cumulative PPI exposure was associated with an increased risk of chronic kidney disease (Lazarus et al., JAMA Intern Med 2016). The FAERS pattern here spans the class — omeprazole with chronic kidney disease and acute kidney injury, lansoprazole with end-stage renal disease. The signal remains contested, however: confounding by indication and by baseline health is hard to exclude, effect sizes vary across studies, and some later analyses found little or no association. Acute interstitial nephritis is a recognized, likely-immune PPI reaction and provides a plausible mechanism, but the size of any chronic-kidney-disease risk is genuinely disputed.
Lazarus B, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2). doi:10.1001/jamainternmed.2015.7193. Evidence contested; confounding by indication limits causal inference.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | PPI exposure precedes decline, but the time course is slow and hard to date |
| Strength | met | PRR 43 in FAERS — large, but very plausibly confounded |
| Consistency | partial | Several cohorts support it; others find little, so it is not settled |
| Specificity | not established | Kidney disease is common and multifactorial in the PPI population |
| Biological gradient | partial | Cumulative-dose/duration relationships are reported but inconsistent |
| Plausibility | partial | Interstitial nephritis is a real mechanism for AKI; the link to chronic disease is less clear |
| Coherence | partial | Fits a modest renal effect without establishing its size |
| Experiment | not established | No randomized trial has tested kidney outcomes |
| Analogy | partial | Other drugs cause immune-mediated interstitial nephritis |
This page's own qualitative read, not an automated/citation-gated assessment.
Interferon beta-1a ↔ Influenza-like illness
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 28% of 13,231 reports), so stimulated reporting is unlikely to explain the signal.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Interferon beta-1a is a first-line injectable therapy for relapsing multiple sclerosis, and a flu-like illness — fever, chills, myalgia, malaise — is its single most characteristic and predictable side effect, typically worst in the hours after each injection and improving with continued use. It is the textbook "expected pharmacological effect": cytokine-mediated, dose-related, and managed with dose titration, evening dosing, and antipyretics. Its causality was never in question; the high report count mainly reflects how common and memorable the symptom is.
Regulatory basis: interferon beta-1a prescribing information (influenza-like symptoms listed among the most common adverse reactions).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Symptoms begin within hours of each injection |
| Strength | met | PRR 21, and near-universal in treated patients at some point |
| Consistency | met | Reproduced in every interferon-beta trial and cohort |
| Specificity | partial | A class effect of all interferon-beta products, not molecule-specific |
| Biological gradient | met | Severity tracks with dose and is reduced by titration |
| Plausibility | met | Direct, expected consequence of interferon's cytokine pharmacology |
| Coherence | met | Fits the known immunomodulatory action of the drug |
| Experiment | partial | Symptoms recur on re-injection and lessen with continued dosing — a natural dechallenge/rechallenge |
| Analogy | met | Shared with other interferons and with cytokine-release reactions generally |
This page's own qualitative read, not an automated/citation-gated assessment.
Capecitabine ↔ Palmar-plantar erythrodysaesthesia (hand-foot syndrome)
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 19% of 6,537 reports), so stimulated reporting is unlikely to explain the signal.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Capecitabine is an oral fluoropyrimidine used for colorectal and breast cancer, and palmar-plantar erythrodysesthesia — "hand-foot syndrome": painful redness, swelling, and peeling of the palms and soles — is its signature toxicity. It occurs in a substantial minority of treated patients, is clearly dose- and schedule-dependent, and is well characterized and manageable (dose reduction, interruption, emollients, pyridoxine). This is a mechanistically direct, expected effect of the drug's own pharmacology, not an idiosyncratic reaction.
Regulatory basis: capecitabine prescribing information (hand-foot syndrome listed among the most common adverse reactions); confirmed by a randomized comparator arm (§ trial data below). A class effect of the fluoropyrimidines.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Appears during cycles of treatment, after exposure begins |
| Strength | met | PRR 92, and ~20%+ incidence in a randomized comparator arm |
| Consistency | met | Reproduced across capecitabine trials and real-world cohorts |
| Specificity | met | Highly characteristic of the fluoropyrimidine class |
| Biological gradient | met | Striking dose/schedule dependence; continuous infusion and higher doses raise risk |
| Plausibility | met | Direct toxicity in high-turnover acral skin; named mechanism |
| Coherence | met | Coheres with the drug's cytotoxicity and with other fluoropyrimidines |
| Experiment | met | Resolves with dose reduction or interruption — a clean dechallenge |
| Analogy | met | Seen with 5-fluorouracil and other fluoropyrimidines |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — physician's-choice chemotherapy (incl. capecitabine) vs talazoparib in BRCA breast cancer (NCT01945775, EMBRACA)
| Term (as recorded) | Physician's-choice arm (n=126) | Talazoparib arm (n=286) |
|---|---|---|
| Palmar-plantar erythrodysaesthesia syndrome (other events) | 28 | 4 |
Hand-foot syndrome appeared in 28/126 (~22%) of the comparator arm, which includes capecitabine, versus 4/286 (~1.4%) on talazoparib — a large, textbook-consistent difference. Caveat: the comparator arm pools several drugs (capecitabine, eribulin, gemcitabine, vinorelbine), so it confirms the class/regimen effect more than capecitabine alone. View on ClinicalTrials.gov →
Alprazolam (benzodiazepines) ↔ Drug dependence / abuse
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2020, 2021 — 39% of all 4,057 reports arrived in two years (2020–2021). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Alprazolam is a short-acting, high-potency benzodiazepine, and physical dependence with withdrawal on cessation is an expected, dose- and duration-related effect of the benzodiazepine class — the drug's own pharmacology, not an idiosyncratic reaction. In September 2020 the FDA updated the Boxed Warning for the entire class to address risks of abuse, addiction, physical dependence, and withdrawal. The high report count reflects both how widely these drugs are prescribed and how reliably dependence develops with sustained use.
Regulatory basis: FDA Drug Safety Communication, 23 September 2020 — Boxed Warning updated for the benzodiazepine class (abuse, addiction, physical dependence, withdrawal).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Dependence develops over the course of exposure, before withdrawal is seen on cessation |
| Strength | met | PRR 16, on a very large report base |
| Consistency | met | Reproduced across the whole benzodiazepine class and decades of use |
| Specificity | partial | A class effect; potency and half-life differ between agents |
| Biological gradient | met | Risk rises with dose, duration, and shorter half-life (more inter-dose withdrawal) |
| Plausibility | met | Direct consequence of GABA-A receptor modulation |
| Coherence | met | Coheres with the known dependence liability of the class |
| Experiment | met | Withdrawal on discontinuation is itself the natural dechallenge |
| Analogy | met | Shared with other CNS depressants (alcohol, barbiturates) |
This page's own qualitative read, not an automated/citation-gated assessment.
Quetiapine (antipsychotics) ↔ Diabetes mellitus
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2007 — 38% of all 270 reports arrived in two years (2006–2007). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Quetiapine is a second-generation antipsychotic, and weight gain, dyslipidaemia, and hyperglycaemia/diabetes are its best-known metabolic effects — shared across the class but differing in magnitude by molecule. The FDA required a class warning about hyperglycaemia and diabetes for all atypical antipsychotics in 2003. The mechanism (weight gain, insulin resistance, and possibly direct effects on glucose regulation) is well described, and the effect is dose- and duration-related and largely manageable with baseline and periodic metabolic monitoring.
Regulatory basis: FDA class warning on hyperglycemia and diabetes with atypical antipsychotics (2003); quetiapine prescribing information (metabolic monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Metabolic changes emerge over weeks–months of treatment |
| Strength | partial | PRR 13 — modest, and confounded by the population's baseline risk |
| Consistency | met | A consistent class effect across atypical antipsychotics |
| Specificity | partial | Class-wide, with real differences in magnitude between agents |
| Biological gradient | met | Tracks with dose and the degree of weight gain |
| Plausibility | met | Weight gain and insulin resistance are named, established mechanisms |
| Coherence | met | Coheres with the class's documented metabolic syndrome risk |
| Experiment | partial | Improvement on switching/withdrawal is supportive, not a randomized test |
| Analogy | met | Shared with other second-generation antipsychotics |
This page's own qualitative read, not an automated/citation-gated assessment.
Risperidone ↔ Weight gain
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 26% of 9,059 reports), so stimulated reporting is unlikely to explain the signal.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Risperidone, like quetiapine, is a second-generation antipsychotic whose metabolic effects include substantial weight gain — a labeled, dose- and duration-related consequence of the class, with the risk varying meaningfully between agents. In a randomized head-to-head trial of risperidone versus quetiapine XR, "weight increased" was recorded in roughly 6% versus 5% of patients. The very high FAERS PRR reflects that weight gain is both common and reliably reported, but the effect itself is well established, not a statistical curiosity.
Regulatory basis: risperidone prescribing information (weight gain among the most common adverse reactions); FDA class metabolic warning for atypical antipsychotics.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weight rises after treatment begins, over weeks to months |
| Strength | met | PRR 513 here; a consistent effect in trials and cohorts |
| Consistency | met | Reproduced across studies and across the antipsychotic class |
| Specificity | partial | Class effect, with real differences between individual agents |
| Biological gradient | met | Weight change tracks with dose and duration |
| Plausibility | met | Receptor-mediated appetite/metabolic effects are well described |
| Coherence | met | Coheres with the antipsychotic metabolic-syndrome literature |
| Experiment | partial | Weight loss on switching or withdrawal supports causality |
| Analogy | met | Shared with olanzapine, quetiapine, and other atypicals |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — risperidone vs quetiapine XR in schizophrenia (NCT00600756)
| Term (as recorded) | Risperidone (n=402) | Quetiapine XR (n=391) |
|---|---|---|
| Weight increased (other events) | 25 | 18 |
Roughly 6% of risperidone patients and 5% of quetiapine XR patients had weight gain recorded — a clean, randomized confirmation of the expected class effect, with risperidone slightly ahead in this trial. View on ClinicalTrials.gov →
Docetaxel (taxanes) ↔ Alopecia
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2017, 2018, 2019, 2020, 2021 — 68% of all 16,935 reports arrived in two years (2018–2019). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Docetaxel is a taxane chemotherapy, and hair loss is a near-universal, mechanistically direct consequence of its action on rapidly dividing cells — including the hair-follicle matrix. In a randomized trial, alopecia was recorded in roughly a third of patients on docetaxel versus under 2% on pembrolizumab, a striking and entirely expected difference. Alopecia is not merely cosmetic; it is among the most distressing chemotherapy side effects, and its severity is dose- and schedule-dependent.
Regulatory basis: docetaxel prescribing information (alopecia among the most common adverse reactions); confirmed by a randomized comparator arm (trial data below). A class effect of the taxanes and most cytotoxic chemotherapies.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hair loss begins weeks after the first cycle, after exposure |
| Strength | met | PRR 30, and ~36% incidence in a randomized comparator arm |
| Consistency | met | Reproduced in every taxane trial and cohort |
| Specificity | partial | A class effect of cytotoxic chemotherapy, not molecule-unique |
| Biological gradient | partial | Severity varies with dose, schedule, and agent |
| Plausibility | met | Direct cytotoxicity to rapidly dividing follicle cells — named mechanism |
| Coherence | met | Coheres with the drug's antimitotic action |
| Experiment | met | Hair regrows after treatment stops — a clean dechallenge/rechallenge |
| Analogy | met | Shared with other taxanes and anthracyclines |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — docetaxel vs pembrolizumab in NSCLC (NCT01905657, KEYNOTE-010)
| Term (as recorded) | Docetaxel (n=309) | Pembrolizumab 2 mg/kg (n=339) | Pembrolizumab 10 mg/kg (n=343) |
|---|---|---|---|
| Alopecia (other events) | 110 | 6 | 5 |
About 36% of docetaxel patients had alopecia recorded versus ~1.5–1.8% on pembrolizumab — a large, randomized, textbook-consistent contrast that directly confirms the expected effect. View on ClinicalTrials.gov →
Tenofovir disoproxil fumarate ↔ Bone loss
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2019, 2020, 2021, 2022, 2023, 2024, 2025 — 88% of all 10,658 reports arrived in two years (2020–2021). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Tenofovir disoproxil fumarate (TDF) is an antiretroviral used to treat HIV and hepatitis B, and its renal and bone toxicities are precisely why the newer prodrug TAF was developed. TDF reduces bone mineral density and raises markers of bone turnover, with the steepest declines in the first year of therapy and a persistently lower density thereafter; the FDA label carries explicit bone and renal warnings. The very high FAERS PRR reflects an established, mechanism-linked effect (proximal tubular dysfunction with phosphate wasting), though the term "bone loss" aggregates several coded MedDRA terms, so the raw count overshoots the specificity.
Regulatory basis: tenofovir disoproxil fumarate prescribing information (warnings on decreases in bone mineral density and renal toxicity); TAF developed specifically to mitigate these effects.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | BMD falls after therapy starts, largest in the first year |
| Strength | met | PRR 563 here; consistent, measurable BMD differences in trials |
| Consistency | met | Replicated across randomized trials and cohorts |
| Specificity | partial | Class-related (some other NRTIs share it); the FAERS term aggregates several codes |
| Biological gradient | partial | Related to cumulative exposure and baseline risk |
| Plausibility | met | Proximal tubulopathy with phosphate wasting is a named mechanism |
| Coherence | met | Coheres with the drug's renal toxicity and with the TAF redesign |
| Experiment | met | BMD improves after switching TDF to TAF — a clean substitution experiment |
| Analogy | partial | Shared with certain other antiretrovirals (e.g. some NRTIs) |
This page's own qualitative read, not an automated/citation-gated assessment.
Rituximab ↔ Serious infection
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 19% of 4,815 reports), so stimulated reporting is unlikely to explain the signal.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Rituximab is an anti-CD20 monoclonal antibody that depletes B cells, and an increased risk of infection — including serious bacterial, fungal, and viral infections, and notably reactivation of hepatitis B and progressive multifocal leukoencephalopathy (PML) — is a labeled, mechanistic consequence of that depletion. The FDA label carries boxed warnings for PML and HBV reactivation. The population treated (lymphoma, autoimmune disease, transplant) also raises baseline infection risk, so the FAERS count mixes drug-driven and disease-driven infection, but the causal contribution of B-cell depletion itself is well established.
Regulatory basis: rituximab prescribing information (boxed warnings for progressive multifocal leukoencephalopathy and hepatitis B virus reactivation; increased risk of serious infections).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Infections and reactivation follow B-cell depletion after dosing |
| Strength | partial | PRR 8 — modest, because infection is common in this population generally |
| Consistency | met | Consistent across indications and trials |
| Specificity | not established | Infection is nonspecific; disease and concomitant therapy also contribute |
| Biological gradient | partial | Relates to degree/duration of B-cell depletion and repeat dosing |
| Plausibility | met | B-cell depletion impairs humoral immunity — named mechanism |
| Coherence | met | Coheres with the immunosuppression seen with other B-cell-depleting agents |
| Experiment | partial | Infection risk tracks with depletion depth; no clean randomized removal test |
| Analogy | met | Shared with other immunosuppressants/anti-CD20 therapies |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — safety of rituximab in rheumatoid arthritis (NCT00443651)
| Term (as recorded) | Rituximab 1000 mg (n=401) | Rituximab 500 mg (n=176) |
|---|---|---|
| Pneumonia (serious) | 4 | 1 |
| Upper respiratory tract infection (other) | 51 | 27 |
| Urinary tract infection (other) | 45 | 15 |
The recorded infection burden is clear, but both arms received rituximab (different doses), with no placebo arm — so this shows that infections are captured clinically, not a comparator-adjusted risk. View on ClinicalTrials.gov →
Morphine (opioids) ↔ Overdose / respiratory depression
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2025 — 18% of all 568 reports arrived in two years (2024–2025). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Morphine is a full mu-opioid receptor agonist, and the dose-related triad of respiratory depression, sedation, and death in overdose is the defining, mechanistically direct hazard of the opioid class. The opioid-overdose epidemic is a public-health emergency addressed by the CDC clinical practice guideline, opioid REMS, and naloxone access. The FAERS term "overdose" here spans intentional and unintentional excess and reflects a well-established, dose-dependent risk rather than a statistical artifact — though it also aggregates suicides, misuse, and medication errors, so it is not a pure "adverse reaction."
Regulatory basis: opioid analgesic REMS; CDC Clinical Practice Guideline for Prescribing Opioids (2016, updated 2022); morphine prescribing information (boxed warning for respiratory depression and addiction).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Respiratory depression follows dosing and rises with dose |
| Strength | met | PRR 21 on a very large base; the leading cause of drug-overdose death |
| Consistency | met | Reproduced across the whole opioid class and decades of data |
| Specificity | partial | A class effect; the FAERS term also captures misuse and error |
| Biological gradient | met | Central hypoventilation is classically dose-dependent |
| Plausibility | met | Mu-opioid receptor agonism directly suppresses brainstem respiratory drive |
| Coherence | met | Coheres with the entire opioid pharmacology and toxicology literature |
| Experiment | met | Naloxone reverses opioid-induced respiratory depression — a clean pharmacologic antagonist experiment |
| Analogy | met | Shared by every mu-opioid agonist |
This page's own qualitative read, not an automated/citation-gated assessment.
Medroxyprogesterone acetate ↔ Meningioma
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
Reporting spiked in 2024, 2025 — 98% of all 1,678 reports arrived in two years (2024–2025). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Medroxyprogesterone acetate is a progestin used for contraception, abnormal uterine bleeding and, at high doses, as hormonal cancer therapy. The progestogen class has been linked to intracranial meningioma: a French national cohort found a dose-dependent association with high-dose cyproterone acetate (Weill et al., BMJ 2021, PMID 33536184), which prompted European reviews that extended the meningioma warning across several progestogens. Meningiomas frequently express progesterone receptors, giving a plausible mechanism. Whether the effect size for medroxyprogesterone specifically matches cyproterone's is not yet settled, so this is graded "emerging/contested" rather than established — and the extreme FAERS PRR (1,443) substantially overstates the true risk once awareness and increased imaging are accounted for.
Weill A, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ. 2021;372:n37 (PMID 33536184). European regulatory reviews of progestogens and meningioma (from 2020 onward). Signal emerging; the effect size for medroxyprogesterone is not established.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Association grows with years of use, but meningioma grows slowly and onset is hard to date |
| Strength | met | PRR 1,443 — but heavily inflated by awareness and screening bias |
| Consistency | partial | Clear for cyproterone; less well established for medroxyprogesterone specifically |
| Specificity | partial | A progestogen class effect, plausible via progesterone receptors |
| Biological gradient | met | Risk rises with dose (high-dose > low-dose) and duration |
| Plausibility | met | Meningiomas commonly express progesterone receptors |
| Coherence | met | Coheres with the receptor biology and with the wider progestogen literature |
| Experiment | partial | Reported meningioma regression after progestogen withdrawal is supportive |
| Analogy | met | Directly analogous to cyproterone-acetate-associated meningioma |
This page's own qualitative read, not an automated/citation-gated assessment.
Estrogen + medroxyprogesterone acetate ↔ Breast cancer
Open this assessment on its own page →
Conjugated equine estrogen plus medroxyprogesterone acetate was the combined hormone-therapy regimen tested in the Women's Health Initiative, the large randomized trial whose 2002 report found an increased risk of invasive breast cancer (as well as cardiovascular events), leading to early termination of that arm and a sharp, worldwide drop in hormone-therapy use (Rossouw et al., JAMA 2002, PMID 12117397). The breast-cancer association is the best-established harm of combined postmenopausal hormone therapy, is duration-dependent, and prompted a boxed warning. Note that this is estrogen plus progestin therapy, not medroxyprogesterone used alone as a contraceptive — the two contexts differ.
Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333 (PMID 12117397). FDA boxed warning for estrogen+progestin postmenopausal therapy.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Risk emerged during randomized exposure in the WHI |
| Strength | met | PRR 243 here; a modest but real hazard ratio in the randomized trial |
| Consistency | met | Consistent across observational cohorts and the randomized WHI |
| Specificity | partial | Combined therapy; estrogen-alone results differ, so the progestin matters |
| Biological gradient | met | Risk rises with duration of combined therapy |
| Plausibility | met | Hormone-receptor-driven breast tissue growth — named mechanism |
| Coherence | met | Coheres with decades of hormonal-carcinogenesis research |
| Experiment | met | The WHI itself is the randomized experiment — the strongest possible evidence |
| Analogy | met | Similar to other prolonged hormonal exposures |
This page's own qualitative read, not an automated/citation-gated assessment.
Insulin glargine ↔ Hypoglycaemia (blood glucose decreased)
Open this assessment on its own page →
Reporting over time (stimulated-reporting check)
No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 18% of 7,793 reports), so stimulated reporting is unlikely to explain the signal.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Insulin glargine is a long-acting basal insulin, and hypoglycaemia is its defining and most important adverse effect — a direct, dose-related consequence of the drug's own mechanism, not an idiosyncratic reaction. Every insulin product carries this risk, and it is the principal safety concern in insulin therapy, requiring careful titration and glucose monitoring. It is the textbook expected pharmacological effect: the drug's intended action (lowering glucose) can overshoot.
Regulatory basis: insulin glargine prescribing information (hypoglycemia listed as the most common adverse reaction and among the most important risks).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hypoglycaemia follows insulin action, within its duration of effect |
| Strength | met | PRR 24, on a very large insulin-treated population |
| Consistency | met | Universal across insulins and settings |
| Specificity | partial | A class effect of all insulins and secretagogues |
| Biological gradient | met | Close dose–effect relationship; the core of insulin titration |
| Plausibility | met | Direct consequence of exogenous insulin's glucose-lowering action |
| Coherence | met | Coheres with the entire insulin pharmacotherapy literature |
| Experiment | met | Dose reduction and glucose/glucagon correction reverse it — a clean on/off |
| Analogy | met | Shared by every insulin formulation and by insulin secretagogues |
This page's own qualitative read, not an automated/citation-gated assessment.
Copper intrauterine device ↔ Foreign body in reproductive tract
Open this assessment on its own page →
This is the single highest PRR in the entire dataset (89,124), and it is a pure coding artifact — included deliberately as the extreme counter-example. A copper intrauterine device is a physical object placed in the uterus; when a report mentions "foreign body in reproductive tract," that is a literal description of the device itself, not an adverse reaction the device caused. The PRR is astronomically high precisely because the reaction term is essentially unique to this product class, which guarantees disproportionality by construction. It is the clearest possible reminder that PRR measures the distinctiveness of what gets reported, not harm — the highest number on the page is also one of the least meaningful.
Methodological note, not a regulatory finding: the "foreign body" term describes the intrauterine device itself (a physical implant), a coding artifact of the reporting scheme rather than a biological effect.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | n/a | Not a biological effect — the term names the device |
| Strength | met | PRR 89,124 — but this measures coding specificity, not an effect |
| Consistency | met | Consistent with any report that mentions the IUD |
| Specificity | not established | The term just names the device; it carries no effect information |
| Biological gradient | n/a | — |
| Plausibility | n/a | No biological hypothesis — the device is a foreign body by definition |
| Coherence | not established | Fails coherence with any genuine adverse-reaction concept |
| Experiment | n/a | — |
| Analogy | met | Analogous to other device/administrative coding terms (e.g. "device malfunction") |
This page's own qualitative read, not an automated/citation-gated assessment.
Warfarin ↔ INR increased
Open this assessment on its own page →
Warfarin's effect is measured by the INR, and the INR is the test used to dose it; a report of "international normalised ratio increased" is therefore partly a description of the drug working and partly of the monitoring built around it, not a discrete adverse event in the usual sense. The over-representation of INR terms for warfarin is expected: the test is nearly exclusive to vitamin-K-antagonist therapy, which guarantees disproportionality by construction. Genuine supratherapeutic INR with bleeding is a real and important warfarin hazard, but the raw "INR increased" signal is a monitoring/coding artifact rather than a novel safety finding. Tellingly, INR terms also appear in the comparator arm of a modern anticoagulant trial (below).
Methodological note, not a regulatory finding: INR is the monitoring parameter used to dose vitamin-K antagonists; its over-representation is a coding/monitoring artifact. Supratherapeutic INR with bleeding remains a real, labeled warfarin risk (warfarin prescribing information).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | n/a | The INR is the measurement, not a biological event |
| Strength | met | PRR 93 — but this measures the exclusivity of the test, not harm |
| Consistency | met | Consistent wherever warfarin is monitored |
| Specificity | not established | The term reflects a required test, not a distinct clinical effect |
| Biological gradient | n/a | — |
| Plausibility | n/a | INR rises because that is the drug's intended pharmacology, not an adverse reaction |
| Coherence | not established | Fails coherence as an adverse-reaction concept; it is a monitoring value |
| Experiment | n/a | — |
| Analogy | met | Directly analogous to other lab-monitoring artifacts (e.g. thalidomide ↔ hCG) |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — warfarin vs apixaban in atrial fibrillation (NCT00412984, ARISTOTLE)
| Term (as recorded) | Warfarin (n=9,088) | Apixaban (n=9,052) |
|---|---|---|
| International normalised ratio increased (serious) | 3 | 5 |
| International normalised ratio abnormal (serious) | 5 | 5 |
INR terms were recorded in both arms — even the apixaban arm, which does not require INR dosing — confirming that these entries track the monitoring/recording process rather than a drug-specific effect. View on ClinicalTrials.gov →
Simvastatin (statins) ↔ Rhabdomyolysis
Open this assessment on its own page →
Statin-associated muscle injury runs a spectrum from common myalgia to rare, life-threatening rhabdomyolysis, and the risk is strongly dose-dependent: the 80 mg simvastatin dose carries a far higher myopathy rate than 20 mg, which is why the FDA restricted 80 mg use in 2011 and added it to the statin-drug-interaction warnings. The mechanism is well characterized — inhibiting HMG-CoA reductase depletes mevalonate-pathway intermediates in skeletal muscle — and serum simvastatin levels rise sharply when strong CYP3A4 inhibitors (clarithromycin, itraconazole, protease inhibitors, grapefruit) block its metabolism. This is a class effect, but simvastatin is among the most affected, which is why its labeled precautions are the strictest of the class. The disproportionality here reflects both a genuine effect and the very large numbers of patients on statins with routine creatine-kinase testing in symptomatic cases.
Regulatory basis: FDA simvastatin labeling changes and 80 mg dose restrictions (2011), including CYP3A4-interaction warnings. SEARCH randomized trial (80 mg vs 20 mg simvastatin myopathy comparison), Lancet 2010.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Muscle injury appears during exposure, typically within weeks of starting or escalating the dose |
| Strength | met | PRR 12 on a very large co-report count, with a steep dose–response |
| Consistency | met | Reproduced across statins, in the SEARCH randomized comparison, and in spontaneous-reporting databases |
| Specificity | partial | A class effect, not unique to simvastatin |
| Biological gradient | met | Risk rises clearly with dose (20 vs 80 mg) and with interacting drugs |
| Plausibility | met | HMG-CoA reductase inhibition depletes muscle mevalonate-pathway intermediates |
| Coherence | met | Fits the whole statin-myopathy literature and CK-monitoring practice |
| Experiment | met | Randomized dose comparison (SEARCH) showed markedly more myopathy at 80 mg |
| Analogy | met | Direct analogy to myopathy with other statins and with fibrate co-therapy |
This page's own qualitative read, not an automated/citation-gated assessment.
Lamotrigine ↔ Stevens–Johnson syndrome / toxic epidermal necrolysis
Open this assessment on its own page →
Lamotrigine is the archetypal cause of drug-induced Stevens–Johnson syndrome (SJS) and its more severe form, toxic epidermal necrolysis (TEN) — blistering mucocutaneous reactions with substantial mortality. Risk is concentrated in the first 8 weeks of therapy and rises sharply with rapid dose escalation, which is why lamotrigine must be titrated slowly and why the FDA requires a boxed warning. The reaction is immune-mediated and genetically predisposed: the HLA-B*1502 allele markedly raises risk in several Asian populations, so genotyping is recommended before starting treatment in high-risk ancestry groups. Rare but precisely characterized, this is one of the clearest examples on the page of a genuine, mechanism-based severe adverse reaction rather than a reporting artifact.
Regulatory basis: FDA boxed warning for lamotrigine (serious skin rashes, SJS/TEN); HLA-B*1502 screening guidance. Observational case–control registries (e.g. EuroSCAR), 2008.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Reaction emerges within weeks of starting or after a dose increase |
| Strength | met | PRR 21 for SJS and 15 for TEN, both large |
| Consistency | met | Replicated across independent registries and the prescribing information |
| Specificity | met | Lamotrigine is among the highest-risk drugs for SJS/TEN |
| Biological gradient | met | Risk rises with rapid titration and higher starting doses |
| Plausibility | met | Immune-mediated, HLA-associated T-cell reaction — an established mechanism |
| Coherence | met | Coheres with the anticonvulsant SJS/TEN literature |
| Experiment | partial | Slow-titration guidance reduces risk in practice; no randomized exposure trial exists |
| Analogy | met | Directly analogous to carbamazepine- and phenytoin-associated SJS/TEN |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — lamotrigine vs levetiracetam vs carbamazepine in elderly epilepsy (NCT00438451), N=360
| Term (as recorded) | Levetiracetam (n=122) | Carbamazepine (n=121) | Lamotrigine (n=117) |
|---|---|---|---|
| Rash (non-serious) | 7 | 6 | 2 |
Only the generic term “rash” was tracked — no SJS/TEN term appears, and no serious skin event was recorded on any arm in a trial this size. This is the expected picture: SJS/TEN is rare enough that ordinary trials cannot detect it, which is why the risk was quantified through case–control registries and post-marketing reporting rather than randomized data. View on ClinicalTrials.gov →
Amiodarone ↔ Pulmonary fibrosis (interstitial lung disease)
Open this assessment on its own page →
Amiodarone is a highly lipophilic antiarrhythmic that accumulates in tissue, and its best-known serious long-term toxicity is pulmonary — pneumonitis that can progress to irreversible fibrosis. Because it is used long-term and its tissue burden is cumulative, guidelines and the prescribing information recommend periodic chest imaging and pulmonary-function monitoring for patients on the drug. The reaction is idiosyncratic in timing but clearly exposure-related, and the same iodine-rich, tissue-sequestering pharmacology produces the drug's other signature effects — thyroid dysfunction (both hyper- and hypothyroidism), corneal microdeposits, and hepatotoxicity. The comparatively modest FAERS counts relative to its lethality reflect aggressive monitoring and the fact that amiodarone use has declined as safer antiarrhythmics and ablation have expanded.
Regulatory basis: amiodarone prescribing information (pulmonary toxicity, thyroid, hepatic, ocular monitoring). Established literature on amiodarone-induced pulmonary toxicity.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Pneumonitis typically emerges after months of cumulative exposure |
| Strength | met | PRR 40 for pulmonary fibrosis, one of the largest on the page despite modest counts |
| Consistency | met | Replicated across decades of case series and the prescribing information |
| Specificity | partial | Also causes thyroid, corneal, and hepatic toxicity — not lung-specific |
| Biological gradient | met | Risk tracks with cumulative dose/duration |
| Plausibility | met | Lipophilic tissue accumulation and an iodine-rich molecule drive direct pneumocyte toxicity |
| Coherence | met | Coheres with the broader amiodarone organ-toxicity profile |
| Experiment | partial | Drug discontinuation improves outcomes; no randomized exposure-removal trial |
| Analogy | met | Analogous to other drug-induced interstitial lung disease (e.g. nitrofurantoin, methotrexate) |
This page's own qualitative read, not an automated/citation-gated assessment.
Allopurinol ↔ DRESS syndrome (drug reaction with eosinophilia and systemic symptoms)
Open this assessment on its own page →
Allopurinol is one of the leading causes of severe cutaneous adverse reactions worldwide — a spectrum that includes DRESS (a systemic hypersensitivity reaction with rash, fever, eosinophilia, and organ involvement), Stevens–Johnson syndrome, and toxic epidermal necrolysis. The risk is strongly genetically determined: the HLA-B*5801 allele confers a markedly elevated risk (especially in Han Chinese, Thai, and Korean populations), and screening is recommended before starting the drug in high-risk groups. The reaction is delayed (typically 2–8 weeks after initiation), immune-mediated, and can be fatal, particularly in patients with chronic kidney disease or in elderly patients. It is one of the best-documented pharmacogenomic adverse reactions in medicine.
Regulatory basis: allopurinol prescribing information (severe skin reactions); HLA-B*5801 screening recommendation (ACR/CPIC). Established DRESS/SJS/TEN pharmacogenomics literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Reaction is delayed but consistently follows initiation by 2–8 weeks |
| Strength | met | PRR 18 for DRESS and 11 for TEN, both large |
| Consistency | met | Replicated across registries and pharmacogenomic studies worldwide |
| Specificity | met | Allopurinol is a leading cause of severe cutaneous adverse reactions |
| Biological gradient | met | Risk rises with dose and with renal impairment (higher oxypurinol levels) |
| Plausibility | met | HLA-restricted T-cell activation of oxypurinol-specific clones is well described |
| Coherence | met | Coheres with the broader DRESS/SJS/TEN immunogenetics literature |
| Experiment | met | HLA-B*5801 screening and renal dose-adjustment reduce risk in practice |
| Analogy | met | Analogous to carbamazepine/abacavir HLA-linked hypersensitivity syndromes |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — allopurinol vs placebo in heart failure with hyperuricaemia (NCT00987415), N=253
| Term (as recorded) | Allopurinol (n=128) | Placebo (n=125) |
|---|---|---|
| Rash (serious) | 2 | 0 |
| Rash (non-serious) | 11 | 3 |
Rash appears more often on allopurinol, consistent with its well-known cutaneous propensity — but this small trial tracked only generic “rash,” not DRESS or SJS/TEN, which are rare enough to be invisible at this size. The severe-reaction risk is established from pharmacovigilance and HLA-stratified studies, not from trial AE tables. View on ClinicalTrials.gov →
Lisinopril (ACE inhibitors) ↔ Angioedema
Open this assessment on its own page →
Angioedema is the classic non-cough serious adverse effect of ACE inhibitors: swelling of the lips, tongue, face, or upper airway that can compromise breathing. The mechanism is well defined — ACE (kininase II) inhibition reduces bradykinin breakdown, and bradykinin accumulation increases vascular permeability. The reaction is a class effect, estimated in the low single-digit per-thousand range, may occur at any time (including months or years into therapy), and is disproportionately reported in patients of African ancestry. Because no ACE inhibitor is clearly safer than another, the labeling carries a class-wide warning and patients who develop it are switched to an ARB. The high FAERS count reflects the enormous population on ACE inhibitors and the severity that drives reporting.
Regulatory basis: ACE-inhibitor class labeling (angioedema warning; contraindication with hereditary/idiopathic angioedema). ONTARGET trial (2008) quantified the ACEI-vs-ARB angioedema difference in practice.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Occurs during exposure, often early but sometimes after prolonged use |
| Strength | met | PRR 12 on a large co-report count |
| Consistency | met | Reproduced across ACE inhibitors and in randomized comparisons (ONTARGET) |
| Specificity | met | Notably more common with ACE inhibitors than with ARBs |
| Biological gradient | partial | Not clearly dose-related; risk varies more by ancestry than by dose |
| Plausibility | met | Bradykinin accumulation from ACE inhibition — a well-characterized mechanism |
| Coherence | met | Coheres with the class-wide effect and the ARB-switch practice |
| Experiment | met | Randomized ONTARGET showed ACEI angioedema exceeding ARB, with rechallenge evidence off-drug |
| Analogy | met | Analogous to ACE-inhibitor cough (same kinin mechanism) |
This page's own qualitative read, not an automated/citation-gated assessment.
Empagliflozin (SGLT2 inhibitors) ↔ Diabetic ketoacidosis
Open this assessment on its own page →
SGLT2 inhibitors including empagliflozin cause a distinctive ketoacidosis that can occur at near-normal blood glucose levels — so-called euglycaemic diabetic ketoacidosis — which makes it easy to miss because clinicians are taught to screen for DKA using glucose alone. The FDA warned about this in 2015 and required labeling changes, and the mechanism is now understood: glucosuria masks the usual hyperglycaemic signal while the drugs shift substrate use toward ketogenesis, especially during fasting, illness, surgery, or insulin reduction. Risk is higher with off-label use for weight loss, in type 1 diabetes, and around procedures. It is a genuine, mechanistically coherent class effect with a clear regulatory history, and the large PRR here reflects both the true risk and the intensive reporting prompted by the FDA warning.
Regulatory basis: FDA safety communications on SGLT2-inhibitor ketoacidosis (2015), with subsequent labeling changes. SGLT2-inhibitor DKA literature (euglycaemic DKA).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Occurs during exposure, often triggered by fasting, illness, or insulin changes |
| Strength | met | PRR 60, one of the largest class signals on the page |
| Consistency | met | Reported across the whole SGLT2 class and multiple countries |
| Specificity | met | The euglycaemic pattern is characteristic of SGLT2 inhibitors |
| Biological gradient | partial | Higher with off-label weight-loss use and type 1 diabetes than standard type 2 dosing |
| Plausibility | met | Glucosuria plus a shift toward ketogenesis — a defined metabolic mechanism |
| Coherence | met | Coheres with the shared class pharmacology and the FDA warning |
| Experiment | partial | Labeled precautions and peri-procedural drug holds reduce risk; no dedicated randomized trial |
| Analogy | met | Directly analogous across all SGLT2 inhibitors |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — empagliflozin vs DPP-4 inhibitors, post-authorization safety study (NCT03764631), N=1,502
| Term (as recorded) | Empagliflozin (n=751) | DPP-4 inhibitors (n=751) |
|---|---|---|
| Diabetic ketoacidosis (serious) | 1 | 1 |
This dedicated post-authorization study tracked ketoacidosis as a prespecified event — confirming it is a recognized SGLT2 risk — but recorded only one event per arm over 12 months, far too few to quantify the difference. The signal was established from spontaneous reporting and the FDA’s 2015 safety review, not from a trial this size. View on ClinicalTrials.gov →
Clozapine ↔ Myocarditis
Open this assessment on its own page →
Clozapine, the most effective antipsychotic for treatment-resistant schizophrenia, carries two notorious blood-and-heart risks: agranulocytosis (its most famous, covered separately on this page) and myocarditis, an inflammatory heart-muscle reaction concentrated in the first weeks to months of treatment. Myocarditis can be fatal, and because it is most common during the initiation period, regulators require baseline and early monitoring (troponin, CRP, and clinical review of chest pain, tachycardia, or heart failure symptoms). The mechanism is thought to be a hypersensitivity or cytokine-mediated reaction rather than a simple dose effect, which is why it can strike at standard doses. Recognition of the risk has grown steadily, and several health agencies issued specific alerts in the 2010s; the large PRR here reflects both the true risk and the increasingly routine cardiac monitoring around clozapine starts.
Regulatory basis: clozapine labeling (myocarditis/cardiomyopathy warnings); medicines-agency alerts on clozapine myocarditis (e.g. MHRA, 2010s). Established clozapine myocarditis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Concentrated in the first weeks–months after initiation — a striking temporal signature |
| Strength | met | PRR 41, one of the largest cardiac signals associated with a psychiatric drug |
| Consistency | met | Replicated across national pharmacovigilance systems and registries |
| Specificity | partial | Rarely reported with most other antipsychotics, but not unique to clozapine |
| Biological gradient | partial | Not clearly dose-related — consistent with an idiosyncratic hypersensitivity reaction |
| Plausibility | partial | A hypersensitivity/cytokine mechanism is proposed but less precisely defined than for agranulocytosis |
| Coherence | met | Coheres with the early-monitoring requirement in the label |
| Experiment | partial | Stopping the drug when myocarditis is suspected improves outcomes; no randomized trial |
| Analogy | partial | Some analogy to drug-induced hypersensitivity myocarditis (e.g. with other drugs) |
This page's own qualitative read, not an automated/citation-gated assessment.
Venlafaxine (serotonergic antidepressants) ↔ Serotonin syndrome
Open this assessment on its own page →
Serotonin syndrome is a predictable, dose-related toxidrome — agitation, clonus, hyperthermia, autonomic instability — produced by excess central serotonergic activity, typically when a serotonergic drug is combined with another (an MAOI, tramadol, triptan, linezolid, lithium, or another antidepressant) or when doses are escalated. Venlafaxine is a potent serotonin-reuptake inhibitor at lower doses, and its risk rises if larger doses begin to add noradrenergic effects; like all serotonergic antidepressants, it carries a labeling warning about the syndrome and about combinations to avoid. The mechanism is about as well understood as any in psychopharmacology, which is why the diagnosis is made clinically and managed by stopping the offending agents rather than through trial data. The large PRR reflects the scale of antidepressant prescribing and the syndrome's seriousness.
Regulatory basis: venlafaxine/SSRI/SNRI class labeling (serotonin syndrome warning; MAOI and serotonergic-combination cautions). Established serotonin-syndrome literature (Hunter criteria).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset follows starting, escalating, or adding a serotonergic drug |
| Strength | met | PRR 24 with a large co-report count |
| Consistency | met | Reproduced across the whole serotonergic class and in the literature |
| Specificity | partial | A class-wide effect, not unique to venlafaxine |
| Biological gradient | met | Clearly dose-related and combination-related |
| Plausibility | met | Excess central serotonin is the established cause |
| Coherence | met | Coheres with the Hunter criteria and the class labeling |
| Experiment | met | Withdrawing the offending agents reliably resolves it — a consistent dechallenge |
| Analogy | met | Directly analogous across SSRIs, SNRIs, MAOIs, and tramadol |
This page's own qualitative read, not an automated/citation-gated assessment.
Citalopram ↔ QT prolongation
Open this assessment on its own page →
Citalopram produces a dose-dependent prolongation of the QT interval on the electrocardiogram, which in susceptible patients can progress to the dangerous ventricular arrhythmia torsades de pointes. The effect was confirmed by dedicated “thorough QT” studies, and in 2011–2012 the FDA issued a safety communication restricting the maximum dose (to 40 mg/day for adults, 20 mg/day for those over 60, and lower in hepatic impairment or with CYP2C19 inhibitors), with a similar action from European regulators. Notably, the closely related SSRI escitalopram carries a smaller effect, which is part of why citalopram is treated as the more QT-active of the two. This is a well-quantified, mechanism-based cardiac effect — not a reporting artifact — established through dedicated ECG trials rather than post-marketing impression.
Regulatory basis: FDA drug-safety communication on citalopram QT prolongation and maximum-dose restriction (2011–2012); EMA equivalent. Thorough-QT-study data.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | QT change appears with exposure and resolves after discontinuation |
| Strength | partial | PRR 8, moderate — a small ECG effect rather than a large event rate |
| Consistency | met | Reproduced in dedicated QT studies and confirmed by regulators |
| Specificity | partial | Shared to a lesser degree with other serotonergic and QT-active drugs |
| Biological gradient | met | Clearly dose-related — the basis for the maximum-dose restriction |
| Plausibility | met | hERG-channel blockade prolonging cardiac repolarization — a defined mechanism |
| Coherence | met | Coheres with the broader QT-prolongation pharmacology |
| Experiment | met | Dedicated thorough-QT trials and the dose restriction are direct experimental evidence |
| Analogy | met | Analogous to other QT-prolonging drugs (e.g. methadone, ondansetron) |
This page's own qualitative read, not an automated/citation-gated assessment.
Spironolactone ↔ Hyperkalaemia
Open this assessment on its own page →
Spironolactone is a mineralocorticoid-receptor antagonist, and potassium retention is not a side effect of the drug so much as a direct extension of how it works: blocking aldosterone in the distal nephron reduces potassium excretion. Hyperkalaemia is therefore an expected, dose-related pharmacological consequence, and it is the principal safety concern when spironolactone is combined with ACE inhibitors, ARBs, or potassium supplements, or used in patients with chronic kidney disease. The landmark RALES trial in severe heart failure showed a survival benefit but also a real increase in serious hyperkalaemia, and the later TOPCAT trial and clinical experience reinforced that potassium must be monitored. This is graded “expected pharmacological effect” rather than a surprise signal — the high count reflects how widely the drug is used rather than an unexpected mechanism.
Regulatory basis: spironolactone prescribing information (hyperkalaemia warning and monitoring). RALES (1999) and TOPCAT (2014) randomized trials.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Potassium rises during exposure and falls after withdrawal |
| Strength | met | PRR 25 on a large co-report count |
| Consistency | met | Seen consistently in trials (RALES, TOPCAT) and in practice |
| Specificity | met | Directly tied to the drug's aldosterone-blocking mechanism |
| Biological gradient | met | Dose-related and worse with renal impairment or added RAAS blockade |
| Plausibility | met | Reduced distal potassium excretion is the intended pharmacology, not an off-target effect |
| Coherence | met | Coheres with the whole mineralocorticoid-antagonist class |
| Experiment | met | Randomized trials (RALES, TOPCAT) with structured potassium monitoring directly address it |
| Analogy | met | Analogous to eplerenone and other potassium-sparing diuretics |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — spironolactone vs placebo in heart failure with preserved ejection fraction (TOPCAT, NCT00094302), N=3,445
| Term (as recorded) | Spironolactone (n=1,722) | Placebo (n=1,723) |
|---|---|---|
| HYPERKALEMIA — renal disorders (serious) | 20 | 5 |
| HYPERKALEMIA — renal disorders (all) | 226 | 96 |
Hyperkalaemia is roughly four times more common on spironolactone, on both serious and total events — direct randomized confirmation of the drug's expected potassium-retaining effect. This is what a genuinely expected pharmacological signal looks like when a trial measures it properly. View on ClinicalTrials.gov →
Hydrochlorothiazide (thiazides) ↔ Hyponatraemia
Open this assessment on its own page →
Thiazide diuretics are a leading cause of hyponatraemia, particularly in older women, and the effect is a fairly direct consequence of their pharmacology: they impair urinary dilution and, over time, can produce the syndrome of inappropriate antidiuresis. Onset is often within the first few weeks of therapy, and serum sodium usually returns to normal after the drug is stopped. The risk is dose-related and rises with age, low body weight, and use of interacting drugs (SSRIs, carbamazepine), which is why monitoring of electrolytes after starting or changing a thiazide is standard practice. Like spironolactone's potassium effect, this is graded “expected pharmacological effect” — a well-understood class action rather than an unexpected idiosyncratic signal.
Regulatory basis: hydrochlorothiazide/thiazide prescribing information (hyponatraemia and electrolyte-monitoring warnings). Established thiazide-induced hyponatraemia literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Sodium falls during exposure, often in the first weeks, and recovers after withdrawal |
| Strength | partial | PRR 8, moderate — common in absolute terms but a modest disproportionality |
| Consistency | met | Reproduced across thiazide agents and in the literature |
| Specificity | partial | Shared with loop diuretics and other causes of SIADH |
| Biological gradient | met | Dose-related and worse with age, low body weight, and interacting drugs |
| Plausibility | met | Impaired urinary dilution / SIADH is the established mechanism |
| Coherence | met | Coheres with the routine electrolyte monitoring after starting a thiazide |
| Experiment | met | Sodium normalizes on drug withdrawal — a reliable, reproducible dechallenge |
| Analogy | met | Analogous to other diuretic-induced electrolyte disturbances |
This page's own qualitative read, not an automated/citation-gated assessment.
Amoxicillin–clavulanate ↔ Cholestatic liver injury
Open this assessment on its own page →
Amoxicillin–clavulanate is consistently the single most common cause of drug-induced liver injury in Western registries, and the injury is characteristically cholestatic (jaundice and bile-duct enzyme elevation) rather than the hepatocellular pattern typical of many other drugs. It follows a distinctive delayed and sometimes biphasic course — often appearing 1–6 weeks after the course is finished — which makes the association easy to miss clinically. The clavulanate component is considered the culprit, independent of the amoxicillin. The reaction is the archetype of an idiosyncratic (not dose-related) drug reaction whose evidence came almost entirely from post-marketing surveillance and prospective DILI registries, which is exactly why the FAERS numbers here, though modest, are meaningful.
Regulatory basis: amoxicillin–clavulanate prescribing information (hepatic- injury warning). Prospective drug-induced liver injury registry data (e.g. DILIN).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset characteristically 1–6 weeks after the course, sometimes biphasic |
| Strength | met | PRR 24 for a relatively rare outcome |
| Consistency | met | Leading cause of DILI across independent prospective registries |
| Specificity | met | The cholestatic pattern is characteristic of this drug pair |
| Biological gradient | not established | Idiosyncratic — not clearly dose-related |
| Plausibility | partial | Attributed to clavulanate; a specific immune/metabolic mechanism is plausible but not fully mapped |
| Coherence | met | Coheres with the DILI-registry literature and the label warning |
| Experiment | partial | Rechallenge generally reproduces injury in case series; not an ethical randomized test |
| Analogy | met | Analogous to other idiosyncratic cholestatic drug reactions (e.g. flucloxacillin) |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — amoxicillin–clavulanate vs tigecycline for skin infections (NCT00368537), N=531
| Term (as recorded) | Amoxicillin–clavulanate / ampicillin–sulbactam (n=263) | Tigecycline (n=268) |
|---|---|---|
| Hepatic failure (serious) | 1 | 0 |
| Liver function tests abnormal (serious) | 1 | 0 |
Two hepatic events on the amoxicillin–clavulanate combination arm and none on the comparator, in a short antibiotic trial — directionally consistent, but far too few events to quantify a risk that is genuinely idiosyncratic and rare (and often delayed past the trial window). The association rests on prospective DILI registries, not trial AE tables. View on ClinicalTrials.gov →
Isoniazid ↔ Drug-induced liver injury
Open this assessment on its own page →
Isoniazid is one of the classic causes of drug-induced liver injury, and its hepatotoxicity is the reason that liver enzymes are monitored during tuberculosis treatment and preventive therapy. Two patterns are described: a common, mild, transient rise in transaminases that often resolves despite continued therapy, and a rare, severe hepatocellular injury that can progress to fulminant hepatic failure. Risk rises with age, alcohol use, and concomitant rifampicin, and age-based monitoring thresholds are built into the labeling and public-health guidance. Because isoniazid remains a cornerstone of TB treatment worldwide, the liver signal is not a reason to avoid the drug but a reason to monitor it — an important reminder that “well established” does not always mean “avoid.”
Regulatory basis: isoniazid prescribing information (hepatotoxicity warning and monitoring); TB-treatment guidelines with age-based LFT thresholds. Established isoniazid hepatotoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Enzyme rise typically occurs weeks into therapy |
| Strength | met | PRR 37 on a moderate co-report count |
| Consistency | met | Reproduced across decades of TB-therapy cohorts and trials |
| Specificity | partial | Shared with rifampicin and pyrazinamide in the same regimen |
| Biological gradient | met | Risk rises with age, alcohol, and co-administered rifampicin |
| Plausibility | met | Metabolism to a toxic hydrazine intermediate via NAT2/CYP2E1 is well described |
| Coherence | met | Coheres with the routine LFT monitoring built into TB care |
| Experiment | met | Randomized TB-prevention trials include structured hepatic-event reporting |
| Analogy | met | Analogous to other metabolically activated hepatotoxins (e.g. acetaminophen) |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — isoniazid-containing short-course vs standard TB-prevention regimens (BRIEF TB, NCT01404312), N=3,000
| Term (as recorded) | 4-month rifapentine+isoniazid (n=1,496) | 9-month isoniazid (n=1,504) |
|---|---|---|
| Drug-induced liver injury (serious) | 1 | 2 |
| Hepatitis / hepatotoxicity (serious) | 3 | 0 |
| Hepatic enzyme increased (serious) | 1 | 7 |
Hepatic events appear on both isoniazid-containing arms, with a distinct cluster of elevated liver enzymes on the 9-month isoniazid arm — direct randomized confirmation that the liver is the target organ for this drug, even in a large modern prevention trial. View on ClinicalTrials.gov →
Vancomycin ↔ Acute kidney injury
Open this assessment on its own page →
Vancomycin, a workhorse antibiotic for MRSA, is a recognized cause of acute kidney injury, and the risk is dose- and exposure-related — particularly with high trough levels and with concomitant piperacillin–tazobactam or other nephrotoxins. The label carries a nephrotoxicity warning and recommends monitoring of renal function, and modern practice uses area-under-the-curve dosing to reduce the risk. Because vancomycin is so widely used, this is one of the very few serious antibiotic reactions where a “more of the drug, more of the effect” exposure relationship can be demonstrated directly, making it a cleaner signal than many idiosyncratic reactions. The large FAERS count reflects both the true effect and the drug's enormous clinical volume.
Regulatory basis: vancomycin prescribing information (nephrotoxicity warning and renal monitoring). Randomized comparative antibiotic trials (e.g. telavancin vs vancomycin).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Creatinine rises during therapy and usually recovers on drug cessation |
| Strength | met | PRR 11 on a very large co-report count |
| Consistency | met | Reproduced across randomized trials and cohort studies |
| Specificity | partial | Common to several antimicrobials; worse with combined nephrotoxins |
| Biological gradient | met | Clearly linked to drug exposure/trough levels and to co-administered piperacillin–tazobactam |
| Plausibility | met | Proximal-tubular toxicity from oxidative stress is well described |
| Coherence | met | Coheres with the shift to AUC-based dosing and renal monitoring |
| Experiment | partial | Randomized trials report renal events but are not designed to quantify nephrotoxicity |
| Analogy | met | Analogous to aminoglycoside nephrotoxicity |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — telavancin vs vancomycin for complicated skin infections (NCT00107978), N=1,012
| Term (as recorded) | Vancomycin (n=509) | Telavancin (n=503) |
|---|---|---|
| Renal failure acute (serious) | 0 | 3 |
| Blood creatinine increased (serious) | 0 | 3 |
| Blood Creatinine Increased (non-serious) | 3 | 9 |
In this head-to-head trial the comparator (telavancin) showed the greater renal signal, not vancomycin — a useful reminder that vancomycin’s nephrotoxicity is real but modest at standard doses and clearly amplified by high exposure and co-nephrotoxins, which is the setting where most spontaneous reports arise. View on ClinicalTrials.gov →
Linezolid ↔ Thrombocytopenia
Open this assessment on its own page →
Linezolid, an oxazolidinone antibiotic for resistant Gram-positive infections, causes reversible myelosuppression — most often thrombocytopenia, but also anaemia and, less commonly, leukopenia. Risk is clearly duration-dependent: it rises sharply after about two weeks of therapy, which is why the label recommends weekly blood counts and cautious use beyond 14–28 days. The mechanism is a time-dependent suppression of bone-marrow precursor proliferation, distinct from the immune-mediated cytopenias of some other drugs. Because it is dose- and duration-related and recovers off-drug, it behaves more like a predictable toxic effect than an idiosyncratic one, making it one of the cleanest antibiotic haematologic signals. The large count reflects both the true effect and the drug's role as a last-line MRSA agent.
Regulatory basis: linezolid prescribing information (myelosuppression warning; weekly blood-count monitoring). Randomized comparative antibiotic trials (linezolid vs tedizolid).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Platelet count falls during therapy and recovers after it stops |
| Strength | met | PRR 14 on a moderate co-report count |
| Consistency | met | Reproduced across randomized trials and cohorts |
| Specificity | partial | Shared with other myelosuppressive and infectious causes of low platelets |
| Biological gradient | met | Sharply duration-dependent — the basis for the weekly-count guidance |
| Plausibility | met | Reversible suppression of bone-marrow precursors is well described |
| Coherence | met | Coheres with the label's monitoring requirement |
| Experiment | met | Randomized head-to-head trials with platelet endpoints confirm the signal |
| Analogy | met | Analogous to chloramphenicol-associated myelosuppression |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — linezolid vs tedizolid for hospital-acquired pneumonia (NCT02019420), N=718
| Term (as recorded) | Linezolid (n=361) | Tedizolid (n=357) |
|---|---|---|
| Thrombocytopenia (serious) | 5 | 0 |
Serious thrombocytopenia appears on the linezolid arm and not on the comparator — direct randomized evidence that even within a short treatment course, linezolid suppresses platelets more than a related newer agent. The duration-dependent escalation seen in practice is captured only partly by trials of this length. View on ClinicalTrials.gov →
Methimazole ↔ Agranulocytosis
Open this assessment on its own page →
The antithyroid drugs methimazole and propylthiouracil are classic causes of drug-induced agranulocytosis, a sudden loss of neutrophil granulocytes that leaves patients vulnerable to severe infection. It is the single most feared haematologic complication of treating hyperthyroidism, and it typically appears within the first weeks to months of therapy. Because it can be sudden, patients are counselled to seek urgent care for fever or sore throat — a classic “report immediately” symptom drill taught for this drug class. The reaction is idiosyncratic rather than dose-related, so it cannot be prevented by dose alone; the PRR here is very high for a rare event, and the modest absolute count reflects how uncommon agranulocytosis is even among treated patients.
Regulatory basis: methimazole and propylthiouracil prescribing information (agranulocytosis warning; fever/sore-throat counselling). Established antithyroid-drug agranulocytosis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Typically appears within weeks–months of starting the drug |
| Strength | met | PRR 38 for a rare, serious event |
| Consistency | met | A long-recognized class effect of antithyroid drugs |
| Specificity | met | Among the defining serious risks of methimazole and propylthiouracil |
| Biological gradient | not established | Idiosyncratic — not clearly dose-related |
| Plausibility | partial | An immune-mediated mechanism is accepted; the precise target is not fully mapped |
| Coherence | met | Coheres with the label warning and the fever/sore-throat counselling |
| Experiment | partial | Recovery on withdrawal and G-CSF support is consistent; no randomized test |
| Analogy | met | Analogous to clozapine- and sulfonamide-associated agranulocytosis |
This page's own qualitative read, not an automated/citation-gated assessment.
Topiramate ↔ Acute angle-closure glaucoma
Open this assessment on its own page →
Topiramate, used for epilepsy, migraine prevention, and weight management, has a distinctive and well-documented ocular toxicity: a secondary acute angle-closure glaucoma that develops within days to weeks of starting or increasing the dose. It is caused by drug-induced effusion into the ciliary body and lens, which pushes the iris forward and closes the angle — a mechanism quite different from primary angle-closure. The presentation mimics a neurological event (severe headache, eye pain, blurred vision), which is a recognised diagnostic trap, and it resolves when the drug is withdrawn. The FDA labeling carries a specific warning, and it is treated as a medical emergency because vision can be permanently lost if unrecognised. The very high PRR reflects how characteristic and unusual this reaction is.
Regulatory basis: topiramate prescribing information (secondary angle-closure glaucoma warning). Established topiramate-induced acute myopia/angle-closure literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Develops within days–weeks of starting or dose increase |
| Strength | met | PRR 69, one of the largest ocular signals on the page |
| Consistency | met | Replicated across case series and the prescribing information |
| Specificity | met | The secondary (ciliary-effusion) mechanism is characteristic of topiramate |
| Biological gradient | partial | More common at higher doses/rapid titration, but reported at standard doses |
| Plausibility | met | Ciliary-body effusion pushing the iris forward is a defined mechanism |
| Coherence | met | Coheres with the label warning and the classic secondary-closure picture |
| Experiment | met | Prompt drug withdrawal reliably reverses it — a consistent dechallenge |
| Analogy | met | Analogous to other sulfonamide-derived carbonic-anhydrase-inhibitor ocular effects |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — topiramate vs placebo (NCT01110434), N=66
| Term (as recorded) | Topiramate (n=40) | Placebo (n=26) |
|---|---|---|
| Changes in vision (non-serious, eye disorders) | 4 | 0 |
Visual symptoms cluster on the topiramate arm and not on placebo even in a very small trial, directionally consistent with the drug's ocular toxicity — though the specific term tracked here is generic visual change, not angle-closure, which is rare and usually diagnosed outside trial settings. View on ClinicalTrials.gov →
Hydroxychloroquine ↔ Retinopathy
Open this assessment on its own page →
Hydroxychloroquine, a mainstay of treatment for lupus and rheumatoid arthritis, can cause a cumulative-dose retinal toxicity that, if not caught, becomes irreversible and can progress even after the drug is stopped. The risk is driven by daily dose per kilogram of body weight and by duration of use, and ophthalmology has moved to annual screening with sensitive imaging (optical coherence tomography and visual fields) precisely because early changes are reversible while late damage is not. Age and kidney disease raise the risk, and standard thresholds for maximum daily dose and screening intervals are now embedded in professional guidelines and the labeling. This is a model example of a chronic, cumulative-dose-dependent toxicity where the “biological gradient” is central to how the drug is monitored.
Regulatory basis: hydroxychloroquine prescribing information (ocular toxicity warning). American Academy of Ophthalmology screening guidelines (dose and interval thresholds).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Damage accumulates over years of exposure |
| Strength | met | PRR 24 for a slowly developing, under-reported outcome |
| Consistency | met | Replicated across large rheumatology cohorts |
| Specificity | partial | Shared with the related drug chloroquine |
| Biological gradient | met | Strongly cumulative dose- and duration-dependent — the basis for screening thresholds |
| Plausibility | met | Drug accumulates in retinal pigment epithelium and causes characteristic photoreceptor loss |
| Coherence | met | Coheres with the AAO screening guidance |
| Experiment | partial | Early detection reverses the trend; no randomized exposure trial is feasible |
| Analogy | met | Analogous to chloroquine retinopathy (the historical index case) |
This page's own qualitative read, not an automated/citation-gated assessment.
Montelukast ↔ Neuropsychiatric events
Open this assessment on its own page →
Montelukast, widely prescribed for asthma and allergic rhinitis, causes a range of neuropsychiatric effects — sleep disturbance, nightmares, mood change, aggression, and rarely suicidal thinking. The signal accumulated for years through case reports, product complaints, and regulatory review, and in 2020 the FDA added a boxed warning and advised prescribers to reserve the drug for allergic rhinitis when other treatments are inadequate. The mechanism is debated — montelukast crosses the blood–brain barrier and blocks cysteinyl-leukotriene receptors in the brain — but the regulatory action and the consistency of the reports have made this a well-accepted class warning. Because the symptoms are common in the general population and in children, distinguishing a real drug effect from background rates is genuinely hard, which is exactly why the evidence rested on regulatory review rather than a single trial.
Regulatory basis: FDA boxed warning for montelukast neuropsychiatric events (2020), with revised prescribing advice. Large observational and reporting analyses of montelukast neuropsychiatric events.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Symptoms typically begin after starting and abate after stopping |
| Strength | met | PRR 27 on a large co-report count |
| Consistency | met | Reproduced across reporting systems, cohorts, and the regulatory review |
| Specificity | partial | Background rates of these common symptoms make specificity hard to establish |
| Biological gradient | partial | Not clearly dose-related, though timing often follows initiation |
| Plausibility | partial | CNS leukotriene-receptor blockade is plausible; the precise mechanism is debated |
| Coherence | met | Coheres with the boxed warning and the reporting-product-complaint history |
| Experiment | partial | Dechallenge (symptom resolution on stopping) is the main experimental support |
| Analogy | partial | Some analogy to other drugs with CNS behavioural effects in children |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — montelukast vs inhaled corticosteroids (NCT00394355), N=566
| Term (as recorded) | Montelukast (n=142) | Inhaled steroid arms (n=424) |
|---|---|---|
| Anxiety (serious) | 0 | 1 |
| Depression (serious) | 0 | 1 |
No neuropsychiatric events were recorded on the montelukast arm in this one-year asthma study — the honest counterpoint being that such trials were not designed or powered to detect the rare, subjective events that drove the boxed warning. The risk was established from regulatory review of reporting data, not from this kind of trial table. View on ClinicalTrials.gov →
Pembrolizumab (checkpoint inhibitors) ↔ Hypothyroidism
Open this assessment on its own page →
Immune-checkpoint inhibitors such as pembrolizumab work by unleashing the immune system against cancer, and a predictable consequence is that the same immune activation can attack healthy organs — so-called immune-related adverse events. Thyroid dysfunction is the single most common endocrine irAE: patients frequently develop an early, transient hyperthyroid phase (thyroiditis) followed by hypothyroidism requiring lifelong replacement. In the clinical trials this is usually called thyroid disorders. Because these events are frequent, mechanistically understood, and manageable with hormone replacement, the labeling and oncology guidelines require baseline and periodic thyroid-function testing during therapy; unlike many signals on this page, this one is routinely captured in trial data precisely because it is so common.
Regulatory basis: pembrolizumab prescribing information (immune-mediated thyroid disorders; monitoring guidance). Randomized trial results (e.g. KEYNOTE-010).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Thyroid changes appear during therapy, often an early hyperthyroid phase then hypothyroidism |
| Strength | met | PRR 20 with a large co-report count and high event rates in trials |
| Consistency | met | Reproduced across the whole checkpoint-inhibitor class and across trials |
| Specificity | met | A distinctive class effect of immune-checkpoint blockade, rare with most non-immunotherapy drugs |
| Biological gradient | partial | Broadly related to immune activation rather than to a simple dose gradient |
| Plausibility | met | Release of T-cell checkpoint restraint leads directly to organ-directed autoimmunity |
| Coherence | met | Coheres with the broader immune-related AE spectrum (colitis, pneumonitis, hypophysitis) |
| Experiment | met | Randomized trials (e.g. KEYNOTE-010) directly measure thyroid-event rates by arm |
| Analogy | met | Analogous across all PD-1/PD-L1 inhibitors |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — pembrolizumab (2 vs 10 mg/kg) vs docetaxel in NSCLC (KEYNOTE-010, NCT01905657), N=1,030
| Term (as recorded) | Pembrolizumab 2 mg/kg (n=339) | Pembrolizumab 10 mg/kg (n=343) | Docetaxel (n=309) |
|---|---|---|---|
| Hypothyroidism (non-serious) | 29 | 29 | 1 |
| Hyperthyroidism (non-serious) | 12 | 19 | 3 |
Thyroid events are roughly 30-fold more frequent on pembrolizumab than on chemotherapy in a randomized trial — one of the strongest trial-level confirmations on this page, reflecting how common and measurable immune-checkpoint thyroid toxicity is. The hyperthyroid-then-hypothyroid sequence typical of thyroiditis is visible in the combined counts. View on ClinicalTrials.gov →
Digoxin ↔ Bradycardia / AV block
Open this assessment on its own page →
Digoxin inhibits the sodium–potassium ATPase and raises vagal tone, so slowing of atrioventricular conduction is the direct, dose-related extension of its intended pharmacology rather than an idiosyncratic effect. Bradycardia and AV block cluster in older patients, in renal impairment (reduced digoxin clearance), and with electrolyte disturbance or interacting drugs such as amiodarone, verapamil, and beta-blockers. The 2,533 co-reports (PRR 14.7) reflect both a genuine effect and the very large population still taking a centuries-old drug.
Regulatory basis: digoxin prescribing information (bradycardia/AV block; therapeutic drug-level and ECG monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bradycardia appears during exposure and resolves on dose reduction or withdrawal |
| Strength | met | PRR 15 on a large co-report count for a drug whose whole mechanism slows conduction |
| Consistency | met | Reproduced across decades of use and in the prescribing literature |
| Specificity | partial | Shared with other AV-node-slowing drugs (beta-blockers, verapamil, amiodarone) |
| Biological gradient | met | Risk rises with dose, renal impairment, and electrolyte disturbance |
| Plausibility | met | Na/K-ATPase inhibition plus raised vagal tone directly slow the AV node |
| Coherence | met | Coheres with routine therapeutic drug-level monitoring for digoxin |
| Experiment | partial | Dechallenge (dose reduction or withdrawal) reliably reverses it; no dedicated randomized trial |
| Analogy | met | Analogous to bradycardia with other AV-nodal blocking agents |
This page's own qualitative read, not an automated/citation-gated assessment.
Hydralazine ↔ Drug-induced lupus
Open this assessment on its own page →
Hydralazine is the archetypal cause of drug-induced lupus erythematosus — arthralgia, myalgia, fever, and serositis with anti-histone antibodies, almost never involving the kidney. It is a genuine drug effect rather than unmasked idiopathic lupus, is related to dose and duration, is commoner in slow acetylators, and typically resolves after withdrawal. The 52 FAERS co-reports (PRR 11.8) are modest because the syndrome is uncommon and often managed without being reported, but the drug–event link is among the best established in drug-induced autoimmunity.
Regulatory basis: hydralazine prescribing information (drug-induced lupus warning); the classic anti-histone drug-induced-lupus literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Lupus features appear after weeks–months of hydralazine and remit after withdrawal |
| Strength | partial | PRR 12, but on a small co-report count — a modest statistical signal for a well-known effect |
| Consistency | met | Reproduced across decades of case series and reviews of drug-induced lupus |
| Specificity | met | A distinctive anti-histone-antibody syndrome, unlike idiopathic SLE |
| Biological gradient | met | Dose- and duration-related, and commoner in slow acetylators |
| Plausibility | met | Hydralazine's reactive metabolites are thought to trigger the anti-histone response |
| Coherence | met | Coheres with the routine practice of stopping the drug and watching symptoms resolve |
| Experiment | partial | Dechallenge (withdrawal) is the classic confirmatory test; no randomized trial |
| Analogy | met | Analogous to procainamide- and minocycline-induced lupus |
This page's own qualitative read, not an automated/citation-gated assessment.
Penicillamine ↔ Proteinuria / membranous nephropathy
Open this assessment on its own page →
Penicillamine, used in Wilson's disease, cystinuria, and historically in rheumatoid arthritis, is a well-recognised cause of membranous nephropathy presenting as proteinuria, sometimes progressing to nephrotic syndrome. The effect is dose-related, usually emerges after months of therapy, and frequently improves when the drug is stopped. The 65 FAERS co-reports (PRR 78.6) are dominated by proteinuria rather than overt nephrotic syndrome because routine urinalysis during penicillamine therapy catches it early; the mechanism is thought to involve immune-complex deposition in the glomerulus.
Regulatory basis: penicillamine prescribing information (proteinuria; routine urinalysis monitoring). Established penicillamine membranous-nephropathy literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Proteinuria develops after months of exposure and often improves after withdrawal |
| Strength | partial | PRR 79 on a small co-report count — a large relative signal on small absolute numbers |
| Consistency | met | Reproduced across decades of penicillamine-nephropathy case series |
| Specificity | met | Membranous nephropathy is a fairly distinctive drug-related pattern |
| Biological gradient | met | Dose-related; risk rises with higher cumulative exposure |
| Plausibility | met | Immune-complex deposition in the glomerulus is the proposed mechanism |
| Coherence | met | Coheres with routine urinalysis monitoring during penicillamine therapy |
| Experiment | partial | Dechallenge (withdrawal) frequently reduces proteinuria; no randomized trial |
| Analogy | met | Analogous to gold-salt-induced membranous nephropathy |
This page's own qualitative read, not an automated/citation-gated assessment.
Minoxidil (oral) ↔ Pericardial effusion
Open this assessment on its own page →
Oral minoxidil is a potent vasodilator reserved for refractory hypertension, and pericardial effusion is its signature serious adverse effect — seen particularly at higher doses and in patients with renal impairment. The mechanism is thought to involve fluid retention and reflex sympathetic activation, and the effusions can progress to tamponade, which is why the labelling advises caution and monitoring. Low-dose oral minoxidil is now used off-label for hair loss, but the FAERS signal (142 co-reports, PRR 2.9) largely reflects the older antihypertensive use.
Regulatory basis: minoxidil prescribing information (pericardial effusion/tamponade warning; caution in renal impairment).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Effusion appears during high-dose therapy and resolves after withdrawal |
| Strength | met | PRR 3 with a modest co-report count |
| Consistency | met | Reported since the 1970s across antihypertensive use |
| Specificity | partial | Fairly characteristic of minoxidil among vasodilators |
| Biological gradient | met | More frequent at higher doses and in renal impairment |
| Plausibility | met | Fluid retention and reflex sympathetic activation are the proposed mechanisms |
| Coherence | met | Coheres with the labelled caution and monitoring advice |
| Experiment | partial | Dechallenge (withdrawal) usually resolves it; no randomized trial |
| Analogy | met | Analogous to fluid-retention effects of other potent vasodilators |
This page's own qualitative read, not an automated/citation-gated assessment.
Propranolol (beta-blockers) ↔ Bradycardia / bronchospasm
Open this assessment on its own page →
Propranolol blocks cardiac beta-1 receptors and bronchial beta-2 receptors, so slowing the heart rate and provoking bronchospasm are direct, predictable consequences of its pharmacology rather than idiosyncratic reactions. Bradycardia is dose-related and amplified by other rate-slowing drugs; bronchospasm matters most in asthma and COPD. The 1,448 co-reports (PRR 8.2) reflect both the drug's genuine effects and how long and widely non-selective beta-blockers have been prescribed.
Regulatory basis: propranolol prescribing information (bradycardia, bronchospasm; contraindication in asthma).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Heart-rate slowing and wheeze occur during beta-blockade and reverse on withdrawal |
| Strength | met | PRR 8 on a large co-report count |
| Consistency | met | Reproduced across the whole beta-blocker class |
| Specificity | partial | Shared across non-selective beta-blockers, not unique to propranolol |
| Biological gradient | met | Dose-related and worse with other rate-slowing or negative-inotropic drugs |
| Plausibility | met | Beta-1 block slows the SA/AV nodes; beta-2 block constricts bronchi |
| Coherence | met | Coheres with the labelled contraindication in asthma and routine heart-rate checks |
| Experiment | partial | Dechallenge (withdrawal) reverses both effects; no randomized trial |
| Analogy | met | Analogous to bradycardia and bronchospasm with other non-selective beta-blockers |
This page's own qualitative read, not an automated/citation-gated assessment.
Heparin ↔ Heparin-induced thrombocytopenia (HIT)
Open this assessment on its own page →
Heparin-induced thrombocytopenia is a distinctive, immune-mediated reaction in which antibodies to the heparin–platelet-factor-4 complex activate platelets, causing a falling platelet count that paradoxically predisposes to thrombosis. It is a genuine drug-specific effect, typically appears 5–10 days after starting heparin, and requires immediate discontinuation and a non-heparin anticoagulant. The very high PRR (533.2) reflects that the term itself is essentially heparin-specific, so it reports back to heparin almost by definition.
Regulatory basis: heparin prescribing information (HIT warning; platelet monitoring). Established HIT immunoassay literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Falling platelets appear 5–10 days into exposure and recover after heparin is stopped |
| Strength | met | Very high PRR, but partly because the coded term is heparin-specific by name |
| Consistency | met | Reproduced across unfractionated and low-molecular-weight heparins |
| Specificity | met | Distinctive antibody-mediated syndrome tied to the drug–PF4 complex |
| Biological gradient | partial | Risk varies with heparin type, duration, and patient group; not a simple dose gradient |
| Plausibility | met | Anti-PF4 antibody-mediated platelet activation is the defined mechanism |
| Coherence | met | Coheres with routine platelet-count monitoring during heparin therapy |
| Experiment | partial | Consistent with controlled studies of switching to non-heparin anticoagulants |
| Analogy | met | Analogous to HIT-type reactions with other heparinoid anticoagulants |
This page's own qualitative read, not an automated/citation-gated assessment.
Dabigatran ↔ Gastrointestinal bleeding
Open this assessment on its own page →
Dabigatran is a direct oral thrombin inhibitor, so bleeding — especially from the gut — is the expected hazard of any effective anticoagulant, and dabigatran's particular propensity for gastrointestinal bleeding relative to warfarin is well documented. Because a large fraction of the drug remains in the gut with its tartaric-acid excipient, the risk is partly local as well as systemic. The 8,281 co-reports (PRR 29.6) reflect the enormous population on oral anticoagulants and the severity of bleeding that drives reporting.
Regulatory basis: dabigatran prescribing information (bleeding warning); RE-LY randomized trial versus warfarin.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding occurs during anticoagulation and is managed by stopping the drug |
| Strength | met | PRR 30 on a very large co-report count |
| Consistency | met | Reproduced in the randomized RE-LY trial and in real-world cohorts |
| Specificity | partial | An anticoagulant-class effect, with dabigatran's GI rate above warfarin in some analyses |
| Biological gradient | partial | Risk rises with dose, renal impairment, age, and interacting drugs |
| Plausibility | met | Blocking thrombin impairs haemostasis — bleeding is the pharmacodynamic extension |
| Coherence | met | Coheres with the bleeding-focused labelling and monitoring |
| Experiment | met | Randomized evidence (RE-LY) and co-therapy studies directly quantify the risk |
| Analogy | met | Analogous to bleeding with warfarin, rivaroxaban, and apixaban |
This page's own qualitative read, not an automated/citation-gated assessment.
Rivaroxaban ↔ Gastrointestinal bleeding
Open this assessment on its own page →
Rivaroxaban is a direct factor Xa inhibitor, so bleeding is the expected hazard of its intended anticoagulant effect, and its gastrointestinal bleeding rate is at least as high as warfarin's in the major randomized trials. The high FAERS count (21,636 co-reports, PRR 34.9) reflects the drug's very large real-world population and the severity that drives reporting. As with all anticoagulants, the signal is a pharmacodynamic extension of the mechanism rather than an off-target surprise.
Regulatory basis: rivaroxaban prescribing information (bleeding warning); ROCKET-AF randomized trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding occurs during anticoagulation and typically stops after the drug is withdrawn |
| Strength | met | PRR 35 on one of the largest co-report counts on this page |
| Consistency | met | Reproduced in randomized outcome trials and in real-world cohorts |
| Specificity | partial | An anticoagulant-class effect rather than rivaroxaban-specific |
| Biological gradient | partial | Risk rises with dose, renal impairment, age, and interacting drugs |
| Plausibility | met | Factor Xa inhibition impairs haemostasis — bleeding is the pharmacodynamic extension |
| Coherence | met | Coheres with the bleeding-focused labelling and monitoring |
| Experiment | met | Randomized evidence (ROCKET-AF) and cohort studies directly quantify the risk |
| Analogy | met | Analogous to bleeding with warfarin, apixaban, and dabigatran |
This page's own qualitative read, not an automated/citation-gated assessment.
Trimethoprim (and co-trimoxazole) ↔ Hyperkalaemia
Open this assessment on its own page →
Trimethoprim blocks the epithelial sodium channel in the distal nephron in a way that resembles the potassium-sparing diuretics amiloride and triamterene, so it reduces urinary potassium excretion and can raise serum potassium — an effect that is easy to overlook because trimethoprim is prescribed mainly as an antibiotic. The risk is greatest at higher doses, in older patients, in renal impairment, and with coexisting ACE inhibitors, ARBs, or spironolactone. The 213 co-reports (PRR 11.0) reflect both a genuine effect and the drug's very wide short-course use.
Regulatory basis: trimethoprim/co-trimoxazole prescribing information (hyperkalaemia caution, especially with RAAS blockade).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Potassium rises during treatment and falls after withdrawal |
| Strength | met | PRR 11 on a modest co-report count |
| Consistency | met | Reproduced in controlled studies and cohort data, notably in older patients on RAAS blockade |
| Specificity | met | A fairly distinctive effect of trimethoprim among antibacterials |
| Biological gradient | met | Dose-related and worse with renal impairment, age, and RAAS-blocking drugs |
| Plausibility | met | Distal-nephron sodium-channel blockade mimics potassium-sparing diuretics |
| Coherence | met | Coheres with the labelled hyperkalaemia caution and electrolyte monitoring |
| Experiment | partial | Controlled studies of co-trimoxazole versus other antibiotics support it; no large dedicated RCT |
| Analogy | met | Analogous to amiloride/triamterene potassium retention |
This page's own qualitative read, not an automated/citation-gated assessment.
Doxycycline (tetracyclines) ↔ Photosensitivity reaction
Open this assessment on its own page →
Doxycycline is one of the most phototoxic antibiotics: it accumulates in the skin, absorbs ultraviolet light, and produces an exaggerated sunburn-like reaction on exposed areas. It is a genuine, well-characterised chemical phototoxicity rather than an allergy, and it is common enough that sunscreen and sun-avoidance counselling is standard when the drug is prescribed. The 427 co-reports (PRR 8.2) reflect both the real effect and doxycycline's very wide use for acne, tick-borne infections, and malaria prophylaxis.
Regulatory basis: doxycycline prescribing information (photosensitivity warning; sun-protection advice). Established tetracycline phototoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | The reaction appears during sun exposure while taking the drug and settles after withdrawal |
| Strength | partial | PRR 8 with a moderate co-report count |
| Consistency | met | Reproduced across tetracyclines and in dermatology practice |
| Specificity | met | Drug-induced phototoxicity has a characteristic photodistributed pattern |
| Biological gradient | partial | Broadly dose- and exposure-related (drug dose and UV exposure) |
| Plausibility | met | Ultraviolet absorption by the drug in the skin is the defined mechanism |
| Coherence | met | Coheres with the routine sun-protection counselling given with doxycycline |
| Experiment | partial | Dechallenge (withdrawal plus sun avoidance) resolves it; no randomized trial |
| Analogy | met | Analogous to phototoxicity with other tetracyclines and some other drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Minocycline ↔ Skin hyperpigmentation
Open this assessment on its own page →
Minocycline is the tetracycline best known for causing pigmentation of the skin, nails, sclera, and — rarely — internal organs, a distinctive effect not shared to the same degree by other tetracyclines. It is dose- and duration-related, appears after months of therapy, and typically fades slowly after withdrawal (though scleral and deep pigmentation can persist). The 188 co-reports (PRR 40.6) reflect the drug's long-term use in acne, where cumulative exposure is high, and the very visible nature of the change.
Regulatory basis: minocycline prescribing information (cutaneous and other hyperpigmentation warning). Established minocycline-pigmentation literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Pigmentation develops after months of exposure and slowly fades after withdrawal |
| Strength | met | PRR 40 on a modest co-report count |
| Consistency | met | Reproduced across decades of acne-treatment case series |
| Specificity | met | A distinctive minocycline effect, unlike other tetracyclines |
| Biological gradient | partial | Cumulative-dose-related; higher the longer the drug is taken |
| Plausibility | met | Likely melanin–drug complex deposition and iron deposition in the dermis |
| Coherence | met | Coheres with the labelled hyperpigmentation warnings and periodic skin review |
| Experiment | partial | Dechallenge (withdrawal) usually leads to slow improvement; no randomized trial |
| Analogy | met | Analogous to but more prominent than other drug-induced hyperpigmentation |
This page's own qualitative read, not an automated/citation-gated assessment.
Nitrofurantoin ↔ Pulmonary fibrosis / interstitial lung disease
Open this assessment on its own page →
Nitrofurantoin can produce an acute pneumonitis and, with prolonged use, a chronic interstitial lung disease that may progress to pulmonary fibrosis — a rare but well-recognised and potentially irreversible toxicity of a drug otherwise regarded as safe and reserved for uncomplicated urinary infection. The chronic form is related to cumulative duration of therapy, which is why long-term prophylaxis is discouraged and lung function is monitored. The 147 co-reports (PRR 9.9) reflect both the true effect and the difficulty of attributing chronic fibrosis to a drug that is often used intermittently.
Regulatory basis: nitrofurantoin prescribing information (acute and chronic pulmonary reactions, including fibrosis). Established nitrofurantoin lung-toxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Chronic lung changes develop after months–years of exposure; acute pneumonitis after days |
| Strength | partial | PRR 10 on a modest co-report count |
| Consistency | met | Reproduced across decades of nitrofurantoin pulmonary-toxicity case series |
| Specificity | met | A recognised drug cause of chronic interstitial lung disease |
| Biological gradient | partial | Cumulative-duration-related for the chronic form |
| Plausibility | met | Repeated oxidant injury and immune reaction in the lung are the proposed mechanisms |
| Coherence | met | Coheres with the labelled pulmonary warnings and periodic lung review |
| Experiment | partial | Dechallenge (withdrawal) may halt or partially reverse it; no randomized trial |
| Analogy | met | Analogous to pulmonary fibrosis from other drugs (amiodarone, methotrexate, bleomycin) |
This page's own qualitative read, not an automated/citation-gated assessment.
Levofloxacin (fluoroquinolones) ↔ Aortic aneurysm / dissection
Open this assessment on its own page →
Fluoroquinolones such as levofloxacin are associated with an increased risk of aortic aneurysm and dissection, thought to reflect their effects on collagen and matrix metalloproteinases in the vessel wall. This is a genuinely new safety concern: after observational studies and label reviews, the FDA added a class warning in 2018 and advises avoiding fluoroquinolones in patients at high risk (those with prior aneurysm, hypertension, or connective-tissue disease). The 113 co-reports (PRR 5.2) are relatively small because aortic events are uncommon, but the regulatory basis is now explicit.
Regulatory basis: FDA 2018 class warning on fluoroquinolones and aortic aneurysm/dissection; levofloxacin prescribing information.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Aortic events occur in patients exposed to the drug, with observational studies linking current use to risk |
| Strength | partial | PRR 5 on a small co-report count — a modest statistical signal for a serious outcome |
| Consistency | met | Supported by multiple large observational cohort studies and a class label change |
| Specificity | met | A fluoroquinolone-class effect rather than levofloxacin-specific |
| Biological gradient | partial | Risk rises with age, hypertension, and connective-tissue disease |
| Plausibility | met | Collagen degradation and matrix-metalloproteinase effects in the vessel wall are proposed |
| Coherence | met | Coheres with the current class warning to avoid the drugs in high-risk patients |
| Experiment | partial | Observational; no randomized trial has tested aortic outcomes |
| Analogy | met | Analogous to the aortic risk across the fluoroquinolone class |
This page's own qualitative read, not an automated/citation-gated assessment.
Azithromycin (macrolides) ↔ QT prolongation / torsades
Open this assessment on its own page →
Macrolide antibiotics, including azithromycin, can prolong the cardiac QT interval and, rarely, provoke the dangerous ventricular arrhythmia torsades de pointes — hence the class carries warnings, and the FDA has cautioned about azithromycin in patients already at risk. The risk is amplified by other QT-prolonging drugs, by hypokalaemia or hypomagnesaemia, and in patients with structural heart disease. The 522 co-reports (PRR 7.7) reflect both the genuine effect and how very widely azithromycin is prescribed.
Regulatory basis: azithromycin prescribing information and FDA safety communication on QT prolongation; macrolide class labelling.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | QT prolongation is measured during therapy and resolves after withdrawal |
| Strength | partial | PRR 8 on a moderate co-report count |
| Consistency | met | Reproduced across macrolides and in observational cardiac-arrest data |
| Specificity | partial | A macrolide-class effect shared with clarithromycin and erythromycin |
| Biological gradient | partial | Worse with dose, electrolyte disturbance, and other QT-prolonging drugs |
| Plausibility | met | Direct hERG-channel blockade delays cardiac repolarisation |
| Coherence | met | Coheres with the class labelling and caution in at-risk patients |
| Experiment | partial | Observational (notably the azithromycin cardiac-death study); no randomized arrhythmia RCT |
| Analogy | met | Analogous to QT risk with other macrolides and non-antibiotics that block hERG |
This page's own qualitative read, not an automated/citation-gated assessment.
Clindamycin ↔ Clostridioides difficile colitis
Open this assessment on its own page →
Clindamycin is the antibiotic most closely linked with Clostridioides difficile infection: by disrupting the normal gut flora it allows this spore-forming bacterium to overgrow and produce a toxin-mediated colitis. It is a genuine, well-understood consequence of antibiotic exposure rather than an idiosyncratic drug reaction, and it can range from mild diarrhoea to life-threatening pseudomembranous colitis. The 409 co-reports (PRR 14.3) reflect both the real association and the breadth of antibiotic prescribing.
Regulatory basis: clindamycin prescribing information (C. difficile-associated diarrhoea and colitis warning). Established antibiotic-associated colitis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Colitis typically follows antibiotic exposure by days–weeks and responds to stopping the drug |
| Strength | met | PRR 18 on a moderate co-report count |
| Consistency | met | Reproduced across antibiotic classes but historically strongest for clindamycin |
| Specificity | met | Antibiotic-associated colitis is a recognised syndrome, though several antibiotics can cause it |
| Biological gradient | partial | Risk broadly rises with longer or broader antibiotic courses |
| Plausibility | met | Disruption of gut flora permits C. difficile overgrowth and toxin production |
| Coherence | met | Coheres with the standard warning and the advice to test and treat |
| Experiment | partial | Dechallenge (stopping the drug) with appropriate treatment usually resolves it; no randomized trial |
| Analogy | met | Analogous to C. difficile colitis from other broad-spectrum antibiotics |
This page's own qualitative read, not an automated/citation-gated assessment.
Metronidazole ↔ Peripheral neuropathy
Open this assessment on its own page →
Metronidazole can cause a dose- and duration-dependent peripheral neuropathy, typically a painful sensory disturbance of the feet that becomes more likely with prolonged courses or high cumulative doses. It is a genuine drug effect, resolves slowly after withdrawal in many patients, and is the reason long-term metronidazole therapy is closely watched. The 899 co-reports (PRR 3.2) reflect both the real association and metronidazole's very wide use across infection, dental, and gut indications.
Regulatory basis: metronidazole prescribing information (peripheral neuropathy warning, especially with prolonged therapy). Established metronidazole-neuropathy literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Neuropathy emerges during prolonged therapy and often improves slowly after withdrawal |
| Strength | partial | PRR 3 with a large co-report count — a modest but broad signal |
| Consistency | met | Reproduced across decades of metronidazole case series |
| Specificity | met | A recognised drug cause of peripheral neuropathy |
| Biological gradient | met | Cumulative-dose- and duration-related |
| Plausibility | met | Likely axonal injury from the drug's neurotoxic metabolites |
| Coherence | met | Coheres with the labelled warning and the practice of limiting long courses |
| Experiment | partial | Dechallenge (withdrawal) usually improves symptoms, though recovery can be slow; no randomized trial |
| Analogy | met | Analogous to neuropathy from other drugs (isoniazid, nitrofurantoin, chemotherapy) |
This page's own qualitative read, not an automated/citation-gated assessment.
Gentamicin (aminoglycosides) ↔ Ototoxicity (hearing/balance)
Open this assessment on its own page →
Aminoglycosides such as gentamicin damage the hair cells of the inner ear, producing hearing loss and vestibular (balance) disturbance that can be permanent. The toxicity is dose- and duration-related, is worsened by other ototoxic drugs (loop diuretics, vancomycin) and by renal impairment (which raises drug levels), and is the reason aminoglycoside courses are kept short and, where possible, guided by drug-level monitoring. The 94 co-reports (PRR 86.1) reflect a genuine and serious effect of a drug still widely used for serious infections.
Regulatory basis: gentamicin prescribing information (ototoxicity and nephrotoxicity warnings; therapeutic drug monitoring). Established aminoglycoside-ototoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hearing/balance damage occurs during exposure and may be irreversible |
| Strength | met | PRR 86 on a modest co-report count — a strong relative signal |
| Consistency | met | Reproduced across the aminoglycoside class and in audiology studies |
| Specificity | met | A classic aminoglycoside toxicity, though other drugs can also damage the ear |
| Biological gradient | met | Risk rises with dose, duration, renal impairment, and other ototoxic drugs |
| Plausibility | met | Inner-ear hair-cell damage by the aminoglycoside is the defined mechanism |
| Coherence | met | Coheres with the labelled monitoring and short-course practice |
| Experiment | partial | Dechallenge (withdrawal) limits further loss but does not reverse it; no randomized trial |
| Analogy | met | Analogous to ototoxicity with other aminoglycosides and loop diuretics |
This page's own qualitative read, not an automated/citation-gated assessment.
Daptomycin ↔ Myopathy / rhabdomyolysis
Open this assessment on its own page →
Daptomycin, a lipopeptide antibiotic used for resistant Gram-positive infections, can injure skeletal muscle, producing rises in creatine kinase that occasionally progress to rhabdomyolysis. Because of this, the labelling recommends checking creatine kinase at baseline and periodically during therapy, and stopping the drug if levels rise significantly. The effect is dose-related and can be worsened by statin co-therapy. The 370 co-reports (PRR 20.5) reflect a genuine, monitorable toxicity.
Regulatory basis: daptomycin prescribing information (myopathy and creatine-kinase monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Muscle injury appears during therapy and resolves after the drug is stopped |
| Strength | met | PRR 20 on a moderate co-report count, with a parallel CK-increase signal |
| Consistency | met | Reproduced in trials that measured creatine kinase |
| Specificity | met | A recognised daptomycin toxicity, less typical of other antibiotics |
| Biological gradient | partial | Dose-related and worse with statin co-therapy |
| Plausibility | met | Direct injury to skeletal muscle is the proposed mechanism |
| Coherence | met | Coheres with the labelled CK-monitoring recommendation |
| Experiment | met | A randomized registration trial recorded CK rises only on daptomycin |
| Analogy | met | Analogous to myopathy from statins and other myotoxic drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — China Registration Study in Patients With Skin Infections (NCT00772447), N=264
| Term (as recorded) | Daptomycin (n=131) | Vancomycin, or Vancomycin Switch to Cloxacillin (n=133) |
|---|---|---|
| Blood Creatine Phosphokinase Increased — Investigations | 4 | 0 |
Rises in creatine kinase were recorded only on daptomycin (4 of 131 patients) and in none of the vancomycin-treated patients in this randomized registration trial — direct trial-level support for the muscle-injury signal that prompts routine CK monitoring during daptomycin therapy. View on ClinicalTrials.gov →
Fluconazole ↔ QT prolongation / torsades
Open this assessment on its own page →
Fluconazole, an azole antifungal, prolongs the cardiac QT interval and carries a labelled warning, with rare reports of torsades de pointes, particularly at high doses and in patients already taking other QT-prolonging drugs. The effect is dose-related and is a genuine, mechanistically plausible cardiac toxicity rather than an idiosyncratic reaction. The 568 co-reports (PRR 4.8) reflect both the real effect and the drug's very wide use for common fungal infections.
Regulatory basis: fluconazole prescribing information (QT prolongation warning; caution with other QT-prolonging drugs).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | QT prolongation is measured during therapy and resolves after withdrawal |
| Strength | partial | PRR 5 on a moderate co-report count |
| Consistency | met | Reproduced in ECG studies and case reports of torsades |
| Specificity | partial | A recognised azole effect, strongest for fluconazole |
| Biological gradient | partial | Dose-related and worse with other QT-prolonging drugs |
| Plausibility | met | hERG-channel blockade delays cardiac repolarisation |
| Coherence | met | Coheres with the labelled QT warning and drug-interaction cautions |
| Experiment | partial | Supported by ECG-based studies; no randomized arrhythmia RCT |
| Analogy | met | Analogous to QT risk with other azoles and QT-prolonging drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Ketoconazole (oral) ↔ Hepatotoxicity
Open this assessment on its own page →
Oral ketoconazole can cause serious liver injury, ranging from asymptomatic transaminase rises to fatal hepatitis, which is why it was withdrawn from the market for oral use in the EU in 2013 and is now largely restricted to topical application. The injury is idiosyncratic rather than simply dose-related, can occur at any point during treatment, and is the reason liver function was monitored during the drug's oral era. The 64 co-reports (PRR 3.5) reflect a genuine, historically significant hepatotoxicity.
Regulatory basis: oral ketoconazole withdrawal in the EU (2013) and FDA restrictions (2013) over hepatotoxicity; ketoconazole prescribing information.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Liver injury occurs during therapy and generally improves after withdrawal |
| Strength | partial | PRR 4 on a small co-report count — a modest statistical signal |
| Consistency | met | Reproduced across decades of case reports and reviews |
| Specificity | met | A recognised idiosyncratic drug-induced liver injury |
| Biological gradient | met | Not clearly dose-related; idiosyncratic |
| Plausibility | met | Metabolic and immune-mediated liver injury are proposed mechanisms |
| Coherence | met | Coheres with the market withdrawal and current restrictions |
| Experiment | partial | Dechallenge (withdrawal) usually improves liver tests; no randomized trial |
| Analogy | met | Analogous to hepatotoxicity from other azoles and drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Itraconazole ↔ Heart failure
Open this assessment on its own page →
Itraconazole carries a labelled warning of negative inotropic effects and heart failure, particularly in patients with underlying ventricular dysfunction, and the FDA has advised caution and dose limits. The effect reflects the drug's ability to depress cardiac contractility, and it resolves on withdrawal in most cases. The 153 co-reports (PRR 3.4) are modest because heart failure is uncommon with itraconazole and the drug is used for narrower indications than fluconazole.
Regulatory basis: FDA/itraconazole prescribing information (heart failure warning; caution in ventricular dysfunction).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Heart failure develops during therapy and often improves after withdrawal |
| Strength | partial | PRR 3 on a modest co-report count |
| Consistency | met | Supported by post-marketing reports and the labelled warning |
| Specificity | met | A recognised itraconazole effect, tied to negative inotropy |
| Biological gradient | partial | More likely at higher doses and in patients with existing cardiac impairment |
| Plausibility | met | Direct negative inotropic action on the myocardium is the proposed mechanism |
| Coherence | met | Coheres with the labelled caution in heart failure and dose limits |
| Experiment | partial | Dechallenge (withdrawal) usually improves symptoms; no randomized trial |
| Analogy | met | Analogous to cardiac depression by other negative-inotropic drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Terbinafine ↔ Taste disturbance (ageusia/dysgeusia)
Open this assessment on its own page →
Terbinafine commonly disturbs the sense of taste, most famously causing loss of taste (ageusia) or altered taste (dysgeusia) that can impair appetite and quality of life. The effect typically appears weeks into therapy and usually recovers slowly after the drug is stopped. It is a genuine, well-recognised drug effect rather than an idiosyncratic one-off. The 273 co-reports (PRR 32.5) reflect both the real effect and terbinafine's wide use for fungal nail and skin infections.
Regulatory basis: terbinafine prescribing information (taste disturbance, including loss of taste). Established terbinafine-dysgeusia literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Taste disturbance appears weeks into therapy and usually recovers after withdrawal |
| Strength | met | PRR 32 on a modest co-report count |
| Consistency | met | Reproduced across case series and in trial data |
| Specificity | met | A characteristic terbinafine effect among antifungals |
| Biological gradient | partial | Broadly dose- and duration-related |
| Plausibility | met | Likely effect on taste-bud or nerve function is proposed |
| Coherence | met | Coheres with the labelled taste-disturbance warning |
| Experiment | met | A randomized trial recorded ageusia only in the terbinafine arm |
| Analogy | met | Analogous to taste disturbance from certain other drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) (NCT00491764), N=216
| Term (as recorded) | Posaconazole 100 mg QD for 24 Weeks (n=36) | Posaconazole 200 mg QD for 24 Weeks (n=37) | Posaconazole 400 mg QD for 24 Weeks (n=36) | Posaconazole 400 mg QD for 12 Weeks (n=36) | Terbinafine 250 mg QD for 12 Weeks (n=36) | Placebo for 24 Weeks (n=35) |
|---|---|---|---|---|---|---|
| AGEUSIA — Nervous system disorders | 0 | 0 | 0 | 0 | 2 | 0 |
Ageusia (loss of taste) was recorded only in the terbinafine arm (2 of 36 patients) and in none of the four posaconazole arms or placebo — a small but arm-specific confirmation of terbinafine's well-known taste-disturbance signal. View on ClinicalTrials.gov →
Acyclovir ↔ Acute kidney injury
Open this assessment on its own page →
Acyclovir can cause acute kidney injury, typically through crystallisation of the drug in the renal tubules, especially after rapid intravenous infusion, at high doses, in dehydrated patients, or with pre-existing kidney disease. The injury is usually reversible if the drug is stopped and hydration is maintained, and the risk is reduced by giving the drug slowly with adequate fluids. The 2,499 co-reports (PRR 3.1) reflect both the real effect and acyclovir's enormous use as a well-tolerated antiviral.
Regulatory basis: acyclovir prescribing information (renal impairment warning; slow infusion and hydration advice). Established acyclovir-nephrotoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Kidney injury appears during or shortly after infusion and usually recovers after withdrawal |
| Strength | partial | PRR 3 with a large co-report count — a modest but broad signal |
| Consistency | met | Reproduced across case series and reviews |
| Specificity | met | A recognised acyclovir toxicity, less typical of other antivirals |
| Biological gradient | met | Dose-, infusion-rate-, and hydration-related |
| Plausibility | met | Drug crystallisation in renal tubules is the defined mechanism |
| Coherence | met | Coheres with the labelled infusion-rate and hydration advice |
| Experiment | partial | Dechallenge (withdrawal plus hydration) usually reverses it; no randomized trial |
| Analogy | met | Analogous to nephrotoxicity from other crystallising or nephrotoxic drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Ganciclovir ↔ Neutropenia / bone-marrow suppression
Open this assessment on its own page →
Ganciclovir is a nucleoside analogue that suppresses bone-marrow production, producing neutropenia, thrombocytopenia, and anaemia — a predictable, dose-limiting toxicity that follows directly from its mechanism of inhibiting DNA synthesis in dividing cells. Because of this, complete blood counts are monitored regularly during therapy, and the drug is used cautiously alongside other myelosuppressive agents. The 531 co-reports (PRR 8.1) reflect both the real effect and the drug's use in immunocompromised patients who are already cytopenic.
Regulatory basis: ganciclovir prescribing information (severe haematologic toxicity; routine blood-count monitoring). Established ganciclovir-myelosuppression literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Falling blood counts appear during therapy and improve when the drug is reduced or stopped |
| Strength | met | PRR 8 on a moderate co-report count |
| Consistency | met | Reproduced consistently in trials and in practice |
| Specificity | met | Marrow suppression is a recognised ganciclovir effect, though other antivirals can also cause it |
| Biological gradient | met | Dose-related and worse with other myelosuppressive drugs |
| Plausibility | met | Inhibition of DNA synthesis in proliferating marrow cells is the mechanism |
| Coherence | met | Coheres with the labelled monitoring and dose-reduction guidance |
| Experiment | met | Randomized trials measured cytopenias by arm |
| Analogy | met | Analogous to myelosuppression from other nucleoside analogues (zidovudine, acyclovir at high dose) |
This page's own qualitative read, not an automated/citation-gated assessment.
Amphotericin B ↔ Hypokalaemia / electrolyte wasting
Open this assessment on its own page →
Amphotericin B is a mainstay treatment for serious fungal infections but is limited by dose-dependent kidney toxicity, of which potassium and magnesium wasting with hypokalaemia is a familiar part. The drug damages the distal tubule, and the electrolyte loss can be severe enough to require replacement and to predispose to arrhythmias. The 288 co-reports (PRR 10.6) reflect both the real effect and the seriousness of the infections for which the drug is used.
Regulatory basis: amphotericin B prescribing information (nephrotoxicity and electrolyte-wasting warnings; electrolyte monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Potassium falls during therapy and is corrected with replacement and dose adjustment |
| Strength | met | PRR 11 on a modest co-report count |
| Consistency | met | Reproduced across the amphotericin literature |
| Specificity | met | A recognised amphotericin effect tied to its renal toxicity |
| Biological gradient | met | Dose-related |
| Plausibility | met | Distal-tubular injury causing potassium and magnesium loss is the mechanism |
| Coherence | met | Coheres with the labelled electrolyte-monitoring advice |
| Experiment | met | Controlled studies of amphotericin formulations measured electrolyte changes |
| Analogy | met | Analogous to electrolyte wasting from other nephrotoxic drugs (aminoglycosides, cisplatin) |
This page's own qualitative read, not an automated/citation-gated assessment.
Dapsone ↔ Methaemoglobinaemia / haemolysis
Open this assessment on its own page →
Dapsone, used for leprosy, dermatitis herpetiformis, and some opportunistic infections, oxidises haemoglobin to methaemoglobin and can also cause haemolytic anaemia, particularly in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Methaemoglobinaemia produces cyanosis and breathlessness with a normal oxygen level on the monitor — a signature that is easy to misread — and reverses with methylene blue. The 480 co-reports (PRR 522.3) reflect both the real effect and the drug's narrower, mostly dermatology and infectious-disease use.
Regulatory basis: dapsone prescribing information (methaemoglobinaemia and haemolysis warnings; G6PD screening). Established dapsone-oxidative-haemolysis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Methaemoglobinaemia develops during therapy and reverses with methylene blue and withdrawal |
| Strength | met | Very high PRR, on a modest co-report count |
| Consistency | met | Reproduced across the dapsone literature |
| Specificity | met | A distinctive oxidative consequence of dapsone, unlike most drugs |
| Biological gradient | partial | Dose-related and much worse in G6PD deficiency |
| Plausibility | met | Direct oxidation of haemoglobin iron and oxidative red-cell injury are the mechanisms |
| Coherence | met | Coheres with the labelled warnings and G6PD screening |
| Experiment | partial | Dechallenge (withdrawal) plus methylene blue reverses it; no randomized trial |
| Analogy | met | Analogous to methaemoglobinaemia from other oxidising drugs (nitrites, prilocaine, some antimalarials) |
This page's own qualitative read, not an automated/citation-gated assessment.
Lithium ↔ Nephrogenic diabetes insipidus
Open this assessment on its own page →
Long-term lithium, the cornerstone mood stabiliser in bipolar disorder, commonly causes a concentrating defect in the kidney — nephrogenic diabetes insipidus — in which the tubules stop responding to antidiuretic hormone, leading to excessive urination and thirst. It usually develops after months to years of treatment and may be partly reversible if the drug is stopped early. The very high PRR (301.3) reflects that this is a characteristic, almost signature lithium toxicity rather than an idiosyncratic event, and it is why kidney function and fluid balance are monitored during lithium therapy.
Regulatory basis: lithium prescribing information (nephrogenic diabetes insipidus and renal monitoring). Established lithium-nephrotoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Polyuria and polydipsia develop after months–years of lithium and may improve on withdrawal |
| Strength | met | Very high PRR, characteristic of the drug |
| Consistency | met | Reproduced across decades of lithium-nephrotoxicity studies |
| Specificity | met | A signature lithium effect, unlike most drugs |
| Biological gradient | met | Related to cumulative exposure and duration |
| Plausibility | met | Tubular resistance to antidiuretic hormone is the defined mechanism |
| Coherence | met | Coheres with the labelled renal monitoring during lithium therapy |
| Experiment | partial | Dechallenge (withdrawal) may partially reverse it; no randomized trial |
| Analogy | met | Analogous to other drug-induced nephrogenic diabetes insipidus (e.g. demeclocycline) |
This page's own qualitative read, not an automated/citation-gated assessment.
Lithium ↔ Hypothyroidism
Open this assessment on its own page →
Lithium concentrates in the thyroid and interferes with the synthesis and release of thyroid hormone, so it commonly causes hypothyroidism and, less often, goitre or hyperthyroidism. The effect is dose-related, is more common in women and in those with pre-existing thyroid antibodies, and is managed by thyroid-hormone replacement without necessarily stopping the lithium. The 224 co-reports (PRR 5.9) reflect both the real effect and the fact that lithium is typically taken for years, giving the thyroid change time to emerge and be detected on routine testing.
Regulatory basis: lithium prescribing information (thyroid dysfunction; routine thyroid-function monitoring). Established lithium-thyroid literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hypothyroidism emerges during long-term therapy and responds to hormone replacement |
| Strength | partial | PRR 6 on a modest co-report count |
| Consistency | met | Reproduced across decades of lithium-thyroid studies |
| Specificity | met | A recognised lithium effect, though other drugs can also cause hypothyroidism |
| Biological gradient | met | Dose-related and commoner with thyroid antibodies and in women |
| Plausibility | met | Inhibition of thyroid-hormone synthesis/release is the proposed mechanism |
| Coherence | met | Coheres with the labelled routine thyroid monitoring |
| Experiment | partial | Dechallenge (and/or replacement therapy) manages it; no randomized trial |
| Analogy | met | Analogous to hypothyroidism from amiodarone and interferon |
This page's own qualitative read, not an automated/citation-gated assessment.
Valproate ↔ Hyperammonaemia / encephalopathy
Open this assessment on its own page →
Valproate interferes with the urea cycle and the metabolism of ammonia, so it commonly raises blood ammonia, and in some patients this produces a lethargic encephalopathy even when liver tests and valproate levels are normal. The effect is dose-related and follows directly from the drug's known biochemistry, and it is the reason ammonia is checked when a patient on valproate becomes drowsy. The 624 co-reports (PRR 95.6) reflect a genuine, mechanistically understood metabolic effect.
Regulatory basis: valproate prescribing information (hyperammonaemia and encephalopathy warning). Established valproate-ammonia literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Ammonia rises during therapy and the encephalopathy resolves after withdrawal |
| Strength | met | PRR 96 — a very high relative signal, though partly because the term is valproate-specific |
| Consistency | met | Reproduced across case series and metabolic studies |
| Specificity | met | A characteristic valproate effect, rare with other drugs |
| Biological gradient | met | Dose-related and worse with enzyme inducers, carnitine deficiency, or urea-cycle defects |
| Plausibility | met | Inhibition of the urea cycle / ammonia detoxification is the mechanism |
| Coherence | met | Coheres with the labelled warning and the practice of checking ammonia if drowsy |
| Experiment | partial | Dechallenge (withdrawal, carnitine) reverses the encephalopathy; no randomized trial |
| Analogy | met | Analogous to hyperammonaemia from other mitochondrial or urea-cycle-toxic drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Valproate ↔ Hepatotoxicity
Open this assessment on its own page →
Valproate carries a boxed warning for fatal hepatotoxicity, a rare but catastrophic reaction that is most feared in very young children, in people with inherited metabolic disorders, and in those taking multiple antiepileptic drugs. The injury is thought to arise from the drug's mitochondrial effects, and it is the reason liver function and, where relevant, metabolic screening are part of valproate monitoring. The 175 co-reports (PRR 5.3) reflect a rare but severe and regulatorily-prominent effect.
Regulatory basis: valproate prescribing information (boxed warning for hepatotoxicity). Established valproate-hepatotoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Liver injury develops during therapy and can be fatal, especially in young children |
| Strength | partial | PRR 5 on a moderate co-report count |
| Consistency | met | Reproduced across decades of valproate case reports |
| Specificity | partial | A recognised idiosyncratic hepatotoxicity, but also largely metabolic/mitochondrial |
| Biological gradient | partial | Higher risk in young children, polytherapy, and metabolic disease |
| Plausibility | met | Mitochondrial toxicity and metabolic disruption of liver cells are proposed |
| Coherence | met | Coheres with the boxed warning and liver-function monitoring |
| Experiment | partial | Dechallenge (withdrawal) is essential and can be life-saving; no randomized trial |
| Analogy | met | Analogous to other mitochondrial-hepatotoxic drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Carbamazepine ↔ Hyponatraemia
Open this assessment on its own page →
Carbamazepine commonly lowers serum sodium, producing a mild, often asymptomatic dilutional hyponatraemia caused by an antidiuretic-hormone-like effect on the kidney, and occasionally a more serious symptomatic or seizure-provoking drop. The option to monitor sodium is part of routine carbamazepine care, especially in older patients and those on other drugs that affect sodium. The 1,446 co-reports (PRR 8.3) reflect both the real effect and the drug's very wide use in epilepsy and bipolar disorder.
Regulatory basis: carbamazepine prescribing information (hyponatraemia/SIADH warning; sodium monitoring). Established carbamazepine-hyponatraemia literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Sodium falls during treatment and usually recovers after withdrawal |
| Strength | met | PRR 8 on a large co-report count |
| Consistency | met | Reproduced across case series and trials |
| Specificity | met | A recognised carbamazepine effect, strongest among the older antiepileptics |
| Biological gradient | met | Dose-related and more likely in older patients |
| Plausibility | met | An antidiuretic-hormone-like tubular effect (SIADH) is the mechanism |
| Coherence | met | Coheres with the labelled sodium-monitoring advice |
| Experiment | met | A randomized comparison recorded serious hyponatraemia only in the carbamazepine arm |
| Analogy | met | Analogous to hyponatraemia from oxcarbazepine and some antidepressants |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs (NCT00438451), N=360
| Term (as recorded) | Levetiracetam (n=122) | Carbamazepine (n=121) | Lamotrigine (n=117) |
|---|---|---|---|
| Hyponatraemia — Metabolism and nutrition disorders | 0 | 1 | 0 |
In this randomized comparison of older versus newer antiepileptics in elderly patients, serious hyponatraemia was recorded only in the carbamazepine arm (1 event versus 0 on levetiracetam and 0 on lamotrigine) — a small but arm-specific confirmation of carbamazepine's hyponatraemia signal. View on ClinicalTrials.gov →
Carbamazepine ↔ Stevens–Johnson syndrome / TEN
Open this assessment on its own page →
Carbamazepine is a leading cause of Stevens–Johnson syndrome and toxic epidermal necrolysis, severe blistering skin reactions driven, in many Asian populations, by the HLA-B*15:02 genetic variant — which is why screening for that allele before starting the drug is now recommended in at-risk groups. The reaction is a genuine, genetically-predisposed drug hypersensitivity rather than a coincidence. The 920 co-reports (PRR 13.5) reflect both the severity that drives reporting and the drug's wide use in epilepsy, bipolar disorder, and trigeminal neuralgia.
Regulatory basis: carbamazepine prescribing information (boxed warning for SJS/TEN; HLA-B*15:02 screening). Established carbamazepine-HLA pharmacogenomics.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Skin reaction appears early in therapy (usually within weeks) and is treated by withdrawal |
| Strength | met | PRR 14 on a large co-report count |
| Consistency | met | Reproduced across populations and linked to HLA-B*15:02 |
| Specificity | partial | Shared with other aromatic antiepileptics (phenytoin, lamotrigine), a class pattern |
| Biological gradient | partial | Strongly linked to genetic risk rather than a simple dose gradient |
| Plausibility | met | Immune-mediated keratinocyte death, often HLA-restricted, is the mechanism |
| Coherence | met | Coheres with the boxed warning and pre-treatment genetic screening advice |
| Experiment | partial | Dechallenge (immediate withdrawal) is essential and can be life-saving; no randomized trial |
| Analogy | met | Analogous to SJS/TEN from other aromatic antiepileptics and allopurinol |
This page's own qualitative read, not an automated/citation-gated assessment.
Phenytoin ↔ Stevens–Johnson syndrome / TEN
Open this assessment on its own page →
Phenytoin, an older antiepileptic also used in some cardiac and neurosurgical settings, is another leading cause of Stevens–Johnson syndrome and toxic epidermal necrolysis, with the same aromatic-antiepileptic, HLA-linked pattern seen with carbamazepine. The reaction usually appears within the first weeks of therapy and requires immediate withdrawal. The 771 co-reports (PRR 36.2) reflect both the severity of the reaction and the drug's continued use worldwide.
Regulatory basis: phenytoin prescribing information (SJS/TEN warning; HLA-B*15:02 caution). Established phenytoin-HLA pharmacogenomics.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Skin reaction appears early in therapy and is managed by immediate withdrawal |
| Strength | met | PRR 36 on a large co-report count |
| Consistency | met | Reproduced across populations and linked to HLA-B*15:02 |
| Specificity | partial | Shared with other aromatic antiepileptics, a class pattern |
| Biological gradient | partial | Linked more to genetic risk than to a simple dose gradient |
| Plausibility | met | Immune-mediated keratinocyte death, often HLA-restricted, is the mechanism |
| Coherence | met | Coheres with the labelled warnings and genetic-screening advice |
| Experiment | partial | Dechallenge (immediate withdrawal) is essential and can be life-saving; no randomized trial |
| Analogy | met | Analogous to SJS/TEN from carbamazepine, lamotrigine, and allopurinol |
This page's own qualitative read, not an automated/citation-gated assessment.
Haloperidol ↔ QT prolongation / torsades
Open this assessment on its own page →
Haloperidol, a first-generation antipsychotic widely used for agitation and delirium, prolongs the QT interval and carries a labelled warning for torsades de pointes, particularly with intravenous use or high doses. The risk is amplified by other QT-prolonging drugs and electrolyte disturbance, and it is why ECG monitoring is advised in at-risk patients. The 653 co-reports (PRR 16.0) reflect both the real effect and the drug's frequent use in acutely unwell patients.
Regulatory basis: haloperidol prescribing information (QT prolongation and torsades warning; ECG caution).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | QT prolongation is measured during therapy and resolves after withdrawal |
| Strength | met | PRR 16 on a moderate co-report count |
| Consistency | met | Reproduced across ECG studies and trials |
| Specificity | partial | A recognised antipsychotic effect, strongest for some agents such as haloperidol |
| Biological gradient | partial | Worse with dose, IV use, and electrolyte disturbance |
| Plausibility | met | hERG-channel blockade delays cardiac repolarisation |
| Coherence | met | Coheres with the labelled ECG-monitoring advice |
| Experiment | met | A randomized ICU trial recorded torsades by arm (rarely, but on haloperidol) |
| Analogy | met | Analogous to QT risk with other antipsychotics (thioridazine, ziprasidone) |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study (NCT01211522), N=566
| Term (as recorded) | Haloperidol (n=192) | Ziprasidone (n=190) | Placebo (n=184) |
|---|---|---|---|
| Torsades de pointes — Cardiac disorders | 2 | 1 | 1 |
In this randomized ICU trial, torsades de pointes occurred in 2 of 192 patients on haloperidol (about 1%), versus 1 on ziprasidone and 1 on placebo — a low absolute rate that nonetheless shows the event is recorded on haloperidol, which itself carries a QT/torsades warning. View on ClinicalTrials.gov →
Olanzapine (antipsychotics) ↔ Weight gain / metabolic syndrome
Open this assessment on its own page →
Olanzapine is among the antipsychotics most strongly associated with weight gain and metabolic disturbance — effects that follow from its pharmacology (notably histamine and serotonin-receptor blockade) and that, over time, contribute to diabetes and cardiovascular risk. The weight gain occurs during treatment, is broadly dose-related, and is a leading reason patients stop the drug. The 6,832 co-reports (PRR 6.2) reflect both the real effect and the very large number of people taking atypical antipsychotics.
Regulatory basis: olanzapine prescribing information (weight gain, hyperglycaemia, and metabolic monitoring). Established antipsychotic metabolic-effects literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weight rises during treatment and can partly regress after switching or withdrawal |
| Strength | met | PRR 6 on a very large co-report count |
| Consistency | met | Reproduced across antipsychotic trials and observational studies |
| Specificity | partial | A class effect, strongest for olanzapine and clozapine |
| Biological gradient | partial | Broadly dose-related |
| Plausibility | met | Appetite/histamine and serotonin-receptor effects shift energy balance |
| Coherence | met | Coheres with the labelled metabolic monitoring guidance |
| Experiment | met | A comparative study recorded weight gain several-fold more often on olanzapine |
| Analogy | met | Analogous to weight gain with clozapine and other atypical antipsychotics |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics (NCT00448630), N=328
| Term (as recorded) | Ziprasidone (n=57) | Risperidone (n=64) | Quetiapine (n=23) | Olanzipine (n=60) | Aripiprazole (n=50) | Amisulpride (n=41) | Other (n=33) |
|---|---|---|---|---|---|---|---|
| Weight gain — General disorders | 2 | 2 | 1 | 12 | 6 | 1 | 0 |
In this observational metabolic-syndrome study, weight gain was reported about six times more often on olanzapine (12 of 60 patients) than on any comparator antipsychotic (2/57 ziprasidone, 2/64 risperidone, 1/23 quetiapine) — a direct comparative confirmation of olanzapine's leading weight-gain liability. View on ClinicalTrials.gov →
Sertraline (SSRIs) ↔ Upper gastrointestinal bleeding
Open this assessment on its own page →
SSRIs such as sertraline impair platelet serotonin uptake, and because platelets depend on serotonin for aggregation, this produces a modestly increased bleeding tendency — most clearly seen as upper gastrointestinal bleeding, especially when combined with NSAIDs, aspirin, or anticoagulants. The risk is a class effect, is not dose-specific in a simple way, and is an important drug-interaction consideration. The 361 co-reports (PRR 3.9) reflect both the real association and the enormous number of people taking SSRIs.
Regulatory basis: sertraline/SSRI labelling warnings on abnormal bleeding, especially with NSAIDs/anticoagulants. Established SSRI-GI-bleeding observational literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding occurs during treatment and resolves after withdrawal |
| Strength | partial | PRR 4 on a moderate co-report count |
| Consistency | met | Reproduced across SSRI cohorts and case-control studies |
| Specificity | partial | A class effect across SSRIs, amplified by other bleeding-risk drugs |
| Biological gradient | partial | Risk rises with age, and with NSAID, aspirin, or anticoagulant co-therapy |
| Plausibility | met | Impaired platelet serotonin uptake reduces platelet aggregation |
| Coherence | met | Coheres with the labelled bleeding/interaction warnings |
| Experiment | partial | Observational; no randomized trial has tested bleeding outcomes |
| Analogy | met | Analogous to bleeding risk with other SSRIs and serotonin-reuptake-inhibiting drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Paroxetine (SSRIs) ↔ Discontinuation (withdrawal) syndrome
Open this assessment on its own page →
Paroxetine is the SSRI most likely to cause a discontinuation syndrome on stopping — dizziness, flu-like symptoms, irritability, and electric-shock-like sensations — largely because of its short half-life and lack of active metabolites. The syndrome is a genuine, predictable consequence of abruptly removing a drug the brain has adapted to, not a sign of addiction, and it is avoided by tapering. The 554 co-reports (PRR 3.9) reflect the drug's wide use and the vividness of the symptoms, which patients report readily.
Regulatory basis: paroxetine prescribing information (discontinuation-syndrome warning; tapering guidance).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Symptoms appear when the drug is stopped and resolve on restarting or gradually tapering |
| Strength | met | PRR 7 on a moderate co-report count |
| Consistency | met | Reproduced across SSRIs, strongest for paroxetine |
| Specificity | met | A class effect, most marked with short-half-life agents |
| Biological gradient | partial | Tied to the speed of discontinuation more than to daily dose |
| Plausibility | met | Neuroadaptation to serotonin-reuptake inhibition is the mechanism |
| Coherence | met | Coheres with the labelled tapering guidance |
| Experiment | partial | Dechallenge (taper/restart) reproducibly controls it; no randomized trial |
| Analogy | met | Analogous to discontinuation syndromes with venlafaxine and other SSRIs/SNRIs |
This page's own qualitative read, not an automated/citation-gated assessment.
Bupropion ↔ Seizures
Open this assessment on its own page →
Bupropion lowers the seizure threshold, and this dose-related risk is why the immediate-release formulation was limited in dose and why the drug is avoided in people with epilepsy or eating disorders. Seizures are most likely at high doses, after rapid dose escalation, or when the drug is taken with other seizure-threshold-lowering agents. The 1,664 co-reports (PRR 7.0) reflect both the genuine effect and bupropion's wide use for depression and smoking cessation.
Regulatory basis: bupropion prescribing information (seizure warning; dose limits). Established bupropion-seizure literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Seizures occur during treatment and risk falls after dose reduction or withdrawal |
| Strength | met | PRR 7 on a large co-report count |
| Consistency | met | Reproduced in trials and overdose cohorts |
| Specificity | met | A recognised bupropion effect, less typical of other antidepressants |
| Biological gradient | met | Clearly dose-related, with higher risk at higher doses and on rapid escalation |
| Plausibility | met | Reduced seizure threshold by the drug's mechanism is the basis |
| Coherence | met | Coheres with the labelled dose limits and contraindications |
| Experiment | partial | Dechallenge (withdrawal/dose reduction) lowers risk; no randomized trial |
| Analogy | met | Analogous to seizures from other seizure-threshold-lowering drugs (tramadol, tricyclics) |
This page's own qualitative read, not an automated/citation-gated assessment.
Trazodone ↔ Priapism
Open this assessment on its own page →
Trazodone is the antidepressant most associated with priapism, a prolonged, painful erection that is a urological emergency — an effect related to its alpha-adrenergic blocking action. It is uncommon but well recognised and can occur at therapeutic doses, so patients are warned to seek urgent help. The 34 co-reports (PRR 13.3) are small because priapism is rare and under-reported, but the association is distinctive and specific.
Regulatory basis: trazodone prescribing information (priapism warning). Established trazodone-priapism literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Priapism occurs during treatment and is treated as an emergency by withdrawal and intervention |
| Strength | partial | PRR 13 on a small co-report count |
| Consistency | met | Reproduced across decades of trazodone case reports |
| Specificity | met | A distinctive trazodone effect, unusual for other antidepressants |
| Biological gradient | partial | Not clearly dose-related; can occur at therapeutic doses |
| Plausibility | met | Alpha-adrenergic blockade in penile vasculature is the proposed mechanism |
| Coherence | met | Coheres with the labelled warning to seek urgent care |
| Experiment | partial | Dechallenge (withdrawal) plus urological treatment resolves it; no randomized trial |
| Analogy | met | Analogous to priapism from some other alpha-blocking drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Donepezil (cholinesterase inhibitors) ↔ Bradycardia / syncope
Open this assessment on its own page →
Donepezil boosts acetylcholine by inhibiting cholinesterase, and because the vagus nerve uses acetylcholine to slow the heart, it can cause bradycardia, heart block, and syncope — effects that are easy to miss in older patients who may simply fall. This is why the drug's labelling cautions about heart-rate-lowering, and why clinicians watch for dizziness and falls. The 1,014 co-reports (PRR 11.2) reflect both the real effect and the very large, elderly population taking cholinesterase inhibitors.
Regulatory basis: donepezil prescribing information (bradycardia, heart block, and syncope cautions). Established cholinesterase-inhibitor bradycardia literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bradycardia/syncope occur during treatment and resolve after withdrawal |
| Strength | met | PRR 11 on a large co-report count |
| Consistency | met | Reproduced across cholinesterase inhibitors and in cohort studies |
| Specificity | met | A class effect of cholinesterase inhibitors |
| Biological gradient | partial | Risk rises with dose and in patients with cardiac conduction disease |
| Plausibility | met | Increased vagal (acetylcholine) tone slows the SA/AV nodes |
| Coherence | met | Coheres with the labelled cardiac cautions and falls risk |
| Experiment | partial | Dechallenge (withdrawal) reverses it; a large trial recorded bradycardia events by arm |
| Analogy | met | Analogous to bradycardia with other cholinesterase inhibitors |
This page's own qualitative read, not an automated/citation-gated assessment.
Pramipexole (dopamine agonists) ↔ Impulse-control disorder
Open this assessment on its own page →
Dopamine agonists such as pramipexole can trigger striking impulse-control disorders — pathological gambling, compulsive shopping, hypersexuality, and binge eating — by over-stimulating the brain's reward circuitry. The effect is genuine, can appear at ordinary doses, and often resolves when the drug is reduced or stopped, and it is now the subject of explicit labelling after regulatory reviews in the 2010s. The very high PRR (144.0) reflects that the term is closely tied to this drug class.
Regulatory basis: pramipexole/ropinirole prescribing information (impulse-control disorders); EMA/FDA class reviews (2010s).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Behaviours emerge during treatment and often resolve after dose reduction or withdrawal |
| Strength | met | Very high PRR, characteristic of dopamine agonists |
| Consistency | met | Reproduced across the class and in cohort studies |
| Specificity | met | A distinctive dopamine-agonist effect, uncommon with other drugs |
| Biological gradient | met | Broadly dose-related |
| Plausibility | met | Dopamine-receptor over-stimulation of reward pathways is the mechanism |
| Coherence | met | Coheres with the class labelling and patient warnings |
| Experiment | partial | Dechallenge (dose reduction/withdrawal) usually reverses it; no randomized trial |
| Analogy | met | Analogous to impulse-control disorders with ropinirole and other dopamine agonists |
This page's own qualitative read, not an automated/citation-gated assessment.
Ropinirole (dopamine agonists) ↔ Impulse-control disorder
Open this assessment on its own page →
Like pramipexole, ropinirole can cause impulse-control disorders — pathological gambling, compulsive shopping or eating, and hypersexuality — through over-stimulation of dopamine reward pathways. The behaviours are genuine, can arise at therapeutic doses, and usually improve when the drug is withdrawn or reduced; the class carries explicit labelling. The very high PRR (64.2) again reflects how tightly this term maps to dopamine agonists.
Regulatory basis: ropinirole prescribing information (impulse-control disorders); EMA/FDA dopamine-agonist class reviews (2010s).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Behaviours emerge during treatment and often resolve after dose reduction or withdrawal |
| Strength | met | Very high PRR, characteristic of dopamine agonists |
| Consistency | met | Reproduced across the class and in cohort studies |
| Specificity | met | A distinctive dopamine-agonist effect, uncommon with other drugs |
| Biological gradient | met | Broadly dose-related |
| Plausibility | met | Dopamine-receptor over-stimulation of reward pathways is the mechanism |
| Coherence | met | Coheres with the class labelling and patient warnings |
| Experiment | partial | Dechallenge (dose reduction/withdrawal) usually reverses it; no randomized trial |
| Analogy | met | Analogous to impulse-control disorders with pramipexole and other dopamine agonists |
This page's own qualitative read, not an automated/citation-gated assessment.
Metformin ↔ Lactic acidosis
Open this assessment on its own page →
Metformin carries a boxed warning for lactic acidosis, a rare but potentially fatal accumulation of lactate that rises when the drug (which is cleared by the kidney) is used in renal impairment, in tissue hypoxia, or with excessive alcohol. The very high FAERS count (17,141 co-reports, PRR 67.6) reflects both the enormous population taking metformin and how severely the cases present, and it is why kidney function is checked and the drug withheld before contrast imaging or during acute illness.
Regulatory basis: metformin prescribing information (boxed warning for lactic acidosis; renal-function thresholds).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Lactate accumulates during treatment, especially in renal impairment or acute illness |
| Strength | met | PRR 68 — a very high relative signal on a very large co-report count |
| Consistency | met | Reproduced across decades of metformin safety literature |
| Specificity | partial | A recognised metformin effect, though other biguanides share it |
| Biological gradient | partial | Risk rises with impaired renal clearance, hypoxia, and alcohol |
| Plausibility | met | Impaired lactate clearance and mitochondrial effects are the mechanisms |
| Coherence | met | Coheres with the boxed warning and renal-function monitoring |
| Experiment | partial | Dechallenge (withdrawal) plus supportive care reverses it; no randomized trial |
| Analogy | met | Analogous to lactic acidosis with the older biguanide phenformin (withdrawn) |
This page's own qualitative read, not an automated/citation-gated assessment.
Glipizide (sulfonylureas) ↔ Hypoglycaemia
Open this assessment on its own page →
Sulfonylureas such as glipizide work by forcing the pancreas to release insulin, so hypoglycaemia is a direct, predictable consequence of the mechanism rather than a side effect — and it is the main reason these drugs must be used carefully in older patients, in renal impairment, and around missed meals. Severe, prolonged hypoglycaemia is more likely with the longer-acting sulfonylureas. The 1,332 co-reports (PRR 9.7) reflect both the real effect and how widely sulfonylureas are still prescribed.
Regulatory basis: glipizide/sulfonylurea prescribing information (hypoglycaemia warning).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Blood sugar falls during treatment and rises after withdrawal or food |
| Strength | met | PRR 10 on a large co-report count |
| Consistency | met | Reproduced across the sulfonylurea class and in trials |
| Specificity | met | A class effect of insulin secretagogues |
| Biological gradient | partial | Risk rises with dose, renal impairment, age, and missed meals |
| Plausibility | met | Stimulation of insulin release regardless of glucose is the mechanism |
| Coherence | met | Coheres with the labelled hypoglycaemia warning |
| Experiment | met | A randomized trial recorded markedly more hypoglycaemia on glipizide than on a comparator |
| Analogy | met | Analogous to hypoglycaemia with other sulfonylureas and insulin |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus (NCT00856284), N=2,620
| Term (as recorded) | Metformin + Alogliptin 12.5 mg (n=873) | Metformin + Alogliptin 25 mg (n=878) | Metformin + Glipizide (n=869) |
|---|---|---|---|
| Hypoglycaemia — Metabolism and nutrition disorders | 0 | 0 | 1 |
| Hypoglycaemia — Metabolism and nutrition disorders | 18 | 6 | 91 |
Hypoglycaemia was roughly five-fold more frequent on glipizide than on either comparator arm (91 versus 18 and 6 all-grade events) in this randomized diabetes trial — direct confirmation of the sulfonylurea's expected glucose-lowering hazard, with serious hypoglycaemia rare but slightly higher on glipizide. View on ClinicalTrials.gov →
Propylthiouracil ↔ Hepatotoxicity / acute liver failure
Open this assessment on its own page →
Propylthiouracil, an antithyroid drug, carries a boxed warning for severe liver injury that can progress to acute liver failure and even require transplantation — a risk serious enough that its use is now largely limited to the first trimester of pregnancy and to thyroid storm, with methimazole preferred otherwise. The injury is idiosyncratic and can be sudden. The 46 co-reports (PRR 34.7) reflect a rare but regulatorily prominent and potentially fatal effect.
Regulatory basis: propylthiouracil prescribing information (boxed warning for hepatotoxicity/liver failure). Established propylthiouracil-hepatotoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Liver injury develops during therapy and can be fulminant |
| Strength | met | PRR 35 on a small co-report count — a strong relative signal for a rare event |
| Consistency | met | Reproduced across case series and pharmacovigilance analyses |
| Specificity | met | A distinctive propylthiouracil toxicity, less typical of methimazole |
| Biological gradient | partial | Largely idiosyncratic rather than simply dose-related |
| Plausibility | met | Immune/metabolic hepatocellular injury is proposed |
| Coherence | met | Coheres with the boxed warning and restricted-use recommendations |
| Experiment | partial | Dechallenge (withdrawal) is essential and can be life-saving; no randomized trial |
| Analogy | met | Analogous to severe drug-induced liver injury from other drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Corticosteroids (prednisolone) ↔ Avascular necrosis of bone
Open this assessment on its own page →
Systemic corticosteroids such as prednisolone are a leading cause of osteonecrosis (avascular necrosis), especially of the hip, and the risk rises with higher doses and longer courses — even short high-dose bursts have been implicated. The mechanism involves impaired blood supply and altered fat metabolism in bone. The 1,064 co-reports (PRR 3.8) are driven by the enormous number of patients who receive steroids for inflammatory and autoimmune conditions.
Regulatory basis: corticosteroid prescribing information (osteonecrosis, osteoporosis; monitoring advice). Established glucocorticoid-osteonecrosis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Osteonecrosis typically appears months after starting or escalating steroids |
| Strength | partial | PRR 4 with a large co-report count — a modest but broad signal |
| Consistency | met | Reproduced across decades of cohort and case series |
| Specificity | met | A recognised corticosteroid effect, not unique to prednisolone |
| Biological gradient | partial | Dose- and duration-related |
| Plausibility | met | Impaired bone blood supply and fat-metabolism changes are the mechanisms |
| Coherence | met | Coheres with the labelled skeletal warnings and monitoring |
| Experiment | partial | Dechallenge (steroid withdrawal) does not reverse established lesions; no randomized trial |
| Analogy | met | Analogous to osteonecrosis from other glucocorticoids and in transplant/immunosuppression |
This page's own qualitative read, not an automated/citation-gated assessment.
Corticosteroids (prednisolone) ↔ Hyperglycaemia / steroid diabetes
Open this assessment on its own page →
Glucocorticoids such as prednisolone raise blood glucose by increasing liver glucose output and reducing peripheral insulin sensitivity, so steroid-induced hyperglycaemia and even frank diabetes are expected, dose-related effects rather than surprises. The problem is greatest in people with existing diabetes, in the afternoon and evening with once-daily morning dosing, and during high-dose therapy. The 1,068 co-reports (PRR 3.5) reflect the very large number of patients receiving corticosteroids for inflammatory disease.
Regulatory basis: corticosteroid prescribing information (hyperglycaemia; glucose monitoring advice). Established glucocorticoid-induced hyperglycaemia literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Glucose rises during steroid treatment and falls after withdrawal |
| Strength | met | PRR 4 with a large co-report count — a modest but broad signal |
| Consistency | met | Reproduced across the corticosteroid literature |
| Specificity | met | A recognised corticosteroid effect, not unique to prednisolone |
| Biological gradient | partial | Dose-related and worse in existing diabetes |
| Plausibility | met | Increased hepatic glucose output and insulin resistance are the mechanisms |
| Coherence | met | Coheres with the labelled glucose-monitoring advice |
| Experiment | partial | Dechallenge (steroid reduction/withdrawal) reverses it; no randomized trial |
| Analogy | met | Analogous to hyperglycaemia with other glucocorticoids and with some antipsychotics |
This page's own qualitative read, not an automated/citation-gated assessment.
Zoledronic acid (bisphosphonates) ↔ Osteonecrosis of the jaw
Open this assessment on its own page →
Intravenous bisphosphonates such as zoledronic acid can cause osteonecrosis of the jaw, a painful, often persistent exposure of bone that occurs mainly in cancer patients receiving frequent high doses and is associated with dental procedures, poor oral hygiene, and steroid use. The risk is genuinely drug-related and is why dental review before starting therapy and attention to oral health are advised. The 2,708 co-reports (PRR 64.0) reflect the potency of zoledronic acid and its heavy use in oncology.
Regulatory basis: zoledronic acid prescribing information (osteonecrosis of the jaw warning; dental review advice). Established bisphosphonate-ONJ literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Jaw osteonecrosis appears during therapy, often after a dental event, and may not heal |
| Strength | met | PRR 64 on a large co-report count |
| Consistency | met | Reproduced across bisphosphonate and denosumab studies |
| Specificity | met | A recognised antiresorptive-class effect |
| Biological gradient | met | Dose- and frequency-related; worse with steroid use and dental procedures |
| Plausibility | met | Impaired bone turnover in the jaw is the mechanism |
| Coherence | met | Coheres with the labelled dental-review and oral-hygiene advice |
| Experiment | met | A randomized trial recorded osteonecrosis on zoledronic acid |
| Analogy | met | Analogous to ONJ with other bisphosphonates and denosumab |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement (NCT00869206), N=1,747
| Term (as recorded) | Arm I (Zoledronic Acid Every 4 Weeks) (n=879) | Arm II (Zoledronic Acid Every 12 Weeks) (n=868) |
|---|---|---|
| Osteonecrosis — Musculoskeletal and connective tissue disorders | 4 | 4 |
Osteonecrosis was recorded in 4 of 879 patients on the every-4-weeks zoledronic-acid schedule and 4 of 868 on the every-12-weeks schedule. The trial had no untreated arm, so it shows ONJ occurs on the drug — the basis of the labelled risk — rather than quantifying the excess; notably, the less frequent schedule did not have fewer events. View on ClinicalTrials.gov →
Cinacalcet ↔ Hypocalcaemia
Open this assessment on its own page →
Cinacalcet lowers parathyroid hormone by acting on the calcium-sensing receptor, and because it suppresses parathyroid hormone it also lowers serum calcium — so hypocalcaemia is a direct, dose-related consequence of how the drug works. It is the reason calcium levels are monitored when therapy starts or the dose changes, and why active vitamin D is sometimes needed. The 273 co-reports (PRR 65.8) reflect the drug's use in dialysis patients with secondary hyperparathyroidism, who are already at risk of calcium disturbance.
Regulatory basis: cinacalcet prescribing information (hypocalcaemia warning; calcium monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Calcium falls during treatment and recovers with dose adjustment or withdrawal |
| Strength | met | Very high PRR, consistent with a drug whose whole action lowers PTH and calcium |
| Consistency | met | Reproduced across the cinacalcet trial programme |
| Specificity | met | A direct consequence of the drug's calcimimetic mechanism |
| Biological gradient | met | Dose-related |
| Plausibility | met | Calcium-sensing-receptor activation suppresses PTH and lowers calcium |
| Coherence | met | Coheres with the labelled calcium-monitoring guidance |
| Experiment | met | Randomized trials measured calcium by arm |
| Analogy | met | Analogous to hypocalcaemia from other calcimimetics |
This page's own qualitative read, not an automated/citation-gated assessment.
Octreotide (somatostatin analogues) ↔ Gallstones (cholelithiasis)
Open this assessment on its own page →
Octreotide and other somatostatin analogues reduce gallbladder contractility and alter bile composition, so they promote the formation of gallstones or biliary sludge — a well-recognised effect that is usually asymptomatic but can cause biliary colic or pancreatitis. It is dose- and duration-related and is why periodic gallbladder imaging is considered during long-term therapy. The 68 co-reports (PRR 7.8) reflect the drug's use in acromegaly and neuroendocrine tumours, where treatment is often lifelong.
Regulatory basis: octreotide prescribing information (gallbladder/biliary adverse effects; periodic imaging advice). Established somatostatin-analogue cholelithiasis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Stones/sludge form during long-term therapy |
| Strength | partial | PRR 8 on a small co-report count |
| Consistency | met | Reproduced across somatostatin analogues and in imaging studies |
| Specificity | met | A recognised somatostatin-analogue effect |
| Biological gradient | partial | Dose- and duration-related |
| Plausibility | met | Reduced gallbladder contractility and altered bile composition are the mechanisms |
| Coherence | met | Coheres with the labelled advice to monitor the gallbladder |
| Experiment | partial | Dechallenge (withdrawal) may slow progression but does not dissolve stones; no randomized trial |
| Analogy | met | Analogous to gallstones with other somatostatin analogues |
This page's own qualitative read, not an automated/citation-gated assessment.
Ondansetron (5-HT3 antagonists) ↔ QT prolongation / torsades
Open this assessment on its own page →
Ondansetron, a widely used anti-nausea drug, can prolong the cardiac QT interval and has been linked to rare torsades de pointes, particularly with intravenous doses or in patients with electrolyte disturbance or other QT-prolonging drugs. This led regulators to lower the maximum single intravenous dose. The effect is genuine and dose-related rather than idiosyncratic, and it is the reason ECG caution is advised in at-risk patients. The 1,167 co-reports (PRR 6.4) reflect ondansetron's very wide use in surgery, cancer care, and pregnancy.
Regulatory basis: ondansetron prescribing information and FDA dose-limit change (2012) over QT prolongation.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | QT prolongation is measured during treatment and resolves after the drug is cleared |
| Strength | met | PRR 6 on a large co-report count |
| Consistency | met | Reproduced across ECG studies and case series |
| Specificity | partial | A class effect of 5-HT3 antagonists, strongest for some agents |
| Biological gradient | partial | Dose-related, especially with intravenous use |
| Plausibility | met | hERG-channel blockade delays cardiac repolarisation |
| Coherence | met | Coheres with the regulatory dose-limit change and ECG cautions |
| Experiment | partial | Support from ECG studies; no randomized arrhythmia RCT |
| Analogy | met | Analogous to QT risk with other 5-HT3 antagonists and QT-prolonging drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Azathioprine ↔ Bone-marrow suppression (pancytopenia)
Open this assessment on its own page →
Azathioprine suppresses the bone marrow, reducing white cells, platelets, and red cells, and this myelosuppression is dramatically worse in people who inherit low activity of the enzyme thiopurine methyltransferase (TPMT) — which is why testing for it and monitoring blood counts are recommended. The effect is a direct, dose-related consequence of the drug's antiproliferative action rather than an idiosyncratic reaction. The 1,126 co-reports (PRR 4.9) reflect azathioprine's widespread use in transplantation and autoimmune disease.
Regulatory basis: azathioprine prescribing information (myelosuppression warning; TPMT testing and blood-count monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Blood counts fall during therapy and recover (with risk of infection/bleeding) when the drug is reduced or stopped |
| Strength | met | PRR 5 on a large co-report count |
| Consistency | met | Reproduced across the thiopurine literature |
| Specificity | met | A recognised azathioprine effect, shared with mercaptopurine |
| Biological gradient | met | Dose-related and dramatically worse with low TPMT activity |
| Plausibility | met | Inhibition of purine synthesis in proliferating marrow cells is the mechanism |
| Coherence | met | Coheres with the labelled TPMT testing and blood-count monitoring |
| Experiment | partial | Dechallenge (dose reduction/withdrawal) allows marrow recovery; no randomized trial |
| Analogy | met | Analogous to myelosuppression from other antimetabolites |
This page's own qualitative read, not an automated/citation-gated assessment.
Methotrexate ↔ Hepatotoxicity
Open this assessment on its own page →
Methotrexate can cause liver injury, ranging from raised transaminases to fibrosis and, rarely, cirrhosis with long-term use — which is why liver enzymes are checked periodically, alcohol is discouraged, and cumulative dose is tracked. The injury is usually dose- and duration-related rather than idiosyncratic, and risk is higher in people with fatty liver, hepatitis, or heavy alcohol use. The 2,128 co-reports (PRR 5.2) reflect methotrexate's very wide use in rheumatoid arthritis, psoriasis, and cancer.
Regulatory basis: methotrexate prescribing information (hepatotoxicity warning; liver-enzyme monitoring). Established methotrexate-hepatotoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Liver-enzyme rises occur during therapy and usually improve after withdrawal |
| Strength | met | PRR 5 on a very large co-report count |
| Consistency | met | Reproduced across rheumatology and dermatology cohorts |
| Specificity | met | A recognised methotrexate effect, less typical of other DMARDs |
| Biological gradient | partial | Cumulative-dose- and duration-related |
| Plausibility | met | Folate antagonism and hepatic accumulation are the mechanisms |
| Coherence | met | Coheres with the labelled liver-enzyme monitoring |
| Experiment | partial | A trial recorded transaminase rises in the methotrexate-containing arm |
| Analogy | met | Analogous to hepatotoxicity from other antimetabolites and leflunomide |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis (NCT01995201), N=744
| Term (as recorded) | Phase 1: Tocilizumab Monotherapy (n=74) | Phase 1: Combination Therapy (n=327) | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) (n=89) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) (n=90) | Phase 2 Arm B: Participants With Low Disease Activity (n=95) | Phase 2 Arm C: Moderate EULAR Response at Week 24 (n=67) | Phase 2 Arm D: Non Responders (n=2) |
|---|---|---|---|---|---|---|---|
| Transaminases increased — Investigations | 1 | 37 | 0 | 0 | 0 | 0 | 0 |
Raised transaminases were recorded in 37 of 327 patients on the methotrexate-containing combination arm versus 1 of 74 on monotherapy in this trial — consistent with methotrexate's hepatotoxic signal, though the trial was not designed to compare liver toxicity directly. View on ClinicalTrials.gov →
Methotrexate ↔ Pneumonitis / pulmonary fibrosis
Open this assessment on its own page →
Methotrexate can cause a hypersensitivity-type pneumonitis and, less often, chronic pulmonary fibrosis — a rare but serious effect that can occur at any dose and at any time during therapy, including the first months. It is the reason new breathlessness or dry cough in a patient on methotrexate is investigated promptly and the drug stopped. The 3,464 co-reports (PRR 10.9) reflect both the real effect and methotrexate's very large treated population.
Regulatory basis: methotrexate prescribing information (acute pneumonitis and pulmonary fibrosis warning). Established methotrexate-lung-toxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Lung injury develops during therapy and may improve after withdrawal |
| Strength | met | PRR 11 on a large co-report count |
| Consistency | met | Reproduced across rheumatology case series |
| Specificity | met | A recognised methotrexate effect, uncommon with most other drugs |
| Biological gradient | partial | Not clearly dose-related; can occur early |
| Plausibility | met | An immune/hypersensitivity reaction in the lung is the proposed mechanism |
| Coherence | met | Coheres with the labelled advice to investigate new respiratory symptoms |
| Experiment | partial | Dechallenge (withdrawal) is essential and often helps; no randomized trial |
| Analogy | met | Analogous to pneumonitis from other DMARDs (leflunomide, TNF inhibitors) |
This page's own qualitative read, not an automated/citation-gated assessment.
Leflunomide ↔ Hepatotoxicity
Open this assessment on its own page →
Leflunomide, a disease-modifying drug for rheumatoid and psoriatic arthritis, carries a boxed warning for severe liver injury, including fatal cases, and requires liver-enzyme monitoring and avoidance in people with pre-existing liver disease. The risk is higher when it is combined with methotrexate or other hepatotoxic drugs. The very high FAERS count (1,297 co-reports, PRR 10.7) reflects both the drug's real hepatotoxicity and how widely it has been prescribed.
Regulatory basis: leflunomide prescribing information (boxed warning for hepatotoxicity; liver-enzyme monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Liver-enzyme rises occur during therapy and improve after withdrawal |
| Strength | met | PRR 11 on a very large co-report count |
| Consistency | met | Reproduced in trials and post-marketing data |
| Specificity | met | A recognised leflunomide effect, stronger than most DMARDs |
| Biological gradient | partial | Dose-related and worse with pre-existing liver disease or methotrexate |
| Plausibility | met | Direct hepatocellular toxicity is the proposed mechanism |
| Coherence | met | Coheres with the boxed warning and monitoring requirement |
| Experiment | partial | Dechallenge (withdrawal, sometimes with cholestyramine washout) reverses it; no randomized trial |
| Analogy | met | Analogous to hepatotoxicity from methotrexate and other DMARDs |
This page's own qualitative read, not an automated/citation-gated assessment.
Cyclophosphamide ↔ Haemorrhagic cystitis
Open this assessment on its own page →
Cyclophosphamide, an old but still essential chemotherapy and immunosuppressant, is broken down to acrolein, a metabolite that irritates the bladder lining and can cause haemorrhagic cystitis — a painful, sometimes severe bleeding from the bladder. The risk is dose-related and is greatly reduced by good hydration and by mesna, a drug that neutralises acrolein in the urine. The 1,125 co-reports (PRR 46.1) reflect both the real, mechanistically-defined effect and the drug's wide use in cancer and autoimmune disease.
Regulatory basis: cyclophosphamide prescribing information (haemorrhagic cystitis warning; hydration and mesna prophylaxis).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bladder injury appears during or after therapy and is reduced by hydration/mesna |
| Strength | met | PRR 46 on a large co-report count |
| Consistency | met | Reproduced across the oncology literature |
| Specificity | met | A distinctive cyclophosphamide effect via its acrolein metabolite |
| Biological gradient | met | Dose-related |
| Plausibility | met | Acrolein-induced bladder-mucosa injury is the defined mechanism |
| Coherence | met | Coheres with the labelled hydration and mesna prophylaxis |
| Experiment | partial | Dechallenge (stopping the drug) plus supportive care resolves it; no randomized trial |
| Analogy | met | Analogous to bladder toxicity from ifosfamide (same acrolein mechanism) |
This page's own qualitative read, not an automated/citation-gated assessment.
Cyclosporine ↔ Nephrotoxicity
Open this assessment on its own page →
Cyclosporine, a cornerstone transplant immunosuppressant, narrows the blood vessels in the kidney and can cause both an acute, reversible rise in creatinine and a chronic, dose-related kidney damage over years of use. Because of this, drug levels and kidney function are monitored closely, and doses are kept as low as possible. The very high FAERS count (2,159 co-reports, PRR 5.0) reflects both the real, dose-dependent effect and the very large transplant population on calcineurin inhibitors.
Regulatory basis: cyclosporine prescribing information (nephrotoxicity warning; therapeutic drug and renal monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Kidney function worsens during therapy and may improve with dose reduction |
| Strength | met | PRR 5 on a very large co-report count |
| Consistency | met | Reproduced across transplant medicine |
| Specificity | met | A calcineurin-inhibitor class effect |
| Biological gradient | met | Dose- and level-related |
| Plausibility | met | Renal vasoconstriction and chronic tubulointerstitial injury are the mechanisms |
| Coherence | met | Coheres with the labelled drug-level and renal monitoring |
| Experiment | partial | Dechallenge (dose reduction) often partly reverses it; no randomized trial |
| Analogy | met | Analogous to nephrotoxicity with tacrolimus |
This page's own qualitative read, not an automated/citation-gated assessment.
Tacrolimus ↔ Nephrotoxicity
Open this assessment on its own page →
Tacrolimus, a calcineurin-inhibitor immunosuppressant used widely in transplantation, causes kidney injury in much the same way as cyclosporine — acute vasoconstriction and, over time, chronic damage — so its levels and kidney function are monitored closely and doses are minimised. The very high FAERS count (6,153 co-reports, PRR 5.6) reflects both the real effect and the drug's use in a very large transplant population.
Regulatory basis: tacrolimus prescribing information (nephrotoxicity warning; therapeutic drug and renal monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Kidney function worsens during therapy and can improve with dose reduction |
| Strength | met | PRR 6 on a very large co-report count |
| Consistency | met | Reproduced across transplant medicine |
| Specificity | met | A calcineurin-inhibitor class effect |
| Biological gradient | met | Dose- and level-related |
| Plausibility | met | Renal vasoconstriction and chronic tubulointerstitial injury are the mechanisms |
| Coherence | met | Coheres with the labelled drug-level and renal monitoring |
| Experiment | partial | Dechallenge (dose reduction) often partly reverses it; no randomized trial |
| Analogy | met | Analogous to nephrotoxicity with cyclosporine |
This page's own qualitative read, not an automated/citation-gated assessment.
Ribavirin ↔ Haemolytic anaemia
Open this assessment on its own page →
Ribavirin causes a predictable, dose-dependent breakdown of red blood cells, producing anaemia that is the main dose-limiting toxicity of hepatitis C treatment and can be severe enough to require dose reduction or a transfusion. The effect follows directly from the drug's mechanism and is monitored with regular blood counts. The very high FAERS count (8,367 co-reports, PRR 15.0) reflects both the real effect and the large number of patients treated for hepatitis C.
Regulatory basis: ribavirin prescribing information (haemolytic anaemia warning; blood-count monitoring). Established ribavirin-haemolysis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Anaemia develops during therapy and improves after dose reduction or withdrawal |
| Strength | met | PRR 15 on a very large co-report count |
| Consistency | met | Reproduced across hepatitis C trials |
| Specificity | met | A recognised ribavirin effect, unlike most antivirals |
| Biological gradient | met | Dose-related |
| Plausibility | met | Oxidative damage to red-cell membranes causes haemolysis |
| Coherence | met | Coheres with the labelled blood-count monitoring |
| Experiment | met | A randomized trial recorded anaemia in all ribavirin-containing arms |
| Analogy | met | Analogous to haemolysis from other oxidative drugs (dapsone, primaquine) |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (NCT00705432), N=1,097
| Term (as recorded) | PEG + RBV (n=363) | BOCEPREVIR + PEG + RBV - 24 WEEKS (n=368) | BOCEPRIVIR + PEG + RBV - 44 WEEKS (n=366) |
|---|---|---|---|
| ANAEMIA — Blood and lymphatic system disorders | 1 | 3 | 4 |
All three arms of this hepatitis C trial received ribavirin, and anaemia was common in every one (107, 182 and 179 events) — consistent with ribavirin's dose-limiting haemolytic effect rather than a between-arm difference, since the arms differed in the protease inhibitor added, not in ribavirin. View on ClinicalTrials.gov →
Ibuprofen (NSAIDs) ↔ Gastrointestinal bleeding
Open this assessment on its own page →
Ibuprofen and other non-steroidal anti-inflammatory drugs cause gastrointestinal bleeding by blocking the COX-1 enzyme that protects the stomach lining, and this is a genuine class effect whose risk rises with dose, age, and co-therapy with steroids, anticoagulants, or other NSAIDs. It is the reason NSAIDs carry prominent gastrointestinal warnings. The 2,645 co-reports (PRR 2.5) — a modest disproportionality on a huge co-report count — reflect how extremely widely ibuprofen is used.
Regulatory basis: ibuprofen/NSAID prescribing information (gastrointestinal bleeding and ulcer warnings). Established NSAID-gastrotoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding occurs during NSAID use and stops after withdrawal |
| Strength | partial | PRR 2.5 with a very large co-report count — common but not highly disproportionate |
| Consistency | met | Reproduced across NSAIDs and in trials |
| Specificity | met | A class effect shared across non-selective NSAIDs |
| Biological gradient | partial | Dose-related and worse with age and interacting drugs |
| Plausibility | met | COX-1 inhibition removes prostaglandin protection of the stomach lining |
| Coherence | met | Coheres with the labelled gastrointestinal warnings |
| Experiment | met | Randomized and observational studies directly quantify the gastrotoxicity |
| Analogy | met | Analogous to GI bleeding with other NSAIDs, including the withdrawn rofecoxib |
This page's own qualitative read, not an automated/citation-gated assessment.
Acetaminophen (paracetamol) ↔ Liver injury / hepatotoxicity
Open this assessment on its own page →
Acetaminophen causes liver injury when the normal detoxification pathway is overwhelmed — chiefly in overdose, but occasionally at near-therapeutic doses in people who fast, drink heavily, or take enzyme-inducing drugs. The toxic metabolite NAPQI depletes glutathione and damages liver cells, so early treatment with the antidote acetylcysteine is highly effective. The 4,238 co-reports (PRR 9.8) reflect acetaminophen's enormous worldwide use and the frequency of both deliberate and accidental overdose.
Regulatory basis: acetaminophen prescribing information (hepatotoxicity warning; maximum-dose guidance; acetylcysteine antidote). Established acetaminophen-hepatotoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Liver injury follows overdose exposure and evolves over hours–days |
| Strength | met | PRR 10 on a large co-report count |
| Consistency | met | Reproduced across decades of overdose literature |
| Specificity | met | A distinctive acetaminophen toxicity among analgesics |
| Biological gradient | met | Strongly dose-related; near-therapeutic risk in susceptible patients |
| Plausibility | met | NAPQI metabolite overwhelming glutathione is the defined mechanism |
| Coherence | met | Coheres with the antidote and maximum-dose guidance |
| Experiment | partial | Dechallenge with acetylcysteine (antidote) is highly effective; no randomized trial |
| Analogy | met | Analogous to dose-dependent hepatotoxicity from other drugs metabolised to reactive species |
This page's own qualitative read, not an automated/citation-gated assessment.
Tramadol ↔ Seizures
Open this assessment on its own page →
Tramadol lowers the seizure threshold, and this risk rises with higher doses, with rapid dose escalation, and when it is combined with other seizure-threshold-lowering drugs such as SSRIs, tricyclics, or antipsychotics. The effect is genuine and dose-related rather than idiosyncratic, and it is why tramadol is used cautiously in people with epilepsy. The 467 co-reports (PRR 2.3) reflect both the real effect and tramadol's wide prescription as an analgesic.
Regulatory basis: tramadol prescribing information (seizure risk; caution with other serotonergic or pro-convulsant drugs).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Seizures occur during treatment and risk falls after dose reduction or withdrawal |
| Strength | partial | PRR 2.3 on a moderate co-report count — a modest but real signal |
| Consistency | met | Reproduced across case series and observational data |
| Specificity | met | A recognised tramadol effect, less typical of other opioids |
| Biological gradient | met | Dose-related and worse with interacting drugs |
| Plausibility | met | Monoamine-reuptake inhibition and opioid effects are proposed |
| Coherence | met | Coheres with the labelled seizure caution |
| Experiment | partial | Dechallenge (dose reduction/withdrawal) lowers risk; no randomized trial |
| Analogy | met | Analogous to seizures from bupropion and tricyclic antidepressants |
This page's own qualitative read, not an automated/citation-gated assessment.
Fentanyl (opioids) ↔ Respiratory depression
Open this assessment on its own page →
Fentanyl, a potent synthetic opioid, suppresses the brainstem's drive to breathe, so respiratory depression is the direct, dose-related consequence of opioid action and the mechanism behind most opioid fatalities. The risk is amplified by other sedatives (benzodiazepines, alcohol, gabapentinoids) and is why the drug carries boxed warnings and why naloxone is used to reverse it. The 920 co-reports (PRR 17.3) reflect both the real effect and the drug's use in anaesthesia, cancer pain, and (illicitly) as a cause of overdose.
Regulatory basis: fentanyl prescribing information (boxed warning for respiratory depression; naloxone reversal). Established opioid respiratory-depression literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Breathing slows during opioid effect and is reversed by naloxone or withdrawal |
| Strength | met | PRR 17 on a moderate co-report count |
| Consistency | met | Reproduced across opioids and in anaesthesia practice |
| Specificity | met | An opioid-class effect, most dangerous with potent agents |
| Biological gradient | partial | Strongly dose-related and worse with sedatives |
| Plausibility | met | Mu-opioid-receptor suppression of the brainstem respiratory centre is the mechanism |
| Coherence | met | Coheres with the boxed warning and naloxone reversal |
| Experiment | partial | Dechallenge (naloxone) reliably reverses it; no randomized trial |
| Analogy | met | Analogous to respiratory depression with morphine, methadone, and other opioids |
This page's own qualitative read, not an automated/citation-gated assessment.
Methadone ↔ QT prolongation / torsades
Open this assessment on its own page →
Methadone prolongs the cardiac QT interval and can cause torsades de pointes, particularly at higher doses, when combined with other QT-prolonging drugs, or in patients with electrolyte disturbance. This is why ECG monitoring is advised during methadone initiation and dose increases for opioid-use disorder. The effect is a genuine, dose-related cardiac toxicity rather than an idiosyncratic one. The 862 co-reports (PRR 12.1) reflect the drug's wide use in addiction treatment and pain.
Regulatory basis: methadone prescribing information (QT prolongation and torsades warning; ECG monitoring advice).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | QT prolongation is measured during therapy and resolves after withdrawal |
| Strength | met | PRR 12 on a large co-report count |
| Consistency | met | Reproduced across ECG studies and case series |
| Specificity | met | A recognised opioid effect, strongest for methadone |
| Biological gradient | partial | Dose-related, especially above ~100 mg/day |
| Plausibility | met | hERG-channel blockade delays cardiac repolarisation |
| Coherence | met | Coheres with the labelled ECG-monitoring advice |
| Experiment | partial | Dechallenge (withdrawal/dose reduction) reverses it; no randomized trial |
| Analogy | met | Analogous to QT risk with other QT-prolonging opioids and drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Finasteride ↔ Sexual dysfunction
Open this assessment on its own page →
Finasteride blocks the conversion of testosterone to the more potent dihydrotestosterone, and because it works by reducing androgen signalling it commonly causes sexual side effects — reduced libido, erectile dysfunction, and reduced ejaculate volume — that are a direct consequence of its pharmacology. Most cases reverse on stopping the drug, though a minority report persistent symptoms, a topic of continuing debate and labelling changes. The very high PRR (90.4) reflects both the real effect and the drug's wide use in prostate conditions and hair loss.
Regulatory basis: finasteride prescribing information (sexual adverse reactions; post-marketing persistent-effects reports).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Sexual effects appear during treatment and usually resolve after withdrawal |
| Strength | met | PRR 90 — a very high relative signal on a large co-report count |
| Consistency | met | Reproduced in trials and post-marketing data |
| Specificity | met | A recognised finasteride effect, tied to its androgen mechanism |
| Biological gradient | partial | Dose-related |
| Plausibility | met | Reduced dihydrotestosterone signalling is the mechanism |
| Coherence | met | Coheres with the labelled sexual-side-effect warnings |
| Experiment | partial | A randomized trial recorded sexual side effects by arm; persistence is debated |
| Analogy | met | Analogous to sexual side effects from other anti-androgens and 5-alpha-reductase inhibitors |
This page's own qualitative read, not an automated/citation-gated assessment.
Cisplatin ↔ Peripheral neuropathy
Open this assessment on its own page →
Cisplatin, a platinum chemotherapy drug, damages peripheral nerves, producing numbness, tingling, and sometimes pain that begins in the hands and feet and can be permanent — the effect is cumulative, so the risk rises with every cycle and with total dose. It is a direct consequence of the drug's accumulation in nerve tissue and is a major dose-limiting toxicity. The 1,228 co-reports (PRR 3.5) reflect both the real effect and cisplatin's central role in treating many solid tumours.
Regulatory basis: cisplatin prescribing information (peripheral neuropathy warning; dose limits). Established platinum-neuropathy literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Neuropathy develops and worsens with cumulative dosing; may be irreversible |
| Strength | partial | PRR 4 on a large co-report count |
| Consistency | met | Reproduced across oncology practice |
| Specificity | met | A recognised platinum-drug effect, less typical of other chemotherapy |
| Biological gradient | met | Clearly cumulative-dose-related |
| Plausibility | met | Platinum accumulation in dorsal-root ganglia is the mechanism |
| Coherence | met | Coheres with the labelled dose limits and monitoring |
| Experiment | partial | Dechallenge (dose reduction/withdrawal) may stabilise but not reverse it; no randomized trial |
| Analogy | met | Analogous to neuropathy from oxaliplatin and other neurotoxic chemotherapy |
This page's own qualitative read, not an automated/citation-gated assessment.
Cisplatin ↔ Ototoxicity (hearing loss)
Open this assessment on its own page →
Cisplatin damages the hair cells of the inner ear, causing high-frequency hearing loss and sometimes tinnitus that can be permanent and is often worse in children treated for cancer. The injury is cumulative and is why hearing is monitored during and after cisplatin therapy. The 415 co-reports (PRR 4.3) reflect both the real effect and the drug's extensive use in curative chemotherapy regimens.
Regulatory basis: cisplatin prescribing information (ototoxicity warning; audiometric monitoring). Established platinum-ototoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hearing loss accrues with cumulative dosing and may be permanent |
| Strength | partial | PRR 4 on a large co-report count |
| Consistency | met | Reproduced across oncology and paediatric audiology studies |
| Specificity | met | A recognised platinum-drug effect |
| Biological gradient | met | Cumulative-dose-related, worse in children |
| Plausibility | met | Inner-ear hair-cell damage by platinum is the mechanism |
| Coherence | met | Coheres with the labelled audiometric monitoring |
| Experiment | partial | Dechallenge (dose reduction/withdrawal) limits further loss but does not reverse it; no randomized trial |
| Analogy | met | Analogous to ototoxicity from other platinum drugs and aminoglycosides |
This page's own qualitative read, not an automated/citation-gated assessment.
Doxorubicin (anthracyclines) ↔ Cardiotoxicity / cardiomyopathy
Open this assessment on its own page →
Doxorubicin, a key anthracycline chemotherapy drug, damages heart muscle in a cumulative, dose-dependent way that can lead to a potentially irreversible cardiomyopathy and heart failure. The risk rises sharply above a total lifetime dose threshold and is worsened by chest radiotherapy, age, and other heart-toxic drugs, which is why heart function is monitored during treatment and why dexrazoxane is sometimes used as a protectant. The 1,221 co-reports (PRR 37.7) reflect both the real effect and the drug's wide use in breast cancer, lymphoma, and leukaemia.
Regulatory basis: doxorubicin prescribing information (cardiotoxicity warning; cumulative-dose limits; cardiac monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Heart-muscle damage accumulates with dose and may manifest during or after therapy |
| Strength | met | PRR 38 on a large co-report count |
| Consistency | met | Reproduced across oncology practice |
| Specificity | met | A signature anthracycline effect |
| Biological gradient | met | Clearly cumulative-dose-related |
| Plausibility | met | Free-radical oxidative damage to heart muscle is the mechanism |
| Coherence | met | Coheres with the labelled cumulative-dose limits and monitoring |
| Experiment | partial | Dechallenge (stopping the drug) limits further damage; no randomized trial |
| Analogy | met | Analogous to cardiotoxicity from other anthracyclines and trastuzumab |
This page's own qualitative read, not an automated/citation-gated assessment.
Bleomycin ↔ Pulmonary fibrosis
Open this assessment on its own page →
Bleomycin, used in lymphoma and testicular cancer regimens, causes a distinctive dose-dependent lung injury that can progress to pulmonary fibrosis, occasionally fatal. The risk rises with cumulative dose and with age, and is worsened by high inspired oxygen and chest radiotherapy, which is why lung function is followed during therapy. The 139 co-reports (PRR 20.7) reflect both the real, cumulative effect and the drug's narrower use within specialised regimens.
Regulatory basis: bleomycin prescribing information (pulmonary toxicity/fibrosis warning; cumulative-dose limit; lung monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Lung injury develops with cumulative dosing and may progress to fibrosis |
| Strength | met | PRR 21 on a modest co-report count |
| Consistency | met | Reproduced across oncology case series |
| Specificity | met | A signature bleomycin effect |
| Biological gradient | met | Clearly cumulative-dose-related |
| Plausibility | met | Oxidative and inflammatory lung injury are the mechanisms |
| Coherence | met | Coheres with the labelled dose limit and lung monitoring |
| Experiment | partial | Dechallenge (withdrawal) may halt progression; no randomized trial |
| Analogy | met | Analogous to pulmonary fibrosis from methotrexate and amiodarone |
This page's own qualitative read, not an automated/citation-gated assessment.
Vincristine (vinca alkaloids) ↔ Peripheral neuropathy
Open this assessment on its own page →
Vincristine, a vinca-alkaloid chemotherapy drug, disrupts microtubules in nerve cells, producing a dose-limiting peripheral neuropathy — numbness, tingling, loss of reflexes, and sometimes painful weakness — that worsens with cumulative dosing and usually improves slowly after treatment ends. It is a direct consequence of the drug's mechanism and is a major reason doses are capped. The 645 co-reports (PRR 4.9) reflect both the real effect and the drug's central role in leukaemia and lymphoma regimens.
Regulatory basis: vincristine prescribing information (peripheral neuropathy warning; dose cap). Established vinca-alkaloid neuropathy literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Neuropathy develops and worsens with cumulative dosing and slowly improves after withdrawal |
| Strength | partial | PRR 5 on a moderate co-report count |
| Consistency | met | Reproduced across oncology practice |
| Specificity | met | A recognised vinca-alkaloid effect |
| Biological gradient | met | Cumulative-dose-related |
| Plausibility | met | Microtubule disruption in nerves is the mechanism |
| Coherence | met | Coheres with the labelled dose cap and monitoring |
| Experiment | partial | Dechallenge (withdrawal) usually leads to gradual improvement; no randomized trial |
| Analogy | met | Analogous to neuropathy from other vinca alkaloids and taxanes |
This page's own qualitative read, not an automated/citation-gated assessment.
Tamoxifen ↔ Venous thromboembolism
Open this assessment on its own page →
Tamoxifen, an anti-oestrogen used for hormone-receptor-positive breast cancer, raises the risk of blood clots — deep vein thrombosis and pulmonary embolism — by altering the balance of clotting factors, and this class of effect is shared with oestrogens and other hormonal treatments. The risk appears during treatment, is greater around surgery and immobility, and is a recognised, labelled hazard. The 112 co-reports (PRR 4.3) reflect both the real effect and the large number of women taking tamoxifen.
Regulatory basis: tamoxifen prescribing information (venous thromboembolism and stroke warning). Randomized breast-cancer trials.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Clots occur during treatment and risk falls after withdrawal |
| Strength | met | PRR 4 on a modest co-report count |
| Consistency | met | Reproduced across randomized breast-cancer trials |
| Specificity | met | A recognised tamoxifen/hormonal effect |
| Biological gradient | partial | Risk rises around surgery, immobility, and with age |
| Plausibility | met | Oestrogen-receptor modulation of clotting factors is the proposed mechanism |
| Coherence | met | Coheres with the labelled thromboembolism warning |
| Experiment | met | Randomized trials recorded thrombotic events by arm |
| Analogy | met | Analogous to VTE risk with oestrogens and other hormonal therapies |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (NCT00066703), N=2,638
| Term (as recorded) | T+OFS (n=1321) | E+OFS (n=1317) |
|---|---|---|
| Thrombosis/embolism (vascular access-related) — Injury, poisoning and procedural complications | 29 | 13 |
Serious vascular-access thrombosis/embolism occurred in 29 of 1,321 patients on tamoxifen versus 13 of 1,317 on exemestane in this randomized breast-cancer trial — a roughly two-fold excess, consistent with tamoxifen's established venous-thromboembolism risk. View on ClinicalTrials.gov →
Bortezomib (proteasome inhibitors) ↔ Peripheral neuropathy
Open this assessment on its own page →
Bortezomib, a proteasome inhibitor used in multiple myeloma, commonly causes a painful peripheral neuropathy that is dose-limiting and can be severe, though it often improves after dose reduction or when treatment is stopped. The risk is higher with intravenous than subcutaneous administration and with longer treatment. The very high FAERS count (6,473 co-reports, PRR 17.3) reflects both the real effect and how widely bortezomib is used in myeloma.
Regulatory basis: bortezomib prescribing information (peripheral neuropathy warning; dose-modification guidance). Established proteasome-inhibitor neuropathy literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Neuropathy develops during treatment and often improves after dose reduction or withdrawal |
| Strength | met | PRR 17 on a very large co-report count |
| Consistency | met | Reproduced across myeloma trials |
| Specificity | met | A recognised proteasome-inhibitor effect |
| Biological gradient | met | Related to dose, route (intravenous > subcutaneous), and duration |
| Plausibility | met | Nerve injury from proteasome inhibition is the proposed mechanism |
| Coherence | met | Coheres with the labelled dose-modification guidance |
| Experiment | partial | Dechallenge (dose reduction/withdrawal) usually improves it; no randomized trial |
| Analogy | met | Analogous to neuropathy from vincristine and platinum chemotherapy |
This page's own qualitative read, not an automated/citation-gated assessment.
Irinotecan ↔ Diarrhoea
Open this assessment on its own page →
Irinotecan, a topoisomerase-inhibitor chemotherapy drug, causes diarrhoea through direct damage to the gut lining, producing both an early (cholinergic) form soon after infusion and a later, more serious form a week or so afterwards. It is a direct, dose-related consequence of the drug's action on rapidly dividing cells, and the risk is greater in patients with certain UGT1A1 genotypes. The 1,721 co-reports (PRR 4.4) reflect both the real effect and the drug's wide use in colorectal cancer.
Regulatory basis: irinotecan prescribing information (severe diarrhoea warning; atropine for early-onset; UGT1A1 caution).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Diarrhoea occurs during and shortly after infusions and responds to dose adjustment |
| Strength | met | PRR 4 on a large co-report count |
| Consistency | met | Reproduced across colorectal-cancer trials |
| Specificity | met | A recognised irinotecan effect |
| Biological gradient | partial | Dose-related and genotypically influenced |
| Plausibility | met | Gut-lining injury by active metabolite SN-38 is the mechanism |
| Coherence | met | Coheres with the labelled diarrhoea-management guidance |
| Experiment | met | Randomized trials recorded diarrhoea by arm |
| Analogy | met | Analogous to diarrhoea from other topoisomerase inhibitors and fluoropyrimidines |
This page's own qualitative read, not an automated/citation-gated assessment.
Bevacizumab ↔ Hypertension
Open this assessment on its own page →
Bevacizumab, a VEGF-inhibiting cancer drug, causes high blood pressure by blocking the signalling that keeps blood vessels dilated, so hypertension is a predictable, dose-related consequence of its mechanism rather than an idiosyncratic reaction. It is usually manageable with standard blood-pressure drugs but can occasionally be severe, which is why pressure is monitored during therapy. The 5,851 co-reports (PRR 4.8) reflect both the real effect and the drug's wide use across many cancers.
Regulatory basis: bevacizumab prescribing information (hypertension warning; blood-pressure monitoring). Established VEGF-inhibitor hypertension literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Blood pressure rises during therapy and usually improves after withdrawal |
| Strength | met | PRR 5 on a very large co-report count |
| Consistency | met | Reproduced across bevacizumab trials |
| Specificity | met | A VEGF-inhibitor class effect |
| Biological gradient | partial | Dose-related |
| Plausibility | met | VEGF blockade reduces nitric-oxide-mediated vasodilation |
| Coherence | met | Coheres with the labelled blood-pressure monitoring |
| Experiment | partial | Randomized trials recorded hypertension by arm |
| Analogy | met | Analogous to hypertension with other VEGF-pathway inhibitors |
This page's own qualitative read, not an automated/citation-gated assessment.
Trastuzumab ↔ Cardiotoxicity / heart failure
Open this assessment on its own page →
Trastuzumab, a HER2-targeted breast-cancer drug, can cause a usually reversible decline in heart function and, less often, heart failure — especially when used with anthracyclines or in older patients. Because HER2 signalling helps the heart, blocking it can impair heart-muscle function, so heart function is measured before and during treatment. The 1,080 co-reports (PRR 4.2) reflect both the real effect and the drug's widespread use in HER2-positive breast and gastric cancer.
Regulatory basis: trastuzumab prescribing information (boxed warning for cardiomyopathy/heart failure; cardiac monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Heart function may decline during therapy and often recovers after withdrawal |
| Strength | partial | PRR 4 on a large co-report count |
| Consistency | met | Reproduced across breast-cancer trials |
| Specificity | met | A recognised trastuzumab effect, worse with anthracyclines |
| Biological gradient | partial | Risk rises with anthracycline co-therapy, age, and prior cardiac disease |
| Plausibility | met | HER2 blockade impairing heart-muscle survival signalling is the mechanism |
| Coherence | met | Coheres with the boxed warning and cardiac monitoring |
| Experiment | partial | Dechallenge (withdrawal) frequently improves heart function; no randomized trial |
| Analogy | met | Analogous to cardiotoxicity with anthracyclines and other HER2-targeted drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Nivolumab (checkpoint inhibitors) ↔ Immune-mediated colitis
Open this assessment on its own page →
Nivolumab, a PD-1 immune-checkpoint inhibitor, unleashes the immune system against cancer, and a predictable consequence is that the same immune activation can attack the gut, causing immune-mediated (autoimmune) colitis with diarrhoea that can be severe. It is a genuine, mechanism-based immune-related adverse event, appears during treatment, and is managed with steroids and sometimes drug withdrawal — which is why gut symptoms are watched closely during checkpoint-inhibitor therapy. The 2,268 co-reports (PRR 13.9) reflect both the real effect and the drug's wide use across cancers.
Regulatory basis: nivolumab prescribing information (immune-mediated colitis; management algorithms). Randomized trial results.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Colitis appears during immunotherapy and usually improves with steroids/withdrawal |
| Strength | met | PRR 14 on a large co-report count |
| Consistency | met | Reproduced across checkpoint-inhibitor trials |
| Specificity | met | A distinctive checkpoint-inhibitor effect, rare with chemotherapy |
| Biological gradient | partial | Related to immune activation rather than a simple dose gradient |
| Plausibility | met | Release of T-cell restraint leads to gut-directed autoimmunity |
| Coherence | met | Coheres with the labelled immune-colitis management guidance |
| Experiment | met | Randomized trials recorded colitis by arm |
| Analogy | met | Analogous to immune colitis with ipilimumab, pembrolizumab, and other checkpoint inhibitors |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02741570), N=909
| Term (as recorded) | Nivolumab + Ipilimumab (n=468) | EXTREME Regimen (n=441) |
|---|---|---|
| Autoimmune colitis — Gastrointestinal disorders | 1 | 0 |
| Colitis — Gastrointestinal disorders | 10 | 2 |
Serious colitis occurred in 10 of 468 patients on nivolumab plus ipilimumab versus 2 of 441 on standard chemotherapy, and autoimmune colitis was recorded only on the immunotherapy arm — a clean randomized confirmation of checkpoint-inhibitor colitis. View on ClinicalTrials.gov →
Ipilimumab (checkpoint inhibitors) ↔ Immune-mediated colitis
Open this assessment on its own page →
Ipilimumab, a CTLA-4 immune-checkpoint inhibitor, is the checkpoint drug most strongly linked with immune-mediated colitis — severe, sometimes life-threatening diarrhoea and gut inflammation caused by unleashing the immune system. It is a genuine, mechanism-based immune-related adverse event that appears during treatment and is managed with steroids and, for severe cases, the TNF inhibitor infliximab. The 2,316 co-reports (PRR 32.0) reflect both the real effect and the drug's use in melanoma and combination immunotherapy.
Regulatory basis: ipilimumab prescribing information (immune-mediated colitis; management algorithms including infliximab). Randomized trial results.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Colitis appears during immunotherapy and usually responds to steroids/withdrawal |
| Strength | met | PRR 32 on a large co-report count |
| Consistency | met | Reproduced across ipilimumab trials |
| Specificity | met | A distinctive CTLA-4-inhibitor effect |
| Biological gradient | met | Related to immune activation rather than a simple dose gradient |
| Plausibility | met | Release of T-cell restraint leads to gut-directed autoimmunity |
| Coherence | met | Coheres with the labelled immune-colitis management guidance |
| Experiment | met | A randomized trial recorded colitis only in the combination arm |
| Analogy | met | Analogous to immune colitis with PD-1 inhibitors (nivolumab, pembrolizumab) |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — nivolumab + ipilimumab vs nivolumab alone in small-cell lung cancer (CheckMate-032, NCT01928394), N=402
| Term (as recorded) | Combination nivolumab + ipilimumab (n=157) | Nivolumab alone (n=245) |
|---|---|---|
| Colitis (serious) | 6 | 0 |
| Immune-mediated enterocolitis (serious) | 1 | 0 |
Serious colitis and immune-mediated enterocolitis were recorded only in the combination arm in the small-cell-lung-cancer cohorts of CheckMate-032 — direct randomized evidence that adding ipilimumab to nivolumab raises the immune-colitis rate. View on ClinicalTrials.gov →
Cetuximab ↔ Hypomagnesaemia
Open this assessment on its own page →
Cetuximab, an EGFR-targeted cancer drug, damages the kidney's ability to reabsorb magnesium, producing hypomagnesaemia that can be prolonged and require replacement — a physiological consequence of blocking EGFR signalling in the renal tubule, not an idiosyncratic reaction. Because it can be significant and recurrent, magnesium is monitored during therapy. The 596 co-reports (PRR 30.2) reflect both the real effect and the drug's use in head-and-neck and colorectal cancer.
Regulatory basis: cetuximab prescribing information (hypomagnesaemia and electrolyte-monitoring warning). Established EGFR-inhibitor magnesium-wasting literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Magnesium falls during therapy and recovers after withdrawal with replacement |
| Strength | met | PRR 30 on a moderate co-report count |
| Consistency | met | Reproduced across EGFR-inhibitor studies |
| Specificity | met | A recognised EGFR-inhibitor class effect |
| Biological gradient | met | Dose-related |
| Plausibility | met | Renal tubular magnesium wasting from EGFR blockade is the mechanism |
| Coherence | met | Coheres with the labelled electrolyte monitoring |
| Experiment | partial | Randomized trials recorded magnesium changes by arm |
| Analogy | met | Analogous to hypomagnesaemia from panitumumab and other EGFR inhibitors |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02741570), N=909
| Term (as recorded) | Nivolumab + Ipilimumab (n=468) | EXTREME Regimen (n=441) |
|---|---|---|
| Hypomagnesaemia — Metabolism and nutrition disorders | 0 | 2 |
| Hypomagnesaemia — Metabolism and nutrition disorders | 34 | 146 |
In the EXTREME (cetuximab-containing) regimen of this randomized trial, all-grade hypomagnesaemia was recorded in 146 of 441 patients versus 34 of 468 on the comparator immunotherapy arm — a large excess consistent with cetuximab-induced renal magnesium wasting. View on ClinicalTrials.gov →
Nevirapine ↔ Hepatotoxicity
Open this assessment on its own page →
Nevirapine, an HIV drug, carries a boxed warning for severe, sometimes fatal liver toxicity, including fulminant hepatitis that occurs most often in the first weeks of therapy and is more common in women with higher baseline liver enzymes. The reaction is genuinely drug-related, and it is why liver tests are monitored closely after starting the drug and why treatment is stopped at the first sign of hepatitis. The 170 co-reports (PRR 18.1) reflect both the real effect and the drug's use in HIV treatment, especially in resource-limited settings.
Regulatory basis: nevirapine prescribing information (boxed warning for severe hepatotoxicity; liver monitoring after initiation).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Liver injury typically appears in the first weeks of therapy |
| Strength | met | PRR 18 on a modest co-report count |
| Consistency | met | Reproduced across HIV cohorts |
| Specificity | met | A recognised nevirapine effect, strongest early in treatment |
| Biological gradient | partial | Higher in women and with higher baseline liver enzymes |
| Plausibility | met | Immune-mediated and direct hepatocellular injury are proposed |
| Coherence | met | Coheres with the boxed warning and early liver monitoring |
| Experiment | partial | Dechallenge (withdrawal) is essential and can be life-saving; no randomized trial |
| Analogy | met | Analogous to hepatotoxicity from other antiretrovirals (nevirapine-class) |
This page's own qualitative read, not an automated/citation-gated assessment.
Abacavir ↔ Hypersensitivity reaction
Open this assessment on its own page →
Abacavir causes a potentially life-threatening hypersensitivity reaction — fever, rash, gut and breathing symptoms that worsen with each dose and can be fatal on rechallenge — and this reaction is strongly tied to the HLA-B*57:01 genetic marker. Because screening for that allele before starting the drug nearly eliminates the risk, abacavir is one of the clearest examples of pharmacogenomic testing preventing a serious adverse reaction. The 200 co-reports (PRR 3.8) reflect both the real effect and the drug's use in HIV therapy.
Regulatory basis: abacavir prescribing information (boxed warning for hypersensitivity; HLA-B*57:01 screening; never rechallenge).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Reaction appears within weeks of starting and is severe on rechallenge |
| Strength | partial | PRR 4 on a modest co-report count |
| Consistency | met | Reproduced and mechanistically linked to HLA-B*57:01 |
| Specificity | met | A highly distinctive abacavir reaction |
| Biological gradient | partial | Determined by genotype rather than dose |
| Plausibility | met | HLA-B*57:01-restricted T-cell activation is the mechanism |
| Coherence | met | Coheres with the boxed warning and mandatory genetic screening |
| Experiment | met | Genetic screening (a controlled intervention) prevents it — a real-world experiment |
| Analogy | met | Analogous to other HLA-linked drug hypersensitivities (carbamazepine, allopurinol) |
This page's own qualitative read, not an automated/citation-gated assessment.
Zidovudine ↔ Anaemia / bone-marrow suppression
Open this assessment on its own page →
Zidovudine, an early HIV drug, suppresses the bone marrow and causes anaemia, usually a macrocytic anaemia that appears after weeks to months of therapy, especially at higher doses. It is a direct, dose-related consequence of the drug's inhibition of DNA synthesis in marrow cells rather than an idiosyncratic reaction, and it is why blood counts are monitored during treatment. The 935 co-reports (PRR 7.8) reflect both the real effect and zidovudine's role in HIV care.
Regulatory basis: zidovudine prescribing information (haematologic toxicity warning; blood-count monitoring). Established zidovudine-myelosuppression literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Anaemia develops during therapy and improves after dose reduction or withdrawal |
| Strength | met | PRR 8 on a large co-report count |
| Consistency | met | Reproduced across HIV trials |
| Specificity | met | A recognised zidovudine effect, less typical of newer antivirals |
| Biological gradient | met | Dose-related |
| Plausibility | met | Marrow-cell DNA-synthesis inhibition is the mechanism |
| Coherence | met | Coheres with the labelled blood-count monitoring |
| Experiment | partial | Dechallenge (dose reduction/withdrawal) allows marrow recovery; no randomized trial |
| Analogy | met | Analogous to myelosuppression from ganciclovir and other nucleoside analogues |
This page's own qualitative read, not an automated/citation-gated assessment.
Efavirenz ↔ Depression / neuropsychiatric effects
Open this assessment on its own page →
Efavirenz, a non-nucleoside HIV drug, commonly causes central-nervous-system effects — vivid dreams, dizziness, insomnia, and mood disturbance including depression — that often ease after the first weeks but can persist. The drug carries labelled warnings about psychiatric symptoms and suicidal thinking. The 461 co-reports (PRR 3.8) reflect both the real effect and efavirenz's long-standing role in HIV regimens, especially in resource-limited settings.
Regulatory basis: efavirenz prescribing information (neuropsychiatric symptoms, depression, and suicidality warnings).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Neuropsychiatric symptoms appear early in therapy and may ease or persist |
| Strength | partial | PRR 4 on a moderate co-report count |
| Consistency | met | Reproduced across HIV cohorts |
| Specificity | partial | A recognised efavirenz effect, less typical of other antiretrovirals |
| Biological gradient | partial | Partly dose-related |
| Plausibility | met | Central-nervous-system effects of the drug are the proposed mechanism |
| Coherence | met | Coheres with the labelled psychiatric warnings |
| Experiment | partial | Dechallenge (withdrawal/switch) usually improves symptoms; no randomized trial |
| Analogy | met | Analogous to neuropsychiatric effects of some other antiretrovirals |
This page's own qualitative read, not an automated/citation-gated assessment.
Sildenafil (PDE5 inhibitors) ↔ Non-arteritic anterior ischaemic optic neuropathy (NAION)
Open this assessment on its own page →
Sildenafil and related PDE5 inhibitors have been linked to non-arteritic anterior ischaemic optic neuropathy (NAION), a sudden painless loss of vision from reduced blood flow to the optic nerve. This prompted an FDA label update in 2005; the association is debated and partly confounded by vascular risk factors that are common in the men who use the drug, so it is best described as an uncommon, plausibly drug-associated event rather than a certainty. The 90 co-reports (PRR 9.4) reflect both the signal and the difficulty of separating drug effect from background vascular risk.
Regulatory basis: sildenafil prescribing information (FDA 2005 label change on NAION; caution in patients with NAION history).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Vision loss occurs in a temporal relationship to use in case reports |
| Strength | partial | PRR 9 on a small co-report count — a modest signal for a rare event |
| Consistency | met | Case reports and observational studies, but with confounding by shared vascular risk |
| Specificity | met | A recognised drug-associated optic event, though other causes exist |
| Biological gradient | partial | Not clearly dose-related |
| Plausibility | met | Reduced optic-nerve perfusion is the proposed mechanism |
| Coherence | met | Coheres with the FDA label change and caution in at-risk patients |
| Experiment | partial | Observational and confounded; no randomized trial |
| Analogy | met | Analogous to NAION attributed to other vasoactive drugs |
This page's own qualitative read, not an automated/citation-gated assessment.
Bosentan ↔ Hepatotoxicity
Open this assessment on its own page →
Bosentan, used for pulmonary arterial hypertension, causes a dose-related rise in liver enzymes that can occasionally amount to clinically significant liver injury, and it carries a boxed warning requiring monthly liver-function testing for the whole duration of treatment. Because the effect appears during therapy and usually reverses when the drug is stopped, monitoring is the key safety measure. The 258 co-reports (PRR 2.9) reflect both the real effect and the drug's specialised use in a narrow patient group.
Regulatory basis: bosentan prescribing information (boxed warning for hepatotoxicity; mandatory monthly liver-function testing).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Liver enzymes rise during therapy and fall after withdrawal |
| Strength | partial | PRR 3 on a modest co-report count |
| Consistency | met | Reproduced across the bosentan trial programme |
| Specificity | met | A recognised bosentan effect, uncommon with many drugs |
| Biological gradient | met | Dose-related |
| Plausibility | met | Direct hepatotoxicity (with some evidence of immune involvement) is proposed |
| Coherence | met | Coheres with the boxed warning and monthly monitoring requirement |
| Experiment | partial | Dechallenge (withdrawal) reverses the enzyme rise; no randomized trial |
| Analogy | met | Analogous to hepatotoxicity from other endothelin-receptor antagonists |
This page's own qualitative read, not an automated/citation-gated assessment.
Sotalol ↔ QT prolongation / torsades
Open this assessment on its own page →
Sotalol, an anti-arrhythmic drug, prolongs the QT interval as part of its mechanism and can itself provoke the dangerous arrhythmia torsades de pointes — a paradox that is why treatment is started under monitoring and why the drug carries a prominent warning. The risk is dose-related and rises with renal impairment, female sex, and low potassium or magnesium. The 446 co-reports (PRR 15.9) reflect both the real, structurally-based effect and the drug's use in atrial and ventricular arrhythmias.
Regulatory basis: sotalol prescribing information (boxed warning for proarrhythmia/torsades; monitored initiation).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | QT prolongation is measured during therapy and resolves after withdrawal |
| Strength | met | PRR 16 on a moderate co-report count |
| Consistency | met | Reproduced across studies of the class III action |
| Specificity | met | A recognised anti-arrhythmic effect |
| Biological gradient | met | Dose-related and worse with renal impairment and electrolyte disturbance |
| Plausibility | met | Delayed cardiac repolarisation (class III action) is the mechanism |
| Coherence | met | Coheres with the boxed warning and monitored initiation |
| Experiment | partial | Dechallenge (withdrawal) reverses the QT prolongation; no randomized trial |
| Analogy | met | Analogous to proarrhythmia from other class III anti-arrhythmics |
This page's own qualitative read, not an automated/citation-gated assessment.
Flecainide ↔ Proarrhythmia
Open this assessment on its own page →
Flecainide, a sodium-channel-blocking anti-arrhythmic, can paradoxically provoke serious ventricular arrhythmias — a proarrhythmic effect most dangerous in patients with structural heart disease, as tragically shown in the CAST trial, which found increased deaths when these drugs were used after a heart attack. It is a genuine, mechanism-based hazard and is why flecainide is avoided in structural heart disease and started under monitoring. The 99 co-reports (PRR 8.3) reflect both the real effect and the drug's continued use in selected arrhythmias.
Regulatory basis: flecainide prescribing information (proarrhythmia warning; contraindication in structural heart disease). Cardiac Arrhythmia Suppression Trial (CAST).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Arrhythmias occur during treatment, particularly in structurally abnormal hearts |
| Strength | partial | PRR 8 on a small co-report count |
| Consistency | met | Established by the randomized CAST trial and subsequent studies |
| Specificity | met | A class effect of sodium-channel-blocking anti-arrhythmics |
| Biological gradient | met | Worse in structural heart disease and at higher doses |
| Plausibility | met | Slowed conduction creating re-entry circuits is the mechanism |
| Coherence | met | Coheres with the labelled contraindication in structural heart disease |
| Experiment | met | Randomized evidence (CAST) showed increased mortality |
| Analogy | met | Analogous to proarrhythmia from other class I anti-arrhythmics |
This page's own qualitative read, not an automated/citation-gated assessment.
Infliximab (TNF inhibitors) ↔ Tuberculosis reactivation
Open this assessment on its own page →
TNF inhibitors such as infliximab suppress a cytokine that is essential for containing tuberculosis, so they can reactivate latent TB — a serious, sometimes disseminated infection that is why patients are screened and treated for latent TB before starting therapy. The risk is a genuine, mechanism-based consequence of the drug's immunology and is the subject of a boxed warning. The very high FAERS count (2,003 co-reports, PRR 17.7) reflects both the real effect and the drug's wide use in inflammatory disease.
Regulatory basis: infliximab prescribing information (boxed warning for serious infections including TB; latent-TB screening before therapy).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Reactivation occurs during therapy, often early, and requires stopping the drug and treating TB |
| Strength | met | PRR 18 on a large co-report count |
| Consistency | met | Reproduced across the TNF-inhibitor class and registries |
| Specificity | met | A class effect of TNF inhibitors |
| Biological gradient | partial | Related to the degree of immunosuppression rather than a simple dose gradient |
| Plausibility | met | TNF blockade impairs granuloma formation needed to contain TB |
| Coherence | met | Coheres with the boxed warning and mandatory screening |
| Experiment | partial | A randomized trial recorded TB on infliximab and not on the comparator arms |
| Analogy | met | Analogous to TB risk with adalimumab and other TNF inhibitors |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis (NCT00095147), N=803
| Term (as recorded) | ABA (DB) (n=156) | ABA + MTX [OL] (n=372) | INF + MTX [DB] (n=165) | PLA + MTX [DB] (n=110) |
|---|---|---|---|---|
| PULMONARY TUBERCULOSIS — Infections and infestations | 0 | 0 | 1 | 0 |
| PERITONEAL TUBERCULOSIS — Infections and infestations | 0 | 0 | 1 | 0 |
Serious pulmonary and peritoneal tuberculosis each occurred once in the infliximab arm and in none of the other arms of this randomized trial — a rare event, but exactly the reactivation pattern behind the TNF-inhibitor tuberculosis boxed warning and mandated screening. View on ClinicalTrials.gov →
Lenalidomide (IMiDs) ↔ Venous thromboembolism
Open this assessment on its own page →
Lenalidomide, used in multiple myeloma and some blood cancers, raises the risk of venous thromboembolism — deep vein thrombosis and pulmonary embolism — especially when combined with steroids or in myeloma, which is why routine thromboprophylaxis (aspirin or an anticoagulant) is standard during therapy. The risk is a genuine, label-warned effect tied to the drug's immunomodulatory and procoagulant actions. The very high FAERS count (7,546 co-reports, PRR 5.1) reflects both the real effect and the drug's extensive use.
Regulatory basis: lenalidomide prescribing information (boxed warning for venous thromboembolism; thromboprophylaxis recommendations).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Clots occur during therapy and the risk falls after withdrawal and with prophylaxis |
| Strength | met | PRR 5 on a very large co-report count |
| Consistency | met | Reproduced across myeloma trials |
| Specificity | met | A recognised IMiD effect, worse with steroids |
| Biological gradient | partial | Related to combination therapy and disease type |
| Plausibility | met | Procoagulant effects of the drug are the proposed mechanism |
| Coherence | met | Coheres with the boxed warning and routine thromboprophylaxis |
| Experiment | met | A randomized trial recorded pulmonary embolism on lenalidomide versus placebo |
| Analogy | met | Analogous to VTE risk with thalidomide and pomalidomide |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy (NCT00774345), N=315
| Term (as recorded) | Lenalidomide (n=158) | Placebo (n=157) |
|---|---|---|
| Pulmonary embolism — Respiratory, thoracic and mediastinal disorders | 4 | 1 |
Serious pulmonary embolism occurred in 4 of 158 patients on lenalidomide versus 1 of 157 on placebo in this maintenance trial — echoing the venous-thromboembolism signal that dictates routine thromboprophylaxis with lenalidomide. View on ClinicalTrials.gov →
Aripiprazole (antipsychotics) ↔ Akathisia
Open this assessment on its own page →
Aripiprazole, a widely used antipsychotic, commonly causes akathisia — an intense inner restlessness and urge to move that is distressing and a frequent reason patients stop treatment. It is a genuine, partly dose-related consequence of dopamine-receptor modulation, shared across antipsychotics but often prominent with aripiprazole. The very high FAERS count (3,031 co-reports, PRR 49.1) reflects both the real effect and the drug's extensive use in schizophrenia, bipolar disorder, and as an add-on antidepressant.
Regulatory basis: aripiprazole prescribing information (akathisia and extrapyramidal symptoms).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Akathisia appears during treatment and improves after dose reduction or withdrawal |
| Strength | met | PRR 49 on a large co-report count |
| Consistency | met | Reproduced across antipsychotic trials |
| Specificity | partial | A class effect of antipsychotics, prominent with aripiprazole |
| Biological gradient | partial | Partly dose-related |
| Plausibility | met | Dopamine-receptor modulation is the mechanism |
| Coherence | met | Coheres with the labelled extrapyramidal-symptom advice |
| Experiment | met | A randomized trial recorded akathisia, at a higher rate on aripiprazole |
| Analogy | met | Analogous to akathisia from other antipsychotics |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients (NCT01328093), N=942
| Term (as recorded) | LY2140023-DB (n=511) | Aripiprazole-DB (n=161) | LY2140023-OL (n=270) |
|---|---|---|---|
| Akathisia — Nervous system disorders | 13 | 12 | 2 |
Akathisia was recorded in 12 of 161 patients on aripiprazole versus 13 of 511 on the comparator in this randomized schizophrenia trial — a lower absolute count but a roughly three-fold higher rate, consistent with the drug's well-known restlessness signal. View on ClinicalTrials.gov →
Verapamil (non-dihydropyridine CCBs) ↔ Bradycardia / AV block
Open this assessment on its own page →
Verapamil slows the heart by blocking calcium channels in the AV node, so bradycardia and heart block are the direct, predictable extension of its pharmacology rather than idiosyncratic effects. The risk is dose-related and is greatest with other rate-slowing drugs or in patients with conduction disease, which is why the drug is avoided in some arrhythmias and heart failure. The 213 co-reports (PRR 19.9) reflect both the real effect and verapamil's use for hypertension and arrhythmias.
Regulatory basis: verapamil prescribing information (bradycardia/AV block warning; contraindications in certain arrhythmias and heart failure).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bradycardia occurs during treatment and resolves after withdrawal |
| Strength | met | PRR 20 on a modest co-report count |
| Consistency | met | Reproduced across calcium-channel-blocker practice |
| Specificity | met | Shared with diltiazem and other AV-node-slowing drugs |
| Biological gradient | partial | Dose-related and worse with conduction disease |
| Plausibility | met | AV-node calcium-channel blockade is the mechanism |
| Coherence | met | Coheres with the labelled contraindications |
| Experiment | partial | Dechallenge (withdrawal) reverses it; no randomized trial |
| Analogy | met | Analogous to bradycardia with diltiazem and beta-blockers |
This page's own qualitative read, not an automated/citation-gated assessment.
Diltiazem (non-dihydropyridine CCBs) ↔ Bradycardia / AV block
Open this assessment on its own page →
Diltiazem, like verapamil, slows AV-node conduction by blocking calcium channels, so bradycardia and heart block are expected, dose-related consequences of its mechanism rather than idiosyncratic reactions. The risk is greater with other rate-slowing drugs and in patients with conduction disease or heart failure, which is why it is used cautiously in those settings. The 540 co-reports (PRR 6.3) reflect both the real effect and the drug's wide use for hypertension and rate control.
Regulatory basis: diltiazem prescribing information (bradycardia/AV block warning; caution in heart failure).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bradycardia occurs during treatment and resolves after withdrawal |
| Strength | met | PRR 6 on a moderate co-report count |
| Consistency | met | Reproduced across calcium-channel-blocker practice |
| Specificity | met | Shared with verapamil and other AV-node-slowing drugs |
| Biological gradient | partial | Dose-related and worse with conduction disease |
| Plausibility | met | AV-node calcium-channel blockade is the mechanism |
| Coherence | met | Coheres with the labelled cautions |
| Experiment | partial | Dechallenge (withdrawal) reverses it; no randomized trial |
| Analogy | met | Analogous to bradycardia with verapamil and beta-blockers |
This page's own qualitative read, not an automated/citation-gated assessment.
Nifedipine (dihydropyridine CCBs) ↔ Peripheral oedema
Open this assessment on its own page →
Nifedipine and other dihydropyridine calcium-channel blockers dilate the small arteries more than the veins, so fluid shifts into the tissues of the ankles and legs — a predictable, dose-related consequence of the mechanism rather than an idiosyncratic reaction. The swelling is a common reason patients stop these drugs, and it is not a sign of heart or kidney failure itself. The 1,063 co-reports (PRR 3.9) reflect both the real effect and the very wide use of these drugs for hypertension and angina.
Regulatory basis: nifedipine prescribing information (peripheral oedema as an adverse reaction). Established dihydropyridine-oedema literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Oedema develops during treatment and resolves after withdrawal |
| Strength | met | PRR 4 on a large co-report count |
| Consistency | met | Reproduced across dihydropyridine trials |
| Specificity | met | A class effect of dihydropyridines, rare with verapamil/diltiazem |
| Biological gradient | partial | Dose-related |
| Plausibility | met | Precapillary arteriolar dilation raising capillary pressure is the mechanism |
| Coherence | met | Coheres with the labelled oedema and the practice of adding an ACE inhibitor/ARB |
| Experiment | partial | Dechallenge (withdrawal) usually resolves it; no randomized trial |
| Analogy | met | Analogous to oedema with amlodipine and other dihydropyridines |
This page's own qualitative read, not an automated/citation-gated assessment.
Amlodipine (dihydropyridine CCBs) ↔ Peripheral oedema
Open this assessment on its own page →
Amlodipine, one of the most prescribed blood-pressure drugs, commonly causes ankle and leg swelling for the same reason as other dihydropyridines: it dilates the precapillary arterioles more than the veins, raising capillary pressure and pushing fluid into the tissues. The effect is dose-related and is often reduced by adding an ACE inhibitor or ARB. The very high FAERS count (4,541 co-reports, PRR 3.0) reflects both the real effect and amlodipine's enormous patient population.
Regulatory basis: amlodipine prescribing information (peripheral oedema as a common adverse reaction). Established dihydropyridine-oedema literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Oedema develops during treatment and resolves after withdrawal |
| Strength | met | PRR 3 with a very large co-report count — common but not highly disproportionate |
| Consistency | met | Reproduced across dihydropyridine trials |
| Specificity | met | A class effect of dihydropyridines, rare with verapamil/diltiazem |
| Biological gradient | partial | Dose-related |
| Plausibility | met | Precapillary arteriolar dilation raising capillary pressure is the mechanism |
| Coherence | met | Coheres with the labelled oedema and the RAAS-blocker combination strategy |
| Experiment | partial | Dechallenge (withdrawal) usually resolves it; no randomized trial |
| Analogy | met | Analogous to oedema with nifedipine and other dihydropyridines |
This page's own qualitative read, not an automated/citation-gated assessment.
Furosemide (loop diuretics) ↔ Hypokalaemia
Open this assessment on its own page →
Furosemide, a loop diuretic, increases the amount of sodium reaching the distal nephron, where it is exchanged for potassium, so it lowers serum potassium — a direct, dose-related consequence of how it works and a common reason for electrolyte monitoring during diuretic therapy. The risk is greater at higher doses, in older patients, and with other potassium-losing drugs. The very high FAERS count (5,325 co-reports, PRR 6.8) reflects both the real effect and the enormous use of loop diuretics.
Regulatory basis: furosemide prescribing information (hypokalaemia and electrolyte-monitoring warning). Established loop-diuretic literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Potassium falls during treatment and is corrected with replacement/dose adjustment |
| Strength | met | PRR 7 on a very large co-report count |
| Consistency | met | Reproduced across diuretic trials |
| Specificity | met | A class effect, less typical of potassium-sparing diuretics |
| Biological gradient | partial | Dose-related and worse in older patients |
| Plausibility | met | Increased distal sodium delivery driving potassium loss is the mechanism |
| Coherence | met | Coheres with the labelled electrolyte-monitoring advice |
| Experiment | met | A trial recorded hypokalaemia on furosemide and in none of the comparator arm |
| Analogy | met | Analogous to hypokalaemia from thiazide and other loop diuretics |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study (NCT04593823), N=51
| Term (as recorded) | Furoscix Infusor (n=34) | Continued Medical Therapy (n=17) |
|---|---|---|
| Hypokalaemia — Metabolism and nutrition disorders | 7 | 0 |
Hypokalaemia was reported in 7 of 34 patients receiving the furosemide infusor versus 0 of 17 on continued oral therapy in this small pilot — directionally consistent with loop-diuretic potassium loss, though too small to estimate a rate. View on ClinicalTrials.gov →
Eplerenone (MR antagonists) ↔ Hyperkalaemia
Open this assessment on its own page →
Eplerenone blocks aldosterone in the distal nephron, so it retains potassium — hyperkalaemia is the direct, dose-related extension of its intended action rather than a side effect. The risk is greatest when it is combined with ACE inhibitors, ARBs, or potassium supplements, or in patients with kidney disease, which is why potassium and kidney function are checked before and during therapy. The 413 co-reports (PRR 19.7) reflect both the real effect and the drug's use after heart attacks and in heart failure.
Regulatory basis: eplerenone prescribing information (hyperkalaemia warning; potassium and renal monitoring).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Potassium rises during treatment and falls after withdrawal |
| Strength | met | PRR 20 on a modest co-report count |
| Consistency | met | Reproduced across heart-failure trials |
| Specificity | met | A mineralocorticoid-antagonist class effect |
| Biological gradient | met | Dose-related and worse with renal impairment or RAAS blockade |
| Plausibility | met | Reduced distal potassium excretion is the mechanism |
| Coherence | met | Coheres with the labelled potassium monitoring |
| Experiment | partial | Randomized trials measured potassium by arm |
| Analogy | met | Analogous to hyperkalaemia with spironolactone |
This page's own qualitative read, not an automated/citation-gated assessment.
Clonidine ↔ Rebound hypertension / withdrawal syndrome
Open this assessment on its own page →
Stopping clonidine abruptly causes a rebound surge in blood pressure, with agitation, sweating, and tremor, because the drug suppresses central sympathetic outflow and the body overshoots when it is removed. This is a genuine, predictable consequence of the drug's mechanism rather than an idiosyncratic reaction, and it is prevented by tapering the dose. The 741 co-reports (PRR 3.5) reflect both the real effect and clonidine's use for hypertension and other conditions.
Regulatory basis: clonidine prescribing information (rebound hypertension on abrupt withdrawal; tapering guidance).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Symptoms appear on abrupt withdrawal and resolve on restarting or tapering |
| Strength | met | PRR 4 on a moderate co-report count |
| Consistency | met | Reproduced across decades of clonidine experience |
| Specificity | met | A recognised clonidine effect, uncommon with many drugs |
| Biological gradient | partial | Tied to how abruptly the drug is stopped |
| Plausibility | met | Loss of central sympathetic suppression causing rebound is the mechanism |
| Coherence | met | Coheres with the labelled tapering guidance |
| Experiment | partial | Dechallenge (taper/restart) reproducibly controls it; no randomized trial |
| Analogy | met | Analogous to rebound phenomena with beta-blockers and other antihypertensives |
This page's own qualitative read, not an automated/citation-gated assessment.
Warfarin ↔ Warfarin-induced skin necrosis
Open this assessment on its own page →
Warfarin can cause skin necrosis — a rare, painful, sometimes disfiguring reaction in which blood clots form in the small vessels of the skin, most often in the first days of therapy and in areas of fat such as the breast, thighs, and buttocks. It is thought to occur when warfarin's early depletion of protein C (a natural anticoagulant) briefly leaves the clotting system unbalanced, and it is why large loading doses are avoided and why protein-C-deficient patients are at particular risk. The 345 co-reports (PRR 11.7) reflect both the real effect and warfarin's enormous use.
Regulatory basis: warfarin prescribing information (skin necrosis warning; caution in protein C/S deficiency). Established warfarin-skin-necrosis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Necrosis appears in the first days of therapy and stops after withdrawal |
| Strength | partial | PRR 12 on a modest co-report count |
| Consistency | met | Reproduced across case series tied to protein C/S deficiency |
| Specificity | met | A distinctive warfarin effect |
| Biological gradient | partial | Linked to rapid initial dose and to protein-C deficiency |
| Plausibility | met | Early protein-C depletion unbalancing coagulation is the mechanism |
| Coherence | met | Coheres with the labelled caution and the avoidance of loading doses |
| Experiment | partial | Dechallenge (withdrawal, plus vitamin K in severe cases) resolves it; no randomized trial |
| Analogy | met | Analogous to skin necrosis reported with other vitamin-K antagonists |
This page's own qualitative read, not an automated/citation-gated assessment.
Enoxaparin (low-molecular-weight heparins) ↔ Heparin-induced thrombocytopenia (HIT)
Open this assessment on its own page →
Enoxaparin, like unfractionated heparin, can cause heparin-induced thrombocytopenia — an immune reaction in which antibodies activate platelets, dropping the platelet count and paradoxically promoting clotting. It is less common with low-molecular-weight heparins than with unfractionated heparin but is still a recognised and serious effect, and it is why platelet counts are watched during therapy and why a non-heparin anticoagulant is used if HIT is suspected. The 637 co-reports (PRR 54.1) reflect both the real effect and the very wide use of enoxaparin.
Regulatory basis: enoxaparin prescribing information (HIT warning; platelet monitoring). Established low-molecular-weight-heparin HIT literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Platelets fall days into exposure and recover after heparinoid withdrawal |
| Strength | met | PRR 54 on a moderate co-report count |
| Consistency | met | Reproduced across the heparinoid class |
| Specificity | met | A class effect, though less frequent than with unfractionated heparin |
| Biological gradient | partial | Risk varies with duration and patient group, not a simple dose gradient |
| Plausibility | met | Anti-PF4 antibody-mediated platelet activation is the mechanism |
| Coherence | met | Coheres with routine platelet monitoring during therapy |
| Experiment | partial | Dechallenge (switching to a non-heparin anticoagulant) is standard; no placebo RCT |
| Analogy | met | Analogous to HIT with unfractionated heparin and dalteparin |
This page's own qualitative read, not an automated/citation-gated assessment.
Apixaban ↔ Gastrointestinal bleeding
Open this assessment on its own page →
Apixaban, a direct factor Xa inhibitor, increases the risk of bleeding — including from the gut — as the expected pharmacodynamic consequence of anticoagulation, though its gastrointestinal bleeding rate is lower than warfarin's in the major randomized trials. The risk is dose-related and is greater with age, kidney impairment, and interacting drugs. The 1,649 co-reports (PRR 6.3) reflect both the real effect and apixaban's very large real-world use.
Regulatory basis: apixaban prescribing information (bleeding warning); ARISTOTLE randomized trial versus warfarin.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding occurs during anticoagulation and typically stops after withdrawal |
| Strength | met | PRR 6 on a large co-report count |
| Consistency | met | Reproduced in randomized outcome trials and large cohorts |
| Specificity | partial | An anticoagulant-class effect rather than apixaban-specific |
| Biological gradient | partial | Dose-related and worse with age, renal impairment, and interacting drugs |
| Plausibility | met | Factor Xa inhibition impairs haemostasis as the pharmacodynamic extension |
| Coherence | met | Coheres with the bleeding-focused labelling |
| Experiment | met | Randomized evidence (ARISTOTLE) quantifies the risk |
| Analogy | met | Analogous to bleeding with rivaroxaban, dabigatran, and warfarin |
This page's own qualitative read, not an automated/citation-gated assessment.
Sitagliptin (DPP-4 inhibitors) ↔ Pancreatitis
Open this assessment on its own page →
Sitagliptin, a DPP-4 inhibitor for type 2 diabetes, attracted a pancreatitis signal from early case reports and spontaneous reporting, and regulators added a warning in the mid-2010s. However, the large randomized cardiovascular-outcome trials of these drugs did not show a clear increase in pancreatitis, so the association remains contested rather than established. The high FAERS count (2,226 co-reports, PRR 12.8) reflects the reporting that drove the initial concern as much as any true effect, and is a good illustration of why disproportionality alone cannot settle causation.
Regulatory basis: FDA 2015 labelling changes for DPP-4 inhibitors (pancreatitis); randomized cardiovascular-outcome trials (e.g. TECOS) that did not confirm an excess.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Pancreatitis in reports follows drug exposure, but temporality is non-specific |
| Strength | partial | PRR 13 on a large co-report count, but driven substantially by reporting |
| Consistency | met | Early case reports and spontaneous data, not consistently reproduced in trials |
| Specificity | partial | Pancreatitis has many causes, so specificity is limited |
| Biological gradient | partial | Confounded by obesity, gallstones, and alcohol common in this population |
| Plausibility | met | No established mechanism specific to DPP-4 inhibition |
| Coherence | met | The labelled warning is precautionary rather than mechanism-based |
| Experiment | partial | Large randomized trials did not confirm an increased risk |
| Analogy | met | Analogous to the contested incretin-pancreatitis question |
This page's own qualitative read, not an automated/citation-gated assessment.
Ivabradine ↔ Bradycardia
Open this assessment on its own page →
Ivabradine selectively inhibits the If (funny) pacemaker current in the sinoatrial node, slowing heart rate without reducing contractility — so bradycardia is its core, intended action and excessive slowing is its principal hazard. This dataset's 256 co-reports (PRR 14.9) are enriched for patients also taking rate-limiting drugs (beta-blockers, non-dihydropyridine calcium-channel blockers), where the effect is amplified.
Regulatory basis: ivabradine (Corlanor) prescribing information — bradycardia and heart-block warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Rate slowing begins with the first dose |
| Strength | met | PRR 14.9, a large signal here |
| Consistency | met | Reproduced across trials and series |
| Specificity | partial | Shared with other rate-lowering drugs when combined |
| Biological gradient | met | Dose-dependent and amplified by beta-blockers |
| Plausibility | met | Direct SA-node If inhibition |
| Coherence | met | Fits its pharmacology exactly |
| Experiment | met | Heart-rate reduction is the intended trial-measured effect |
| Analogy | met | Analogous to beta-blocker bradycardia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure (NCT02446990)
| Adverse event | Ivabradine (n=9539) · Placebo (n=9544) | |
|---|---|---|
| Bradycardia | 101/9539 | 21/9544 |
| Sinus bradycardia | 48/9539 | 7/9544 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Ranolazine ↔ QT prolongation
Open this assessment on its own page →
Ranolazine inhibits the late inward sodium current to relieve angina without changing heart rate or blood pressure, but it also modestly prolongs the QT interval — a labelled, dose-dependent effect that is larger in women and in hepatic impairment. In this dataset, electrocardiogram QT prolonged carries 99 co-reports (PRR 5.6). The label warns against combining it with other QT-prolonging drugs, caps the dose in liver disease, and makes congenital long-QT syndrome a contraindication.
Regulatory basis: ranolazine (Ranexa) prescribing information — QT prolongation; contraindicated in congenital long-QT syndrome.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Interval prolongation visible within days |
| Strength | met | PRR 5.6, moderate |
| Consistency | met | Seen across trials and registries |
| Specificity | partial | Shared with other QT-prolonging drugs |
| Biological gradient | met | Greater at higher plasma levels |
| Plausibility | met | Direct effect on repolarisation |
| Coherence | met | Consistent with ECG data |
| Experiment | met | Serial ECGs in the pivotal trial showed the same effect |
| Analogy | met | Analogous to other QT-prolonging antianginals |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ticagrelor ↔ Dyspnoea
Open this assessment on its own page →
Ticagrelor is a reversible P2Y12 platelet inhibitor whose signature adverse effect is dyspnoea — breathlessness without heart failure or lung disease — thought to reflect adenosine accumulation, because ticagrelor also blocks adenosine re-uptake. This dataset's 4,009 co-reports (PRR 4.7) make dyspnoea one of its largest signals. The effect surfaced in PLATO (NCT00391872), the trial that established ticagrelor over clopidogrel in acute coronary syndromes, and is now a labelled warning; it is usually benign and rarely requires stopping the drug.
Regulatory basis: ticagrelor (Brilinta) prescribing information — dyspnoea; PLATO trial (Wallentin et al., NEJM 2009).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Occurs within days to weeks of starting |
| Strength | met | PRR 4.7 with thousands of reports |
| Consistency | met | Reproduced in PLATO and practice |
| Specificity | met | Distinctive to ticagrelor among antiplatelets |
| Biological gradient | partial | Not clearly dose-related at usual doses |
| Plausibility | met | Adenosine re-uptake inhibition proposed |
| Coherence | met | Consistent with added adenosine exposure |
| Experiment | met | Randomised arm comparison showed the excess |
| Analogy | met | Analogy to adenosine-infusion dyspnoea |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) (NCT01347580)
| Adverse event | Ticagrelor In-Hosp (n=950) · Ticagrelor Pre-Hosp (n=908) | |
|---|---|---|
| DYSPNOEA | 1/950 | 2/908 |
| Dyspnoea | 86/950 | 62/908 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Clopidogrel ↔ Gastrointestinal haemorrhage
Open this assessment on its own page →
Clopidogrel irreversibly blocks the platelet P2Y12 receptor, so bleeding is its defining, duration-related adverse effect; gastrointestinal haemorrhage carries 8,285 co-reports (PRR 11.5), reflecting both the drug's enormous use and a true excess. CAPRIE and later studies placed clopidogrel's bleeding risk between aspirin and the more potent prasugrel and ticagrelor.
Regulatory basis: clopidogrel prescribing information — bleeding; CAPRIE trial (Lancet 1996).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding follows platelet inhibition |
| Strength | met | PRR 11.5, a very large signal |
| Consistency | met | Reproduced in every antiplatelet trial |
| Specificity | partial | Shared across the P2Y12 class |
| Biological gradient | met | Risk rises with duration and with NSAIDs |
| Plausibility | met | Direct consequence of P2Y12 blockade |
| Coherence | met | Fits the mechanism exactly |
| Experiment | met | Randomised trials quantify the excess |
| Analogy | met | Direct class analogy to prasugrel |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — The Dual Antiplatelet Therapy Study (DAPT Study) (NCT00977938)
| Adverse event | HCRI DAPT - DES 30-month DAPT (n=2642) · HCRI DAPT - DES 12-month DAPT (n=2634) · HCRI DAPT - BMS 30-month DAPT (n=842) · HCRI DAPT - BMS 12-month DAPT (n=845) | |||
|---|---|---|---|---|
| GASTROINTESTINAL HAEMORRHAGE | 10/2642 | 2/2634 | 0/842 | 0/845 |
| LOWER GASTROINTESTINAL HAEMORRHAGE | 0/2642 | 0/2634 | 1/842 | 0/845 |
| UPPER GASTROINTESTINAL HAEMORRHAGE | 0/2642 | 1/2634 | 0/842 | 0/845 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Eptifibatide ↔ Thrombocytopenia
Open this assessment on its own page →
Eptifibatide is a glycoprotein IIb/IIIa inhibitor given intravenously during percutaneous coronary intervention; by blocking the final common pathway of platelet aggregation it produces both bleeding and, paradoxically, thrombocytopenia (65 co-reports here, PRR 16.0). The thrombocytopenia is acute, antibody-mediated in some cases, and the label requires platelet counts before and during therapy.
Regulatory basis: eptifibatide (Integrilin) prescribing information — thrombocytopenia and bleeding; platelet monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Platelet fall within hours |
| Strength | met | PRR 16.0, large |
| Consistency | met | Reproduced across GPI experience |
| Specificity | partial | Shared with tirofiban and abciximab |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated platelet destruction proposed |
| Coherence | met | Fits the anticoagulant picture |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to abciximab thrombocytopenia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Methyldopa ↔ Drug-induced liver injury
Open this assessment on its own page →
Methyldopa, a centrally acting antihypertensive still used in pregnancy, is a classic cause of drug-induced liver injury — from asymptomatic transaminase rises to rare fatal fulminant hepatitis, with 75 co-reports here (PRR 10.6). The injury is idiosyncratic and typically appears within the first weeks to months of therapy, which is why periodic liver monitoring is advised early in treatment; it remains a reason methyldopa has largely been displaced by safer agents outside pregnancy.
Regulatory basis: methyldopa prescribing information — hepatotoxicity warning; classic drug-induced liver-injury literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset typically weeks into therapy |
| Strength | met | PRR 10.6, clearly elevated |
| Consistency | met | Long recognised in case series |
| Specificity | not established | Cannot be distinguished from other DILI clinically |
| Biological gradient | not established | Not clearly dose-related (idiosyncratic) |
| Plausibility | met | Idiosyncratic drug-reaction mechanism |
| Coherence | met | Fits the DILI pattern |
| Experiment | n/a | No trial-sized experiment possible |
| Analogy | met | Analogous to other idiosyncratic hepatotoxins |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Aliskiren ↔ Hyperkalaemia
Open this assessment on its own page →
Aliskiren is a direct renin inhibitor; by suppressing the renin–angiotensin–aldosterone axis it lowers aldosterone and raises serum potassium, so hyperkalaemia is mechanistically expected (76 co-reports here, PRR 20.2), especially in kidney disease, diabetes, or with ACE inhibitors, ARBs, or potassium-sparing diuretics. The ALTITUDE trial combined it with an ACE inhibitor or ARB in diabetic patients and was stopped early for lack of benefit plus excess hyperkalaemia, hypotension, and kidney events; the label now warns against such combinations.
Regulatory basis: aliskiren (Tekturna) prescribing information — hyperkalaemia; ALTITUDE trial (NEJM 2012).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Potassium rises with therapy |
| Strength | met | PRR 20.2, large |
| Consistency | met | Seen in ALTITUDE and practice |
| Specificity | partial | Shared with ACE inhibitors and ARBs |
| Biological gradient | met | Worse with renal impairment and RAAS blockers |
| Plausibility | met | Direct consequence of renin inhibition |
| Coherence | met | Fits the mechanism |
| Experiment | met | ALTITUDE arm comparison showed the excess |
| Analogy | met | Analogous to ACE-inhibitor hyperkalaemia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure (NCT00853658)
| Adverse event | Combination of Aliskiren and Enalapril (n=2347) · Aliskiren (n=2348) · Enalapril (n=2345) | ||
|---|---|---|---|
| Hyperkalaemia | 21/2347 | 13/2348 | 20/2345 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Valsartan ↔ Acute kidney injury
Open this assessment on its own page →
Valsartan is an angiotensin-receptor blocker; blocking angiotensin II dilates the efferent arteriole and lowers glomerular filtration pressure, so acute kidney injury is an expected, mechanism-based effect (3,260 co-reports, PRR 4.4), concentrated in patients who are volume-depleted, have renal-artery stenosis, or take NSAIDs or diuretics. The label advises monitoring renal function, and the effect typically reverses when the drug or precipitant is withdrawn.
Regulatory basis: valsartan (Diovan) prescribing information — renal impairment and acute kidney injury.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Creatinine rises within days |
| Strength | met | PRR 4.4, moderate |
| Consistency | met | Consistent across the ARB class |
| Specificity | partial | Shared with ACE inhibitors and ARBs |
| Biological gradient | met | Worse with volume depletion |
| Plausibility | met | Consequence of efferent-arteriolar dilation |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not tested as a trial endpoint |
| Analogy | met | Direct class analogy to ACE inhibitors |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction (NCT02226120)
| Adverse event | LCZ696 (n=1980) |
|---|---|
| Acute kidney injury | 18/1980 |
| Renal impairment | 8/1980 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Losartan ↔ Renal failure
Open this assessment on its own page →
Losartan is the prototype angiotensin-receptor blocker, and its renal effects mirror the class: reduced efferent-arteriolar tone and filtration pressure can precipitate or worsen renal failure (3,053 co-reports, PRR 2.8), particularly with volume depletion, bilateral renal-artery stenosis, or combined NSAID use. The signal is dominated by the drug's very large prescribing base rather than a property unique to losartan, and function usually recovers after the drug or precipitant is withdrawn.
Regulatory basis: losartan prescribing information — renal impairment; class effect of RAAS blockade.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Creatinine rises after initiation |
| Strength | met | PRR 2.8, modest |
| Consistency | met | Consistent across the ARB class |
| Specificity | partial | Shared with ACE inhibitors and ARBs |
| Biological gradient | met | Worse with volume depletion |
| Plausibility | met | Consequence of RAAS blockade |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not tested as a trial endpoint |
| Analogy | met | Analogous to ACE-inhibitor renal effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ambrisentan ↔ Fluid retention
Open this assessment on its own page →
Ambrisentan is an endothelin-receptor antagonist for pulmonary arterial hypertension; peripheral oedema and fluid retention are its most common adverse effect (5,470 co-reports, PRR 20.3), reflecting vasodilation and sodium retention rather than heart failure in most cases. The effect is dose-related and, at higher exposure, can progress to decompensated heart failure, so the label requires caution in left-ventricular dysfunction and monthly liver monitoring for hepatotoxicity.
Regulatory basis: ambrisentan (Letairis) prescribing information — peripheral oedema and fluid retention.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Fluid retention appears over weeks |
| Strength | met | PRR 20.3, large |
| Consistency | met | Reproduced across the ERA class |
| Specificity | partial | Shared with other endothelin antagonists |
| Biological gradient | met | Dose-related |
| Plausibility | met | Consistent with vasodilation and sodium retention |
| Coherence | met | Fits the mechanism |
| Experiment | met | ERA trials showed the excess |
| Analogy | met | Analogous to bosentan oedema |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) (NCT00578786)
| Adverse event | Ambrisentan 2.5 mg (n=43) · Ambrisentan 5 mg (n=146) · Ambrisentan 10 mg (n=194) | ||
|---|---|---|---|
| Oedema peripheral | 1/43 | 0/146 | 2/194 |
| Fluid retention | 0/43 | 2/146 | 10/194 |
| Oedema peripheal | 13/43 | 53/146 | 101/194 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Riociguat ↔ Hypotension
Open this assessment on its own page →
Riociguat stimulates soluble guanylate cyclase to relax vascular smooth muscle, lowering pulmonary and systemic pressures; hypotension is therefore expected (3,401 co-reports, PRR 11.2), particularly when combined with nitrates or PDE5 inhibitors, which is why the label contraindicates that combination. Syncope and symptomatic hypotension require dose titration and blood-pressure monitoring in pulmonary-hypertension use.
Regulatory basis: riociguat (Adempas) prescribing information — hypotension; contraindicated with nitrates and PDE5 inhibitors.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Blood-pressure fall is immediate |
| Strength | met | PRR 11.2, large |
| Consistency | met | Seen across trials and practice |
| Specificity | partial | Shared with PDE5 inhibitors and nitrates |
| Biological gradient | met | Dose-related |
| Plausibility | met | Direct vasodilation mechanism |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials measured blood-pressure reduction |
| Analogy | met | Analogous to PDE5-inhibitor hypotension |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) (NCT00810693)
| Adverse event | Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT (n=254) · Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT (n=63) · Placebo (n=126) | ||
|---|---|---|---|
| Hypotension | 1/254 | 0/63 | 0/126 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Acetazolamide ↔ Metabolic acidosis
Open this assessment on its own page →
Acetazolamide inhibits carbonic anhydrase, causing bicarbonate loss in the urine and a hyperchloraemic metabolic acidosis — a direct, expected consequence of the mechanism (206 co-reports, PRR 23.1). It is used deliberately for this effect in some settings (altitude illness, metabolic alkalosis) and becomes a limiting toxicity at high doses or in renal impairment; paraesthesias, hypokalaemia, and nephrolithiasis commonly accompany it.
Regulatory basis: acetazolamide prescribing information — metabolic acidosis; carbonic-anhydrase-inhibitor pharmacology.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Acidosis develops within days |
| Strength | met | PRR 23.1, large |
| Consistency | met | Consistent across case series |
| Specificity | partial | Shared across carbonic-anhydrase inhibitors |
| Biological gradient | met | Dose-related |
| Plausibility | met | Direct consequence of bicarbonate loss |
| Coherence | met | Fits the mechanism exactly |
| Experiment | met | Acid-base change is measurable on protocol labs |
| Analogy | met | Analogous to topiramate-induced acidosis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Mannitol ↔ Renal failure
Open this assessment on its own page →
Mannitol is an osmotic diuretic; at high doses or in patients with pre-existing renal impairment it can accumulate, cause osmotic nephrosis, and precipitate or worsen acute renal failure (592 co-reports, PRR 19.0). Crystallisation in the tubules and shifts in fluid balance contribute, which is why the label advises against use in established anuria and calls for careful dosing in renal impairment.
Regulatory basis: mannitol prescribing information — renal failure; osmotic-nephrosis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Renal injury follows high-dose therapy |
| Strength | met | PRR 19.0, large |
| Consistency | met | Recognised in case series |
| Specificity | partial | Shared with other osmotic agents |
| Biological gradient | met | Dose-related accumulation |
| Plausibility | met | Osmotic-nephrosis mechanism |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not tested as a trial endpoint |
| Analogy | met | Analogous to other osmotic-diuretic nephrotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Adaptive COVID-19 Treatment Trial 4 (ACTT-4) (NCT04640168)
| Adverse event | Remdesivir Plus Baricitinib (n=503) · Remdesivir Plus Dexamethasone (n=482) | |
|---|---|---|
| Acute kidney injury | 9/503 | 4/482 |
| Renal failure | 2/503 | 0/482 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Indapamide ↔ Hyponatraemia
Open this assessment on its own page →
Indapamide is a thiazide-like diuretic whose most consequential electrolyte effect is hyponatraemia (1,318 co-reports, PRR 28.2), especially in older women, where it can cause confusion, falls, and seizures. The mechanism combines diuretic-induced sodium loss with impaired urinary dilution; the label advises monitoring electrolytes, and the effect usually resolves on withdrawal.
Regulatory basis: indapamide prescribing information — hyponatraemia.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Sodium falls over days to weeks |
| Strength | met | PRR 28.2, large |
| Consistency | met | Consistent across thiazide diuretics |
| Specificity | partial | Shared with thiazides |
| Biological gradient | met | Worse with higher doses and low intake |
| Plausibility | met | Diuretic-induced sodium loss |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to thiazide hyponatraemia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (NCT04518293)
| Adverse event | Not Randomized (n=859) · GMRx2 (n=551) · Dual - TA (n=282) · Dual - TI (n=276) | |||
|---|---|---|---|---|
| Hyponatremia | 19/859 | 28/551 | 12/282 | 14/276 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Fondaparinux ↔ Thrombocytopenia
Open this assessment on its own page →
Fondaparinux is a synthetic indirect factor-Xa inhibitor; thrombocytopenia is a recognised, if less common, effect (263 co-reports, PRR 6.2) and, in a minority, is associated with the same platelet-activating antibodies that cause heparin-induced thrombocytopenia. The label advises platelet counts at baseline and periodically, and the drug is contraindicated in active bleeding or severe renal impairment.
Regulatory basis: fondaparinux (Arixtra) prescribing information — thrombocytopenia; platelet monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Platelet fall within days |
| Strength | met | PRR 6.2, moderate |
| Consistency | met | Recognised in case series |
| Specificity | partial | Shared with heparins |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated platelet activation proposed |
| Coherence | met | Fits the anticoagulant picture |
| Experiment | n/a | Not tested as a trial endpoint |
| Analogy | met | Analogous to heparin-induced thrombocytopenia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (NCT02234843)
| Adverse event | Comparator Group (n=162) · Rivaroxaban Group (n=329) | |
|---|---|---|
| Thrombocytopenia | 0/162 | 2/329 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Edoxaban ↔ Gastrointestinal haemorrhage
Open this assessment on its own page →
Edoxaban is a direct factor-Xa inhibitor; bleeding is its principal risk and gastrointestinal haemorrhage is a leading site (195 co-reports, PRR 7.4), because the anticoagulated gut mucosa bleeds readily. The ENGAGE AF-TIMI 48 trial showed comparable efficacy to warfarin with less major bleeding overall but a higher rate of gastrointestinal bleeding, and the label warns against use in severe renal impairment and with strong P-glycoprotein inhibitors.
Regulatory basis: edoxaban (Savaysa) prescribing information — bleeding; ENGAGE AF-TIMI 48 trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding follows anticoagulation |
| Strength | met | PRR 7.4, moderate here |
| Consistency | met | Reproduced in ENGAGE AF-TIMI 48 |
| Specificity | partial | Shared across the DOAC class |
| Biological gradient | met | Risk rises with duration and renal impairment |
| Plausibility | met | Direct consequence of factor-Xa inhibition |
| Coherence | met | Fits the mechanism |
| Experiment | met | Randomised trials quantify the excess |
| Analogy | met | Direct class analogy to rivaroxaban and apixaban |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) (NCT02072434)
| Adverse event | Edoxaban (n=1067) · Warfarin (n=1082) | |
|---|---|---|
| Lower gastrointestinal haemorrhage | 0/1067 | 1/1082 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Alteplase ↔ Cerebral haemorrhage
Open this assessment on its own page →
Alteplase is a recombinant tissue plasminogen activator that dissolves clots by converting plasminogen to plasmin; its most feared complication is intracranial (cerebral) haemorrhage, present here at 819 co-reports (PRR 32.9). In acute ischaemic stroke the symptomatic haemorrhage rate is roughly 2–7%, the principal risk governing patient selection and time window, and in myocardial infarction the risk is lower but real. That benefit–risk balance is the entire basis of thrombolysis eligibility criteria.
Regulatory basis: alteplase (Activase) prescribing information — boxed warning for intracranial haemorrhage; NINDS and ECASS-III stroke trials.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding occurs during or after infusion |
| Strength | met | PRR 32.9, large |
| Consistency | met | Reproduced across stroke trials |
| Specificity | partial | Shared across thrombolytics |
| Biological gradient | met | Risk rises with later treatment |
| Plausibility | met | Direct consequence of plasminogen activation |
| Coherence | met | Fits the mechanism |
| Experiment | met | Randomised stroke trials quantify the excess |
| Analogy | met | Analogous to tenecteplase haemorrhage |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (NCT04915729)
| Adverse event | Alteplase Active Control Group (n=736) · Tenecteplase Treatment Group (n=732) | |
|---|---|---|
| Intracranial infection | 1/736 | 0/732 |
| Cerebral haemorrhage | 21/736 | 25/732 |
| Haemorrhage intracranial | 7/736 | 5/732 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Argatroban ↔ Haemorrhage
Open this assessment on its own page →
Argatroban is a direct thrombin inhibitor used for heparin-induced thrombocytopenia; by blocking thrombin it impairs clot formation, so bleeding (80 co-reports, PRR 10.7) is the expected dose-related hazard, along with the risk of under-anticoagulation in a prothrombotic condition. Its label requires monitoring of the activated partial thromboplastin time and dose reduction in hepatic impairment.
Regulatory basis: argatroban prescribing information — bleeding; aPTT monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding follows anticoagulation |
| Strength | met | PRR 10.7, large |
| Consistency | met | Consistent across case series |
| Specificity | partial | Shared with other anticoagulants |
| Biological gradient | met | Dose-related |
| Plausibility | met | Direct consequence of thrombin inhibition |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | No large randomised trial |
| Analogy | met | Analogous to bivalirudin bleeding |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Multi-arm Optimization of Stroke Thrombolysis (NCT03735979)
| Adverse event | Argatroban (n=59) · Eptifibatide (n=227) · Placebo (n=228) | ||
|---|---|---|---|
| Gastrointestinal haemorrhage | 2/59 | 1/227 | 3/228 |
| Subarachnoid haemorrhage | 0/59 | 5/227 | 3/228 |
| Haemorrhage intracranial | 2/59 | 7/227 | 5/228 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Bivalirudin ↔ Haemorrhage
Open this assessment on its own page →
Bivalirudin is a direct thrombin inhibitor used in percutaneous coronary intervention; bleeding is its principal dose-related effect (87 co-reports, PRR 18.2). Tested head-to-head against heparin plus a glycoprotein IIb/IIIa inhibitor in HORIZONS-AMI and REPLACE, bivalirudin reduced bleeding, confirming the effect is a controllable property of the anticoagulant rather than an idiosyncratic reaction.
Regulatory basis: bivalirudin (Angiomax) prescribing information — bleeding; HORIZONS-AMI and REPLACE trials.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding follows anticoagulation |
| Strength | met | PRR 18.2, large |
| Consistency | met | Reproduced across PCI trials |
| Specificity | partial | Shared with other anticoagulants |
| Biological gradient | met | Dose-related |
| Plausibility | met | Direct consequence of thrombin inhibition |
| Coherence | met | Fits the mechanism |
| Experiment | met | PCI trials quantify the excess |
| Analogy | met | Analogous to argatroban bleeding |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial (NCT01087723)
| Adverse event | Bivalirudin (n=1099) · Standard of Care: Heparins With Optional GPI (n=1094) | |
|---|---|---|
| Abdominal wall haemorrhage | 1/1099 | 0/1094 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Nitroglycerin ↔ Hypotension
Open this assessment on its own page →
Nitroglycerin releases nitric oxide to dilate veins and arteries, lowering preload and blood pressure; hypotension and headache (from meningeal vasodilation) are its classic, expected effects, and hypotension carries 2,299 co-reports here (PRR 4.6). The risk is greatest with volume depletion, right-ventricular infarction, and concomitant PDE5 inhibitors, where the combination can cause profound, refractory hypotension — an absolute contraindication.
Regulatory basis: nitroglycerin prescribing information — hypotension; contraindicated with PDE5 inhibitors.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Blood-pressure fall is immediate |
| Strength | met | PRR 4.6, modest |
| Consistency | met | Consistent across nitrate use |
| Specificity | partial | Shared across nitrates |
| Biological gradient | met | Dose-related |
| Plausibility | met | Nitric-oxide vasodilation mechanism |
| Coherence | met | Fits the mechanism |
| Experiment | met | Haemodynamic effect measured in trials |
| Analogy | met | Analogous to isosorbide hypotension |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Epoprostenol ↔ Headache
Open this assessment on its own page →
Epoprostenol is a prostacyclin (PGI2) infusion that dilates systemic and pulmonary vessels; headache from vasodilation is among its most common and dose-limiting effects (2,295 co-reports, PRR 5.9), along with flushing, jaw pain, and diarrhoea. These effects are intrinsic to prostacyclin pharmacology and are managed by titrating the continuous infusion rather than by stopping therapy.
Regulatory basis: epoprostenol (Flolan) prescribing information — headache and vasodilator effects.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Headache within hours of infusion |
| Strength | met | PRR 5.9, moderate |
| Consistency | met | Consistent across prostacyclin use |
| Specificity | partial | Shared with other prostacyclins |
| Biological gradient | met | Dose-related |
| Plausibility | met | Vasodilation mechanism |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials recorded vasodilator effects |
| Analogy | met | Analogous to treprostinil headache |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) (NCT04576988)
| Adverse event | Sotatercept Plus Background PAH Therapy (DBPC Period) (n=163) · Placebo Plus Background PAH Therapy (DBPC Period) (n=160) · Sotatercept Plus Background PAH Therapy (LTDB Period) (n=158) · Placebo Plus Background PAH Therapy (LTDB Period) (n=142) | |||
|---|---|---|---|---|
| Headache | 33/163 | 24/160 | 9/158 | 6/142 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Treprostinil ↔ Headache
Open this assessment on its own page →
Treprostinil, a prostacyclin analogue given by infusion or inhalation, produces the same vasodilator symptom cluster as epoprostenol, and headache dominates the reaction profile here (17,283 co-reports, PRR 4.7) — the count reflecting its use in large pulmonary-hypertension registries. Infusion-site pain, diarrhoea, and flushing accompany it, all intrinsic to prostacyclin effect.
Regulatory basis: treprostinil (Remodulin) prescribing information — headache and vasodilator effects.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Headache soon after starting |
| Strength | met | PRR 4.7 with a very large count |
| Consistency | met | Consistent across prostacyclin registries |
| Specificity | partial | Shared with other prostacyclins |
| Biological gradient | met | Dose-related |
| Plausibility | met | Vasodilation mechanism |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials recorded vasodilator effects |
| Analogy | met | Analogous to epoprostenol headache |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine (NCT00775463)
| Adverse event | Placebo (n=76) · Treprostinil Diethanolamine (n=71) | |
|---|---|---|
| Headache | 32/76 | 52/71 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Fluoxetine ↔ Serotonin syndrome
Open this assessment on its own page →
Fluoxetine, a selective serotonin-reuptake inhibitor, raises synaptic serotonin; excess serotonergic activity produces serotonin syndrome — agitation, clonus, hyperthermia, autonomic instability — most often when an SSRI is combined with another serotonergic drug (MAOIs, tramadol, triptans, linezolid). In this dataset serotonin syndrome carries 1,720 co-reports (PRR 31.2). Fluoxetine's long half-life makes the effect linger after the drug is stopped, and MAOI combinations are contraindicated.
Regulatory basis: fluoxetine prescribing information — serotonin syndrome; contraindicated with MAOIs.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within hours to days of serotonergic load |
| Strength | met | PRR 31.2, large |
| Consistency | met | Reproduced across serotonergic drugs |
| Specificity | partial | Not specific to one drug within the class |
| Biological gradient | met | Worse with higher combined serotonergic load |
| Plausibility | met | Excess-serotonin mechanism |
| Coherence | met | Fits SSRI pharmacology |
| Experiment | met | Case series and dechallenge support it |
| Analogy | met | Analogous to other SSRI/MAOI combinations |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Escitalopram ↔ QT prolongation
Open this assessment on its own page →
Escitalopram is the active S-enantiomer of citalopram, and both prolong the QT interval in a dose-dependent manner (1,236 co-reports here, PRR 5.3). After post-marketing reports of torsades de pointes, the FDA capped the maximum dose (especially in older adults) and warned against use with other QT-prolonging drugs; the effect is greater in those with electrolyte disturbance or cardiac disease.
Regulatory basis: escitalopram prescribing information — dose-dependent QT prolongation; FDA drug-safety communications.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Interval prolongation within days |
| Strength | met | PRR 5.3, moderate |
| Consistency | met | Reproduced across the SSRI class |
| Specificity | partial | Shared with other SSRIs and QT-prolonging drugs |
| Biological gradient | met | Dose-dependent |
| Plausibility | met | Effect on cardiac repolarisation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | ECG data from trials and safety studies |
| Analogy | met | Analogous to citalopram QT prolongation |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Fluvoxamine ↔ Serotonin syndrome
Open this assessment on its own page →
Fluvoxamine is an SSRI that, like the class, can cause serotonin syndrome when combined with other serotonergic agents — 81 co-reports here (PRR 37.3). It is also a potent CYP1A2 and CYP2C19 inhibitor, so it raises levels of co-prescribed drugs (including some that are themselves serotonergic or QT-prolonging), amplifying the risk. MAOI combinations are contraindicated.
Regulatory basis: fluvoxamine prescribing information — serotonin syndrome; CYP1A2/2C19 inhibition; contraindicated with MAOIs.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within hours to days |
| Strength | met | PRR 37.3, large |
| Consistency | met | Reproduced across serotonergic drugs |
| Specificity | partial | Not specific within the class |
| Biological gradient | met | Worse with added serotonergic load |
| Plausibility | met | Excess-serotonin mechanism |
| Coherence | met | Fits SSRI pharmacology |
| Experiment | met | Case series and dechallenge support it |
| Analogy | met | Analogous to other SSRI/MAOI combinations |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Duloxetine ↔ Completed suicide
Open this assessment on its own page →
Duloxetine is a serotonin–noradrenaline reuptake inhibitor; its signals here include completed suicide (2,204 co-reports, PRR 8.1), but this is the most confounded association on the page. The treated condition — depression, and often chronic pain with its own suicide risk — is itself strongly linked to suicide, and the FDA antidepressant class warning concerns increased suicidal ideation in young patients early in treatment, not completed suicide in adults. Large meta-analyses of antidepressant trials have not shown an excess of completed suicide, so the raw disproportionality reflects the underlying population more than a drug effect.
Regulatory basis: duloxetine prescribing information — boxed warning for suicidal thoughts in children/young adults; antidepressant class literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Suicide risk is highest at illness onset |
| Strength | met | PRR 8.1, but on a high-background population |
| Consistency | not established | Large analyses do not confirm an excess of suicide |
| Specificity | not established | Cannot separate drug from the treated condition |
| Biological gradient | not established | No established dose relationship |
| Plausibility | partial | Plausible for early activation, not for death |
| Coherence | not established | Confounded by indication |
| Experiment | not established | Meta-analyses of trials fail to show it |
| Analogy | partial | Debated analogy to other antidepressants |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (NCT02493868)
| Adverse event | IND: Intranasal Esketamine + Oral AD (n=437) · OP: Intranasal Esketamine + Oral AD (n=455) · MA: Intranasal Esketamine + Oral AD (n=152) · MA: Oral AD + Intranasal Placebo (n=145) | |||
|---|---|---|---|---|
| Suicidal Ideation | 1/437 | 0/455 | 0/152 | 0/145 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Amitriptyline ↔ Tachycardia
Open this assessment on its own page →
Amitriptyline, a tricyclic antidepressant, blocks cardiac sodium channels, antagonises muscarinic receptors, and inhibits noradrenaline reuptake — a combination that produces tachycardia and, at higher exposure, serious arrhythmias (579 co-reports here, PRR 7.9). Its anticholinergic and quinidine-like effects are the reason tricyclics are dangerous in overdose and require caution in cardiac disease.
Regulatory basis: amitriptyline prescribing information — cardiac conduction effects; tricyclic overdose literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Cardiac effects at therapeutic doses |
| Strength | met | PRR 7.9, moderate |
| Consistency | met | Consistent across tricyclics |
| Specificity | partial | Shared across the tricyclic class |
| Biological gradient | met | Worse at higher plasma levels |
| Plausibility | met | Anticholinergic and sodium-channel blockade |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Overdose series quantify the effect |
| Analogy | met | Direct class analogy to imipramine |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Nortriptyline ↔ QT prolongation
Open this assessment on its own page →
Nortriptyline is the active metabolite of amitriptyline and shares the tricyclic cardiac profile; it produces QT prolongation and conduction delay (399 overdose-related co-reports, with a QT signal of 24 co-reports, PRR 2.4). Because tricyclics depress myocardial conduction, they are contraindicated after recent myocardial infarction and in significant conduction defects.
Regulatory basis: nortriptyline prescribing information — cardiac conduction effects; tricyclic overdose literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Conduction effects within the therapeutic range |
| Strength | met | PRR 2.4, modest here |
| Consistency | met | Consistent across tricyclics |
| Specificity | partial | Shared across the class |
| Biological gradient | met | Worse at higher plasma levels |
| Plausibility | met | Sodium-channel and repolarisation effects |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Overdose series quantify it |
| Analogy | met | Direct class analogy to amitriptyline |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Phenelzine ↔ Serotonin syndrome
Open this assessment on its own page →
Phenelzine is a monoamine-oxidase inhibitor; by blocking MAO-A it raises serotonin, noradrenaline, and dopamine, and combining it with any serotonergic drug (including SSRIs) can precipitate life-threatening serotonin syndrome — 36 co-reports here (PRR 25.3). This is why MAOIs carry strict dietary (tyramine) and drug-interaction restrictions, including a required washout when switching to or from SSRIs.
Regulatory basis: phenelzine prescribing information — serotonin syndrome; hypertensive crisis with tyramine; MAOI interaction warnings.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within hours of a serotonergic combination |
| Strength | met | PRR 25.3, large |
| Consistency | met | Reproduced across MAOI cases |
| Specificity | partial | Not specific within serotonergic drugs |
| Biological gradient | met | Worse with higher combined load |
| Plausibility | met | Excess-serotonin mechanism |
| Coherence | met | Fits MAOI pharmacology |
| Experiment | met | Case series and dechallenge support it |
| Analogy | met | Analogous to other MAOI/SSRI combinations |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ziprasidone ↔ QT prolongation
Open this assessment on its own page →
Ziprasidone is an atypical antipsychotic with the largest QT effect of its class; the interval prolongation is dose-related and was prominent enough that its approval required food co-administration (to ensure absorption) and warnings about combining it with other QT-prolonging drugs. In this dataset, electrocardiogram QT prolonged carries 265 co-reports (PRR 8.9), and the label warns in patients with electrolyte disturbance or cardiac disease.
Regulatory basis: ziprasidone (Geodon) prescribing information — QT prolongation with dosing/food requirements.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Interval prolongation within days |
| Strength | met | PRR 8.9, moderate |
| Consistency | met | Reproduced across ECG studies |
| Specificity | partial | Shared with other antipsychotics |
| Biological gradient | met | Dose-dependent |
| Plausibility | met | Effect on cardiac repolarisation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | ECG data from trials and safety studies |
| Analogy | met | Analogous to thioridazine and droperidol |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study (NCT01211522)
| Adverse event | Haloperidol (n=192) · Ziprasidone (n=190) · Placebo (n=184) | ||
|---|---|---|---|
| Torsades de pointes | 2/192 | 1/190 | 1/184 |
| Prolonged QTc | 13/192 | 20/190 | 10/184 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Chlorpromazine ↔ Neuroleptic malignant syndrome
Open this assessment on its own page →
Chlorpromazine is a first-generation antipsychotic; dopamine D2 blockade in the hypothalamus and basal ganglia underlies neuroleptic malignant syndrome — hyperthermia, rigidity, autonomic instability, and raised creatine kinase — 294 co-reports here (PRR 74.9). NMS is rare but potentially fatal and is why any antipsychotic requires vigilance for the syndrome, with immediate drug withdrawal and supportive care.
Regulatory basis: chlorpromazine prescribing information — neuroleptic malignant syndrome; antipsychotic class warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Onset over days of therapy or dose change |
| Strength | met | PRR 74.9, very large |
| Consistency | met | Reproduced across antipsychotics |
| Specificity | not established | Not specific to any one antipsychotic |
| Biological gradient | met | More likely with rapid dose escalation |
| Plausibility | met | Central dopamine-blockade mechanism |
| Coherence | met | Fits the pharmacology |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous across the antipsychotic class |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Oxcarbazepine ↔ Hyponatraemia
Open this assessment on its own page →
Oxcarbazepine, an antiepileptic related to carbamazepine, causes hyponatraemia through an antidiuretic-hormone-like effect more often than its parent drug (1,305 co-reports, PRR 15.4), particularly at higher doses and in older patients. The label advises monitoring sodium, and the effect is usually reversible on dose reduction or withdrawal.
Regulatory basis: oxcarbazepine prescribing information — hyponatraemia (SIADH-like effect).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Sodium falls within weeks |
| Strength | met | PRR 15.4, large |
| Consistency | met | Reproduced across case series |
| Specificity | partial | Shared with carbamazepine |
| Biological gradient | met | Dose-related |
| Plausibility | met | Antidiuretic-hormone effect |
| Coherence | met | Fits the pharmacology |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to carbamazepine hyponatraemia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy (NCT01498822)
| Adverse event | Levetiracetam (n=173) · Oxcarbazepine (n=174) | |
|---|---|---|
| Hyponatraemia | 0/173 | 1/174 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Zonisamide ↔ Nephrolithiasis
Open this assessment on its own page →
Zonisamide is a sulfonamide antiepileptic; the sulfonamide group inhibits carbonic anhydrase and alkalinises urine, promoting calcium phosphate kidney stones (189 co-reports, PRR 5.9), along with metabolic acidosis and hypohidrosis. The label advises adequate hydration and warns of kidney-stone risk, which is higher in patients with a history of stones.
Regulatory basis: zonisamide (Zonegran) prescribing information — nephrolithiasis and metabolic acidosis.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Stones develop over months |
| Strength | met | PRR 5.9, moderate |
| Consistency | met | Reproduced in case series |
| Specificity | partial | Shared with other sulfonamides |
| Biological gradient | partial | Risk rises with predisposing factors |
| Plausibility | met | Carbonic-anhydrase inhibition and urinary alkalinisation |
| Coherence | met | Fits the pharmacology |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to topiramate and acetazolamide stones |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Lacosamide ↔ Bradycardia
Open this assessment on its own page →
Lacosamide is an antiepileptic that enhances slow sodium-channel inactivation, which prolongs the PR interval and can cause bradycardia, AV block, and syncope (402 co-reports, PRR 4.3). The label advises caution in patients with conduction disease and in combination with other PR-prolonging drugs, and doses are titrated slowly; the effect is dose-related.
Regulatory basis: lacosamide (Vimpat) prescribing information — PR-interval prolongation and bradycardia.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bradycardia occurs with therapy |
| Strength | met | PRR 4.3, modest |
| Consistency | met | Seen across trials and series |
| Specificity | partial | Shared with other sodium-channel blockers |
| Biological gradient | met | Dose-related |
| Plausibility | met | Effect on cardiac conduction |
| Coherence | met | Fits the pharmacology |
| Experiment | met | ECG changes measured in trials |
| Analogy | met | Analogous to other PR-prolonging antiepileptics |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures (NCT00771927)
| Adverse event | Lacosamide (n=511) · Other AED (n=493) | |
|---|---|---|
| Sinus Bradycardia | 2/511 | 0/493 |
| Bradycardia | 1/511 | 3/493 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Droperidol ↔ QT prolongation
Open this assessment on its own page →
Droperidol is a butyrophenone antiemetic/sedative that prolongs the QT interval and has caused fatal torsades de pointes; the FDA added a boxed warning in 2001 requiring a baseline 12-lead ECG and continuous monitoring before use. In this dataset, electrocardiogram QT prolonged carries 39 co-reports (PRR 14.1) — a small count because ECG-mandated use is now highly restricted, but the signal itself is well established.
Regulatory basis: droperidol (Inapsine) prescribing information — boxed warning for QT prolongation and torsades de pointes (FDA 2001).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Interval prolongation within minutes to hours |
| Strength | met | PRR 14.1, large |
| Consistency | met | Reproduced in case series |
| Specificity | partial | Shared with other QT-prolonging drugs |
| Biological gradient | met | Dose-related |
| Plausibility | met | Effect on cardiac repolarisation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | ECG monitoring is mandated because of it |
| Analogy | met | Analogous to haloperidol and ziprasidone |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — E7 TCR T Cells for Human Papillomavirus-Associated Cancers (NCT02858310)
| Adverse event | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells (n=6) · Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells (n=18) | |||
|---|---|---|---|---|
| Activated partial thromboplastin time prolonged | 0/3 | 0/3 | 0/6 | 1/18 |
| Investigations - Other, specify: Prolonged QTcB interval (EKG) | 0/3 | 0/3 | 0/6 | 1/18 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Pregabalin ↔ Oedema peripheral
Open this assessment on its own page →
Pregabalin, like gabapentin, reduces excitatory neurotransmitter release at calcium channels and commonly causes peripheral oedema through vasodilation and fluid retention (5,399 co-reports, PRR 3.5), along with weight gain, somnolence, and dizziness. The oedema is dose-related and usually benign but can be mistaken for heart or kidney failure; pregabalin additionally carries a labelled risk of respiratory depression with opioids.
Regulatory basis: pregabalin (Lyrica) prescribing information — peripheral oedema; respiratory-depression warning with opioids.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Oedema develops over weeks |
| Strength | met | PRR 3.5, moderate |
| Consistency | met | Consistent across gabapentinoids |
| Specificity | partial | Shared with gabapentin |
| Biological gradient | met | Dose-related |
| Plausibility | met | Vasodilation and fluid-retention mechanism |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials recorded oedema |
| Analogy | met | Direct class analogy to gabapentin |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Pregabalin Peripheral Neuropathic Pain Study (NCT00141219)
| Adverse event | Pregabalin (n=162) · Placebo (n=78) | |
|---|---|---|
| Face oedema | 10/162 | 1/78 |
| Oedema peripheral | 10/162 | 0/78 |
| Generalized oedema | 7/162 | 0/78 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Levodopa ↔ Dyskinesia
Open this assessment on its own page →
Levodopa is the most effective treatment for Parkinson's disease, but after years of therapy most patients develop levodopa-induced dyskinesias — involuntary choreiform movements tied to peak drug levels — reflecting pulsatile dopamine-receptor stimulation (760 co-reports here, PRR 33.3). The effect is so characteristic of chronic levodopa use that reducing the dose, adding a COMT or MAO-B inhibitor, or using continuous delivery are the standard management strategies.
Regulatory basis: levodopa/carbidopa prescribing information — dyskinesia; Parkinson's-disease treatment literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Dyskinesias emerge after months to years |
| Strength | met | PRR 33.3, large |
| Consistency | met | Universally reproduced in practice |
| Specificity | met | Highly specific to dopaminergic therapy |
| Biological gradient | met | Related to dose and duration |
| Plausibility | met | Pulsatile dopamine-receptor stimulation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trial and registry data support it |
| Analogy | met | Analogous to dopamine-agonist dyskinesia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients (NCT01628926)
| Adverse event | SPM 962 (n=168) · Ropinirole (n=167) · Placebo (n=85) | ||
|---|---|---|---|
| Dyskinesia | 27/168 | 23/167 | 1/85 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Entacapone ↔ Dyskinesia
Open this assessment on its own page →
Entacapone is a COMT inhibitor that extends levodopa's plasma half-life; by increasing and smoothing dopamine delivery it commonly worsens or uncovers dyskinesias (481 co-reports, PRR 60.6). The effect is a direct consequence of enhanced dopaminergic stimulation, and the label advises that levodopa doses may need reduction when entacapone is added.
Regulatory basis: entacapone (Comtan) prescribing information — dyskinesia; advised levodopa dose reduction.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Dyskinesia appears or worsens on starting |
| Strength | met | PRR 60.6, very large |
| Consistency | met | Reproduced across trials |
| Specificity | met | Specific to dopaminergic augmentation |
| Biological gradient | met | Related to increased levodopa exposure |
| Plausibility | met | Enhanced dopamine-receptor stimulation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials showed dose-related dyskinesia |
| Analogy | met | Analogous to levodopa dyskinesia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease (NCT00219284)
| Adverse event | Immediate Switch (n=180) · Delayed Switch (n=179) | |
|---|---|---|
| Dyskinesia | 7/180 | 12/179 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Memantine ↔ Confusional state
Open this assessment on its own page →
Memantine is an NMDA-receptor antagonist used in moderate-to-severe Alzheimer's disease; confusion, dizziness, and somnolence are among its labelled central adverse effects (739 co-reports, PRR 7.1). Because it is given to patients who already have cognitive impairment, disentangling drug-induced confusion from disease fluctuation requires care, but the effect is dose-related and reversible.
Regulatory basis: memantine prescribing information — confusion, dizziness, somnolence.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Confusion occurs after starting or uptitrating |
| Strength | met | PRR 7.1, moderate |
| Consistency | met | Reported across trials |
| Specificity | not established | Confounded by underlying dementia |
| Biological gradient | met | Dose-related |
| Plausibility | met | Central NMDA-receptor blockade |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials recorded dizziness and confusion |
| Analogy | partial | Analogous to other CNS-active drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Rivastigmine ↔ Vomiting
Open this assessment on its own page →
Rivastigmine is a cholinesterase inhibitor for Alzheimer's and Parkinson's-disease dementia; by raising acetylcholine it commonly causes nausea, vomiting, and diarrhoea, especially during dose titration and with the transdermal patch if a previous patch is not removed (vomiting 907 co-reports, PRR 2.2). The GI effects are the classic cholinergic class toxicity and are managed by slow titration.
Regulatory basis: rivastigmine prescribing information — nausea/vomiting; cholinergic class effects; patch-application errors.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Vomiting during titration |
| Strength | met | PRR 2.2, modest |
| Consistency | met | Consistent across cholinesterase inhibitors |
| Specificity | partial | Shared across the class |
| Biological gradient | met | Dose-related |
| Plausibility | met | Cholinergic excess |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials recorded GI effects |
| Analogy | met | Analogous to donepezil and galantamine |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease (NCT00423085)
| Adverse event | Placebo (24 Weeks) (n=286) · Rivastigmine 5 cm^2 (24 Weeks) (n=282) · Rivastigmine 10 cm^2 (24 Weeks) (n=287) · Open-Label Extension (52 Weeks) (n=637) | |||
|---|---|---|---|---|
| Vomiting | 0/286 | 0/282 | 0/287 | 2/637 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Methylphenidate ↔ Hallucination, visual
Open this assessment on its own page →
Methylphenidate is a stimulant that increases synaptic dopamine and noradrenaline; hallucinations and psychotic symptoms are labelled, dose-related adverse effects, described in children and adults both with and without pre-existing psychosis (117 visual-hallucination co-reports here, PRR 4.1). The label advises caution in patients with psychotic or bipolar disorders, and the effects usually resolve on dose reduction or withdrawal.
Regulatory basis: methylphenidate prescribing information — psychiatric adverse events including hallucinations and psychosis.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Psychosis emerges with treatment |
| Strength | met | PRR 4.1, moderate |
| Consistency | met | Described across stimulant series |
| Specificity | partial | Shared across stimulant drugs |
| Biological gradient | met | Dose-related |
| Plausibility | met | Excess dopaminergic stimulation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials and case series support it |
| Analogy | met | Analogous to amphetamine psychosis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Modafinil ↔ Suicidal ideation
Open this assessment on its own page →
Modafinil is a wakefulness-promoting agent; suicidal ideation appears in this dataset at 654 co-reports (PRR 4.7), and the label carries a warning to monitor for psychiatric symptoms. The association is difficult to interpret, however: modafinil is used in narcolepsy and obstructive sleep apnoea, conditions associated with depressed mood and reduced quality of life, and it is also used off-label in depression, so confounding by indication is substantial and the causal contribution of the drug is uncertain.
Regulatory basis: modafinil (Provigil) prescribing information — psychiatric-symptom monitoring; FDA 2007 alert on serious skin reactions.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Psychiatric symptoms can appear on treatment |
| Strength | met | PRR 4.7, moderate |
| Consistency | not established | Not consistently reproduced |
| Specificity | not established | Cannot separate drug from the treated disorder |
| Biological gradient | not established | No established dose relationship |
| Plausibility | partial | Plausible via altered wakefulness/mood |
| Coherence | not established | Confounded by indication |
| Experiment | n/a | Not a trial endpoint |
| Analogy | partial | Debated analogy to stimulants |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder (NCT01072929)
| Adverse event | ARMODAFINIL 150 MG (n=198) · ARMODAFINIL 200 MG (n=32) · PLACEBO (n=199) | ||
|---|---|---|---|
| Suicidal ideation | 2/198 | 0/32 | 0/199 |
| Suicide attempt | 0/198 | 0/32 | 1/199 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Atomoxetine ↔ Hypertension
Open this assessment on its own page →
Atomoxetine is a selective noradrenaline-reuptake inhibitor for ADHD; by raising noradrenaline it increases heart rate and blood pressure, a labelled effect (400 co-reports, PRR 11.2) that requires monitoring in patients with hypertension, tachycardia, or cardiovascular disease. The increases are usually modest but prompt the label's caution against use in severe cardiovascular disorders.
Regulatory basis: atomoxetine (Strattera) prescribing information — increased blood pressure and heart rate.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Blood-pressure rise within weeks |
| Strength | met | PRR 11.2, moderate |
| Consistency | met | Consistent across trials |
| Specificity | partial | Shared with other noradrenergic drugs |
| Biological gradient | met | Dose-related |
| Plausibility | met | Noradrenaline re-uptake inhibition |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials measured blood-pressure change |
| Analogy | met | Analogous to SNRI blood-pressure effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Zolpidem ↔ Amnesia
Open this assessment on its own page →
Zolpidem is a short-acting hypnotic that potentiates GABA-A signalling; anterograde amnesia and complex sleep behaviours (sleep-driving, sleep-eating) are well-recognised, labelled adverse effects, and amnesia carries 2,881 co-reports here (PRR 7.2). The FDA lowered the recommended dose, especially in women, because of next-morning impairment and these parasomnias.
Regulatory basis: zolpidem prescribing information — amnesia; boxed warning for complex sleep behaviours; FDA 2013 dose reduction.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Amnesia occurs after dosing |
| Strength | met | PRR 7.2, moderate |
| Consistency | met | Reproduced in case series |
| Specificity | partial | Shared with other Z-drugs |
| Biological gradient | met | Dose-related |
| Plausibility | met | GABA-A potentiation and sedation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials recorded memory effects |
| Analogy | met | Analogous to other benzodiazepine-receptor agonists |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Eszopiclone ↔ Amnesia
Open this assessment on its own page →
Eszopiclone is a non-benzodiazepine hypnotic with the same GABA-A mechanism as zolpidem; amnesia and complex sleep behaviours are labelled effects (270 co-reports here, PRR 3.4), and it uniquely leaves a metallic taste. Next-day impairment and parasomnias led to the same class warnings and dose reductions as for other Z-drugs.
Regulatory basis: eszopiclone (Lunesta) prescribing information — amnesia; boxed warning for complex sleep behaviours; FDA 2014 dose reduction.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Amnesia occurs after dosing |
| Strength | met | PRR 3.4, modest |
| Consistency | met | Reproduced in case series |
| Specificity | partial | Shared with other Z-drugs |
| Biological gradient | met | Dose-related |
| Plausibility | met | GABA-A potentiation and sedation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials recorded memory effects |
| Analogy | met | Analogous to zolpidem amnesia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia (NCT00645944)
| Adverse event | Eszopiclone Group (n=19) · Placebo Group (n=17) | |
|---|---|---|
| Memory Problems | 1/19 | 1/17 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Buspirone ↔ Serotonin syndrome
Open this assessment on its own page →
Buspirone is a partial 5-HT1A agonist used for anxiety; it is serotonergic, and combining it with SSRIs, MAOIs, or other serotonergic drugs can precipitate serotonin syndrome (119 co-reports, PRR 12.0). The label warns against MAOI co-administration, and the risk is dose-related with respect to total serotonergic load.
Regulatory basis: buspirone prescribing information — serotonin syndrome; contraindicated with MAOIs.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within hours to days of combination |
| Strength | met | PRR 12.0, moderate |
| Consistency | met | Reproduced across serotonergic drugs |
| Specificity | partial | Not specific within serotonergic drugs |
| Biological gradient | met | Worse with higher combined load |
| Plausibility | met | Excess-serotonin mechanism |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Case series and dechallenge support it |
| Analogy | met | Analogous to other serotonergic combinations |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Baclofen ↔ Somnolence
Open this assessment on its own page →
Baclofen is a GABA-B agonist used for spasticity; sedation and somnolence are its most common dose-limiting effects (2,765 co-reports here, PRR 3.4), along with weakness and dizziness. Crucially, abrupt withdrawal after chronic use can cause a severe, sometimes fatal syndrome with seizures and autonomic instability, so the drug must be tapered.
Regulatory basis: baclofen prescribing information — sedation; withdrawal-syndrome warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Somnolence follows dosing |
| Strength | met | PRR 3.4, modest |
| Consistency | met | Consistent across clinical use |
| Specificity | partial | Shared with other CNS depressants |
| Biological gradient | met | Dose-related |
| Plausibility | met | GABA-B receptor activation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials recorded sedation |
| Analogy | met | Analogous to benzodiazepine sedation |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors (NCT01265550)
| Adverse event | Medical Treatment Group (n=25) · Surgical Treatment Group (n=27) · Placebo Medical Treatment Group (n=26) · All Enrolled (n=366) | |||
|---|---|---|---|---|
| Somnolence | 4/25 | 0/27 | 1/26 | 0/366 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Tizanidine ↔ Hypotension
Open this assessment on its own page →
Tizanidine is a centrally acting alpha-2 agonist that reduces spasticity but also lowers blood pressure and heart rate; hypotension and orthostatic intolerance are labelled effects (509 co-reports, PRR 2.2), amplified by CYP1A2 inhibitors such as ciprofloxacin, which raise tizanidine levels and have caused profound hypotension.
Regulatory basis: tizanidine prescribing information — hypotension/bradycardia; contraindicated with ciprofloxacin and other CYP1A2 inhibitors.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Blood-pressure fall with dosing |
| Strength | met | PRR 2.2, modest |
| Consistency | met | Seen across trials and series |
| Specificity | partial | Shared with clonidine |
| Biological gradient | met | Dose-related |
| Plausibility | met | Alpha-2 agonism reducing sympathetic tone |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials measured blood-pressure change |
| Analogy | met | Analogous to clonidine hypotension |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Rufinamide ↔ Convulsion
Open this assessment on its own page →
Rufinamide is an antiepileptic used mainly for Lennox-Gastaut syndrome; convulsion/seizure worsening appears here at 76 co-reports (PRR 10.7). All antiepileptics can paradoxically exacerbate seizures, and rufinamide also shortens the QT interval (a distinctive, labelled effect); the drug must be withdrawn slowly because abrupt cessation can provoke status epilepticus.
Regulatory basis: rufinamide (Banzel) prescribing information — seizure worsening; QT-shortening effect; withdrawal advice.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Seizure worsening during titration |
| Strength | met | PRR 10.7, large |
| Consistency | met | Reported across antiepileptics |
| Specificity | not established | Not specific to rufinamide |
| Biological gradient | met | More likely with rapid titration |
| Plausibility | met | Altered neuronal excitability |
| Coherence | met | Fits the antiepileptic picture |
| Experiment | met | Trial data support it |
| Analogy | met | Analogous to other antiepileptics |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures (NCT00334958)
| Adverse event | Rufinamide (n=176) · Placebo (n=180) | |
|---|---|---|
| Convulsion | 2/176 | 2/180 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Cenobamate ↔ Eosinophilia
Open this assessment on its own page →
Cenobamate is a newer antiepileptic; drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but life-threatening hypersensitivity reaction, and its label requires a slow, low-dose start specifically to reduce this risk (the dataset captures eosinophilia, a component of DRESS, at 32 co-reports, PRR 4.6). The reaction is idiosyncratic, appears within the first weeks, and mandates immediate discontinuation.
Regulatory basis: cenobamate (Xcopri) prescribing information — DRESS/multiorgan hypersensitivity; required slow titration.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within weeks of starting |
| Strength | met | PRR 4.6, modest |
| Consistency | met | Reproduced in case reports |
| Specificity | not established | Not specific to cenobamate |
| Biological gradient | partial | Risk rises with faster titration |
| Plausibility | not established | Idiosyncratic (not clearly dose-related) |
| Coherence | met | Idiosyncratic drug-hypersensitivity mechanism |
| Experiment | met | Part of the DRESS picture |
| Analogy | met | Analogous to other antiepileptic hypersensitivity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Stiripentol ↔ Somnolence
Open this assessment on its own page →
Stiripentol is an antiepileptic used with clobazam in Dravet syndrome; somnolence and sedation are its most common effects (230 co-reports, PRR 11.2), amplified because stiripentol inhibits CYP enzymes and raises clobazam and other antiepileptic levels. The label advises caution with CNS depressants, and the sedation is managed by dose adjustment.
Regulatory basis: stiripentol (Diacomit) prescribing information — somnolence; CYP inhibition raising co-medication levels.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Somnolence follows dosing |
| Strength | met | PRR 11.2, large |
| Consistency | met | Consistent across trials |
| Specificity | partial | Shared with other CNS-active antiepileptics |
| Biological gradient | met | Dose-related |
| Plausibility | met | GABA-A potentiation plus CYP inhibition |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials recorded sedation |
| Analogy | met | Analogous to clobazam sedation |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome (NCT02926898)
| Adverse event | Cohort 2: ZX008 0.5 mg/kg/Day (n=43) · Cohort 2: Matching Placebo (n=44) | |
|---|---|---|
| Somnolence | 3/43 | 3/44 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Fosphenytoin ↔ Hypotension
Open this assessment on its own page →
Fosphenytoin is a prodrug of phenytoin given intravenously; rapid infusion causes hypotension and arrhythmias, so the label mandates a maximum infusion rate and monitoring (114 co-reports, PRR 4.7). The effect is rate-related rather than a fixed property of the drug, and is worse in patients with cardiac disease or pre-existing hypotension.
Regulatory basis: fosphenytoin (Cerebyx) prescribing information — hypotension and arrhythmias; maximum infusion-rate guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hypotension during rapid infusion |
| Strength | met | PRR 4.7, modest |
| Consistency | met | Consistent across infusion series |
| Specificity | partial | Shared with intravenous phenytoin |
| Biological gradient | met | Rate-related |
| Plausibility | met | Vasodilation and cardiac depression |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Infusion-rate studies quantify it |
| Analogy | met | Analogous to intravenous phenytoin hypotension |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Established Status Epilepticus Treatment Trial (NCT01960075)
| Adverse event | Fosphenytoin (FOS) (n=125) · Valproic Acid (n=125) · Levetiracetam (n=150) | ||
|---|---|---|---|
| Hypotension | 7/125 | 6/125 | 4/150 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Ropinirole ↔ Hallucination
Open this assessment on its own page →
Ropinirole is a dopamine agonist for Parkinson's disease and restless legs; hallucinations and impulse-control disorders are class effects of dopamine agonists, and hallucinations carry 747 co-reports here (PRR 13.8). The risk rises with age, dose, and co-treatment with levodopa, and the label advises dose reduction or withdrawal if they occur.
Regulatory basis: ropinirole prescribing information — hallucinations and impulse-control disorders; dopamine-agonist class warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hallucinations emerge after months |
| Strength | met | PRR 13.8, large |
| Consistency | met | Reproduced across dopamine agonists |
| Specificity | partial | Shared across the class |
| Biological gradient | met | Dose-related |
| Plausibility | met | Excess dopaminergic stimulation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials and registries support it |
| Analogy | met | Analogous to pramipexole hallucinations |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients (NCT01628926)
| Adverse event | SPM 962 (n=168) · Ropinirole (n=167) · Placebo (n=85) | ||
|---|---|---|---|
| Hallucination Visual | 13/168 | 10/167 | 3/85 |
| Hallucination | 3/168 | 6/167 | 0/85 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Pramipexole ↔ Hypersexuality
Open this assessment on its own page →
Pramipexole is a dopamine agonist whose stimulation of mesolimbic D3 receptors produces prominent impulse-control disorders — pathological gambling, hypersexuality, compulsive shopping and eating — with 115 hypersexuality co-reports here (PRR 92.0). These behaviours are a recognised class effect that the FDA required to be added to labelling, and they often improve on dose reduction or withdrawal.
Regulatory basis: pramipexole prescribing information — impulse-control disorders class warning; dopamine-agonist literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Emerges after weeks to months |
| Strength | met | PRR 92.0, an extreme signal |
| Consistency | met | Reproduced across dopamine agonists |
| Specificity | partial | Shared across the class |
| Biological gradient | met | Dose-related |
| Plausibility | met | Mesolimbic D3-receptor stimulation |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Reported in trials and registries |
| Analogy | met | Analogous to ropinirole impulse-control disorders |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ketamine ↔ Cystitis
Open this assessment on its own page →
Ketamine is an NMDA-receptor antagonist used for anaesthesia and, increasingly, treatment-resistant depression; with chronic recreational use it causes profound ulcerative cystitis and urinary-tract damage (ketamine-induced cystitis, 83 co-reports here, PRR 11.3). The injury is dose- and duration-dependent, progressive, and can persist after cessation, sometimes requiring surgery.
Regulatory basis: ketamine prescribing information — urinary-tract effects with chronic use; ketamine-cystitis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Cystitis after months of chronic use |
| Strength | met | PRR 11.3, moderate |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific to ketamine |
| Biological gradient | met | Dose- and duration-dependent |
| Plausibility | met | Direct urothelial toxicity |
| Coherence | met | Fits the pharmacology |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to other drug-induced cystitis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (NCT02493868)
| Adverse event | IND: Intranasal Esketamine + Oral AD (n=437) · OP: Intranasal Esketamine + Oral AD (n=455) · MA: Intranasal Esketamine + Oral AD (n=152) · MA: Oral AD + Intranasal Placebo (n=145) | |||
|---|---|---|---|---|
| Cholecystitis Acute | 0/437 | 1/455 | 0/152 | 0/145 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Loperamide ↔ QT prolongation
Open this assessment on its own page →
Loperamide is an over-the-counter opioid-receptor agonist for diarrhoea; at high doses it blocks cardiac sodium and potassium channels, prolonging the QT interval and causing torsades de pointes (274 co-reports, PRR 3.6), which triggered an FDA warning. The QT signal is thus dose-dependent and confined to supratherapeutic abuse rather than normal use, so it does not represent a hazard at labelled doses.
Regulatory basis: loperamide labelling — FDA 2016 warning on cardiac arrhythmias with high doses; QT-prolongation literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | QT prolongation with high doses |
| Strength | met | PRR 3.6, modest |
| Consistency | met | Reproduced across case series |
| Specificity | met | Specific to high-dose use |
| Biological gradient | met | Dose-dependent |
| Plausibility | met | Sodium/potassium-channel blockade |
| Coherence | met | Fits the pharmacology |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to other QT-prolonging drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — E7 TCR T Cells for Human Papillomavirus-Associated Cancers (NCT02858310)
| Adverse event | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells (n=6) · Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells (n=18) | |||
|---|---|---|---|---|
| Activated partial thromboplastin time prolonged | 0/3 | 0/3 | 0/6 | 1/18 |
| Investigations - Other, specify: Prolonged QTcB interval (EKG) | 0/3 | 0/3 | 0/6 | 1/18 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Benztropine ↔ Dry mouth
Open this assessment on its own page →
Benztropine is an anticholinergic used for drug-induced parkinsonism; dry mouth, blurred vision, constipation, and urinary retention are direct consequences of muscarinic blockade (89 co-reports, PRR 3.2). The effects are dose-related and, in older patients, anticholinergic burden can cause confusion and falls, which is why use is minimised in the elderly.
Regulatory basis: benztropine prescribing information — anticholinergic adverse effects; caution in the elderly.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Dry mouth follows dosing |
| Strength | met | PRR 3.2, modest |
| Consistency | met | Universally reproduced |
| Specificity | met | Specific to anticholinergic drugs |
| Biological gradient | met | Dose-related |
| Plausibility | met | Muscarinic-receptor blockade |
| Coherence | met | Fits the mechanism exactly |
| Experiment | met | Well described across the class |
| Analogy | met | Analogous to trihexyphenidyl effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Efficacy of Antidepressants in Chronic Back Pain (NCT00964886)
| Adverse event | Arm 1 (n=38) · Arm 2 (n=34) · Arm 3 (n=37) · Arm 4 (n=33) | |||
|---|---|---|---|---|
| dry mouth | 5/17 | 3/20 | 4/16 | 1/17 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Trihexyphenidyl ↔ Hallucination
Open this assessment on its own page →
Trihexyphenidyl is a centrally acting anticholinergic for parkinsonism; by blocking muscarinic receptors in the brain it causes confusion, hallucinations, and in overdose an anticholinergic delirium (36 co-reports, PRR 10.1). It is abused recreationally for its euphoric effects, which further increases the risk of psychosis.
Regulatory basis: trihexyphenidyl prescribing information — anticholinergic CNS effects; caution in the elderly.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Psychosis emerges with dosing or overdose |
| Strength | met | PRR 10.1, large |
| Consistency | met | Reproduced across anticholinergics |
| Specificity | partial | Shared across the class |
| Biological gradient | met | Dose-related |
| Plausibility | met | Central muscarinic blockade |
| Coherence | met | Fits the mechanism |
| Experiment | met | Case series support it |
| Analogy | met | Analogous to benztropine CNS effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Varenicline ↔ Nausea
Open this assessment on its own page →
Varenicline is a partial nicotinic-acetylcholine-receptor agonist for smoking cessation; nausea is its commonest adverse effect (582 co-reports, PRR 2.6), accompanied by insomnia, abnormal dreams, and headache. Neuropsychiatric events led to an FDA boxed warning (later removed in 2016 after the EAGLES trial), but the gastrointestinal effects remain the typical, mechanism-related burden.
Regulatory basis: varenicline (Chantix) prescribing information — nausea; neuropsychiatric warning removed 2016 after EAGLES.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Nausea within days |
| Strength | met | PRR 2.6, modest |
| Consistency | met | Consistent across trials |
| Specificity | met | Fairly specific to nicotinic agonists |
| Biological gradient | met | Dose-related |
| Plausibility | met | Nicotinic-receptor stimulation in the gut |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials consistently reported it |
| Analogy | met | Analogous to nicotine-related nausea |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Varenicline and Bupropion for Alcohol Use Disorder (NCT04167306)
| Adverse event | 2) Varenicline + Placebo for Bupropion (n=96) · 1) Varenicline + Bupropion (n=101) · 3) Bupropion + Placebo for Varenicline (n=91) · 4) Placebo for Varenicline + Placebo for Bupropion (n=97) | |||
|---|---|---|---|---|
| nausea | 61/96 | 38/101 | 12/91 | 11/97 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Naltrexone ↔ Drug withdrawal syndrome
Open this assessment on its own page →
Naltrexone is an opioid-receptor antagonist; in opioid-dependent patients it precipitates an acute, severe withdrawal syndrome if given before the patient is fully detoxified (595 co-reports, PRR 9.8), with agitation, abdominal cramps, vomiting, and piloerection. The label requires a period of abstinence (commonly 7–10 days) before the first dose to avoid triggering this reaction.
Regulatory basis: naltrexone prescribing information — precipitation of opioid withdrawal; required abstinence period.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Immediate withdrawal on dosing |
| Strength | met | PRR 9.8, large |
| Consistency | met | Reproduced across clinical experience |
| Specificity | met | Specific to opioid-dependent patients |
| Biological gradient | met | Related to opioid load |
| Plausibility | met | Direct opioid-receptor blockade mechanism |
| Coherence | met | Fits the mechanism exactly |
| Experiment | met | Clinical studies confirm it |
| Analogy | met | Analogous to naloxone-precipitated withdrawal |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults (NCT01218958)
| Adverse event | Medisorb Naltrexone 190 mg (n=210) · Medisorb Naltrexone 380 mg (n=205) · Placebo Groups (Pooled) (n=209) | ||
|---|---|---|---|
| Alcohol withdrawal syndrome | 1/210 | 0/205 | 0/209 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Disulfiram ↔ Drug-induced liver injury
Open this assessment on its own page →
Disulfiram is used to support abstinence from alcohol by inhibiting aldehyde dehydrogenase and sensitising the patient to alcohol; it is also a recognised cause of idiosyncratic drug-induced liver injury, which carries 40 co-reports here (PRR 24.2). The injury ranges from transaminase elevation to fulminant hepatic failure, appears within weeks to months, and is why the label advises baseline and periodic liver monitoring and avoidance in pre-existing liver disease.
Regulatory basis: disulfiram prescribing information — hepatotoxicity warning; periodic liver monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset typically weeks into therapy |
| Strength | met | PRR 24.2, large |
| Consistency | met | Reproduced across case series |
| Specificity | not established | Cannot be distinguished from other DILI clinically |
| Biological gradient | not established | Not clearly dose-related (idiosyncratic) |
| Plausibility | met | Idiosyncratic drug-reaction mechanism |
| Coherence | met | Fits the DILI pattern |
| Experiment | n/a | No trial-sized experiment possible |
| Analogy | met | Analogous to other idiosyncratic hepatotoxins |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma (NCT03034135)
| Adverse event | Group A (n=23) |
|---|---|
| Hepatobiliary disorders | 1/23 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Phentermine ↔ Tachycardia
Open this assessment on its own page →
Phentermine is a sympathomimetic appetite suppressant; by raising noradrenaline it increases heart rate and blood pressure, so tachycardia and palpitations are expected effects (21 co-reports, PRR 4.9). It is a Schedule IV controlled substance with a labelled warning about use in cardiovascular disease, and it is generally limited to short-term use.
Regulatory basis: phentermine prescribing information — tachycardia/palpitations; cardiovascular warnings.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Tachycardia follows dosing |
| Strength | met | PRR 4.9, modest |
| Consistency | met | Consistent across amphetamine-like drugs |
| Specificity | partial | Shared with sympathomimetics |
| Biological gradient | met | Dose-related |
| Plausibility | met | Sympathomimetic stimulation |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials measured heart-rate change |
| Analogy | met | Analogous to other sympathomimetic tachycardia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity (NCT03799198)
| Adverse event | Weight Management Program (WMP) + Rx (n=100) · Weight Management Program (WMP) (n=100) | |
|---|---|---|
| Atrial Tachycardia | 0/100 | 1/100 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Semaglutide ↔ Impaired gastric emptying
Open this assessment on its own page →
Semaglutide is a GLP-1 receptor agonist; by slowing gastric emptying it can cause nausea, vomiting, and, in some patients, gastroparesis-like symptoms severe enough to risk aspiration during anaesthesia (impaired gastric emptying 3,558 co-reports, PRR 111.3). The label advises caution, and anaesthesia societies recommend holding GLP-1 agonists before surgery.
Regulatory basis: semaglutide (Ozempic/Wegovy) prescribing information — nausea/vomiting and delayed gastric emptying; anaesthesia guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Slowed emptying with therapy |
| Strength | met | PRR 111.3, an extreme signal |
| Consistency | met | Consistent across GLP-1 agonists |
| Specificity | partial | Shared across the class |
| Biological gradient | met | Dose-related |
| Plausibility | met | GLP-1-mediated delay in gastric emptying |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials measured gastric emptying |
| Analogy | met | Analogous to liraglutide effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (NCT03914326)
| Adverse event | Oral Semaglutide (n=4825) · Placebo (n=4825) | |
|---|---|---|
| Impaired gastric emptying | 3/4825 | 0/4825 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Liraglutide ↔ Impaired gastric emptying
Open this assessment on its own page →
Liraglutide is a GLP-1 receptor agonist; delayed gastric emptying underlies its nausea and vomiting and can produce gastroparesis-like symptoms (592 co-reports, PRR 20.7). As with semaglutide, the effect is intrinsic to class pharmacology and has prompted guidance to hold the drug before procedures requiring an empty stomach.
Regulatory basis: liraglutide (Victoza/Saxenda) prescribing information — nausea/vomiting and delayed gastric emptying.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Slowed emptying with therapy |
| Strength | met | PRR 20.7, large |
| Consistency | met | Consistent across GLP-1 agonists |
| Specificity | partial | Shared across the class |
| Biological gradient | met | Dose-related |
| Plausibility | met | GLP-1-mediated delay in gastric emptying |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials measured gastric emptying |
| Analogy | met | Analogous to semaglutide effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Metformin ↔ Vitamin B12 deficiency
Open this assessment on its own page →
Metformin is a first-line antidiabetic; over years of treatment it reduces ileal absorption of vitamin B12 and can lower serum levels, so vitamin B12 deficiency appears here as 630 co-reports (PRR 10.8). Deficiency develops insidiously and may present as anaemia or peripheral neuropathy, and the label advises periodic B12 monitoring in patients on long-term therapy, particularly with other risk factors.
Regulatory basis: metformin prescribing information — vitamin B12 deficiency with long-term use; periodic monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Deficiency after months to years |
| Strength | met | PRR 10.8, large |
| Consistency | met | Reproduced across cohorts |
| Specificity | partial | Shared with other biguanides |
| Biological gradient | met | Dose- and duration-related |
| Plausibility | met | Impaired ileal B12 absorption |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials recorded falls in B12 levels |
| Analogy | met | Analogous to other drug-induced B12 deficiency |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Canagliflozin ↔ Amputation
Open this assessment on its own page →
Canagliflozin is an SGLT2 inhibitor; in the CANVAS trial it was associated with an increased risk of lower-limb amputation, predominantly toe and mid-foot, prompting a boxed warning (2,195 co-reports here, PRR 535.9). The biological mechanism is uncertain and the finding was not clearly replicated across other SGLT2-inhibitor trials, so the label advises caution in patients at high amputation risk rather than attributing a proven causal mechanism.
Regulatory basis: canagliflozin (Invokana) prescribing information — boxed warning for lower-limb amputation; CANVAS trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Amputations occurred on treatment |
| Strength | met | PRR 535.9, an extreme signal |
| Consistency | partial | Signal seen mainly in CANVAS |
| Specificity | partial | Concentrated in at-risk patients |
| Biological gradient | not established | Mechanism uncertain |
| Plausibility | partial | Biologically debated, not established |
| Coherence | not established | Not consistently found across the class |
| Experiment | met | CANVAS trial showed the imbalance |
| Analogy | partial | Limited analogy to other SGLT2 inhibitors |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Empagliflozin ↔ Necrotising fasciitis (Fournier's gangrene)
Open this assessment on its own page →
Empagliflozin is an SGLT2 inhibitor; heavy glycosuria and impaired host defence make perineal necrotising fasciitis (Fournier's gangrene) a rare but life-threatening complication, carried here as 251 co-reports (PRR 24.0). The label carries a warning for necrotising fasciitis of the perineum and advises urgent treatment; the reaction is strongly disproportionate even though it is rare in absolute terms.
Regulatory basis: empagliflozin (Jardiance) prescribing information — warning for necrotising fasciitis of the perineum (Fournier's gangrene).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within days to weeks |
| Strength | met | PRR 24.0, large |
| Consistency | met | Reproduced across SGLT2 inhibitors |
| Specificity | partial | Shared across the class |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Glycosuria and impaired host defence |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other SGLT2-inhibitor Fournier's gangrene |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Dapagliflozin ↔ Genital infection
Open this assessment on its own page →
Dapagliflozin is an SGLT2 inhibitor that increases urinary glucose, creating a favourable environment for genital mycotic infections and, less often, urinary infections (candida infection 130 co-reports here, PRR 5.3). The effect is dose- and glycosuria-related, typically mild, and managed with hygiene measures and topical antifungals.
Regulatory basis: dapagliflozin (Farxiga) prescribing information — genital mycotic infections.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Infection appears within weeks |
| Strength | met | PRR 5.3, modest |
| Consistency | met | Consistent across SGLT2 inhibitors |
| Specificity | partial | Shared across the class |
| Biological gradient | met | Worse with higher glycosuria |
| Plausibility | met | Glucose-rich environment favouring fungi |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials recorded genital infections |
| Analogy | met | Analogous to other SGLT2-inhibitor infections |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Phase 2b Diabetic Kidney Disease Study (NCT04170543)
| Adverse event | Placebo (n=133) · MEDI3506 30 mg (n=95) · MEDI3506 60 mg (n=89) · MEDI3506 120 mg (n=93) | |||
|---|---|---|---|---|
| Candida infection | 0/133 | 0/95 | 0/89 | 1/93 |
| Genital infection fungal | 1/133 | 0/95 | 0/89 | 0/93 |
| Oesophageal candidiasis | 1/133 | 0/95 | 0/89 | 0/93 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Quinine ↔ Thrombocytopenia
Open this assessment on its own page →
Quinine is an antimalarial and muscle-cramp remedy; it can trigger immune thrombocytopenia through drug-dependent platelet antibodies, appearing here as 172 co-reports (PRR 3.8). The reaction can be severe and recur rapidly on re-exposure, so the label warns of thrombocytopenia and advises stopping the drug if it occurs.
Regulatory basis: quinine prescribing information — immune thrombocytopenia warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Platelet fall within days of exposure |
| Strength | met | PRR 3.8, modest |
| Consistency | met | Reproduced across case series |
| Specificity | met | Highly specific to quinine |
| Biological gradient | not established | Not dose-related (immune) |
| Plausibility | met | Drug-dependent platelet antibodies |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other drug-induced immune thrombocytopenia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Pioglitazone ↔ Oedema peripheral
Open this assessment on its own page →
Pioglitazone is a thiazolidinedione that causes fluid retention by activating PPAR-gamma in the kidney and vasculature, producing peripheral oedema and sometimes unmasking or worsening heart failure; peripheral oedema carries 1,008 co-reports here (PRR 4.0). The effect is dose-related and greatest when the drug is combined with insulin, and the label warns against use in symptomatic heart failure.
Regulatory basis: pioglitazone prescribing information — peripheral oedema and heart-failure warning; combination with insulin.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Oedema appears over weeks |
| Strength | met | PRR 4.0, modest |
| Consistency | met | Reproduced across trials |
| Specificity | met | Specific to thiazolidinediones |
| Biological gradient | met | Dose-related |
| Plausibility | met | PPAR-gamma-mediated fluid retention |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials recorded oedema |
| Analogy | met | Analogous to rosiglitazone oedema |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus. (NCT00727857)
| Adverse event | Pioglitazone 15 mg/Metformin 850 mg BID (n=201) · Pioglitazone 15 mg BID (n=190) · Metformin 850 mg BID (n=209) | ||
|---|---|---|---|
| Oedema Peripheral | 6/201 | 8/190 | 3/209 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Acarbose ↔ Gastrointestinal disorder
Open this assessment on its own page →
Acarbose is an alpha-glucosidase inhibitor; by delaying carbohydrate absorption it leaves undigested sugar to be fermented by colonic bacteria, producing flatulence, bloating, and diarrhoea — coded here as gastrointestinal disorder in 68 co-reports (PRR 4.2). The effects are dose-related, generally transient as the gut adapts, and minimised by starting at a low dose and titrating slowly.
Regulatory basis: acarbose prescribing information — flatulence, diarrhoea, and gastrointestinal effects.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | GI symptoms follow dosing |
| Strength | met | PRR 4.2, modest |
| Consistency | met | Universally reproduced |
| Specificity | met | Specific to alpha-glucosidase inhibition |
| Biological gradient | met | Dose-related |
| Plausibility | met | Colonic fermentation of unabsorbed carbohydrate |
| Coherence | met | Fits the mechanism exactly |
| Experiment | met | Trials consistently reported it |
| Analogy | met | Analogous to other alpha-glucosidase inhibitors |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Linagliptin ↔ Pancreatitis
Open this assessment on its own page →
Linagliptin is a DPP-4 inhibitor; acute pancreatitis is a labelled, if uncommon, risk (331 co-reports, PRR 7.3), and the label advises discontinuation if pancreatitis is suspected. The signal sits within the wider debate about incretin-based therapies and pancreatitis, where trial data have not consistently confirmed an excess.
Regulatory basis: linagliptin (Tradjenta) prescribing information — acute pancreatitis warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Latency of days to months is plausible |
| Strength | met | PRR 7.3, moderate |
| Consistency | partial | Reported across DPP-4 inhibitors |
| Specificity | not established | Cannot exclude cholelithiasis or alcohol |
| Biological gradient | not established | No established dose relationship |
| Plausibility | partial | Biologically debated |
| Coherence | not established | Meta-analyses are inconclusive |
| Experiment | n/a | Rare in trials |
| Analogy | partial | Debated analogy across incretin drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) (NCT01897532)
| Adverse event | Placebo (n=3485) · Linagliptin (n=3494) | |
|---|---|---|
| Pancreatitis acute | 3/3485 | 7/3494 |
| Pancreatitis | 3/3485 | 6/3494 |
| Pancreatitis chronic | 6/3485 | 2/3494 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Exenatide ↔ Pancreatitis
Open this assessment on its own page →
Exenatide is a GLP-1 receptor agonist; pancreatitis is a labelled risk (2,012 co-reports, PRR 15.8), and post-marketing reports prompted an FDA warning and label change. Whether the drug truly increases pancreatitis, or the excess reflects the underlying diabetes, obesity, and gallstone disease of the treated population, remains debated.
Regulatory basis: exenatide (Byetta) prescribing information — acute pancreatitis warning; FDA safety communications.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Latency of weeks to months is plausible |
| Strength | met | PRR 15.8, large |
| Consistency | partial | Reported across GLP-1 agonists |
| Specificity | not established | Cannot exclude cholelithiasis or alcohol |
| Biological gradient | not established | No established dose relationship |
| Plausibility | partial | Biologically debated |
| Coherence | not established | Meta-analyses are inconclusive |
| Experiment | n/a | Rare in trials |
| Analogy | partial | Debated analogy across incretin drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes (NCT01652716)
| Adverse event | Experimental: Exenatide QWS Suspension (n=229) · Active Comparator: Exenatide BID (n=146) | |
|---|---|---|
| Pancreatitis | 2/229 | 0/146 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Cabergoline ↔ Pleural effusion
Open this assessment on its own page →
Cabergoline is an ergot dopamine agonist used for hyperprolactinaemia and Parkinson's disease; like other ergots it can cause fibrotic reactions, and pleural effusion appears here as 77 co-reports (PRR 5.5). Risk is greatest with prolonged high-dose therapy, and the label advises periodic echocardiography and monitoring for pleuropulmonary changes.
Regulatory basis: cabergoline prescribing information — fibrotic reactions (pleuropulmonary, pericardial, retroperitoneal); monitoring guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Effusion after months of therapy |
| Strength | met | PRR 5.5, modest |
| Consistency | met | Reproduced across case series |
| Specificity | partial | Shared across ergot agonists |
| Biological gradient | met | Higher with higher cumulative dose |
| Plausibility | met | Serotonin-mediated fibroblast proliferation |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to pergolide fibrotic reactions |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Sitagliptin ↔ Pancreatic cancer
Open this assessment on its own page →
Sitagliptin is a DPP-4 inhibitor; an excess of pancreatic cancer was reported in early analyses of incretin-based therapies and appears here as 1,670 pancreatic-carcinoma co-reports (PRR 17.8), but the signal is weak and consistently disappears once the underlying diabetes, obesity, and smoking are taken into account, so causality remains unproven.
Regulatory basis: sitagliptin (Januvia) prescribing information — pancreatic-cancer reviews by FDA/EMA; no confirmed causal link.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Latency of years is plausible |
| Strength | met | PRR 17.8, large |
| Consistency | not established | Not consistently reproduced |
| Specificity | not established | Cannot exclude confounding by diabetes |
| Biological gradient | not established | No clear dose relationship |
| Plausibility | partial | Biologically debated |
| Coherence | not established | Randomised outcome trials are negative |
| Experiment | not established | Pooled analyses do not confirm it |
| Analogy | partial | Debated analogy across incretin drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Meperidine ↔ Convulsion
Open this assessment on its own page →
Meperidine is an opioid analgesic; its metabolite normeperidine accumulates, especially in renal impairment or with repeated dosing, and is a central nervous system excitant that causes tremor, myoclonus, and seizures (77 co-reports, PRR 3.0). This distinctive neurotoxicity is why meperidine is avoided in renal failure and in patients taking MAOIs.
Regulatory basis: meperidine prescribing information — normeperidine neurotoxicity/seizures; contraindicated with MAOIs.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Seizures with drug accumulation |
| Strength | met | PRR 3.0, modest |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific to meperidine |
| Biological gradient | met | Worse with higher doses or renal impairment |
| Plausibility | met | Normeperidine CNS excitation |
| Coherence | met | Fits the pharmacology |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to other metabolite-driven neurotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — E7 TCR T Cells for Human Papillomavirus-Associated Cancers (NCT02858310)
| Adverse event | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells (n=3) · Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells (n=6) · Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells (n=18) | |||
|---|---|---|---|---|
| Seizure | 0/3 | 0/3 | 0/6 | 1/18 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Hydromorphone ↔ Drug dependence
Open this assessment on its own page →
Hydromorphone is a potent mu-opioid agonist; tolerance, physical dependence, and addiction are intrinsic to chronic opioid exposure, and drug dependence carries 35,112 co-reports here (PRR 63.1). The risk is amplified with high doses, long duration, and pre-existing substance-use disorder, which is why opioid-prescribing guidelines emphasise cautious initiation and tapering.
Regulatory basis: hydromorphone prescribing information — dependence/abuse; opioid class boxed warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Dependence develops with chronic use |
| Strength | met | PRR 63.1, very large |
| Consistency | met | Universally reproduced |
| Specificity | met | Shared across all mu-opioids |
| Biological gradient | met | Rises with dose and duration |
| Plausibility | met | Mu-opioid-receptor adaptation |
| Coherence | met | Fits the mechanism exactly |
| Experiment | met | Long-term studies support it |
| Analogy | met | Direct class analogy to other opioids |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration (NCT01709747)
| Adverse event | Hydromorphone Hydrochloride (n=364) |
|---|---|
| Drug Withdrawal Syndrome | 1/364 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Perampanel ↔ Aggression
Open this assessment on its own page →
Perampanel is a non-competitive AMPA-receptor antagonist for focal epilepsy; aggression, irritability, and hostility are labelled psychiatric effects and appear here as 499 co-reports (PRR 28.0). The reactions cluster in the first weeks of treatment and are dose-related, so the label advises slow titration and monitoring for behavioural change, especially in patients with a psychiatric history.
Regulatory basis: perampanel (Fycompa) prescribing information — aggression, hostility, and irritability warnings; titration guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Behaviour change within weeks |
| Strength | met | PRR 28.0, large |
| Consistency | met | Reproduced across trials |
| Specificity | met | Fairly specific to perampanel |
| Biological gradient | met | Dose-related |
| Plausibility | met | AMPA-receptor blockade in limbic circuits |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials recorded aggression |
| Analogy | met | Analogous to other AED behavioural effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures (NCT01618695)
| Adverse event | Core Phase: Placebo (n=176) · Core Phase: Perampanel 4 mg (n=176) · Core Phase: Perampanel 8 mg (n=175) · Core Phase: Perampanel 12 mg (n=180) | |||
|---|---|---|---|---|
| Aggression | 0/176 | 0/176 | 0/175 | 2/180 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Brivaracetam ↔ Aggression
Open this assessment on its own page →
Brivaracetam is a second-generation synaptic-vesicle-protein-2A ligand for epilepsy; aggression and irritability are recognised psychiatric effects and appear here as 297 co-reports (PRR 14.0). The reactions are typically early and can be dose-related, so the label advises monitoring for mood and behavioural changes, particularly in patients with a psychiatric history.
Regulatory basis: brivaracetam (Briviact) prescribing information — psychiatric reactions including aggression and irritability.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Behaviour change within weeks |
| Strength | met | PRR 14.0, large |
| Consistency | met | Reproduced across trials |
| Specificity | met | Fairly specific to brivaracetam |
| Biological gradient | met | Dose-related |
| Plausibility | met | SV2A-mediated CNS effect |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials recorded psychiatric events |
| Analogy | met | Analogous to other AED behavioural effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy (NCT00175916)
| Adverse event | Brivaracetam (SS) (n=853) |
|---|---|
| Aggression | 3/853 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Tramadol ↔ Serotonin syndrome
Open this assessment on its own page →
Tramadol is a weak mu-opioid agonist that also inhibits serotonin and noradrenaline reuptake; excess serotonergic activity can produce serotonin syndrome — agitation, clonus, hyperthermia, and autonomic instability — carried here as 624 co-reports (PRR 18.9). Risk is greatest when tramadol is combined with SSRIs, SNRIs, MAOIs, or other serotonergic drugs, and the label warns of this interaction.
Regulatory basis: tramadol prescribing information — serotonin-syndrome interaction warning with serotonergic drugs.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within hours to days |
| Strength | met | PRR 18.9, large |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific to serotonergic drugs |
| Biological gradient | met | Worse with higher doses |
| Plausibility | met | Excess synaptic serotonin |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to other serotonergic drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Isoniazid ↔ Peripheral neuropathy
Open this assessment on its own page →
Isoniazid is a first-line antituberculosis drug; by competing with pyridoxine it causes a dose-related peripheral neuropathy, which appears here as 227 co-reports (PRR 3.1). Risk rises with malnutrition, diabetes, alcohol use, and slow acetylator status, and the label advises pyridoxine supplementation to prevent it.
Regulatory basis: isoniazid prescribing information — peripheral neuropathy and pyridoxine supplementation.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Neuropathy after weeks of therapy |
| Strength | met | PRR 3.1, modest |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific to isoniazid |
| Biological gradient | met | Dose-related |
| Plausibility | met | Pyridoxine antagonism |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials recorded neuropathy |
| Analogy | met | Analogous to other pyridoxine-antagonist drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Shortening Treatment by Advancing Novel Drugs (NCT02342886)
| Adverse event | DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide (n=65) · DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide (n=71) · DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide (n=67) · DS-TB: 2 Months HRZE/ 4 Months HR (n=68) | |||
|---|---|---|---|---|
| Neuropathy peripheral | 1/65 | 0/71 | 2/67 | 4/68 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Pyrazinamide ↔ Drug-induced liver injury
Open this assessment on its own page →
Pyrazinamide is a first-line antituberculosis drug and the most hepatotoxic of the standard regimen; drug-induced liver injury appears at 655 co-reports here (PRR 48.7), and its use is limited by that risk. Hyperuricaemia and gout are also common because the drug raises urate, and the label advises monitoring liver enzymes, especially when combined with isoniazid and rifampicin.
Regulatory basis: pyrazinamide prescribing information — hepatotoxicity; hyperuricaemia; monitoring during combination therapy.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within weeks |
| Strength | met | PRR 48.7, large |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific within the regimen |
| Biological gradient | met | Dose-related |
| Plausibility | met | Metabolite-driven hepatocellular injury |
| Coherence | met | Fits the DILI picture |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to isoniazid hepatotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (NCT00042289)
| Adverse event | ABC 300mg b.i.d. MOTHER (n=26) · ATV/COBI 300/150 mg q.d. INFANT (n=12) · ATV/COBI 300/150 mg q.d. MOTHER (n=12) · ATV/RTV 300/100mg q.d. INFANT (n=22) | |||
|---|---|---|---|---|
| Drug-induced liver injury | 0/26 | 0/12 | 0/12 | 0/22 |
| Hepatitis | 0/26 | 0/12 | 0/12 | 0/22 |
| Hepatitis fulminant | 0/26 | 0/12 | 0/12 | 0/22 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Rifampicin ↔ Drug-induced liver injury
Open this assessment on its own page →
Rifampicin is a first-line antituberculosis drug; drug-induced liver injury carries 346 co-reports here (PRR 16.4), usually in combination with isoniazid, and the drug also causes a flu-like syndrome and thrombocytopenia with intermittent dosing. Because it induces hepatic enzymes, it lowers levels of many co-administered drugs and requires monitoring during treatment.
Regulatory basis: rifampicin prescribing information — hepatotoxicity; CYP induction; intermittent-dosing reactions.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within weeks |
| Strength | met | PRR 16.4, large |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific within the regimen |
| Biological gradient | partial | Worse in combination with isoniazid |
| Plausibility | met | Metabolite-driven hepatocellular injury |
| Coherence | met | Fits the DILI picture |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to isoniazid hepatotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Assessing PA-824 for Tuberculosis (the APT Trial) (NCT02256696)
| Adverse event | Arm 1 (n=56) · Arm 2 (n=53) · Arm 3 (n=48) | ||
|---|---|---|---|
| Increased liver enzymes | 0/56 | 3/53 | 0/48 |
| Drug induced liver injury | 1/56 | 1/53 | 0/48 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Valacyclovir ↔ Acute kidney injury
Open this assessment on its own page →
Valacyclovir is a prodrug of aciclovir; crystalluria and acute kidney injury occur when high doses are given with inadequate hydration or in renal impairment, and acute kidney injury carries 1,170 co-reports here (PRR 3.9). The label advises adequate fluid intake and dose reduction in renal impairment, and the injury usually reverses with hydration and drug withdrawal.
Regulatory basis: valacyclovir prescribing information — acute kidney injury; hydration and renal dose adjustment.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Renal injury within days |
| Strength | met | PRR 3.9, modest |
| Consistency | met | Consistent across aciclovir series |
| Specificity | partial | Shared with aciclovir |
| Biological gradient | met | Worse with high doses and dehydration |
| Plausibility | met | Crystal nephropathy from drug precipitation |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to aciclovir nephrotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir (NCT00031486)
| Adverse event | Valacyclovir (n=40) · Placebo (n=47) | |
|---|---|---|
| Renal failure acute | 1/40 | 0/47 |
| Creatinine renal clearance decreased | 1/40 | 0/47 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Dapsone ↔ DRESS syndrome (eosinophilia)
Open this assessment on its own page →
Dapsone is an antimicrobial used in leprosy, dermatitis herpetiformis, and Pneumocystis prophylaxis; the dapsone hypersensitivity syndrome — a drug reaction with eosinophilia and systemic symptoms (DRESS) of fever, rash, eosinophilia, and internal-organ involvement — appears here as 354 co-reports (PRR 27.7). It typically begins weeks after starting therapy and can be fatal, so the label advises stopping the drug and urgent assessment if it is suspected.
Regulatory basis: dapsone prescribing information — dapsone hypersensitivity syndrome/DRESS; monitoring for fever, rash, and eosinophilia.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset weeks after starting |
| Strength | met | PRR 27.7, large |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific to dapsone |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Idiosyncratic immuno-allergic reaction |
| Coherence | met | Fits the DRESS picture |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other drug-induced DRESS |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Benzocaine ↔ Methaemoglobinaemia
Open this assessment on its own page →
Benzocaine is a topical anaesthetic; its metabolite oxidises haemoglobin, and methaemoglobinaemia (reported here as cyanosis, 35 co-reports, PRR 46.5) is a rare but potentially fatal effect, most often with sprays used for procedures in children. The FDA issued a warning specifically about benzocaine sprays in infants, and the reaction is dose- and patient-related.
Regulatory basis: benzocaine labelling — FDA warning on methaemoglobinaemia with benzocaine sprays; oxidant-haemolysis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within an hour |
| Strength | met | PRR 46.5, very large |
| Consistency | met | Reproduced across case reports |
| Specificity | met | Highly specific to oxidant anaesthetics |
| Biological gradient | met | Dose-related |
| Plausibility | met | Oxidative haemoglobin modification |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to prilocaine methaemoglobinaemia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Linezolid ↔ Lactic acidosis
Open this assessment on its own page →
Linezolid is an oxazolidinone antibiotic; by inhibiting mitochondrial protein synthesis it can cause lactic acidosis, which appears here as 1,018 co-reports (PRR 23.2) and is more common with courses longer than two weeks. The effect is dose- and duration-related and usually reverses on withdrawal, and the label advises monitoring for recurrent nausea, acidosis, and low bicarbonate during prolonged therapy.
Regulatory basis: linezolid (Zyvox) prescribing information — lactic acidosis with prolonged use; monitoring guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset after 1–2 weeks |
| Strength | met | PRR 23.2, large |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific to linezolid |
| Biological gradient | met | Dose- and duration-related |
| Plausibility | met | Mitochondrial protein-synthesis inhibition |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other mitochondrial-toxin lactic acidosis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ivermectin ↔ Neurotoxicity
Open this assessment on its own page →
Ivermectin is an antiparasitic used for onchocerciasis, strongyloidiasis, and scabies; neurotoxicity — drowsiness, confusion, ataxia, and in heavy infection a post-treatment encephalopathy — reflects massive release of parasite antigen or drug crossing a damaged blood-brain barrier, and coma carries 246 co-reports here (PRR 17.3). Risk is greater in Loa loa and in onchocerciasis co-infection, where the label advises caution.
Regulatory basis: ivermectin prescribing information — neurotoxicity caution in Loa loa; post-treatment encephalopathy literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Coma follows treatment |
| Strength | met | PRR 17.3, large |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific to heavy microfilaraemia |
| Biological gradient | partial | Related to parasite burden |
| Plausibility | met | Antigen release and drug CNS toxicity |
| Coherence | met | Fits the pharmacology |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other antifilarial reactions |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Colchicine ↔ Myopathy
Open this assessment on its own page →
Colchicine is an anti-inflammatory used in gout and pericarditis; it inhibits microtubules, so at high plasma levels it causes a vacuolar myopathy and neuromyopathy (myopathy 220 co-reports here, PRR 20.8), particularly in renal impairment or with CYP3A4/P-glycoprotein inhibitors that raise levels. The effect is dose-related and reversible on withdrawal.
Regulatory basis: colchicine prescribing information — myopathy/neuromyopathy; caution with renal impairment and CYP3A4/P-gp inhibitors.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Myopathy after weeks of therapy |
| Strength | met | PRR 20.8, large |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific to colchicine |
| Biological gradient | met | Dose-related |
| Plausibility | met | Microtubule inhibition in muscle |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to other drug-induced myopathy |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Vigabatrin ↔ Visual field defect
Open this assessment on its own page →
Vigabatrin is an irreversible GABA-transaminase inhibitor for infantile spasms and refractory epilepsy; it causes a characteristic, often irreversible concentric visual-field defect, appearing here as 141 co-reports (PRR 28.8). Risk rises with cumulative dose and duration, so the label requires baseline and periodic visual-field testing and limits use where benefit does not clearly outweigh the risk.
Regulatory basis: vigabatrin (Sabril) prescribing information — boxed warning for permanent vision loss; mandatory visual-field monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Field loss after months of therapy |
| Strength | met | PRR 28.8, large |
| Consistency | met | Reproduced across cohort studies |
| Specificity | met | Fairly specific to vigabatrin |
| Biological gradient | met | Cumulative dose-related |
| Plausibility | met | GABA accumulation and retinal toxicity |
| Coherence | met | Fits the mechanism |
| Experiment | met | Cohort and monitoring data support it |
| Analogy | met | Analogous to other retinotoxic drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Hydroxychloroquine ↔ QT prolongation
Open this assessment on its own page →
Hydroxychloroquine is an antimalarial and immunomodulator used in lupus and rheumatoid arthritis; it blocks cardiac potassium channels and can prolong the QT interval, carried here as 921 co-reports (PRR 7.4). Risk rises with high dose, hypokalaemia, and co-administration of other QT-prolonging drugs, and the label advises caution and ECG monitoring in at-risk patients.
Regulatory basis: hydroxychloroquine prescribing information — QT prolongation and ventricular-arrhythmia caution.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | QT change during therapy |
| Strength | met | PRR 7.4, moderate |
| Consistency | met | Reproduced across case series |
| Specificity | partial | Shared with other 4-aminoquinolines |
| Biological gradient | met | Higher with higher dose |
| Plausibility | met | Cardiac potassium-channel blockade |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to chloroquine QT prolongation |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Temozolomide ↔ Thrombocytopenia
Open this assessment on its own page →
Temozolomide is an oral alkylating agent for glioblastoma; myelosuppression, especially thrombocytopenia and neutropenia, is its dose-limiting toxicity and carries 1,572 thrombocytopenia co-reports here (PRR 14.3). The effect is cumulative, which is why the label requires frequent blood counts throughout each cycle and dose adjustment by haematological nadir.
Regulatory basis: temozolomide (Temodar) prescribing information — myelosuppression/thrombocytopenia; frequent monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Platelet fall during cycles |
| Strength | met | PRR 14.3, large |
| Consistency | met | Consistent across trials |
| Specificity | met | Fairly specific to alkylating agents |
| Biological gradient | met | Cumulative dose-related |
| Plausibility | met | Bone-marrow stem-cell damage |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials recorded thrombocytopenia |
| Analogy | met | Analogous to other alkylating-agent myelosuppression |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (NCT03345095)
| Adverse event | Experimental Arm (n=305) · Standard Arm (n=297) | |
|---|---|---|
| Pancytopenia | 1/305 | 0/297 |
| Thrombocytopenia | 7/305 | 1/297 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Mesalamine ↔ Pancreatitis
Open this assessment on its own page →
Mesalamine (5-aminosalicylic acid) is the mainstay of ulcerative colitis treatment; acute pancreatitis is a rare, idiosyncratic effect (636 co-reports here, PRR 4.6) that appears shortly after the drug is started, and it recurs if the drug is reintroduced. The reaction is one reason a short drug holiday is considered when pancreatitis develops in inflammatory bowel disease.
Regulatory basis: mesalamine prescribing information — pancreatitis; drug-induced pancreatitis literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within days to weeks |
| Strength | met | PRR 4.6, modest |
| Consistency | met | Reproduced across case reports |
| Specificity | not established | Not specific to mesalamine |
| Biological gradient | not established | Idiosyncratic (not dose-related) |
| Plausibility | met | Proposed immuno-allergic mechanism |
| Coherence | partial | Consistent with drug-induced pancreatitis |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to sulfasalazine pancreatitis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis (NCT01124149)
| Adverse event | MMX Mesalamine/ Mesalazine (Acute Phase) (n=717) · MMX Mesalamine/ Mesalazine (Maintenance Phase) (n=461) | |
|---|---|---|
| Pancreatitis acute | 1/717 | 0/461 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Ursodiol ↔ Pruritus
Open this assessment on its own page →
Ursodiol (ursodeoxycholic acid) is a bile acid used for primary biliary cholangitis and gallstones; diarrhoea and pruritus are its common effects, and pruritus carries 1,299 co-reports here (PRR 3.3) — a high count partly because pruritus is itself a symptom of the cholestatic disease being treated. The drug is otherwise well tolerated, and effects are usually dose-related.
Regulatory basis: ursodiol prescribing information — diarrhoea and gastrointestinal effects.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Pruritus and diarrhoea follow dosing |
| Strength | met | PRR 3.3, modest |
| Consistency | met | Reported across practice |
| Specificity | not established | Cannot separate drug from cholestatic disease |
| Biological gradient | met | Dose-related |
| Plausibility | met | Bile-acid effect on gut and skin |
| Coherence | met | Fits the pharmacology |
| Experiment | n/a | Not a trial endpoint |
| Analogy | partial | Analogous to other bile-acid effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) (NCT03602560)
| Adverse event | Seladelpar 5/10 mg (n=89) · Seladelpar 10 mg (n=89) · Placebo (n=87) | ||
|---|---|---|---|
| Pruritus | 3/89 | 10/89 | 11/87 |
| Pruritus generalised | 3/89 | 3/89 | 3/87 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Oseltamivir ↔ Neuropsychiatric events
Open this assessment on its own page →
Oseltamivir is a neuraminidase inhibitor for influenza; neuropsychiatric events — delirium, confusion, and in rare cases self-injury — have been reported, particularly in children and adolescents (delirium 66 co-reports here, PRR 5.1). The reports prompted regulatory review and warning label changes, but causality remains uncertain because influenza itself can cause encephalopathy and delirium, and controlled trials have not confirmed an excess.
Regulatory basis: oseltamivir prescribing information — neuropsychiatric events; regulatory reviews of delirium/self-injury.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Onset during treatment |
| Strength | met | PRR 5.1, moderate |
| Consistency | met | Reported across case series |
| Specificity | not established | Not specific to oseltamivir |
| Biological gradient | not established | Cannot exclude influenza encephalopathy |
| Plausibility | not established | No established dose relationship |
| Coherence | partial | Mechanism debated |
| Experiment | not established | Not reproduced in trials |
| Analogy | partial | Debated analogy to influenza-related delirium |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza (NCT01231620)
| Adverse event | Intravenous (IV) Zanamivir 300mg Twice Daily (n=201) · Intravenous (IV) Zanamivir 600mg Twice Daily (n=209) · Oral Oseltamivir 75mg Twice Daily (n=205) | ||
|---|---|---|---|
| Delirium febrile | 0/201 | 0/209 | 1/205 |
| Encephalopathy | 1/201 | 0/209 | 1/205 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Voriconazole ↔ Hallucination
Open this assessment on its own page →
Voriconazole is a triazole antifungal; in addition to visual disturbances and photosensitivity, it causes hallucinations at a rate higher than other azoles (hallucination 704 co-reports here, PRR 6.6), especially with high plasma concentrations. The effect is dose-related and reversible, and monitoring of trough levels is advised.
Regulatory basis: voriconazole prescribing information — visual and CNS adverse events including hallucinations.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hallucinations during therapy |
| Strength | met | PRR 6.6, moderate |
| Consistency | met | Reproduced across series |
| Specificity | partial | Shared across the azole class |
| Biological gradient | met | Related to plasma concentration |
| Plausibility | met | Central CNS effect of the triazole |
| Coherence | met | Fits the pharmacology |
| Experiment | met | Trials recorded CNS events |
| Analogy | met | Analogous to other azole CNS effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) (NCT01151085)
| Adverse event | Voriconazole (n=946) |
|---|---|
| Hallucination | 11/946 |
| Hallucination, visual | 3/946 |
| Hallucination, auditory | 1/946 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Iodixanol ↔ Contrast-induced nephropathy
Open this assessment on its own page →
Iodixanol is an iso-osmolar iodinated contrast medium; contrast-induced nephropathy is the principal hazard of any intravascular contrast and appears here as 40 nephropathy-toxic co-reports (PRR 21.5). Risk rises with pre-existing renal impairment, diabetes, dehydration, and high contrast volume, and the label advises adequate hydration and minimising volume in at-risk patients.
Regulatory basis: iodixanol (Visipaque) prescribing information — contrast-induced nephropathy; hydration guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Renal injury within days |
| Strength | met | PRR 21.5, large |
| Consistency | met | Consistent across contrast agents |
| Specificity | partial | Shared across iodinated contrast |
| Biological gradient | met | Dose- and volume-related |
| Plausibility | met | Tubular toxicity and renal vasoconstriction |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to other contrast media |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Propofol ↔ Infusion syndrome
Open this assessment on its own page →
Propofol is an intravenous anaesthetic; with high-dose, prolonged infusion it causes propofol-related infusion syndrome — metabolic acidosis, rhabdomyolysis, cardiac failure, and renal injury (rhabdomyolysis 910 co-reports here, PRR 12.9). The syndrome is a direct consequence of impaired mitochondrial fatty-acid oxidation, and the label advises limiting dose and duration and monitoring for the early signs.
Regulatory basis: propofol prescribing information — propofol-related infusion syndrome; dose/duration limits.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset during prolonged infusion |
| Strength | met | PRR 12.9, large |
| Consistency | met | Reproduced across case series |
| Specificity | met | Fairly specific to propofol |
| Biological gradient | met | Dose- and duration-related |
| Plausibility | met | Mitochondrial fatty-acid oxidation defect |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Rare in trials |
| Analogy | met | Analogous to other anaesthetic-related myotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Tocilizumab ↔ Gastrointestinal perforation
Open this assessment on its own page →
Tocilizumab is an interleukin-6 receptor antagonist used in rheumatoid arthritis and cytokine-release syndrome; gastrointestinal perforation is a well-recognised, serious effect (duodenal ulcer perforation 5,011 co-reports here, PRR 406.8) that occurs in patients on combination disease-modifying therapy or corticosteroids. The label carries a warning and advises vigilance for abdominal symptoms, especially in patients with a history of diverticulitis.
Regulatory basis: tocilizumab (Actemra) prescribing information — gastrointestinal perforation warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Onset over weeks of therapy |
| Strength | met | PRR 406.8, an extreme signal |
| Consistency | met | Reproduced across registries |
| Specificity | met | Fairly specific to IL-6 blockade |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | IL-6 blockade impairing mucosal healing |
| Coherence | met | Fits the pharmacology |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other biologic GI perforation |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS) (NCT01185522)
| Adverse event | Tocilizumab (n=693) |
|---|---|
| Intestinal perforation | 1/693 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Deferiprone ↔ Agranulocytosis
Open this assessment on its own page →
Deferiprone is an oral iron chelator used in transfusional iron overload; it can cause agranulocytosis or neutropenia, a severe and potentially fatal idiosyncratic effect, appearing here as 158 co-reports (PRR 60.2). Because of this risk the label requires regular blood-count monitoring, instructs patients to report fever or sore throat immediately, and allows resumption only after counts recover.
Regulatory basis: deferiprone (Ferriprox) prescribing information — agranulocytosis/neutropenia; mandatory blood-count monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within weeks to months |
| Strength | met | PRR 60.2, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to deferiprone |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Idiosyncratic myeloid suppression |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other drug-induced agranulocytosis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients (NCT01825512)
| Adverse event | Deferiprone (n=193) · Deferasirox (n=197) | |
|---|---|---|
| agranulocytosis | 3/193 | 0/197 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Lithium ↔ Tremor
Open this assessment on its own page →
Lithium is the leading mood stabiliser for bipolar disorder and a fine tremor is its most common neurological effect, progressing to a coarse tremor at higher concentrations; post-marketing data capture 1,509 co-reports (PRR 7.7). It usually appears early, often at therapeutic levels, worsens with dose and concentration, and is managed by dose adjustment or a beta-blocker.
Regulatory basis: lithium (Eskalith) prescribing information — treatment-emergent tremor; periodic lithium-level, thyroid and renal monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Earliest neurological effect |
| Strength | met | PRR 7.7 with 1,509 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Tremor is common in the population |
| Biological gradient | met | Clear dose and concentration gradient |
| Plausibility | met | Known neurotoxic effect of lithium |
| Coherence | met | Fits lithium's narrow therapeutic index |
| Experiment | n/a | Not a randomised trial endpoint |
| Analogy | met | Analogous to other tremorogenic drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Lithium ↔ Nephrogenic diabetes insipidus
Open this assessment on its own page →
Lithium blunts antidiuretic-hormone signalling in the collecting duct, producing nephrogenic diabetes insipidus with polyuria and polydipsia; 304 co-reports carry an extreme PRR of 301.3. The effect is concentration-related, often insidious over months to years and only partly reversible, so fluid balance and renal function are monitored during long-term therapy.
Regulatory basis: lithium (Eskalith) prescribing information — nephrogenic diabetes insipidus; renal-function monitoring during chronic use.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Insidious over months to years |
| Strength | met | PRR 301.3, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to lithium |
| Biological gradient | met | Strong concentration dependence |
| Plausibility | met | Well-defined tubular mechanism |
| Coherence | met | Fits lithium's renal toxicity |
| Experiment | n/a | Too chronic for trial capture |
| Analogy | met | Analogous to demeclocycline-type diabetes insipidus |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Lithium ↔ Hypothyroidism
Open this assessment on its own page →
Lithium concentrates in the thyroid and inhibits hormone release, causing hypothyroidism and goitre; 224 co-reports give PRR 5.9. The effect is often subclinical at first and emerges over the first year or two of therapy, so thyroid function is checked periodically and treated with levothyroxine when required.
Regulatory basis: lithium (Eskalith) prescribing information — hypothyroidism and goitre; periodic thyroid-function monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Evolves over the first 1-2 years |
| Strength | met | PRR 5.9 with 224 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | not established | Hypothyroidism is common in the population |
| Biological gradient | met | Related to duration and level |
| Plausibility | met | Known lithium thyroid blockade |
| Coherence | met | Fits lithium's antithyroid action |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to amiodarone thyroid effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Carbamazepine ↔ Hyponatraemia
Open this assessment on its own page →
Carbamazepine potentiates antidiuretic hormone, producing dilutional hyponatraemia that can become symptomatic when severe; 1,446 co-reports give PRR 8.3. The effect is dose-related and more frequent in older adults, so baseline and periodic sodium checks are advised.
Regulatory basis: carbamazepine (Tegretol) prescribing information — hyponatraemia/SIADH; serum-sodium monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Gradual, days to weeks |
| Strength | met | PRR 8.3 with 1,446 co-reports |
| Consistency | met | Consistent across studies |
| Specificity | not established | Hyponatraemia has many causes |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known ADH-potentiating mechanism |
| Coherence | met | Fits carbamazepine's renal effect |
| Experiment | n/a | Not a routine trial endpoint |
| Analogy | met | Analogous to oxcarbazepine hyponatraemia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs (NCT00438451)
| Adverse event | Levetiracetam (n=122) · Carbamazepine (n=121) · Lamotrigine (n=117) | ||
|---|---|---|---|
| Hyponatraemia | 0/122 | 1/121 | 0/117 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Carbamazepine ↔ Agranulocytosis
Open this assessment on its own page →
Carbamazepine can cause blood dyscrasias including agranulocytosis and aplastic anaemia; 184 co-reports give PRR 3.2. The risk is idiosyncratic and potentially fatal, so the label advises immediate blood counts if fever, sore throat or infection develops.
Regulatory basis: carbamazepine (Tegretol) prescribing information — aplastic anaemia and agranulocytosis; prompt blood-count monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Idiosyncratic, weeks to months |
| Strength | met | PRR 3.2 with 184 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | met | Fairly specific to carbamazepine |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible marrow toxicity |
| Coherence | met | Fits aromatic anticonvulsant dyscrasias |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to phenytoin and valproate cytopenias |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Carbamazepine ↔ Stevens-Johnson syndrome
Open this assessment on its own page →
Carbamazepine is a leading cause of Stevens-Johnson syndrome and toxic epidermal necrolysis, strongly linked to the HLA-B*1502 allele in certain ancestries; 920 co-reports give PRR 13.5. The label recommends genetic screening in at-risk groups and immediate withdrawal at the first sign of rash.
Regulatory basis: carbamazepine (Tegretol) prescribing information — SJS/TEN and HLA-B*1502 screening recommendation.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Erupts within first weeks |
| Strength | met | PRR 13.5 with 920 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Strong HLA association |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated mechanism |
| Coherence | met | Fits aromatic anticonvulsant risk |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to phenytoin and lamotrigine SJS |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Valproate ↔ Hepatotoxicity
Open this assessment on its own page →
Valproate can cause serious, sometimes fatal hepatotoxicity, with the highest risk in children under two and in polytherapy; 65 co-reports give PRR 3.0. A boxed warning mandates baseline and periodic liver-function testing, and the drug is stopped if hepatic injury is suspected.
Regulatory basis: valproate prescribing information — boxed warning for hepatotoxicity; liver-function monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Can be rapid in high-risk patients |
| Strength | met | PRR 3.0 with 65 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Highest in defined risk groups |
| Biological gradient | met | Dose and age related |
| Plausibility | met | Known mitochondrial/β-oxidation toxicity |
| Coherence | met | Fits valproate's metabolic profile |
| Experiment | n/a | Too rare and severe for trial capture |
| Analogy | met | Analogous to other antiepileptic hepatotoxins |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Valproate ↔ Acute pancreatitis
Open this assessment on its own page →
Valproate is associated with acute pancreatitis, which can be life-threatening and may appear soon after starting or after years of use; 120 co-reports give PRR 5.5. Pancreatitis is a labelled warning and the drug is discontinued if it is suspected.
Regulatory basis: valproate prescribing information — acute pancreatitis warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Variable, early or late |
| Strength | met | PRR 5.5 with 120 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | not established | Pancreatitis has many causes |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible direct toxicity |
| Coherence | met | Fits valproate's metabolic effects |
| Experiment | n/a | Not a trial endpoint |
| Analogy | met | Analogous to other drug-induced pancreatitis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Valproate ↔ Thrombocytopenia
Open this assessment on its own page →
Valproate commonly lowers platelet counts through dose-related marrow suppression and can impair platelet function; 455 co-reports give PRR 4.2. Blood counts are checked before surgery and in patients with bruising or bleeding.
Regulatory basis: valproate prescribing information — thrombocytopenia; blood-count monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Gradual, dose-related |
| Strength | met | PRR 4.2 with 455 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Low platelets are common |
| Biological gradient | met | Dose-related |
| Plausibility | met | Plausible marrow suppression |
| Coherence | met | Fits valproate haematological effects |
| Experiment | n/a | Rarely coded as a trial endpoint |
| Analogy | met | Analogous to other drug-induced thrombocytopenia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Valproate ↔ Hyperammonaemia
Open this assessment on its own page →
Valproate can raise blood ammonia even when liver enzymes are normal, occasionally causing encephalopathy; 298 co-reports give an extreme PRR of 64.7. The label warns of hyperammonaemic encephalopathy, especially with concomitant topiramate or in urea-cycle disorders.
Regulatory basis: valproate prescribing information — hyperammonaemia and hyperammonaemic encephalopathy warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hours to days |
| Strength | met | PRR 64.7, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to valproate |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known urea-cycle interference |
| Coherence | met | Fits valproate's metabolic effects |
| Experiment | n/a | Too specific for routine trial capture |
| Analogy | met | Analogous to topiramate interaction |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Phenytoin ↔ Gingival hypertrophy
Open this assessment on its own page →
Phenytoin causes fibrous gingival overgrowth in a substantial minority of long-term users, related to concentration, oral hygiene and age; 85 co-reports give an extreme PRR of 60.6. The label lists gingival hyperplasia and advises good dental hygiene and monitoring.
Regulatory basis: phenytoin (Dilantin) prescribing information — gingival hyperplasia.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months of therapy |
| Strength | met | PRR 60.6, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to phenytoin |
| Biological gradient | met | Concentration-related |
| Plausibility | met | Known fibroblast-proliferation mechanism |
| Coherence | met | Fits phenytoin's connective-tissue effect |
| Experiment | n/a | Not a short-term trial endpoint |
| Analogy | met | Analogous to cyclosporine gingival overgrowth |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Phenytoin ↔ Stevens-Johnson syndrome
Open this assessment on its own page →
Phenytoin is a well-known cause of Stevens-Johnson syndrome and toxic epidermal necrolysis, an idiosyncratic mucocutaneous reaction; 771 co-reports give PRR 36.2. The label warns of serious skin reactions and advises stopping the drug at the first sign of rash.
Regulatory basis: phenytoin (Dilantin) prescribing information — serious dermatological reactions including SJS/TEN.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Within the first weeks |
| Strength | met | PRR 36.2 with 771 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Associated with HLA alleles |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated mechanism |
| Coherence | met | Fits aromatic anticonvulsant risk |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to carbamazepine and lamotrigine SJS |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Allopurinol ↔ Toxic epidermal necrolysis
Open this assessment on its own page →
Allopurinol can trigger toxic epidermal necrolysis and Stevens-Johnson syndrome, a severe cutaneous reaction closely associated with the HLA-B*5801 allele; 1,170 co-reports give PRR 11.3. The label recommends screening in high-prevalence ancestries and stopping the drug immediately if a rash develops.
Regulatory basis: allopurinol prescribing information — SJS/TEN and HLA-B*5801 screening.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks after start |
| Strength | met | PRR 11.3 with 1,170 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Strong HLA association |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated mechanism |
| Coherence | met | Fits aromatic-drug hypersensitivity |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to carbamazepine SJS/TEN |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Nevirapine ↔ Hepatotoxicity
Open this assessment on its own page →
Nevirapine carries a boxed warning for severe, sometimes fatal hepatotoxicity, especially in the first weeks of therapy and in patients with higher CD4 counts; 170 co-reports give PRR 18.1. The label requires a lead-in dose and frequent liver monitoring early on.
Regulatory basis: nevirapine (Viramune) prescribing information — boxed warning for hepatotoxicity; lead-in dosing and liver monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | First 18 weeks of therapy |
| Strength | met | PRR 18.1 with 170 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Higher in defined risk groups |
| Biological gradient | not established | Not simply dose-related |
| Plausibility | met | Plausible immune-mediated injury |
| Coherence | met | Fits nevirapine hypersensitivity |
| Experiment | n/a | Too rare and severe for trial capture |
| Analogy | met | Analogous to other antiretroviral hepatotoxins |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children (NCT00978068)
| Adverse event | Group 1 (n=84) · Group 2 (n=86) | |
|---|---|---|
| Stevens-Johnson Syndrome | 0/84 | 1/86 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Nevirapine ↔ Stevens-Johnson syndrome
Open this assessment on its own page →
Nevirapine is a recognised cause of severe cutaneous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis; 192 co-reports give PRR 20.3. These reactions cluster in the first weeks, so the label advises stopping the drug and seeking care at the first sign of rash.
Regulatory basis: nevirapine (Viramune) prescribing information — severe cutaneous reactions including SJS/TEN.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | First weeks of therapy |
| Strength | met | PRR 20.3 with 192 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Associated with HLA alleles |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated mechanism |
| Coherence | met | Fits nevirapine hypersensitivity syndrome |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to carbamazepine SJS/TEN |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Efavirenz ↔ Suicidal depression
Open this assessment on its own page →
Efavirenz carries a boxed warning for serious psychiatric symptoms including depression and suicidality, which can occur at any time during therapy; 36 co-reports give PRR 19.9. Patients are warned to report mood change, and the drug is stopped if symptoms are severe.
Regulatory basis: efavirenz (Sustiva) prescribing information — boxed warning for psychiatric symptoms and suicidality.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Any time on therapy |
| Strength | met | PRR 19.9 with 36 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | not established | Depression is common in the population |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible CNS mechanism |
| Coherence | met | Fits efavirenz neuropsychiatric effects |
| Experiment | n/a | Rarely coded as a trial endpoint |
| Analogy | met | Analogous to other antiretroviral CNS effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ganciclovir ↔ Neutropenia
Open this assessment on its own page →
Ganciclovir suppresses bone marrow and commonly causes neutropenia, which is dose-limiting and is accentuated by other myelosuppressive drugs; 531 co-reports give PRR 8.1. The label requires frequent blood-count monitoring and dose adjustment.
Regulatory basis: ganciclovir prescribing information — neutropenia and thrombocytopenia; blood-count monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 8.1 with 531 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Neutropenia has many causes |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known nucleoside-analogue marrow toxicity |
| Coherence | met | Fits ganciclovir's myelosuppression |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to other myelosuppressive antivirals |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients (NCT00294515)
| Adverse event | Valganciclovir up to 100 Days (n=164) · Valganciclovir up to 200 Days (n=156) | |
|---|---|---|
| Neutropenia | 3/164 | 9/156 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Amphotericin B ↔ Acute kidney injury
Open this assessment on its own page →
Amphotericin B is classically nephrotoxic, causing dose-dependent renal injury with electrolyte wasting that frequently limits therapy; 436 co-reports give PRR 4.8. The label advises renal monitoring, hydration and electrolyte replacement.
Regulatory basis: amphotericin B prescribing information — nephrotoxicity with renal-function and electrolyte monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks |
| Strength | met | PRR 4.8 with 436 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Acute kidney injury has many causes |
| Biological gradient | met | Clear dose gradient |
| Plausibility | met | Known membrane-pore mechanism |
| Coherence | met | Fits amphotericin's tubular toxicity |
| Experiment | n/a | Often captured in trials |
| Analogy | met | Analogous to other nephrotoxic antifungals |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals (NCT00885703)
| Adverse event | Stage 1: 1200mg Fluconazole (n=22) · Stage 1: 1600mg Fluconazole (n=26) · Stage 1: 2000mg Fluconazole (n=24) · Stage 1: Ampho B (n=24) | |||
|---|---|---|---|---|
| Acute kidney injury | 1/22 | 0/26 | 0/24 | 0/24 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Colchicine ↔ Pancytopenia
Open this assessment on its own page →
Colchicine is a mitotic poison and at high exposure causes marrow suppression with pancytopenia, especially in overdose or renal impairment; 400 co-reports give PRR 5.8. The label warns of blood dyscrasias and advises caution in organ impairment.
Regulatory basis: colchicine prescribing information — blood dyscrasias including pancytopenia; caution in renal/hepatic impairment.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days after high exposure |
| Strength | met | PRR 5.8 with 400 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to overdose |
| Biological gradient | met | Strong dose/exposure relation |
| Plausibility | met | Known mitotic-spindle mechanism |
| Coherence | met | Fits colchicine's narrow therapeutic index |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other antimitotic myelosuppression |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Colchicine ↔ Rhabdomyolysis
Open this assessment on its own page →
Colchicine can cause myopathy and rhabdomyolysis, particularly with concomitant statins or in renal impairment where it accumulates; 519 co-reports give PRR 10.1. The label warns of neuromuscular toxicity and advises caution with interacting drugs.
Regulatory basis: colchicine prescribing information — myopathy/rhabdomyolysis, especially with statins or renal impairment.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks |
| Strength | met | PRR 10.1 with 519 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | not established | Rhabdomyolysis has many causes |
| Biological gradient | met | Dose/exposure-related |
| Plausibility | met | Known microtubule mechanism in muscle |
| Coherence | met | Fits the colchicine-statin interaction |
| Experiment | n/a | Not a routine trial endpoint |
| Analogy | met | Analogous to statin-associated myopathy |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Vancomycin ↔ Neutropenia
Open this assessment on its own page →
Prolonged vancomycin therapy can cause reversible neutropenia, usually after more than a week of treatment; 1,361 co-reports give PRR 3.7. The label advises periodic blood counts during extended therapy and withdrawal if counts fall.
Regulatory basis: vancomycin prescribing information — reversible neutropenia during prolonged therapy; blood-count monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | After 1-2 weeks of therapy |
| Strength | met | PRR 3.7 with 1,361 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | not established | Neutropenia has many causes |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible immune/marrow mechanism |
| Coherence | met | Fits vancomycin haematological effects |
| Experiment | n/a | Not a routine trial endpoint |
| Analogy | met | Analogous to beta-lactam neutropenia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) (NCT01513239)
| Adverse event | MK-3415A + SOC (n=390) · MK-6072 + SOC (n=396) · Placebo + SOC (n=381) · MK-3415 + SOC (n=1) | |||
|---|---|---|---|---|
| Neutropenia | 2/390 | 0/396 | 1/381 | 0/1 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Vancomycin ↔ DRESS (eosinophilia and systemic symptoms)
Open this assessment on its own page →
Vancomycin is a recognised cause of DRESS (drug reaction with eosinophilia and systemic symptoms), a delayed multi-organ hypersensitivity syndrome; 2,386 co-reports give PRR 37.5. Management is prompt withdrawal and corticosteroid support.
Regulatory basis: vancomycin prescribing information and case literature — DRESS/hypersensitivity syndrome.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | 2-8 weeks after start |
| Strength | met | PRR 37.5 with 2,386 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Associated with HLA alleles |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated mechanism |
| Coherence | met | Fits vancomycin hypersensitivity |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other antibiotic DRESS |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Gentamicin ↔ Ototoxicity
Open this assessment on its own page →
Gentamicin carries a boxed warning for ototoxicity: it damages the cochlea and vestibular apparatus, sometimes irreversibly, with risk rising with high or prolonged levels; 94 co-reports give an extreme PRR of 86.1. The label requires level monitoring and caution in renal impairment.
Regulatory basis: gentamicin prescribing information — boxed warning for ototoxicity; aminoglycoside level and renal monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days into therapy |
| Strength | met | PRR 86.1, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to aminoglycosides |
| Biological gradient | met | Level/dose-related |
| Plausibility | met | Known hair-cell toxicity |
| Coherence | met | Fits gentamicin's cochlear effect |
| Experiment | n/a | Hearing testing rarely a trial endpoint |
| Analogy | met | Analogous to amikacin/tobramycin ototoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Clopidogrel ↔ Thrombotic thrombocytopenic purpura
Open this assessment on its own page →
Clopidogrel carries a boxed warning for thrombotic thrombocytopenic purpura, a rare but life-threatening microangiopathy that can appear within days to weeks of starting; 456 co-reports give PRR 15.7. Prompt plasma exchange is required.
Regulatory basis: clopidogrel (Plavix) prescribing information — boxed warning for TTP.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks after start |
| Strength | met | PRR 15.7 with 456 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | met | Fairly specific to thienopyridines |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated mechanism |
| Coherence | met | Fits thienopyridine-associated TTP |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to ticlopidine TTP |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Terbinafine ↔ Hepatic enzyme increased
Open this assessment on its own page →
Terbinafine can raise liver enzymes and, rarely, cause hepatic failure, so the label advises stopping therapy if hepatic injury develops; 62 co-reports give PRR 2.7. Baseline liver tests are recommended in patients at risk.
Regulatory basis: terbinafine prescribing information — hepatic enzyme elevation and rare hepatic failure; liver-function caution.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 2.7 with 62 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | not established | Enzyme rises have many causes |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible hepatocellular injury |
| Coherence | met | Fits terbinafine hepatotoxicity |
| Experiment | n/a | Not a routine trial endpoint |
| Analogy | met | Analogous to other antifungal hepatotoxins |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) (NCT00491764)
| Adverse event | Posaconazole 100 mg QD for 24 Weeks (n=36) · Posaconazole 200 mg QD for 24 Weeks (n=37) · Posaconazole 400 mg QD for 24 Weeks (n=36) · Posaconazole 400 mg QD for 12 Weeks (n=36) | |||
|---|---|---|---|---|
| HEPATIC ENZYME INCREASED | 1/36 | 0/37 | 2/36 | 0/36 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Ketoconazole ↔ Hepatotoxicity
Open this assessment on its own page →
Oral ketoconazole can cause serious hepatotoxicity and has been largely restricted to specific indications because of it; 64 co-reports give PRR 3.5. The label requires baseline and periodic liver tests and prompt withdrawal at the first sign of injury.
Regulatory basis: ketoconazole prescribing information — severe hepatotoxicity; liver-function monitoring and restricted use.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 3.5 with 64 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | not established | Hepatotoxicity has many causes |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible hepatocellular injury |
| Coherence | met | Fits azole-associated hepatotoxicity |
| Experiment | n/a | Not a routine trial endpoint |
| Analogy | met | Analogous to other antifungal hepatotoxins |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Dapsone ↔ Methaemoglobinaemia
Open this assessment on its own page →
Dapsone oxidises haemoglobin and causes dose-dependent methaemoglobinaemia, which can be severe and even fatal; 480 co-reports give an extreme PRR of 522.3. The label warns of this effect and advises monitoring, especially at higher doses.
Regulatory basis: dapsone prescribing information — methaemoglobinaemia; clinical monitoring and supportive care.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hours to days |
| Strength | met | PRR 522.3, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to dapsone |
| Biological gradient | met | Clear dose dependence |
| Plausibility | met | Known haem-oxidation mechanism |
| Coherence | met | Fits dapsone's redox toxicity |
| Experiment | n/a | Not a routine trial endpoint |
| Analogy | met | Analogous to other oxidant drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Dapsone ↔ Haemolytic anaemia
Open this assessment on its own page →
Dapsone causes oxidative haemolysis that is dose-related and much more severe in glucose-6-phosphate-dehydrogenase deficiency; 165 co-reports give PRR 36.9. The label advises caution and G6PD awareness before use.
Regulatory basis: dapsone prescribing information — haemolysis, especially in G6PD deficiency.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks |
| Strength | met | PRR 36.9 with 165 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Strong G6PD association |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known oxidative haemolysis |
| Coherence | met | Fits dapsone's redox toxicity |
| Experiment | n/a | Not a routine trial endpoint |
| Analogy | met | Analogous to primaquine haemolysis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Linezolid ↔ Serotonin syndrome
Open this assessment on its own page →
Linezolid is a weak monoamine-oxidase inhibitor and can precipitate serotonin syndrome when combined with serotonergic drugs; 917 co-reports give PRR 35.6. The label warns of this interaction and advises careful monitoring or avoidance of the combination.
Regulatory basis: linezolid (Zyvox) prescribing information — serotonin syndrome with serotonergic drugs.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hours to days of combination |
| Strength | met | PRR 35.6 with 917 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | met | Fairly specific to the interaction |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Known MAO-inhibition mechanism |
| Coherence | met | Fits linezolid's interaction profile |
| Experiment | n/a | Interaction seldom studied in trials |
| Analogy | met | Analogous to MAOI serotonin syndrome |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Nitrofurantoin ↔ Peripheral neuropathy
Open this assessment on its own page →
Nitrofurantoin can cause peripheral neuropathy that may become irreversible, particularly with prolonged use or renal impairment; 207 co-reports give PRR 2.8. The label warns of this effect and advises prompt withdrawal if numbness or paraesthesia appears.
Regulatory basis: nitrofurantoin prescribing information — peripheral neuropathy; caution in renal impairment and prolonged use.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 2.8 with 207 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | not established | Peripheral neuropathy has many causes |
| Biological gradient | met | Duration/exposure-related |
| Plausibility | met | Plausible axonal toxicity |
| Coherence | met | Fits nitrofurantoin neurotoxicity |
| Experiment | n/a | Not a routine trial endpoint |
| Analogy | met | Analogous to other drug-induced neuropathies |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Minocycline ↔ Drug-induced lupus
Open this assessment on its own page →
Minocycline is a well-recognised cause of drug-induced lupus, typically with arthralgia, myalgia and positive antinuclear antibodies that resolve after withdrawal; 569 co-reports give PRR 29.6. The label lists lupus-like syndrome among its hypersensitivity reactions.
Regulatory basis: minocycline prescribing information — lupus-like syndrome and autoimmune reactions.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months of therapy |
| Strength | met | PRR 29.6 with 569 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to minocycline |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible immune mechanism |
| Coherence | met | Fits tetracycline-induced autoimmunity |
| Experiment | n/a | Too chronic for trial capture |
| Analogy | met | Analogous to hydralazine/procainamide lupus |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Minocycline ↔ DRESS (eosinophilia and systemic symptoms)
Open this assessment on its own page →
Minocycline can cause DRESS (drug reaction with eosinophilia and systemic symptoms), a severe delayed hypersensitivity syndrome with rash, fever and organ involvement; 279 co-reports give PRR 20.0. Management is withdrawal and corticosteroid support.
Regulatory basis: minocycline prescribing information — severe hypersensitivity/DRESS.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | 2-6 weeks after start |
| Strength | met | PRR 20.0 with 279 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | met | Associated with HLA alleles |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated mechanism |
| Coherence | met | Fits minocycline hypersensitivity |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other antibiotic DRESS |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Isotretinoin ↔ Inflammatory bowel disease
Open this assessment on its own page →
Isotretinoin has been linked to inflammatory bowel disease in case reports and some observational studies, but large cohort and meta-analytic analyses have not confirmed a causal increase; 5,252 co-reports nevertheless give PRR 494.6, a signal inflated by channeling and confounding. It is graded contested rather than established.
Regulatory basis: literature — isotretinoin and inflammatory bowel disease; label lists IBD among reported events but the association is disputed.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Courses over months |
| Strength | met | PRR 494.6, inflated by channeling |
| Consistency | partial | Observational studies disagree |
| Specificity | not established | Acne populations differ |
| Biological gradient | not established | No clear dose relation |
| Plausibility | partial | Mechanism proposed but unproven |
| Coherence | partial | Cohort data argue against causality |
| Experiment | n/a | Large cohorts did not confirm |
| Analogy | partial | Contrasted with other acne therapies |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Thalidomide ↔ Peripheral neuropathy
Open this assessment on its own page →
Thalidomide carries a boxed warning for peripheral neuropathy, a dose- and duration-related axonal injury that may be irreversible and is often the dose-limiting toxicity; 1,823 co-reports give PRR 11.3. The label advises baseline and periodic neurological assessment.
Regulatory basis: thalidomide prescribing information — boxed warning for peripheral neuropathy.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months of therapy, cumulative |
| Strength | met | PRR 11.3 with 1,823 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to thalidomide |
| Biological gradient | met | Strong cumulative-dose relation |
| Plausibility | met | Known axonal toxicity |
| Coherence | met | Fits thalidomide neurotoxicity |
| Experiment | n/a | Neuropathy is a coded trial endpoint |
| Analogy | met | Analogous to bortezomib neuropathy |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Pomalidomide for the Treatment of Bleeding in HHT (NCT03910244)
| Adverse event | Placebo (n=49) · Pomalidomide (n=95) | |
|---|---|---|
| Neuropathy peripheral | 0/49 | 2/95 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Lenalidomide ↔ Deep vein thrombosis
Open this assessment on its own page →
Lenalidomide carries a boxed warning for venous thromboembolism, including deep vein thrombosis and pulmonary embolism, with risk increased by dexamethasone and in myeloma; 4,404 co-reports give PRR 3.5. The label mandates thromboprophylaxis guidance.
Regulatory basis: lenalidomide (Revlimid) prescribing information — boxed warning for venous thromboembolism; thromboprophylaxis.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 3.5 with 4,404 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | not established | VTE risk is high in myeloma |
| Biological gradient | met | Dose/regimen-related |
| Plausibility | met | Plausible prothrombotic mechanism |
| Coherence | met | Fits IMiD-associated thrombosis |
| Experiment | n/a | VTE is often a coded trial event |
| Analogy | met | Analogous to thalidomide-associated VTE |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (NCT00833833)
| Adverse event | Phase 1: 2 mg Pomalidomide (n=6) · Phase 1: 3 mg Pomalidomide (n=8) · Phase 1: 4 mg Pomalidomide (n=14) · Phase 1: 5 mg Pomalidomide (n=10) | |||
|---|---|---|---|---|
| Deep vein thrombosis | 0/6 | 0/8 | 1/14 | 1/10 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Clonidine ↔ Blood pressure increased (rebound)
Open this assessment on its own page →
Abrupt withdrawal of clonidine causes rebound hypertension with catecholamine surge, especially after high doses or concomitant beta-blockade; 1,733 co-reports give PRR 4.7. The label warns against abrupt discontinuation and advises tapering.
Regulatory basis: clonidine (Catapres) prescribing information — rebound hypertension on abrupt withdrawal; taper guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hours to days after stopping |
| Strength | met | PRR 4.7 with 1,733 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | not established | BP readings are non-specific |
| Biological gradient | met | Higher with higher doses |
| Plausibility | met | Known withdrawal catecholamine surge |
| Coherence | met | Fits clonidine's mechanism |
| Experiment | n/a | Withdrawal not studied in trials |
| Analogy | met | Analogous to beta-blocker withdrawal |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Propylthiouracil ↔ Agranulocytosis
Open this assessment on its own page →
Propylthiouracil can cause agranulocytosis, a potentially fatal idiosyncratic effect, usually within the first weeks to months of therapy; 60 co-reports give PRR 33.3. The label advises patients to report fever or sore throat immediately for an urgent blood count.
Regulatory basis: propylthiouracil prescribing information — agranulocytosis; patient and blood-count monitoring advice.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | First weeks to months |
| Strength | met | PRR 33.3 with 60 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to antithyroid drugs |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Idiosyncratic marrow suppression |
| Coherence | met | Fits thionamide agranulocytosis |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to methimazole agranulocytosis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Sotalol ↔ Prolonged QT interval
Open this assessment on its own page →
Sotalol prolongs the QT interval through potassium-channel blockade and can cause torsades de pointes; it carries a boxed warning for this proarrhythmia and requires initiation with ECG monitoring and attention to renal function; 446 co-reports give PRR 15.9.
Regulatory basis: sotalol prescribing information — boxed warning for QT prolongation and torsades de pointes; ECG monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hours after dosing |
| Strength | met | PRR 15.9 with 446 co-reports |
| Consistency | met | Consistent across studies |
| Specificity | not established | QT prolongation has many causes |
| Biological gradient | met | Concentration/dose-related |
| Plausibility | met | Known potassium-channel blockade |
| Coherence | met | Fits class III antiarrhythmic effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to other QT-prolonging antiarrhythmics |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (NCT00911508)
| Adverse event | Left Atrial Ablation (n=1108) · Rate or Rhythm Control Therapy (n=1096) | |
|---|---|---|
| ELECTROCARDIOGRAM QT PROLONGED | 2/1108 | 1/1096 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Dofetilide ↔ Prolonged QT interval
Open this assessment on its own page →
Dofetilide is a potent QT-prolonging antiarrhythmic that can cause torsades de pointes and carries a boxed warning plus mandatory initiation monitoring and renal-function checks; 445 co-reports give PRR 25.1.
Regulatory basis: dofetilide (Tikosyn) prescribing information — boxed warning for QT prolongation/torsades; mandatory in-hospital initiation.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hours after initiation |
| Strength | met | PRR 25.1 with 445 co-reports |
| Consistency | met | Consistent across studies |
| Specificity | met | Fairly specific to class III |
| Biological gradient | met | Concentration/dose-related |
| Plausibility | met | Known IKr blockade |
| Coherence | met | Fits dofetilide's mechanism |
| Experiment | n/a | Monitored in trials by design |
| Analogy | met | Analogous to sotalol QT effect |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (NCT00911508)
| Adverse event | Left Atrial Ablation (n=1108) · Rate or Rhythm Control Therapy (n=1096) | |
|---|---|---|
| ELECTROCARDIOGRAM QT PROLONGED | 2/1108 | 1/1096 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Haloperidol ↔ Neuroleptic malignant syndrome
Open this assessment on its own page →
Haloperidol is a leading cause of neuroleptic malignant syndrome, a life-threatening reaction of hyperthermia, rigidity and autonomic instability that can occur after any exposure; 1,630 co-reports give an extreme PRR of 138.0. Prompt recognition and withdrawal are essential.
Regulatory basis: haloperidol prescribing information — neuroleptic malignant syndrome warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days after start or dose change |
| Strength | met | PRR 138.0, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to antipsychotics |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Known dopaminergic blockade mechanism |
| Coherence | met | Fits haloperidol's D2 antagonism |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other antipsychotic NMS |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study (NCT01211522)
| Adverse event | Haloperidol (n=192) · Ziprasidone (n=190) · Placebo (n=184) | ||
|---|---|---|---|
| Neuroleptic malignant syndrome | 0/192 | 0/190 | 0/184 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Haloperidol ↔ Prolonged QT interval
Open this assessment on its own page →
Haloperidol prolongs the QT interval and can cause torsades de pointes, particularly with intravenous or high-dose use and co-administered QT-prolonging drugs; 653 co-reports give PRR 16.0. The label warns of this risk and advises ECG monitoring in at-risk patients.
Regulatory basis: haloperidol prescribing information — QT prolongation/torsades de pointes warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hours after dosing |
| Strength | met | PRR 16.0 with 653 co-reports |
| Consistency | met | Consistent across reports |
| Specificity | not established | QT prolongation has many causes |
| Biological gradient | met | Dose/route-related |
| Plausibility | met | Known hERG blockade |
| Coherence | met | Fits haloperidol's cardiac effect |
| Experiment | n/a | Monitored in some trials |
| Analogy | met | Analogous to other antipsychotic QT effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Haloperidol ↔ Tardive dyskinesia
Open this assessment on its own page →
Haloperidol, as a high-potency typical antipsychotic, carries a substantial risk of tardive dyskinesia with prolonged use; 378 co-reports give PRR 11.7. The label warns of this potentially irreversible effect and advises the lowest effective dose and periodic assessment.
Regulatory basis: haloperidol prescribing information — tardive dyskinesia warning; lowest effective dose.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months to years of use |
| Strength | met | PRR 11.7 with 378 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to antipsychotics |
| Biological gradient | met | Cumulative dose-related |
| Plausibility | met | Known dopaminergic supersensitivity |
| Coherence | met | Fits haloperidol's chronic effect |
| Experiment | n/a | Chronic and under-coded in trials |
| Analogy | met | Analogous to other antipsychotic tardive syndromes |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Pimozide ↔ Prolonged QT interval
Open this assessment on its own page →
Pimozide prolongs the QT interval and carries a boxed warning for this proarrhythmia, with ECG assessment advised before and during therapy; 23 co-reports give PRR 28.5. The label limits dose and warns against QT-prolonging co-medication.
Regulatory basis: pimozide (Orap) prescribing information — boxed warning for QT prolongation/torsades; ECG monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hours after dosing |
| Strength | met | PRR 28.5, an extreme signal |
| Consistency | met | Reproduced across reports |
| Specificity | met | Fairly specific to pimozide |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known hERG blockade |
| Coherence | met | Fits pimozide's cardiac effect |
| Experiment | n/a | Small numbers limit trial capture |
| Analogy | met | Analogous to other antipsychotic QT effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Quetiapine ↔ Hypotension
Open this assessment on its own page →
Quetiapine blocks alpha-1 adrenergic receptors and commonly causes orthostatic hypotension and dizziness, especially during dose titration; 4,265 co-reports give PRR 2.4. The label advises slow titration and caution in older adults.
Regulatory basis: quetiapine prescribing information — orthostatic hypotension and syncope; slow titration guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | During titration |
| Strength | met | PRR 2.4 with 4,265 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Hypotension is common |
| Biological gradient | met | Dose/titration-related |
| Plausibility | met | Known alpha-1 blockade |
| Coherence | met | Fits quetiapine's receptor profile |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to other antipsychotic hypotension |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Olanzapine ↔ Weight gain
Open this assessment on its own page →
Olanzapine produces marked weight gain, among the largest of the atypical antipsychotics, through appetite and metabolic effects; 6,832 co-reports give PRR 6.2. The label advises baseline weight monitoring and counselling.
Regulatory basis: olanzapine prescribing information — weight gain; metabolic monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 6.2 with 6,832 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Weight gain is common |
| Biological gradient | met | Dose/duration-related |
| Plausibility | met | Known appetite/metabolic mechanism |
| Coherence | met | Fits olanzapine's metabolic profile |
| Experiment | n/a | Often a coded trial endpoint |
| Analogy | met | Analogous to clozapine weight gain |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Olanzapine ↔ Diabetes mellitus
Open this assessment on its own page →
Olanzapine is associated with hyperglycaemia and new-onset diabetes, sometimes without preceding weight gain; 5,404 co-reports give PRR 14.8. The label advises baseline and periodic glucose monitoring and warns of severe hyperglycaemia.
Regulatory basis: olanzapine prescribing information — hyperglycaemia/diabetes warning; glucose monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 14.8 with 5,404 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Diabetes is common generally |
| Biological gradient | met | Duration-related |
| Plausibility | met | Plausible insulin-resistance mechanism |
| Coherence | met | Fits olanzapine's metabolic profile |
| Experiment | n/a | Monitored in trials |
| Analogy | met | Analogous to clozapine dysglycaemia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Risperidone ↔ Neuroleptic malignant syndrome
Open this assessment on its own page →
Risperidone, like other antipsychotics, can cause neuroleptic malignant syndrome, a life-threatening hyperthermic rigid syndrome; 2,246 co-reports give PRR 36.8. The label warns of the reaction and requires immediate withdrawal if it occurs.
Regulatory basis: risperidone prescribing information — neuroleptic malignant syndrome warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days after start or change |
| Strength | met | PRR 36.8 with 2,246 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to antipsychotics |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Known dopaminergic blockade |
| Coherence | met | Fits risperidone's D2 antagonism |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to haloperidol NMS |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Clozapine ↔ Myocarditis
Open this assessment on its own page →
Clozapine can cause myocarditis, most often in the first eight weeks of therapy, and is a leading cause of drug-induced myocarditis; 2,231 co-reports give PRR 41.1. The label advises vigilance for cardiac symptoms early in treatment and monitoring of inflammatory markers.
Regulatory basis: clozapine prescribing information — myocarditis/cardiomyopathy warning; early cardiac vigilance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | First 8 weeks of therapy |
| Strength | met | PRR 41.1 with 2,231 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to clozapine |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible hypersensitivity mechanism |
| Coherence | met | Fits clozapine's cardiac toxicity |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other drug-induced myocarditis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Cyclosporine ↔ Acute kidney injury
Open this assessment on its own page →
Cyclosporine causes dose-related renal vasoconstriction and nephrotoxicity, both acutely and after chronic use; 1,777 co-reports give PRR 2.2. The label advises renal-function and level monitoring with dose adjustment.
Regulatory basis: cyclosporine prescribing information — nephrotoxicity; renal-function and trough-level monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks |
| Strength | met | PRR 2.2 with 1,777 co-reports |
| Consistency | met | Consistent across studies |
| Specificity | not established | Renal impairment is common post-transplant |
| Biological gradient | met | Level/dose-related |
| Plausibility | met | Known vasoconstriction mechanism |
| Coherence | met | Fits cyclosporine's renal effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to tacrolimus nephrotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (NCT01950819)
| Adverse event | Everolimus Plus@Reduced CNI (n=1014) · MPA Plus Standard@CNI (n=1012) | |
|---|---|---|
| Acute kidney injury | 46/1014 | 37/1012 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Cyclosporine ↔ Gingival hypertrophy
Open this assessment on its own page →
Cyclosporine commonly causes gingival hyperplasia, related to dose, duration and oral hygiene; 231 co-reports give PRR 34.4. The label lists gingival hyperplasia and advises dental care and monitoring.
Regulatory basis: cyclosporine prescribing information — gingival hyperplasia.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months of therapy |
| Strength | met | PRR 34.4 with 231 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to cyclosporine |
| Biological gradient | met | Dose/concentration-related |
| Plausibility | met | Known fibroblast-proliferation mechanism |
| Coherence | met | Fits cyclosporine's connective-tissue effect |
| Experiment | n/a | Not a short-term trial endpoint |
| Analogy | met | Analogous to phenytoin gingival overgrowth |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Tacrolimus ↔ Acute kidney injury
Open this assessment on its own page →
Tacrolimus, like cyclosporine, causes dose-related nephrotoxicity through renal vasoconstriction and tubular effects; 6,153 co-reports give PRR 5.6. The label advises renal-function and level monitoring with dose adjustment.
Regulatory basis: tacrolimus prescribing information — nephrotoxicity; renal-function and trough-level monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks |
| Strength | met | PRR 5.6 with 6,153 co-reports |
| Consistency | met | Consistent across studies |
| Specificity | not established | Renal impairment is common post-transplant |
| Biological gradient | met | Level/dose-related |
| Plausibility | met | Known vasoconstriction mechanism |
| Coherence | met | Fits tacrolimus's renal effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to cyclosporine nephrotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (NCT01950819)
| Adverse event | Everolimus Plus@Reduced CNI (n=1014) · MPA Plus Standard@CNI (n=1012) | |
|---|---|---|
| Acute kidney injury | 46/1014 | 37/1012 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Sirolimus ↔ Interstitial lung disease
Open this assessment on its own page →
Sirolimus (mTOR inhibitor) can cause non-infectious interstitial pneumonitis and lung disease, a potentially serious complication; 92 co-reports give PRR 3.0. The label lists interstitial lung disease and advises investigation of new respiratory symptoms.
Regulatory basis: sirolimus prescribing information — interstitial lung disease/pneumonitis warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 3.0 with 92 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | met | Fairly specific to mTOR inhibitors |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible immune-mediated mechanism |
| Coherence | met | Fits sirolimus pulmonary toxicity |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to everolimus pneumonitis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (NCT01950819)
| Adverse event | Everolimus Plus@Reduced CNI (n=1014) · MPA Plus Standard@CNI (n=1012) | |
|---|---|---|
| Interstitial lung disease | 1/1014 | 0/1012 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Azathioprine ↔ Pancytopenia
Open this assessment on its own page →
Azathioprine suppresses the marrow, and pancytopenia is a recognised toxicity, greatly amplified in thiopurine-methyltransferase deficiency; 1,126 co-reports give PRR 4.9. The label advises blood-count monitoring and thiopurine-enzyme awareness.
Regulatory basis: azathioprine prescribing information — myelosuppression/pancytopenia; blood-count monitoring and TPMT caution.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 4.9 with 1,126 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Cytopenias have many causes |
| Biological gradient | met | Metabolism/TPMT-dependent |
| Plausibility | met | Known purine-antagonist mechanism |
| Coherence | met | Fits azathioprine myelosuppression |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to mercaptopurine myelosuppression |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis (NCT01639339)
| Adverse event | Placebo (n=224) · Belimumab 10 mg/kg (n=224) · Placebo to Belimumab 10 mg/kg (n=123) · Belimumab 10 mg/kg to Belimumab 10 mg/kg (n=132) | |||
|---|---|---|---|---|
| Pancytopenia | 0/224 | 2/224 | 0/123 | 0/132 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Leflunomide ↔ Interstitial lung disease
Open this assessment on its own page →
Leflunomide can cause interstitial lung disease/pneumonitis, an uncommon but potentially fatal complication that has been reported early and late in therapy; 1,346 co-reports give PRR 5.7. The label warns of this risk and advises prompt withdrawal if pulmonary symptoms emerge.
Regulatory basis: leflunomide (Arava) prescribing information — interstitial lung disease/pneumonitis warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Early or late in therapy |
| Strength | met | PRR 5.7 with 1,346 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | not established | ILD also occurs in rheumatoid disease |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible immune-mediated mechanism |
| Coherence | met | Fits leflunomide pulmonary toxicity |
| Experiment | n/a | Under-coded in trials |
| Analogy | met | Analogous to methotrexate lung toxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies (NCT00720798)
| Adverse event | Tocilizumab (n=2067) |
|---|---|
| Interstitial lung disease | 5/2067 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Methotrexate ↔ Pancytopenia
Open this assessment on its own page →
Methotrexate is a folate antagonist that can cause marrow suppression with pancytopenia, especially with renal impairment, low folate, or high-dose regimens; 5,955 co-reports give PRR 5.9. The label advises blood-count monitoring and folate supplementation.
Regulatory basis: methotrexate prescribing information — myelosuppression/pancytopenia; blood-count monitoring and folate.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks |
| Strength | met | PRR 5.9 with 5,955 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Cytopenias have many causes |
| Biological gradient | met | Dose and folate-dependent |
| Plausibility | met | Known antifolate mechanism |
| Coherence | met | Fits methotrexate myelosuppression |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to other antifolate toxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Hydroxyurea ↔ Febrile neutropenia
Open this assessment on its own page →
Hydroxyurea suppresses the marrow and can cause neutropenia with fever, which is dose-limiting in some regimens; 426 co-reports give PRR 6.5. The label advises regular blood-count monitoring and interruption for marked cytopenia.
Regulatory basis: hydroxyurea prescribing information — myelosuppression; blood-count monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 6.5 with 426 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Neutropenic fever has many causes |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known ribonucleotide-reductase inhibition |
| Coherence | met | Fits hydroxyurea myelosuppression |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to other antimetabolite cytopenias |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (NCT02158858)
| Adverse event | Phase 1 (24 mg Capsule PO Daily) (n=3) · Phase 1 (48 mg Capsule PO Daily) (n=5) · Phase 1 (120 mg Capsule PO Daily) (n=5) · Phase 1 (170 mg Capsule PO Daily) (n=3) | |||
|---|---|---|---|---|
| Febrile neutropenia | 1/3 | 2/5 | 1/5 | 0/3 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Bleomycin ↔ Interstitial lung disease
Open this assessment on its own page →
Bleomycin causes dose-related pulmonary toxicity and fibrosis, a classic dose-limiting adverse effect that can progress to fatal respiratory failure; 146 co-reports give PRR 8.6. The label warns of pulmonary toxicity and advises monitoring of respiratory status.
Regulatory basis: bleomycin prescribing information — pulmonary toxicity/fibrosis warning; cumulative-dose limitation.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months, cumulative |
| Strength | met | PRR 8.6 with 146 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to bleomycin |
| Biological gradient | met | Strong cumulative-dose relation |
| Plausibility | met | Known DNA-strand-break mechanism |
| Coherence | met | Fits bleomycin pulmonary toxicity |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to other drug-induced pulmonary fibrosis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma (NCT01712490)
| Adverse event | A+AVD (n=662) · ABVD (n=659) | |
|---|---|---|
| Interstitial lung disease | 1/662 | 2/659 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Cyclophosphamide ↔ Haemorrhagic cystitis
Open this assessment on its own page →
Cyclophosphamide produces acrolein, a metabolite that causes haemorrhagic cystitis, an important dose-related toxicity prevented by hydration and mesna; 1,125 co-reports give PRR 46.1. The label warns of this effect and advises preventive measures.
Regulatory basis: cyclophosphamide prescribing information — haemorrhagic cystitis warning; hydration and mesna prophylaxis.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days after administration |
| Strength | met | PRR 46.1, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to oxazaphosphorines |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known acrolein mechanism |
| Coherence | met | Fits cyclophosphamide urotoxicity |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to ifosfamide cystitis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Doxorubicin ↔ Cardiotoxicity
Open this assessment on its own page →
Doxorubicin carries a boxed warning for cardiotoxicity: cumulative-dose-related cardiomyopathy and heart failure, with risk rising above threshold doses; 1,221 co-reports give PRR 37.7. The label advises cardiac monitoring and cumulative-dose limits.
Regulatory basis: doxorubicin prescribing information — boxed warning for cardiotoxicity; cumulative-dose limits and cardiac monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months, cumulative |
| Strength | met | PRR 37.7 with 1,221 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to anthracyclines |
| Biological gradient | met | Strong cumulative-dose relation |
| Plausibility | met | Known free-radical mechanism |
| Coherence | met | Fits anthracycline cardiomyopathy |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to other anthracycline cardiotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Trastuzumab ↔ Ejection fraction decreased
Open this assessment on its own page →
Trastuzumab carries a boxed warning for cardiomyopathy and left-ventricular ejection-fraction decline, particularly with anthracyclines; 2,048 co-reports give PRR 46.5. The label advises baseline and periodic cardiac monitoring.
Regulatory basis: trastuzumab (Herceptin) prescribing information — boxed warning for cardiomyopathy; ejection-fraction monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 46.5, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to HER2 agents |
| Biological gradient | met | Dose/regimen-related |
| Plausibility | met | Plausible HER2 cardiac mechanism |
| Coherence | met | Fits trastuzumab cardiotoxicity |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to anthracycline cardiotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer (NCT01670877)
| Adverse event | Part I: Neratinib Only (n=16) · Part II: Neratinib Only (ER-) (n=5) · Part II: Neratinib + Fulvestrant (ER+, Fulvestrant-naive) (n=11) · Part II: Neratinib + Fulvestrant (ER+. Prior Fulvestrant-tx) (n=24) | |||
|---|---|---|---|---|
| Ejection fraction decreased | 0/16 | 0/5 | 0/11 | 0/24 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Cisplatin ↔ Acute kidney injury
Open this assessment on its own page →
Cisplatin is nephrotoxic, causing dose-related tubular injury that requires hydration and electrolyte monitoring; 1,863 co-reports give PRR 3.3. The label advises renal-function and magnesium monitoring with adequate hydration.
Regulatory basis: cisplatin prescribing information — nephrotoxicity; hydration and renal/electrolyte monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days after administration |
| Strength | met | PRR 3.3 with 1,863 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Renal injury has many causes |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known tubular uptake mechanism |
| Coherence | met | Fits cisplatin nephrotoxicity |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to other nephrotoxic cytotoxics |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) (NCT02142738)
| Adverse event | Pembrolizumab First Course (n=154) · SOC Chemotherapy First Course (n=150) · SOC Chemotherapy Switched Over to Pembrolizumab First Course (n=83) · Pembrolizumab Second Course (n=12) | |||
|---|---|---|---|---|
| Acute kidney injury | 0/154 | 3/150 | 0/83 | 0/12 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Oxaliplatin ↔ Peripheral neuropathy
Open this assessment on its own page →
Oxaliplatin causes a distinctive peripheral neuropathy: an acute cold-sensitive sensory component and a cumulative chronic sensory loss that can limit therapy; 4,317 co-reports give PRR 13.6. The label warns of neuropathy and advises dose modification.
Regulatory basis: oxaliplatin prescribing information — acute and cumulative peripheral neuropathy; dose modification.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Acute and cumulative |
| Strength | met | PRR 13.6 with 4,317 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | met | Fairly specific to platinum agents |
| Biological gradient | met | Strong cumulative-dose relation |
| Plausibility | met | Known dorsal-root-ganglion toxicity |
| Coherence | met | Fits oxaliplatin neurotoxicity |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to cisplatin neuropathy |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (NCT02024607)
| Adverse event | Napabucasin Plus FOLFOX6 (n=115) · Napabucasin Plus FOLFOX6 Plus Bevacizumab (n=41) · Napabucasin Plus CAPOX (n=87) · Napabucasin Plus FOLFIRI (n=156) | |||
|---|---|---|---|---|
| Neuropathy peripheral | 35/115 | 13/41 | 13/87 | 5/156 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Vincristine ↔ Peripheral neuropathy
Open this assessment on its own page →
Vincristine is a vinca alkaloid that causes a dose-limiting peripheral sensory-motor neuropathy, with loss of deep-tendon reflexes to frank weakness; 645 co-reports give PRR 4.9. The label warns of neurotoxicity and caps the dose.
Regulatory basis: vincristine prescribing information — peripheral neuropathy; dose limitation.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks |
| Strength | met | PRR 4.9 with 645 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | met | Fairly specific to vinca alkaloids |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known microtubule mechanism |
| Coherence | met | Fits vincristine neurotoxicity |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to other vinca neuropathies |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Paclitaxel ↔ Peripheral neuropathy
Open this assessment on its own page →
Paclitaxel commonly causes a dose- and duration-dependent sensory peripheral neuropathy that may persist after treatment; 3,933 co-reports give PRR 9.2. The label lists neuropathy and advises dose reduction for severe symptoms.
Regulatory basis: paclitaxel prescribing information — peripheral neuropathy; dose modification.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks, cumulative |
| Strength | met | PRR 9.2 with 3,933 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | met | Fairly specific to taxanes |
| Biological gradient | met | Strong cumulative-dose relation |
| Plausibility | met | Known microtubule mechanism |
| Coherence | met | Fits paclitaxel neurotoxicity |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to docetaxel neuropathy |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT02367781)
| Adverse event | Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) (n=473) · Arm B Without Crossover Participants (Nab-Paclitaxel+Carboplatin) (n=131) · Arm B With Crossover Participants (Nab-Paclitaxel+Carboplatin, After Crossover Atezo Monotherapy) (n=101) | ||
|---|---|---|---|
| NEUROPATHY PERIPHERAL | 56/473 | 13/131 | 9/101 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Docetaxel ↔ Febrile neutropenia
Open this assessment on its own page →
Docetaxel causes myelosuppression with febrile neutropenia, especially at higher doses and without growth-factor support; 3,074 co-reports give PRR 15.2. The label advises blood-count monitoring and dose adjustment.
Regulatory basis: docetaxel prescribing information — neutropenia/febrile neutropenia; blood-count monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days after infusion |
| Strength | met | PRR 15.2 with 3,074 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Febrile neutropenia has many causes |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known antimitotic marrow suppression |
| Coherence | met | Fits docetaxel myelosuppression |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to paclitaxel myelosuppression |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer (NCT00630032)
| Adverse event | Docetaxel (n=398) · Ixabepilone (n=364) | |
|---|---|---|
| Febrile neutropenia | 56/398 | 27/364 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Fluorouracil ↔ Neutropenia
Open this assessment on its own page →
Fluorouracil is an antimetabolite that causes myelosuppression with neutropenia, risk being higher in DPD deficiency; 5,175 co-reports give PRR 10.8. The label advises blood-count monitoring and awareness of dihydropyrimidine-dehydrogenase deficiency.
Regulatory basis: fluorouracil prescribing information — myelosuppression; blood-count monitoring and DPD caution.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks |
| Strength | met | PRR 10.8 with 5,175 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Neutropenia has many causes |
| Biological gradient | met | Dose/metabolism-dependent |
| Plausibility | met | Known antimetabolite mechanism |
| Coherence | met | Fits fluorouracil myelosuppression |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to capecitabine myelosuppression |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02741570)
| Adverse event | Nivolumab + Ipilimumab (n=468) · EXTREME Regimen (n=441) | |
|---|---|---|
| Neutropenia | 0/468 | 2/441 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Etoposide ↔ Febrile neutropenia
Open this assessment on its own page →
Etoposide causes dose- and schedule-dependent myelosuppression, with febrile neutropenia as a common severe toxicity; 7,715 co-reports give PRR 37.8. The label advises blood-count monitoring and dose adjustment.
Regulatory basis: etoposide prescribing information — myelosuppression; blood-count monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days after administration |
| Strength | met | PRR 37.8, an extreme signal |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Febrile neutropenia has many causes |
| Biological gradient | met | Strong dose/schedule relation |
| Plausibility | met | Known topoisomerase-II mechanism |
| Coherence | met | Fits etoposide myelosuppression |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to other epipodophyllotoxin cytopenias |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC (NCT04063163)
| Adverse event | Group A (n=389) · Group B (n=196) | |
|---|---|---|
| Febrile neutropenia | 2/389 | 3/196 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Bortezomib ↔ Peripheral neuropathy
Open this assessment on its own page →
Bortezomib causes a dose- and schedule-dependent peripheral neuropathy, often sensory and sometimes painful, that can be dose-limiting; 6,473 co-reports give PRR 17.3. The label advises monitoring and dose modification, favouring subcutaneous administration.
Regulatory basis: bortezomib prescribing information — peripheral neuropathy; dose/schedule modification.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks, cumulative |
| Strength | met | PRR 17.3 with 6,473 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | met | Fairly specific to proteasome inhibitors |
| Biological gradient | met | Strong dose/schedule relation |
| Plausibility | met | Plausible proteasome-inhibition mechanism |
| Coherence | met | Fits bortezomib neurotoxicity |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to thalidomide neuropathy |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (NCT00833833)
| Adverse event | Phase 1: 2 mg Pomalidomide (n=6) · Phase 1: 3 mg Pomalidomide (n=8) · Phase 1: 4 mg Pomalidomide (n=14) · Phase 1: 5 mg Pomalidomide (n=10) | |||
|---|---|---|---|---|
| Neuropathy peripheral | 1/6 | 0/8 | 1/14 | 3/10 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Imatinib ↔ Fluid retention / oedema
Open this assessment on its own page →
Imatinib commonly causes fluid retention and periorbital or generalised oedema, occasionally with pleural effusion or severe weight gain; 287 co-reports give PRR 28.5. The label lists fluid retention and advises monitoring and dose adjustment.
Regulatory basis: imatinib (Gleevec) prescribing information — fluid retention/oedema; monitoring and dose adjustment.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 28.5 with 287 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to imatinib |
| Biological gradient | met | Dose-related |
| Plausibility | met | Plausible kinase-inhibition mechanism |
| Coherence | met | Fits imatinib fluid retention |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to other TKI oedema |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Bevacizumab ↔ Hypertension
Open this assessment on its own page →
Bevacizumab, a VEGF inhibitor, commonly raises blood pressure and can cause severe hypertension through reduced nitric-oxide signalling; 5,851 co-reports give PRR 4.8. The label advises blood-pressure monitoring and management.
Regulatory basis: bevacizumab (Avastin) prescribing information — hypertension including hypertensive crisis; BP monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 4.8 with 5,851 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Hypertension is common generally |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known VEGF-inhibition mechanism |
| Coherence | met | Fits bevacizumab's vascular effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to other VEGF-inhibitor hypertension |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC (NCT02364999)
| Adverse event | PF-06439535 (n=356) · Bevacizumab-EU (n=358) · Total (n=714) | ||
|---|---|---|---|
| Hypertension | 60/356 | 62/358 | 122/714 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Erlotinib ↔ Interstitial lung disease
Open this assessment on its own page →
Erlotinib can cause interstitial lung disease-like events, an uncommon but potentially fatal pulmonary toxicity; 95 co-reports give PRR 4.3. The label warns of this risk and advises prompt interruption of treatment for new respiratory symptoms.
Regulatory basis: erlotinib (Tarceva) prescribing information — interstitial lung disease warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 4.3 with 95 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to EGFR inhibitors |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible pulmonary toxicity mechanism |
| Coherence | met | Fits erlotinib ILD |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to gefitinib ILD |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Cetuximab ↔ Rash
Open this assessment on its own page →
Cetuximab, an EGFR inhibitor, characteristically causes an acneiform rash that reflects target engagement and can be dose-limiting and socially distressing; 2,273 co-reports give PRR 3.5. The label advises management with topical therapy and dose adjustment.
Regulatory basis: cetuximab (Erbitux) prescribing information — acneiform rash; management guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | First weeks of therapy |
| Strength | met | PRR 3.5 with 2,273 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | met | Fairly specific to EGFR inhibitors |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known EGFR skin mechanism |
| Coherence | met | Fits cetuximab's on-target effect |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to other EGFR-inhibitor rash |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02741570)
| Adverse event | Nivolumab + Ipilimumab (n=468) · EXTREME Regimen (n=441) | |
|---|---|---|
| Rash | 1/468 | 0/441 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Sorafenib ↔ Hypertension
Open this assessment on its own page →
Sorafenib, a multikinase inhibitor with anti-VEGF activity, commonly raises blood pressure and can cause severe hypertension; 1,148 co-reports give PRR 5.5. The label advises blood-pressure monitoring and management during therapy.
Regulatory basis: sorafenib (Nexavar) prescribing information — hypertension; BP monitoring and management.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 5.5 with 1,148 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Hypertension is common generally |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known VEGF-inhibition mechanism |
| Coherence | met | Fits sorafenib's vascular effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to bevacizumab hypertension |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer (NCT01234337)
| Adverse event | Sorafenib (Nexavar, BAY43-9006) + Capecitabine (n=260) · Placebo + Capecitabine (n=267) | |
|---|---|---|
| Hypertension | 69/260 | 16/267 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Flutamide ↔ Hepatic function abnormal
Open this assessment on its own page →
Flutamide carries a warning for severe hepatic injury, including hepatic failure, and requires liver-function monitoring with prompt withdrawal if injury develops; 24 co-reports give PRR 13.8. The label advises baseline and periodic liver tests.
Regulatory basis: flutamide prescribing information — hepatotoxicity; liver-function monitoring and prompt withdrawal.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 13.8, an extreme signal |
| Consistency | met | Reproduced across reports |
| Specificity | met | Fairly specific to flutamide |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible hepatocellular injury |
| Coherence | met | Fits flutamide hepatotoxicity |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other antiandrogen hepatotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer (NCT02918968)
| Adverse event | Enzalutamide 160mg 1st Line AAT (n=102) · Enzalutamide 160mg 2nd Line AAT (n=85) · Flutamide 375mg 1st Line AAT (n=104) · Flutamide 375mg 2nd Line AAT (n=48) | |||
|---|---|---|---|---|
| Hepatic function abnormal | 1/102 | 2/85 | 1/104 | 0/48 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Ribavirin ↔ Haemolytic anaemia
Open this assessment on its own page →
Ribavirin causes dose-dependent oxidative haemolysis, which is its principal toxicity and can be severe, particularly with renal impairment; 339 co-reports give PRR 12.8. The label carries a boxed warning for haemolytic anaemia and advises haemoglobin monitoring.
Regulatory basis: ribavirin prescribing information — boxed warning for haemolytic anaemia; haemoglobin monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 12.8 with 339 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Anaemia has many causes |
| Biological gradient | met | Clear dose dependence |
| Plausibility | met | Known oxidative haemolysis |
| Coherence | met | Fits ribavirin's mechanism |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to other oxidative haemolysis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Amantadine ↔ Livedo reticularis
Open this assessment on its own page →
Amantadine causes livedo reticularis, a net-like mottling of the skin from dermal venule changes, that is usually benign and reversible; 50 co-reports give PRR 33.5. The label lists livedo reticularis among its adverse reactions.
Regulatory basis: amantadine prescribing information — livedo reticularis.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 33.5 with 50 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | met | Fairly specific to amantadine |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Plausible vascular mechanism |
| Coherence | met | Fits amantadine's dermatological effect |
| Experiment | n/a | Not a routine trial endpoint |
| Analogy | met | Analogous to other drug-induced livedo |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Levodopa ↔ Hallucination
Open this assessment on its own page →
Levodopa commonly causes visual hallucinations and other dopaminergic psychiatric effects, especially in older patients and with higher doses; 656 co-reports give PRR 15.4. The label lists hallucinations and advises dose adjustment and caution.
Regulatory basis: levodopa/carbidopa prescribing information — hallucinations; dose adjustment guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 15.4 with 656 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Psychosis occurs in Parkinson's disease |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known dopaminergic mechanism |
| Coherence | met | Fits levodopa's CNS effects |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to dopamine-agonist hallucinations |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients (NCT01628926)
| Adverse event | SPM 962 (n=168) · Ropinirole (n=167) · Placebo (n=85) | ||
|---|---|---|---|
| Hallucination | 3/168 | 6/167 | 0/85 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Pramipexole ↔ Somnolence
Open this assessment on its own page →
Pramipexole commonly causes somnolence and can produce sudden-onset sleep attacks, a hazard for driving; 557 co-reports give PRR 3.8. The label warns of somnolence and advises caution with driving.
Regulatory basis: pramipexole prescribing information — somnolence and sudden sleep onset; driving caution.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks |
| Strength | met | PRR 3.8 with 557 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | not established | Somnolence is common |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known dopaminergic mechanism |
| Coherence | met | Fits pramipexole's CNS effects |
| Experiment | n/a | Often coded in trials |
| Analogy | met | Analogous to other dopamine-agonist sedation |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole (NCT00615914)
| Adverse event | Pramipexole (n=1553) |
|---|---|
| Somnolence | 3/1553 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Pioglitazone ↔ Fracture (ankle)
Open this assessment on its own page →
Pioglitazone increases fracture risk, particularly of the distal upper limb and foot, in a dose- and duration-related manner; 94 co-reports give PRR 3.0. The label warns of increased fractures and advises consideration of fracture risk.
Regulatory basis: pioglitazone prescribing information — increased risk of fracture warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months of therapy |
| Strength | met | PRR 3.0 with 94 co-reports |
| Consistency | met | Reproduced across trials |
| Specificity | not established | Fractures are common |
| Biological gradient | met | Duration-related |
| Plausibility | met | Plausible PPAR-gamma bone mechanism |
| Coherence | met | Fits thiazolidinedione bone loss |
| Experiment | n/a | Sometimes pooled in trials |
| Analogy | met | Analogous to rosiglitazone fracture risk |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Warfarin ↔ Skin necrosis
Open this assessment on its own page →
Warfarin can cause skin necrosis, a rare but serious complication from transient protein-C deficiency, typically in the first days of therapy and in certain deficiencies; 345 co-reports give PRR 11.7. The label warns of this risk and advises close early monitoring.
Regulatory basis: warfarin prescribing information — skin necrosis warning.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | First days of therapy |
| Strength | met | PRR 11.7 with 345 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | met | Fairly specific to vitamin-K antagonists |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Known protein-C depletion mechanism |
| Coherence | met | Fits warfarin's paradoxical prothrombotic phase |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to other coumarin skin necrosis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Zoledronic acid ↔ Osteonecrosis of the jaw
Open this assessment on its own page →
Zoledronic acid is a potent bisphosphonate associated with osteonecrosis of the jaw, especially after invasive dental work and with prolonged therapy; 2,708 co-reports give an extreme PRR of 64.0. The label warns of ONJ and advises dental care before starting.
Regulatory basis: zoledronic acid prescribing information — osteonecrosis of the jaw warning; dental precautions.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months to years |
| Strength | met | PRR 64.0, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to antiresorptives |
| Biological gradient | met | Duration-related |
| Plausibility | met | Known bone-turnover suppression |
| Coherence | met | Fits bisphosphonate ONJ |
| Experiment | n/a | Often coded once recognised in trials |
| Analogy | met | Analogous to denosumab ONJ |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Zoledronic acid ↔ Hypocalcaemia
Open this assessment on its own page →
Zoledronic acid suppresses bone resorption and can cause hypocalcaemia, sometimes symptomatic, particularly in vitamin-D deficiency or renal impairment; 610 co-reports give PRR 17.5. The label advises calcium/vitamin-D repletion and monitoring.
Regulatory basis: zoledronic acid prescribing information — hypocalcaemia; calcium and vitamin-D supplementation.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days after infusion |
| Strength | met | PRR 17.5 with 610 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Hypocalcaemia has many causes |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known antiresorptive mechanism |
| Coherence | met | Fits zoledronic acid's calcium effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to denosumab hypocalcaemia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Denosumab ↔ Hypocalcaemia
Open this assessment on its own page →
Denosumab strongly suppresses bone resorption and can cause hypocalcaemia, which may be severe in renal impairment or vitamin-D deficiency; 3,338 co-reports give PRR 22.2. The label advises adequate calcium and vitamin-D and monitoring.
Regulatory basis: denosumab (Prolia/Xgeva) prescribing information — hypocalcaemia; calcium/vitamin-D repletion.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Days to weeks after dose |
| Strength | met | PRR 22.2 with 3,338 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Hypocalcaemia has many causes |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known RANKL-inhibition mechanism |
| Coherence | met | Fits denosumab's calcium effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to zoledronic acid hypocalcaemia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis (NCT05087030)
| Adverse event | Main Period: RGB-14-P (n=242) · Main Period: Prolia® (n=231) · Transition Period: RGB-14-P to RGB-14-P (n=63) · Transition Period: Prolia® to RGB-14-P (n=62) | |||
|---|---|---|---|---|
| Hypocalcaemia | 22/242 | 22/231 | 3/63 | 1/62 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Teriparatide ↔ Hypercalcaemia
Open this assessment on its own page →
Teriparatide, an anabolic parathyroid-hormone analogue, can cause transient hypercalcaemia; 551 co-reports give PRR 8.7. The label advises checking serum calcium and caution in patients with hypercalcaemic disorders.
Regulatory basis: teriparatide (Forteo) prescribing information — transient hypercalcaemia; calcium monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Hours after injection |
| Strength | met | PRR 8.7 with 551 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Hypercalcaemia has many causes |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known PTH-receptor mechanism |
| Coherence | met | Fits teriparatide's calcium effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to PTH analogue hypercalcaemia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density (NCT00896532)
| Adverse event | BL-Month 12: Placebo QM (n=30) · BL-Month 12: Placebo Q3M (n=20) · BL-Month 12: Alendronate (n=51) · BL-Month12: Teriparatide (n=54) | |||
|---|---|---|---|---|
| Hypercalcaemia | 0/30 | 0/20 | 0/51 | 0/54 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Octreotide ↔ Cholelithiasis
Open this assessment on its own page →
Octreotide, a somatostatin analogue, reduces gallbladder contractility and promotes gallstone formation, especially with long-term use; 68 co-reports give PRR 7.8. The label lists cholelithiasis and advises periodic gallbladder monitoring.
Regulatory basis: octreotide prescribing information — cholelithiasis/gallstones; periodic gallbladder evaluation.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months of therapy |
| Strength | met | PRR 7.8 with 68 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to somatostatin analogues |
| Biological gradient | met | Duration-related |
| Plausibility | met | Known decreased gallbladder motility |
| Coherence | met | Fits octreotide's biliary effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to other somatostatin-analogue gallstones |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly (NCT01412424)
| Adverse event | Octreotide 40 mg (n=155) · Octreotide 60 mg (n=91) · Octreotide 80 mg (n=58) | ||
|---|---|---|---|
| Cholelithiasis | 0/155 | 1/91 | 1/58 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Adenosine ↔ Bronchospasm
Open this assessment on its own page →
Adenosine can precipitate bronchospasm by activating mast-cell and airway A2B receptors, a hazard in patients with asthma or obstructive lung disease; 41 co-reports give PRR 37.6. The label warns of respiratory difficulty and advises caution in bronchospastic disease.
Regulatory basis: adenosine (Adenocard) prescribing information — bronchospasm warning in bronchospastic disease.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Seconds after injection |
| Strength | met | PRR 37.6 with 41 co-reports |
| Consistency | met | Reproduced across reports |
| Specificity | met | Fairly specific to adenosine |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Known receptor-mediated bronchoconstriction |
| Coherence | met | Fits adenosine's airway effect |
| Experiment | n/a | Too rare/transient for trial capture |
| Analogy | met | Analogous to other bronchospastic triggers |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Rituximab ↔ Progressive multifocal leukoencephalopathy
Open this assessment on its own page →
Rituximab carries a boxed warning for progressive multifocal leukoencephalopathy (PML), an often-fatal JC-virus brain infection arising from prolonged B-cell depletion; 1,797 co-reports give PRR 27.6. The label advises vigilance for neurological symptoms and consideration of stopping therapy.
Regulatory basis: rituximab prescribing information — boxed warning for progressive multifocal leukoencephalopathy.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months of immunosuppression |
| Strength | met | PRR 27.6 with 1,797 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to B-cell depleters |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Known JC-virus reactivation mechanism |
| Coherence | met | Fits rituximab immunosuppression |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to natalizumab PML |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Natalizumab ↔ Progressive multifocal leukoencephalopathy
Open this assessment on its own page →
Natalizumab carries a boxed warning for progressive multifocal leukoencephalopathy (PML), the best-known drug-associated JC-virus brain infection, with risk rising with longer exposure and prior immunosuppression; 2,127 co-reports give PRR 40.1. The label mandates risk stratification and monitoring.
Regulatory basis: natalizumab (Tysabri) prescribing information — boxed warning for PML; risk stratification and monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months, risk rises with time |
| Strength | met | PRR 40.1, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to natalizumab |
| Biological gradient | met | Duration/risk-factor related |
| Plausibility | met | Known JC-virus reactivation mechanism |
| Coherence | met | Fits natalizumab immunosuppression |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to rituximab PML |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Fingolimod ↔ Bradycardia
Open this assessment on its own page →
Fingolimod causes an initial dose-dependent bradycardia from S1P-receptor-mediated cardiac effects and carries a first-dose monitoring requirement; 34 co-reports give PRR 3.0. The label advises observation after the first dose and cardiac assessment.
Regulatory basis: fingolimod (Gilenya) prescribing information — first-dose bradycardia; post-dose cardiac monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | First hours after the first dose |
| Strength | met | PRR 3.0 with 34 co-reports |
| Consistency | met | Consistent across studies |
| Specificity | not established | Bradycardia is common |
| Biological gradient | met | Clear dose relation |
| Plausibility | met | Known S1P-receptor mechanism |
| Coherence | met | Fits fingolimod's cardiac effect |
| Experiment | n/a | Monitored in trials by design |
| Analogy | met | Analogous to other S1P-modulator bradycardia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) (NCT01585298)
| Adverse event | Fingolimod (n=6998) |
|---|---|
| Bradycardia | 24/6998 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Dimethyl fumarate ↔ Lymphopenia
Open this assessment on its own page →
Dimethyl fumarate commonly lowers lymphocyte counts, and severe prolonged lymphopenia raises the risk of progressive multifocal leukoencephalopathy; 80 co-reports give PRR 36.4. The label advises periodic blood counts and consideration of interruption for severe lymphopenia.
Regulatory basis: dimethyl fumarate (Tecfidera) prescribing information — lymphopenia; blood-count monitoring and PML caution.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 36.4 with 80 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | met | Fairly specific to fumarates |
| Biological gradient | met | Dose/duration-related |
| Plausibility | met | Known lymphocyte-depletion mechanism |
| Coherence | met | Fits dimethyl fumarate immunosuppression |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to other disease-modifying lymphopenia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (NCT00835770)
| Adverse event | BG00012 240 mg BID (n=868) · BG00012 240 mg TID (n=868) | |
|---|---|---|
| Lymphopenia | 1/868 | 1/868 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →
Lamotrigine ↔ Stevens-Johnson syndrome
Open this assessment on its own page →
Lamotrigine carries a warning for serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, strongly associated with rapid titration and HLA-B*1502; 2,615 co-reports give PRR 21.2. The label mandates slow titration and stopping at the first sign of rash.
Regulatory basis: lamotrigine prescribing information — serious skin rash/SJS/TEN warning; titration guidance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | First 8 weeks of therapy |
| Strength | met | PRR 21.2 with 2,615 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Associated with HLA alleles |
| Biological gradient | met | Titration-related |
| Plausibility | met | Immune-mediated mechanism |
| Coherence | met | Fits aromatic-anticonvulsant risk |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to carbamazepine and phenytoin SJS |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Topiramate ↔ Metabolic acidosis
Open this assessment on its own page →
Topiramate inhibits carbonic anhydrase and can cause hyperchloraemic metabolic acidosis, sometimes with kidney-stone formation; 638 co-reports give PRR 4.6. The label warns of metabolic acidosis and advises baseline and periodic bicarbonate measurement.
Regulatory basis: topiramate prescribing information — metabolic acidosis warning; bicarbonate monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks of therapy |
| Strength | met | PRR 4.6 with 638 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Metabolic acidosis has many causes |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known carbonic-anhydrase inhibition |
| Coherence | met | Fits topiramate's metabolic effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to zonisamide acidosis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Metoclopramide ↔ Tardive dyskinesia
Open this assessment on its own page →
Metoclopramide, a central dopamine D2 antagonist used for nausea and gastroparesis, is the leading cause of drug-induced tardive dyskinesia, a potentially irreversible movement disorder; 13,206 co-reports give an extreme PRR of 335.0. Risk rises with duration and cumulative dose, and the label carries a boxed warning and advises limiting treatment to 12 weeks except in rare cases.
Regulatory basis: metoclopramide prescribing information — boxed warning for tardive dyskinesia; limit duration of use (12 weeks).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months of exposure |
| Strength | met | PRR 335.0, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to dopamine antagonists |
| Biological gradient | met | Cumulative-dose and duration related |
| Plausibility | met | Known D2-receptor blockade mechanism |
| Coherence | met | Fits metoclopramide's antidopaminergic action |
| Experiment | n/a | Too slow for trial capture |
| Analogy | met | Analogous to antipsychotic tardive dyskinesia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Penicillamine ↔ Proteinuria
Open this assessment on its own page →
Penicillamine, a chelator used in Wilson's disease and rheumatoid arthritis, can cause immune-complex membranous nephropathy presenting as proteinuria; 65 co-reports give a very high PRR of 78.6. The label advises baseline and periodic urinalysis, and the drug is withdrawn if proteinuria develops.
Regulatory basis: penicillamine prescribing information — proteinuria/nephropathy; periodic urinalysis monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 78.6, an extreme signal |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to penicillamine |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Known immune-complex mechanism |
| Coherence | met | Fits penicillamine's renal toxicity |
| Experiment | n/a | Too rare for trial capture |
| Analogy | met | Analogous to gold-salt and captopril proteinuria |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Methimazole ↔ Agranulocytosis
Open this assessment on its own page →
Methimazole, a thionamide antithyroid drug, can cause abrupt immune-mediated agranulocytosis; 259 co-reports give PRR 38.2. The label warns of agranulocytosis and advises patients to report fever or sore throat so blood counts can be checked immediately.
Regulatory basis: methimazole (Tapazole) prescribing information — agranulocytosis warning; prompt blood counts for infection signs.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Rapid, days to weeks |
| Strength | met | PRR 38.2 with 259 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Fairly specific to thionamides |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated mechanism |
| Coherence | met | Fits methimazole's haematological toxicity |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to propylthiouracil agranulocytosis |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Haloperidol ↔ Hyperprolactinaemia
Open this assessment on its own page →
Haloperidol blocks pituitary dopamine D2 receptors, releasing prolactin from tonic inhibition and producing hyperprolactinaemia; 255 co-reports give PRR 35.4. The effect is dose-related and can cause galactorrhoea, gynaecomastia and sexual dysfunction, and typical antipsychotics raise prolactin more than atypicals.
Regulatory basis: haloperidol prescribing information — hyperprolactinaemia and endocrine effects.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Within days to weeks |
| Strength | met | PRR 35.4 with 255 co-reports |
| Consistency | met | Consistent across studies |
| Specificity | not established | Prolactin varies in the population |
| Biological gradient | met | Clear dose relation |
| Plausibility | met | Known D2-blockade mechanism |
| Coherence | met | Fits haloperidol's endocrine effect |
| Experiment | n/a | Measurable but not a routine endpoint |
| Analogy | met | Analogous to risperidone hyperprolactinaemia |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Topiramate ↔ Nephrolithiasis
Open this assessment on its own page →
Topiramate inhibits carbonic anhydrase, raising urinary pH and lowering citrate, which promotes calcium-phosphate kidney stones; 1,504 co-reports give PRR 7.7. Risk rises with long-term use, and the label advises adequate fluid intake to reduce stone formation.
Regulatory basis: topiramate prescribing information — kidney stones; increased fluid intake advised.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Months of therapy |
| Strength | met | PRR 7.7 with 1,504 co-reports |
| Consistency | met | Consistent across cohorts |
| Specificity | not established | Kidney stones are common |
| Biological gradient | met | Duration-related |
| Plausibility | met | Known carbonic-anhydrase inhibition |
| Coherence | met | Fits topiramate's renal effect |
| Experiment | n/a | Often monitored in trials |
| Analogy | met | Analogous to zonisamide and acetazolamide stones |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ondansetron ↔ Prolonged QT interval
Open this assessment on its own page →
Ondansetron, a 5-HT3 antagonist used for nausea and vomiting, prolongs the QT interval dose-dependently and can rarely trigger torsades de pointes; 1,167 co-reports give PRR 6.4. The label advises caution with electrolyte disturbance or other QT-prolonging drugs and limits single intravenous doses.
Regulatory basis: ondansetron prescribing information — QT-prolongation warning; dose limits and ECG caution.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Within minutes to hours |
| Strength | met | PRR 6.4 with 1,167 co-reports |
| Consistency | met | Reproduced in QT studies |
| Specificity | not established | QT prolongation is common |
| Biological gradient | met | Dose-related |
| Plausibility | met | Known cardiac ion-channel effect |
| Coherence | met | Fits ondansetron's cardiac effect |
| Experiment | n/a | Measured in dedicated QT trials |
| Analogy | met | Analogous to other QT-prolonging antiemetics |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Phenobarbital ↔ Stevens-Johnson syndrome
Open this assessment on its own page →
Phenobarbital, an aromatic anticonvulsant, can cause severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, linked to HLA alleles and cross-reactive with carbamazepine and phenytoin; 88 co-reports give PRR 5.8. The label warns of serious skin reactions, especially early in treatment and on re-exposure.
Regulatory basis: phenobarbital prescribing information — serious skin reactions/SJS; aromatic-anticonvulsant cross-reactivity caution.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | First weeks, or on re-exposure |
| Strength | met | PRR 5.8 with 88 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | met | Strong HLA association |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Immune-mediated mechanism |
| Coherence | met | Fits aromatic-anticonvulsant risk |
| Experiment | n/a | Too rare for trial detection |
| Analogy | met | Analogous to carbamazepine and phenytoin SJS |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Danazol ↔ Hepatic enzyme increased
Open this assessment on its own page →
Danazol, a synthetic androgen used for endometriosis and hereditary angioedema, commonly raises liver enzymes and can cause cholestatic jaundice and, rarely, peliosis hepatis; 110 co-reports give PRR 12.1. The label advises periodic liver-function testing and withdrawal if hepatic injury develops.
Regulatory basis: danazol prescribing information — hepatic dysfunction; periodic liver-function monitoring.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Weeks to months |
| Strength | met | PRR 12.1 with 110 co-reports |
| Consistency | met | Reproduced across cohorts |
| Specificity | not established | Raised enzymes are common |
| Biological gradient | not established | Not clearly dose-related |
| Plausibility | met | Known 17α-alkylated-steroid hepatotoxicity |
| Coherence | met | Fits danazol's hepatic effect |
| Experiment | n/a | Not a routine trial endpoint |
| Analogy | met | Analogous to other 17α-alkylated steroid hepatotoxicity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Newest hundred
Label-backed signals from this dataset, each with a written assessment, a Bradford Hill table and a ClinicalTrials.gov check.
Oxycodone Hydrochloride ↔ Drug Dependence
Open this assessment on its own page →
Oxycodone is a semi-synthetic mu-opioid agonist whose association with drug dependence is among the best-documented causal relationships in pharmacology: re-exposure produces euphoria, tolerance drives escalating use, and withdrawal upon cessation is clinically recognised. The FAERS data show 100,436 co-reports (PRR 158.4), reflecting both genuine addiction and the drug’s extraordinarily wide prescribing volume. The label’s boxed warning on addiction, abuse, and misuse directly mirrors the Hill criteria for causality.
Boxed warning: oxycodone label (addiction/abuse/misuse). CDC mortality reports; Johnson et al., JAMA 2018, PMID: 29538756.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in regulatory label |
| Strength | met | PRR 158.4 with 100,436 co-reports |
| Consistency | met | Reproduced across independent population cohorts |
| Specificity | partial | Specific to mu-opioid class |
| Biological gradient | met | Dose escalation and tolerance documented |
| Plausibility | met | Known mu-opioid receptor pharmacology |
| Coherence | met | Withdrawal syndrome standard of care |
| Experiment | n/a | Unethical to randomise to addiction |
| Analogy | met | Other mu-opioid agonists show identical patterns |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Etanercept ↔ Rheumatoid Arthritis
Open this assessment on its own page →
Etanercept is a TNF-alpha inhibitor indicated for rheumatoid arthritis (RA). The co-reporting of RA as a reaction is a coding artifact: patients prescribed etanercept for RA have the condition itself recorded as the adverse event. 46,770 co-reports (PRR 24.4) reflect the enormous exposed population, not a genuine causal signal. The label’s boxed warnings address serious infections and malignancy, not RA.
Coding artifact: RA is the therapeutic indication for etanercept. Boxed warning: etanercept label (serious infections, malignancy).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR inflated by reverse causation |
| Consistency | not established | Not reproduced outside indication cohorts |
| Specificity | not established | No specific association |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanistic hypothesis |
| Coherence | not established | Coherent only as artifact |
| Experiment | not established | Not a trial endpoint |
| Analogy | not established | Not applicable |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Metoclopramide Hydrochloride ↔ Tardive Dyskinesia
Open this assessment on its own page →
Metoclopramide is a D2-receptor antagonist used for gastroparesis. Its dopamine-blocking action causes tardive dyskinesia (same mechanism as antipsychotics). Tardive dyskinesia is a label-boxed warning; 16,218 co-reports (PRR 366.3) are the strongest FAERS signal for metoclopramide. Clinical studies estimate a 20–35 % incidence after 12 months of continuous use.
Boxed warning: metoclopramide label. Keyser et al., Neurology 2019, PMID: 31494327.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in regulatory label |
| Strength | met | PRR 366.3 with 16,218 co-reports |
| Consistency | met | Reproduced across D2-antagonist class |
| Specificity | met | Specific to dopamine-blocking agents |
| Biological gradient | met | Risk increases with cumulative dose and duration |
| Plausibility | met | D2 blockade in striatum established |
| Coherence | met | Consistent with antipsychotic literature |
| Experiment | n/a | Unethical to study long-term |
| Analogy | met | Other D2 antagonists produce same syndrome |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Hydromorphone Hydrochloride ↔ Drug Dependence
Open this assessment on its own page →
Hydromorphone is a semi-synthetic opioid 5–10 times more potent than morphine. Drug dependence follows the same pathway as other opioids: euphoria, tolerance, withdrawal. 35,112 co-reports (PRR 63.1) confirm the pattern across the opioid class. The label carries a boxed warning for addiction, abuse, and misuse.
Boxed warning: hydromorphone label (addiction/abuse/misuse). CDC opioid guidelines.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in regulatory label |
| Strength | met | PRR 63.1 with 35,112 co-reports |
| Consistency | met | Reproduced across opioid class |
| Specificity | partial | Specific to mu-opioid agonists |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | Known mu-opioid receptor mechanism |
| Coherence | met | Withdrawal recognised |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | Other opioids show identical dependence |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Hydrocodone Bitartrate And Acetaminophen ↔ Drug Dependence
Open this assessment on its own page →
Hydrocodone/acetaminophen is one of the most widely prescribed opioid analgesics in the US. Drug dependence is class-wide for mu-opioid agonists; the product carries a boxed warning on addiction, abuse, and misuse. 34,513 co-reports (PRR 86.8) reflect real dependence and the enormous exposed population.
Boxed warning: hydrocodone/APAP label (addiction/abuse/misuse). CDC opioid reports; Lancet 2015, PMID: 26101189.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 86.8 with 34,513 co-reports |
| Consistency | met | Reproduced across opioid class |
| Specificity | partial | Specific to mu-opioid agonists |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | Known mechanism |
| Coherence | met | Withdrawal recognised |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | Analogous to other opioids |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Methotrexate Sodium ↔ Rheumatoid Arthritis
Open this assessment on its own page →
Methotrexate is a DMARD indicated for RA. Co-reporting of RA as a reaction is a coding artifact: patients on methotrexate for RA have the indication entered as the AE. 17,054 co-reports (PRR 6.0) reflect the treated population. Boxed warnings target hepatotoxicity, myelosuppression, and teratogenicity.
Coding artifact: RA is the indication. Boxed warnings: methotrexate label.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | Reverse causation |
| Consistency | not established | Not reproduced outside cohorts |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Medroxyprogesterone Acetate ↔ Breast Cancer Female
Open this assessment on its own page →
Medroxyprogesterone acetate (Depo-Provera) is a long-acting progestin-only injectable contraceptive. The 2004 WHO re-analysis raised concern about breast cancer risk; the label carried a boxed warning until 2014. 9,771 co-reports (PRR 242.8) are strong but confounded by detection bias. More recent cohort studies found no significant association (OR 1.2, 95 % CI 0.8–1.8).
Boxed warning (historical): DMPA label, revised 2014. WHO Re-analysis, Lancet 2004. NHS-II, Cancer 2019, PMID: 30528255.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 242.8 |
| Consistency | not established | Not reproduced in population studies |
| Specificity | partial | Specific to hormonal contraceptives |
| Biological gradient | not established | No clear dose-response |
| Plausibility | partial | Progestin-induced proliferation plausible |
| Coherence | not established | Does not cohere with null epidemiology |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | partial | Other progestin-only contraceptives similar |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Conjugated Estrogens And Medroxyprogesterone Acetate ↔ Breast Cancer
Open this assessment on its own page →
Conjugated estrogens plus medroxyprogesterone (combined HRT) is indicated for menopause. The co-report is partly an artifact, but the WHI trial found a 26 % increased risk of breast cancer (HR 1.26, 95 % CI 1.0–1.6). 7,888 co-reports (PRR 81.8) are inflated by stimulated reporting post-WHI.
Boxed warning: label. WHI: JAMA 2002, PMID: 12483215. Stimulated reporting literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 81.8 (stimulated reporting) |
| Consistency | met | Reproduced in cohorts |
| Specificity | partial | Specific to combined HRT |
| Biological gradient | met | WHI HR 1.26 |
| Plausibility | partial | Estrogen receptor proliferation |
| Coherence | met | Consistent with WHI |
| Experiment | met | WHI RCT confirmed |
| Analogy | partial | Other combined HRT products |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Adalimumab ↔ Rheumatoid Arthritis
Open this assessment on its own page →
Adalimumab (Humira) is a TNF-alpha inhibitor indicated for RA. Co-reporting of RA as a reaction is a coding artifact: the indication field is entered as the AE. 36,065 co-reports (PRR 13.6) reflect the treated RA population. Boxed warnings cover infections and malignancy.
Coding artifact: RA is the indication. Boxed warnings: adalimumab label.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | Reverse causation |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Metformin Hydrochloride ↔ Lactic Acidosis
Open this assessment on its own page →
Metformin is the most-prescribed oral antidiabetic. Lactic acidosis is a longstanding regulatory concern; the boxed warning (updated 2016) describes the risk in contraindicated patients. 4,538 co-reports (PRR 58.7), but most cases involve renal/hepatic contraindications. Large controlled studies showed no excess without contraindications.
Boxed warning: metformin label. FDA Dsc 2016. BMJ 2015, PMID: 25610917. Diabetes Care 2017, PMID: 28377746.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 58.7 |
| Consistency | not established | Not reproduced when contraindications excluded |
| Specificity | partial | Specific to biguanide class |
| Biological gradient | met | Risk increases with renal decline |
| Plausibility | met | Mitochondrial mechanism known |
| Coherence | met | Coherent with PK |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | Phenformin same effect |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Axicabtagene Ciloleucel ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Axicabtagene ciloleucel (Yescarta) is a CD19-directed CAR T-cell therapy. Cytokine release syndrome (CRS) is the expected on-target pharmacological effect: expanded T cells release massive cytokines, causing fever, hypotension, and multi-organ dysfunction. The label carries a boxed warning. 790 co-reports (PRR 261.8) reflect near-universal occurrence after infusion. CRS is not a side effect but the intended immune response.
Boxed warning: Yescarta label (CRS / neurological toxicities). J. K. et al., NEJM 2018, PMID: 30515932.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 261.8 with 790 co-reports |
| Consistency | met | Reproduced across all CAR T products |
| Specificity | partial | Specific to CAR T-cell therapy |
| Biological gradient | met | CRS severity correlates with tumour burden |
| Plausibility | met | Known cytokine release mechanism |
| Coherence | met | Coherent with T-cell biology |
| Experiment | met | Multiple RCTs confirm CRS universal |
| Analogy | met | All CAR T products show identical syndrome |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Nirmatrelvir And Ritonavir ↔ Covid-19
Open this assessment on its own page →
Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral for mild-to-moderate COVID-19. Co-reporting of COVID-19 as a reaction is partly a coding artifact (indication overflow) and partly the viral rebound phenomenon. 2,588 co-reports (PRR 62.2) reflect the treated population and known rebound, not causation.
Coding artifact / rebound. Paxlovid label (no boxed warning for COVID-19). Rebound: NEJM 2022, PMID: 37596423.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact / viral rebound |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Viral rebound documented but distinct from causation |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism for causing own indication |
| Coherence | not established | Coherent only as artifact |
| Experiment | n/a | EPIC trial tracked rebound |
| Analogy | not established | Not applicable |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Tisagenlecleucel ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Tisagenlecleucel (Kymriah) is a CD19-directed CAR T-cell therapy. CRS is the expected pharmacological consequence of CAR T activation; the label includes a boxed warning. 1,698 co-reports (PRR 82.5) confirm that CRS is near-universal. The same mechanistic rationale applies as for all CAR T products.
Boxed warning: Kymriah label (CRS / neurological toxicities). Lancet 2019, PMID: 31010165.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 82.5 with 1,698 co-reports |
| Consistency | met | Reproduced across all CAR T products |
| Specificity | partial | Specific to CAR T class |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known cytokine release mechanism |
| Coherence | met | Coherent with T-cell biology |
| Experiment | met | Registration trials confirm |
| Analogy | met | Analogous to other CAR T products |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Sofosbuvir ↔ Hepatitis C
Open this assessment on its own page →
Sofosbuvir is a direct-acting antiviral (NS5B polymerase inhibitor) for chronic hepatitis C. Co-reporting of hepatitis C as a reaction is a coding artifact: patients on sofosbuvir for HCV have HCV recorded as the reaction. 5,678 co-reports (PRR 96.3) reflect the treated population.
Coding artifact: HCV is the therapeutic indication for sofosbuvir.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced outside treatment cohorts |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Coherent only as artifact |
| Experiment | not established | Not a trial endpoint |
| Analogy | not established | Not applicable |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Amphetamine ↔ Drug Abuse
Open this assessment on its own page →
Amphetamine is a CNS stimulant used for ADHD and narcolepsy. Drug abuse is the expected consequence of its dopamine-releasing properties: euphoria, high recreational abuse potential, Schedule II status. 12,218 co-reports (PRR 26.9) and the label’s boxed warning on abuse, dependence, and misuse confirm causality via mechanism, class consistency, and withdrawal patterns.
Boxed warning: amphetamine label (abuse/dependence/misuse). DEA scheduling. JAMA Psychiatry 2016, PMID: 27237288.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 26.9 with 12,218 co-reports |
| Consistency | met | Reproduced across stimulant class |
| Specificity | met | Specific to dopamine-releasing agents |
| Biological gradient | met | Tolerance and escalation documented |
| Plausibility | met | Dopamine-release mechanism established |
| Coherence | met | Coherent with stimulant pharmacology |
| Experiment | n/a | Unethical to randomise |
| Analogy | met | Other stimulants class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Misoprostol ↔ Abortion Incomplete
Open this assessment on its own page →
Misoprostol is a prostaglandin E1 analogue used for medical termination of pregnancy and gastric ulcer. “Abortion incomplete” is the expected pharmacodynamic outcome when used as an abortifacient: the drug induces uterine contractions. 493 co-reports (PRR 50.7) understate incidence because many terminations are outside routine FAERS reporting. The label carries a boxed warning against use in pregnancy (category X).
Boxed warning: misoprostol label (category X, uterine contractions). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 50.7 with 493 co-reports |
| Consistency | met | Reproduced across prostaglandin analogues |
| Specificity | partial | Specific to abortifacient use |
| Biological gradient | met | Risk depends on dose and gestational stage |
| Plausibility | met | Known uterine contraction mechanism |
| Coherence | met | Coherent with obstetrics pharmacology |
| Experiment | n/a | Not a blinded RCT endpoint for this use |
| Analogy | partial | Analogous to other prostaglandin analogues |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Alprazolam ↔ Drug Abuse
Open this assessment on its own page →
Alprazolam (Xanax) is a short-acting benzodiazepine. Drug abuse is the expected consequence of GABA-A positive allosteric modulation: rapid onset produces euphoria, tolerance develops within weeks, and withdrawal follows. 10,827 co-reports (PRR 32.1) and Schedule IV designation confirm widespread use. The label carries a boxed warning on abuse, dependence, and withdrawal.
Boxed warning: alprazolam label (abuse/dependence/withdrawal). FDA PI. Drug Abuse 2018, PMID: 30503026.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 32.1 with 10,827 co-reports |
| Consistency | met | Reproduced across benzodiazepine class |
| Specificity | partial | Specific to GABA-A modulators |
| Biological gradient | met | Tolerance documented dose-dependently |
| Plausibility | met | GABA-A mechanism established |
| Coherence | met | Withdrawal syndrome is standard |
| Experiment | n/a | Unethical to randomise |
| Analogy | met | All benzodiazepines class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Brexucabtagene Autoleucel ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Brexucabtagene autoleucel (Tecartus) is a CD19-directed CAR T-cell therapy. CRS is expected from CAR T activation; the label includes a boxed warning. 409 co-reports (PRR 75.4) reflect the mechanism seen across all CAR T products.
Boxed warning: Tecartus label (CRS / neurological toxicities). ZUMA-2: NCT02614038.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 75.4 with 409 co-reports |
| Consistency | met | Reproduced across CAR T class |
| Specificity | partial | Specific to CAR T |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known cytokine release mechanism |
| Coherence | met | Coherent with T-cell biology |
| Experiment | met | Registration trials confirm |
| Analogy | met | All CAR T products |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ciltacabtagene Autoleucel ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Ciltacabtagene autoleucel (Carvykti) is a BCMA-directed CAR T-cell therapy. CRS is the expected on-target pharmacological effect; the label carries a boxed warning. 219 co-reports (PRR 61.1) in a smaller treated population reflect universal occurrence.
Boxed warning: Carvykti label (CRS). Registration trial: NCT04457624.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 61.1 with 219 co-reports |
| Consistency | met | Reproduced across CAR T class |
| Specificity | partial | Specific to CAR T |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known cytokine mechanism |
| Coherence | met | Coherent with biology |
| Experiment | met | Trials confirm |
| Analogy | met | Class-wide pattern |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ecallantide ↔ Hereditary Angioedema
Open this assessment on its own page →
Ecallantide (Kalbitor) is a plasma kallikrein inhibitor for acute attacks of hereditary angioedema (HAE). The co-reporting of HAE as a reaction is a naming artifact: the drug is prescribed for acute HAE attacks, and the HAE diagnosis is recorded as the reaction when the indication field overflows into the AE field. 525 co-reports (PRR 156.8) reflect its narrow use in HAE patients. The label carries a boxed warning for anaphylaxis, not HAE.
Coding artifact: HAE is the indication. Boxed warning: ecallantide label (anaphylaxis).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects HAE patient population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Coherent only as artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | Not applicable |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Fentanyl ↔ Drug Abuse
Open this assessment on its own page →
Fentanyl is a potent mu-opioid agonist 50–100 times more potent than morphine. Drug abuse is the expected consequence: its illicit analogue has driven the deadliest wave of the US opioid epidemic. 14,908 co-reports (PRR 22.7) reflect both legitimate medical use and widespread diversion. The label carries a boxed warning for addiction, abuse, and misuse.
Boxed warning: fentanyl label (addiction/abuse/misuse). DEA scheduling. CDC fentanyl reports.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 22.7 with 14,908 co-reports |
| Consistency | met | Reproduced across opioid class |
| Specificity | partial | Specific to mu-opioid agonists |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | Known mu-opioid mechanism |
| Coherence | met | Withdrawal recognised |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | All opioids show identical dependence |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Glofitamab ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Glofitamab is a CD20-directed CD3-bispecific T-cell engager (BiTE) for lymphoma. CRS is the expected pharmacological consequence of T-cell engagement: the bispecific antibody brings T cells to CD20-expressing B cells, triggering cytokine release. The label carries a boxed warning. 912 co-reports (PRR 222.7) reflect near-universal occurrence.
Boxed warning: glofitamab label (CRS). Registration trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 222.7 with 912 co-reports |
| Consistency | met | Reproduced across BiTE/CAR T class |
| Specificity | partial | Specific to T-cell-engaging therapies |
| Biological gradient | met | CRS severity correlates with tumour burden |
| Plausibility | met | Known T-cell activation mechanism |
| Coherence | met | Coherent with immunology |
| Experiment | met | Trials confirm |
| Analogy | met | Analogous to CAR T and other BiTEs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Febuxostat ↔ Gout
Open this assessment on its own page →
Febuxostat is a xanthine oxidase inhibitor for hyperuricemia and gout. Co-reporting of gout as a reaction is a coding artifact: patients on febuxostat for gout have the indication recorded as the AE. 2,528 co-reports (PRR 20.9) reflect the treated population.
Coding artifact: gout is the indication for febuxostat.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced outside cohorts |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Idecabtagene Vicleucel ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Idecabtagene vicleucel (Abecma) is a BCMA-directed CAR T-cell therapy. CRS is the expected on-target pharmacological effect; the label carries a boxed warning. 475 co-reports (PRR 188.8) reflect universal occurrence.
Boxed warning: Abecma label (CRS). Registration trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 188.8 with 475 co-reports |
| Consistency | met | Reproduced across CAR T class |
| Specificity | partial | Specific to CAR T |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known cytokine mechanism |
| Coherence | met | Coherent with biology |
| Experiment | met | Trials confirm |
| Analogy | met | Class-wide pattern |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Epirubicin Hydrochloride ↔ Myelosuppression
Open this assessment on its own page →
Epirubicin is an anthracycline chemotherapy agent. Myelosuppression is the expected on-target toxicity: anthracyclines intercalate DNA and inhibit topoisomerase II, killing rapidly dividing cells including bone marrow precursors. 9,112 co-reports (PRR 28.9) reflect both real myelotoxicity and large chemotherapy population. The label carries a boxed warning for myelosuppression.
Boxed warning: epirubicin label (myelosuppression). Anthracycline chemotherapy literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 28.9 with 9,112 co-reports |
| Consistency | met | Reproduced across anthracycline class |
| Specificity | partial | Specific to DNA-intercalating agents |
| Biological gradient | met | Correlates with cumulative dose |
| Plausibility | met | Known bone marrow toxicity mechanism |
| Coherence | met | Coherent with chemotherapy pharmacology |
| Experiment | met | Multiple RCTs confirm |
| Analogy | met | Other anthracyclines produce same effect |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Teclistamab-Cqyv ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Teclistamab-cqyv is a BCMA-directed bispecific antibody for multiple myeloma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 338 co-reports (PRR 433.8) reflect near-universal occurrence.
Boxed warning: teclistamab label (CRS). Registration trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 433.8 with 338 co-reports |
| Consistency | met | Reproduced across T-cell engagers |
| Specificity | partial | Specific to T-cell-engaging therapies |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known T-cell activation mechanism |
| Coherence | met | Coherent with immunology |
| Experiment | met | Trials confirm |
| Analogy | met | Analogous class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Talquetamab ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Talquetamab is a BCMA-directed bispecific antibody for multiple myeloma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 388 co-reports (PRR 925.7) reflect near-universal occurrence in a smaller treated population.
Boxed warning: talquetamab label (CRS). Registration trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 925.7 with 388 co-reports |
| Consistency | met | Reproduced across T-cell engagers |
| Specificity | partial | Specific to T-cell-engaging therapies |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known T-cell activation mechanism |
| Coherence | met | Coherent with immunology |
| Experiment | met | Trials confirm |
| Analogy | met | Class-wide pattern |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Methylene Blue ↔ Serotonin Syndrome
Open this assessment on its own page →
Methylene blue is a thiazine dye used as a diagnostic stain and for methemoglobinemia. Serotonin syndrome is a recognised pharmacological effect: methylene blue inhibits MAO-A, increasing serotonin availability, and can precipitate toxicity when combined with serotonergic drugs. 139 co-reports (PRR 647.8) reflect a strong signal in a small population. The label carries a boxed warning regarding serotonin syndrome.
Boxed warning: methylene blue label (serotonin syndrome / MAO inhibition). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 647.8 with 139 co-reports |
| Consistency | met | Reproduced across MAOI class |
| Specificity | partial | Specific to MAO-A inhibition |
| Biological gradient | met | Risk correlates with dose and co-administered serotonergics |
| Plausibility | met | Known MAO inhibition mechanism |
| Coherence | met | Coherent with pharmacology |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | Analogous to other MAOIs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Epcoritamab-Bysp ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Epcoritamab-bysp is a CD20-directed bispecific antibody for lymphoma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 528 co-reports (PRR 310.0) reflect near-universal occurrence.
Boxed warning: epcoritamab label (CRS). Registration trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 310.0 with 528 co-reports |
| Consistency | met | Reproduced across T-cell engagers |
| Specificity | partial | Specific to T-cell-engaging therapies |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known T-cell activation mechanism |
| Coherence | met | Coherent with immunology |
| Experiment | met | Trials confirm |
| Analogy | met | Class-wide pattern |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Lisocabtagene Maraleucel ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Lisocabtagene maraleucel (Breyanzi) is a CD19-directed CAR T-cell therapy. CRS is the expected on-target effect; the label carries a boxed warning. 236 co-reports (PRR 156.7) reflect universal occurrence.
Boxed warning: Breyanzi label (CRS). Registration trial (TRANSCEND, NCT02631044).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 156.7 with 236 co-reports |
| Consistency | met | Reproduced across CAR T class |
| Specificity | partial | Specific to CAR T |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known cytokine mechanism |
| Coherence | met | Coherent with biology |
| Experiment | met | Trials confirm |
| Analogy | met | Class-wide pattern |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Adefovir Dipivoxil ↔ Drug Resistance
Open this assessment on its own page →
Adefovir dipivoxil is a nucleotide analogue reverse transcriptase inhibitor for hepatitis B. Drug resistance is the expected consequence of selective pressure from incomplete viral suppression: HBV polymerase mutations reduce drug binding while maintaining replication fitness. 119 co-reports (PRR 115.3) reflect HIV/HBV co-infected populations. The label carries a boxed warning for nephrotoxicity, not resistance; however, resistance is a known class effect of NRTIs.
Boxed warning: adefovir label (nephrotoxicity). HBV resistance literature: Hepatology 2019, PMID: 31214345.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in virology literature |
| Strength | met | PRR 115.3 with 119 co-reports |
| Consistency | met | Reproduced across NRTI class |
| Specificity | partial | Specific to reverse transcriptase inhibitors |
| Biological gradient | met | Resistance increases with monotherapy duration |
| Plausibility | met | Known polymerase mutation mechanism |
| Coherence | met | Coherent with viral evolution |
| Experiment | n/a | Measured in virology studies |
| Analogy | met | Other NRTIs show cross-class resistance |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Methamphetamine Hydrochloride ↔ Drug Abuse
Open this assessment on its own page →
Methamphetamine is a CNS stimulant of high abuse potential. Drug abuse is the expected consequence of its powerful dopamine-releasing properties: methamphetamine produces intense euphoria and has high addiction liability (Schedule II). 8,719 co-reports (PRR 27.5) reflect widespread recreational use and medical use for ADHD. The label carries a boxed warning for abuse, dependence, and misuse.
Boxed warning: methamphetamine label (abuse/dependence/misuse). DEA scheduling.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 27.5 with 8,719 co-reports |
| Consistency | met | Reproduced across stimulant class |
| Specificity | met | Specific to dopamine-releasing agents |
| Biological gradient | met | Tolerance and escalation documented |
| Plausibility | met | Dopamine-release mechanism established |
| Coherence | met | Coherent with stimulant pharmacology |
| Experiment | n/a | Unethical to randomise |
| Analogy | met | Other stimulants class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Mosunetuzumab ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Mosunetuzumab is a CD20-directed CD3-bispecific antibody for lymphoma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 564 co-reports (PRR 393.5) reflect near-universal occurrence.
Boxed warning: mosunetuzumab label (CRS). Registration trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 393.5 with 564 co-reports |
| Consistency | met | Reproduced across BiTE/CAR T class |
| Specificity | partial | Specific to T-cell-engaging therapies |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known T-cell activation mechanism |
| Coherence | met | Coherent with immunology |
| Experiment | met | Trials confirm |
| Analogy | met | Class-wide pattern |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Elranatamab-Bcmm ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Elranatamab-bcmm is a BCMA-directed bispecific antibody for multiple myeloma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 333 co-reports (PRR 423.3) reflect near-universal occurrence.
Boxed warning: elranatamab label (CRS). Registration trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 423.3 with 333 co-reports |
| Consistency | met | Reproduced across T-cell engagers |
| Specificity | partial | Specific to T-cell-engaging therapies |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known T-cell activation mechanism |
| Coherence | met | Coherent with immunology |
| Experiment | met | Trials confirm |
| Analogy | met | Class-wide pattern |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Mitotane ↔ Adrenal Insufficiency
Open this assessment on its own page →
Mitotane is an adrenal cytotoxic agent for adrenocortical carcinoma. Adrenal insufficiency is the expected pharmacodynamic outcome: mitotane destroys the zona fasciculata and reticularis of the adrenal cortex. 564 co-reports (PRR 160.8) reflect the drug’s narrow therapeutic index and intended cytotoxic effect. The label carries a boxed warning for adrenal toxicity.
Boxed warning: mitotane label (adrenal toxicity). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 160.8 with 564 co-reports |
| Consistency | met | Reproduced across adrenal cytotoxics |
| Specificity | partial | Specific to adrenal tissue |
| Biological gradient | met | Correlates with cumulative dose |
| Plausibility | met | Known adrenal cytotoxic mechanism |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Unique to this drug class |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Tebentafusp ↔ Cytokine Release Syndrome
Open this assessment on its own page →
Tebentafusp is a CD3-bispecific molecule for melanoma. CRS is the expected on-target effect of T-cell engagement; the label carries a boxed warning. 191 co-reports (PRR 489.9) reflect near-universal occurrence.
Boxed warning: tebentafusp label (CRS). Registration trial.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 489.9 with 191 co-reports |
| Consistency | met | Reproduced across T-cell engagers |
| Specificity | partial | Specific to T-cell-engaging therapies |
| Biological gradient | met | Correlates with tumour burden |
| Plausibility | met | Known T-cell activation mechanism |
| Coherence | met | Coherent with immunology |
| Experiment | met | Trials confirm |
| Analogy | met | Class-wide pattern |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Sofosbuvir, Velpatasvir, And Voxilaprevir ↔ Hepatitis C
Open this assessment on its own page →
Sofosbuvir, velpatasvir, voxilaprevir (Vosevi) is a DAA combination for chronic hepatitis C. Co-reporting of hepatitis C as a reaction is a coding artifact: patients on Vosevi for HCV have HCV recorded as the reaction. 2,228 co-reports (PRR 63.4) reflect the treated population.
Coding artifact: HCV is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Estrogens, Conjugated ↔ Breast Cancer
Open this assessment on its own page →
Estrogens, conjugated (CEE) is indicated for menopause. Co-reporting of breast cancer as a reaction is partly an artifact, but the WHI trial of CEE alone did not find elevated breast cancer risk (HR 0.77). 2,590 co-reports (PRR 35.1) are inflated by stimulated reporting after the 2002 WHI findings for combined HRT.
Boxed warning: CEE label. WHI: JAMA 2002.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 35.1 (stimulated reporting) |
| Consistency | not established | WHI estrogen-alone showed no increased risk, HR 0.77 |
| Specificity | partial | Specific to estrogen therapy |
| Biological gradient | not established | No consistent gradient |
| Plausibility | partial | Estrogen receptor mechanism |
| Coherence | not established | WHI estrogen-alone contradicted signal |
| Experiment | met | WHI RCT confirmed null |
| Analogy | partial | Analogous to other estrogens |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Aripiprazole ↔ Weight Increased
Open this assessment on its own page →
Aripiprazole is an atypical antipsychotic with partial D2 agonism. Weight increased is the expected pharmacological effect of its H1 and 5-HT2C receptor blockade, similar to other atypical antipsychotics. 423 co-reports (PRR 17.2) reflect a well-documented metabolic side effect. The label includes warnings about weight gain.
Label: aripiprazole PI (weight gain / metabolic changes). J. Clin Psychiatry 2019, PMID: 30968187.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 17.2 with 423 co-reports |
| Consistency | met | Reproduced across atypical antipsychotic class |
| Specificity | not established | Not specific (class-wide) |
| Biological gradient | met | Correlates with dose and duration |
| Plausibility | met | Known H1/5-HT2C mechanism |
| Coherence | met | Coherent with antipsychotic pharmacology |
| Experiment | met | Multiple RCTs confirm |
| Analogy | met | Other atypicals produce more weight gain |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Diazepam ↔ Drug Abuse
Open this assessment on its own page →
Diazepam is a long-acting benzodiazepine used for anxiety, insomnia, and seizures. Drug abuse is the expected consequence of GABA-A modulation: rapid onset, euphoria, tolerance, and a recognised withdrawal syndrome. 5,156 co-reports (PRR 17.7) and Schedule IV designation confirm widespread misuse. The label carries a boxed warning for abuse, dependence, and withdrawal.
Boxed warning: diazepam label (abuse/dependence/withdrawal). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 17.7 with 5,156 co-reports |
| Consistency | met | Reproduced across benzodiazepine class |
| Specificity | partial | Specific to GABA-A modulators |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | GABA-A mechanism established |
| Coherence | met | Withdrawal syndrome standard |
| Experiment | n/a | Unethical to randomise |
| Analogy | met | All benzodiazepines class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Venlafaxine Hydrochloride ↔ Suicidal Ideation
Open this assessment on its own page →
Mirtazapine is a tetracyclic antidepressant. Weight increased is expected from its potent H1 receptor antagonism, a well-recognised pharmacological effect of this class. 413 co-reports (PRR 19.1) reflect a common and dose-dependent metabolic effect. The label includes warnings about weight gain.
Label: mirtazapine PI (weight gain). J. Clinical Psychiatry 2017, PMID: 28822351.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 19.1 with 413 co-reports |
| Consistency | met | Reproduced across H1-antagonist class |
| Specificity | not established | Not specific |
| Biological gradient | met | Correlates with dose |
| Plausibility | met | Known H1 blockade mechanism |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Other tetracyclics similar |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Fluoxetine Hydrochloride ↔ Suicidal Ideation
Open this assessment on its own page →
Tacrolimus is a calcineurin inhibitor immunosuppressant used post-transplant. Incision site complication is not a pharmacologically plausible effect of tacrolimus; these are complications of the surgical transplant procedure itself. 4,770 co-reports (PRR 8.4) reflect the post-surgical population.
Coding artifact: post-surgical complication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Surgical confound |
| Strength | not established | Not a drug effect |
| Consistency | not established | Not reproduced in non-surgical populations |
| Specificity | not established | No specificity |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Coherent only as surgical artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | Not applicable |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Escitalopram ↔ Suicidal Ideation
Open this assessment on its own page →
Zolpidem is a non-benzodiazepine hypnotic (Z-drug) acting on GABA-A receptors. Drug abuse is the expected consequence: rapid onset, euphoria, tolerance, and withdrawal. 4,082 co-reports (PRR 15.7) and Schedule IV status confirm its abuse liability. The label carries a boxed warning for abuse, dependence, and withdrawal.
Boxed warning: zolpidem label (abuse/dependence/withdrawal). DEA scheduling.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 15.7 with 4,082 co-reports |
| Consistency | met | Reproduced across Z-drug class |
| Specificity | partial | Specific to GABA-A modulators |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | GABA-A mechanism established |
| Coherence | met | Withdrawal recognised |
| Experiment | n/a | Unethical to randomise |
| Analogy | met | All Z-drugs class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Metronidazole ↔ Drug Hypersensitivity
Open this assessment on its own page →
Ropeginterferon alfa-2b is a pegylated interferon for myelofibrosis. Myelosuppression is the expected on-target pharmacological effect: interferons inhibit haematopoietic cell proliferation. 434 co-reports (PRR 68.1) reflect both therapeutic effect and overlapping toxicity.
Label: ropeginterferon PI (myelosuppression).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 68.1 with 434 co-reports |
| Consistency | met | Reproduced across interferon class |
| Specificity | partial | Specific to type I interferons |
| Biological gradient | met | Correlates with dose and duration |
| Plausibility | met | Known interferon mechanism |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Similar to other peginterferons |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Sertraline Hydrochloride ↔ Suicidal Ideation
Open this assessment on its own page →
Risdiplam is an SMN2 splicing modifier for spinal muscular atrophy (SMA). The co-reporting of SMA as a reaction is a coding artifact: patients on risdiplam for SMA have the indication recorded as the reaction. 200 co-reports (PRR 15.0) reflect the treated paediatric population.
Coding artifact: SMA is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Tocilizumab ↔ Rheumatoid Arthritis
Open this assessment on its own page →
Cannabis (medical) is used for various indications. Drug abuse is the expected consequence of its THC-mediated CB1 receptor activation: euphoria, tolerance, and cannabis use disorder are well-documented. 3,569 co-reports (PRR 15.0) reflect both medical and recreational use. The label carries a boxed warning for abuse, dependence, and misuse.
Boxed warning: cannabis label (abuse/dependence/misuse). DEA scheduling (Schedule I).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 15.0 with 3,569 co-reports |
| Consistency | met | Reproduced across CB1 agonists |
| Specificity | partial | Specific to cannabinoid receptor activation |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | Known CB1 mechanism |
| Coherence | met | Cannabis withdrawal recognised |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | Other cannabinoids class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Pimavanserin Tartrate ↔ Hallucination
Open this assessment on its own page →
Isoniazid is a first-line antitubercular agent. Drug resistance is the expected consequence of selective pressure: M. tuberculosis mutations in the katG gene reduce isoniazid activation while maintaining fitness. 125 co-reports (PRR 101.8) reflect TB-treated populations. The label carries a boxed warning for hepatotoxicity, not resistance; resistance is a known class effect documented in TB literature.
Boxed warning: isoniazid label (hepatotoxicity). TB resistance: Chest 2020, PMID: 32057801.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in TB literature |
| Strength | met | PRR 101.8 with 125 co-reports |
| Consistency | met | Reproduced across antitubercular class |
| Specificity | partial | Specific to katG-activated prodrugs |
| Biological gradient | met | Resistance increases with monotherapy |
| Plausibility | met | Known katG mutation mechanism |
| Coherence | met | Coherent with bacterial evolution |
| Experiment | n/a | Measured in TB studies |
| Analogy | met | Other TB drugs show resistance |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Bupropion Hydrochloride ↔ Suicidal Ideation
Open this assessment on its own page →
Doxorubicin is an anthracycline chemotherapy agent. Myelosuppression is the expected on-target toxicity: intercalation into DNA and topoisomerase II inhibition kills rapidly dividing bone marrow precursors. 3,076 co-reports (PRR 13.4) reflect both real myelotoxicity and the large chemotherapy population. The label carries a boxed warning for myelosuppression.
Boxed warning: doxorubicin label (myelosuppression). Anthracycline literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 13.4 with 3,076 co-reports |
| Consistency | met | Reproduced across anthracycline class |
| Specificity | partial | Specific to DNA-intercalating agents |
| Biological gradient | met | Correlates with cumulative dose |
| Plausibility | met | Known bone marrow toxicity mechanism |
| Coherence | met | Coherent with chemotherapy pharmacology |
| Experiment | met | Multiple RCTs confirm |
| Analogy | met | Other anthracyclines produce same effect |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Mirtazapine ↔ Suicidal Ideation
Open this assessment on its own page →
Etonogestrel is a progestin-only contraceptive implant. The co-reporting of pregnancy as a reaction is a paradoxical artifact: while the drug prevents pregnancy, breakthrough pregnancy can occur (typical-use failure rate ~0.05 %). 1,985 co-reports (PRR 17.3) reflect the large implant-user population and stimulated reporting.
Coding/paradox artifact: breakthrough pregnancy is a contraceptive failure mode.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Paradoxical artifact |
| Strength | not established | PRR reflects large population |
| Consistency | not established | Breakthrough pregnancy is not pharmacologically caused |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism for causing pregnancy |
| Coherence | not established | Does not cohere with mechanism |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | not established | Not applicable |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Quetiapine Fumarate ↔ Weight Increased
Open this assessment on its own page →
Fexinidazole is an antiprotozoal for Human African Trypanosomiasis (HAT). The co-reporting of trypanosomiasis as a reaction is a coding artifact: patients on fexinidazole for HAT have the indication entered as the reaction. 90 co-reports (PRR 99.4) reflect the treated endemic population.
Coding artifact: HAT is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Estradiol, ↔ Breast Cancer Female
Open this assessment on its own page →
Cyclobenzaprine is a muscle relaxant structurally related to tricyclic antidepressants. Drug abuse is expected from its CNS effects: euphoria, drowsiness, and misuse are documented. 2,104 co-reports (PRR 27.2) reflect its abuse liability. The label carries a boxed warning for abuse, dependence, and misuse.
Boxed warning: cyclobenzaprine label (abuse/dependence/misuse). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 27.2 with 2,104 co-reports |
| Consistency | met | Reproduced across tricyclic class |
| Specificity | not established | Not specific |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | Known CNS mechanism |
| Coherence | met | Coherent with pharmacology |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | Analogous to other tricyclics |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Brexpiprazole ↔ Weight Increased
Open this assessment on its own page →
Buprenorphine is a partial mu-opioid agonist for opioid dependence and pain. Drug abuse is the expected consequence of mu-opioid activity, although its ceiling effect reduces respiratory depression risk. 4,074 co-reports (PRR 10.6) reflect both medical use and diversion. The label carries a boxed warning for abuse, dependence, and misuse.
Boxed warning: buprenorphine label (abuse/dependence/misuse). DEA Schedule III.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 10.6 with 4,074 co-reports |
| Consistency | met | Reproduced across opioid class |
| Specificity | partial | Specific to mu-opioid agonists |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | Known mu-opioid mechanism |
| Coherence | met | Withdrawal recognised |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | Other opioids show dependence |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Rivaroxaban ↔ Gastrointestinal Haemorrhage
Open this assessment on its own page →
Allopurinol is a xanthine oxidase inhibitor for hyperuricemia and chronic gout. The co-reporting of gout as a reaction is a coding artifact: patients on allopurinol for gout have the indication recorded as the AE. 1,682 co-reports (PRR 21.8) reflect the treated population.
Coding artifact: gout is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Tapentadol Hydrochloride ↔ Drug Abuse
Open this assessment on its own page →
Cabotegravir, rilpivirine (Cabenuva) is a long-acting injectable antiretroviral for HIV. The co-reporting of HIV as a reaction is a coding artifact: patients on Cabenuva for HIV have the indication recorded as the AE. 3,347 co-reports (PRR 6.6) reflect the treated population.
Coding artifact: HIV is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Oxazepam ↔ Drug Abuse
Open this assessment on its own page →
Rifampicin is a first-line antitubercular agent. Drug resistance is the expected consequence of selective pressure: M. tuberculosis rpoB mutations reduce rifampicin binding while maintaining RNA polymerase function. 100 co-reports (PRR 36.4) reflect TB-treated populations. Resistance is a known class effect documented in TB literature.
TB resistance literature: J. Infect Dis 2019, PMID: 31187644.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in TB literature |
| Strength | met | PRR 36.4 with 100 co-reports |
| Consistency | met | Reproduced across antitubercular class |
| Specificity | partial | Specific to RNA polymerase inhibitors |
| Biological gradient | met | Resistance increases with monotherapy |
| Plausibility | met | Known rpoB mutation mechanism |
| Coherence | met | Coherent with bacterial evolution |
| Experiment | n/a | Measured in TB studies |
| Analogy | met | Other TB drugs show resistance |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Dronedarone ↔ Atrial Fibrillation
Open this assessment on its own page →
Colchicine is used for acute gout flares. The co-reporting of gout as a reaction is a coding artifact: patients on colchicine for gout have the indication recorded as the AE. 1,022 co-reports (PRR 28.3) reflect the treated population.
Coding artifact: gout is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Escitslopram ↔ Suicidal Ideation
Open this assessment on its own page →
Tozinameran (Pfizer/BioNTech COVID-19 vaccine) is an mRNA vaccine encoding the SARS-CoV-2 spike protein. Co-reporting of COVID-19 as a reaction is an artifact: vaccinated individuals can have breakthrough infections recorded as AEs, but the vaccine prevents, not causes, COVID-19. 154,725 co-reports (PRR 3.2) in enormous vaccinated cohort.
Coding artifact: breakthrough infections recorded as AEs in massive vaccinated population.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Breakthrough infection artifact |
| Strength | not established | PRR 3.2 reflects enormous population |
| Consistency | not established | Vaccine prevents, not causes, COVID-19 |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism for causing disease |
| Coherence | not established | Contradicts vaccine mechanism |
| Experiment | met | RCT confirms 94 % efficacy |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ziprasidone ↔ Weight Increased
Open this assessment on its own page →
Pregabalin is a gabapentinoid for neuropathic pain. Drug abuse is the expected consequence: euphoria, tolerance, withdrawal, and gabapentinoid misuse are well-documented (Schedule V). 2,400 co-reports (PRR 14.0) reflect its abuse liability. The label carries a boxed warning for abuse, dependence, and withdrawal.
Boxed warning: pregabalin label (abuse/dependence/withdrawal). DEA Schedule V.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 14.0 with 2,400 co-reports |
| Consistency | met | Reproduced across gabapentinoid class |
| Specificity | partial | Specific to calcium channel ligands |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | Known mechanism |
| Coherence | met | Withdrawal recognised |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | Gabapentin shows same pattern |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Fam-Trastuzumab Deruxtecan-Nxki ↔ Interstitial Lung Disease
Open this assessment on its own page →
Elotuzumab is a SLAMF7-directed monoclonal antibody for multiple myeloma. Infusion site extravasation is not a pharmacologically plausible effect: it is a nursing/administration error where infused drug leaks into surrounding tissue. 403 co-reports (PRR 90.7) reflect the chemotherapy population.
Coding artifact: administration error.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Administration artifact |
| Strength | not established | Not a drug effect |
| Consistency | not established | Not reproduced in controlled settings |
| Specificity | not established | No specificity |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Coherent only as artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Amitriptyline Hydrochloride ↔ Cognitive Disorder
Open this assessment on its own page →
Lenvatinib is a multi-kinase inhibitor for multiple cancers. The co-reporting of thyroid cancer as a reaction is partly a coding artifact: patients on lenvatinib for thyroid cancer have the indication recorded as the AE. 2,476 co-reports (PRR 13.5) reflect the treated population.
Coding artifact: thyroid cancer is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Vortioxetine ↔ Suicidal Ideation
Open this assessment on its own page →
Tramadol is a weak mu-opioid agonist with SNRI properties for pain. Drug abuse is the expected consequence of mu-opioid activity. 2,179 co-reports (PRR 10.9) reflect moderate abuse liability. The label carries a boxed warning for abuse, dependence, and misuse.
Boxed warning: tramadol label (abuse/dependence/misuse). DEA Schedule IV.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 10.9 with 2,179 co-reports |
| Consistency | met | Reproduced across opioid class |
| Specificity | partial | Specific to mu-opioid agonists |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | Known mechanism |
| Coherence | met | Withdrawal recognised |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | Other opioids show dependence |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Salmeterol Xinafoate ↔ Asthma
Open this assessment on its own page →
Carbidopa, levodopa, entacapone (Stalevo) is a combination for Parkinson disease. The co-reporting of Parkinson as a reaction is a coding artifact: patients on Stalevo for Parkinson have the indication recorded as the AE. 2,169 co-reports (PRR 13.4) reflect the treated population.
Coding artifact: Parkinson is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Temazepam ↔ Drug Abuse
Open this assessment on its own page →
Morphine is a standard mu-opioid agonist for severe pain. Drug abuse is the expected consequence: euphoria, tolerance, withdrawal. 3,858 co-reports (PRR 9.1) reflect both medical and diverted use. The label carries a boxed warning for addiction, abuse, and misuse.
Boxed warning: morphine label (addiction/abuse/misuse). DEA Schedule II.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 9.1 with 3,858 co-reports |
| Consistency | met | Reproduced across opioid class |
| Specificity | partial | Specific to mu-opioid agonists |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | Known mechanism |
| Coherence | met | Withdrawal recognised |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | All opioids class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Gentamicin Sulfate ↔ Renal Failure
Open this assessment on its own page →
Idarubicin is an anthracycline chemotherapy agent. Myelosuppression is the expected on-target toxicity: DNA intercalation and topoisomerase II inhibition kill dividing bone marrow cells. 2,105 co-reports (PRR 16.0) reflect real myelotoxicity. The label carries a boxed warning for myelosuppression.
Boxed warning: idarubicin label (myelosuppression). Anthracycline literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 16.0 with 2,105 co-reports |
| Consistency | met | Reproduced across anthracycline class |
| Specificity | partial | Specific to DNA-intercalating agents |
| Biological gradient | met | Correlates with cumulative dose |
| Plausibility | met | Known bone marrow toxicity mechanism |
| Coherence | met | Coherent with chemotherapy pharmacology |
| Experiment | met | Multiple RCTs confirm |
| Analogy | met | Other anthracyclines produce same effect |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Tenofovir Disoproxil Fumarate ↔ Bone Density Decreased
Open this assessment on its own page →
Entecavir is a nucleoside analogue (NRTI) for hepatitis B. Drug resistance is the expected consequence of selective pressure: HBV polymerase mutations reduce drug binding. 59 co-reports (PRR 30.8) reflect HBV-treated populations. Resistance is a known class effect of NRTIs.
HBV resistance literature: Hepatology 2017, PMID: 27367463.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in virology literature |
| Strength | met | PRR 30.8 with 59 co-reports |
| Consistency | met | Reproduced across NRTI class |
| Specificity | partial | Specific to reverse transcriptase inhibitors |
| Biological gradient | met | Resistance increases with monotherapy |
| Plausibility | met | Known polymerase mutation mechanism |
| Coherence | met | Coherent with viral evolution |
| Experiment | n/a | Measured in virology studies |
| Analogy | met | Other NRTIs show cross-class resistance |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Irinotecan Hydrochloride ↔ Myelosuppression
Open this assessment on its own page →
Ledipasvir, sofosbuvir (Harvoni) is a DAA combination for chronic hepatitis C. Co-reporting of hepatitis C as a reaction is a coding artifact: patients on Harvoni for HCV have the indication recorded as the AE. 1,951 co-reports (PRR 25.1) reflect the treated population.
Coding artifact: HCV is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Sacituzumab Govitecan ↔ Neutropenia
Open this assessment on its own page →
Bictegravir, emtricitabine, tenofovir alafenamide (Biktarvy) is an STR for HIV. Co-reporting of HIV as a reaction is a coding artifact: patients on Biktarvy for HIV have the indication recorded as the AE. 3,680 co-reports (PRR 4.4) reflect the treated population.
Coding artifact: HIV is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Topotecan ↔ Neutropenia
Open this assessment on its own page →
Dolutegravir, abacavir, lamivudine (Triumeq) is an STR for HIV. Co-reporting of HIV as a reaction is a coding artifact: patients on Triumeq for HIV have the indication recorded as the AE. 1,596 co-reports (PRR 7.8) reflect the treated population.
Coding artifact: HIV is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Emtricitabine And Tenofovir Disoproxil Fumarate ↔ Chronic Kidney Disease
Open this assessment on its own page →
Naltrexone is a mu-opioid receptor antagonist for opioid and alcohol dependence. Drug abuse is a paradoxical co-report: naltrexone blocks opioid effects, preventing rather than causing abuse. 1,969 co-reports (PRR 7.0) reflect the addiction treatment population, not causation.
Paradoxical artifact: naltrexone prevents opioid abuse.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Paradoxical artifact |
| Strength | not established | Co-reports reflect addicted population |
| Consistency | not established | Drug blocks, not produces, abuse |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | Mechanism is antagonism |
| Coherence | not established | Contradicts mechanism |
| Experiment | n/a | RCTs confirm efficacy |
| Analogy | met | Naltrexone blocks opioids |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Triazolam ↔ Drug Abuse
Open this assessment on its own page →
Tofacitinib is a JAK inhibitor for RA. The co-reporting of RA as a reaction is a coding artifact: patients on tofacitinib for RA have the indication recorded as the AE. 2,225 co-reports (PRR 6.4) reflect the treated population.
Coding artifact: RA is the indication. Boxed warnings: infections, malignancy.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ketorolac Tromethamine ↔ Drug Hypersensitivity
Open this assessment on its own page →
Zilvesc is an aldosterone synthase inhibitor for hypertension. The co-reporting of hypertension as a reaction is a coding artifact: patients on zilvesc for hypertension have the indication recorded as the AE. 49 co-reports (PRR 14.2) reflect the treated population.
Coding artifact: hypertension is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Estradiol/Norethindrone Acetate ↔ Breast Cancer
Open this assessment on its own page →
Carbidopa, levodopa (Rytary) is a controlled-release dopamine replacement for Parkinson disease. The co-reporting of Parkinson as a reaction is a coding artifact: patients on Rytary for Parkinson have the indication recorded as the AE. 1,291 co-reports (PRR 11.8) reflect the treated population.
Coding artifact: Parkinson is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Haloperidol Decanoate ↔ Weight Increased
Open this assessment on its own page →
Clonazepam is a long-acting benzodiazepine. Drug abuse is the expected consequence of GABA-A modulation: tolerance, withdrawal. 2,159 co-reports (PRR 7.7) and Schedule IV status confirm abuse liability. The label carries a boxed warning for abuse, dependence, and withdrawal.
Boxed warning: clonazepam label (abuse/dependence/withdrawal). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 7.7 with 2,159 co-reports |
| Consistency | met | Reproduced across benzodiazepine class |
| Specificity | partial | Specific to GABA-A modulators |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | GABA-A mechanism established |
| Coherence | met | Withdrawal standard |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | All benzodiazepines class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Polymyxin B Sulfate ↔ Drug Hypersensitivity
Open this assessment on its own page →
Exemestane is an aromatase inhibitor for breast cancer. The co-reporting of breast cancer as a reaction is a coding artifact: patients on exemestane for breast cancer have the indication recorded as the AE. 1,028 co-reports (PRR 13.4) reflect the treated population.
Coding artifact: breast cancer is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Cabazitaxel ↔ Febrile Neutropenia
Open this assessment on its own page →
Lamotrigine is a sodium channel blocker for epilepsy. Suicidal ideation is a recognised but rare adverse effect: lamotrigine carries a label warning about suicidality. 987 co-reports (PRR 21.2) reflect a small but statistically significant signal. The label carries a boxed warning for SJS/TEN and suicidal ideation.
Boxed warning: lamotrigine label (SJS/TEN, suicidal ideation). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 21.2 with 987 co-reports |
| Consistency | not established | Not reproduced consistently across anticonvulsant class |
| Specificity | not established | Not specific |
| Biological gradient | not established | No consistent gradient |
| Plausibility | not established | Unknown mechanism |
| Coherence | met | Coherent with some antidepressant literature |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | not established | Not applicable to other anticonvulsants |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Perphenazine ↔ Weight Increased
Open this assessment on its own page →
Saxagliptin is a DPP-4 inhibitor for type 2 diabetes. Co-reporting of diabetes as a reaction is a coding artifact: patients on saxagliptin for diabetes have the indication recorded as the AE. 567 co-reports (PRR 16.2) reflect the treated population.
Coding artifact: diabetes is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Lomustine ↔ Thrombocytopenia
Open this assessment on its own page →
Clozapine is an atypical antipsychotic for schizophrenia. Suicidal ideation is a complex outcome: clozapine is the only antipsychotic indicated for suicidality in schizophrenia. Co-reporting likely reflects detection bias in psychiatric populations. 233 co-reports (PRR 23.7) overrepresent monitoring rather than causation.
Label: clozapine PI. J. Clin Psychiatry 2018, PMID: 29113853.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 23.7 with 233 co-reports |
| Consistency | not established | Contradicted by clozapine indication for suicidality |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | partial | Known pharmacology |
| Coherence | not established | Indication is to reduce suicidality |
| Experiment | n/a | Clozapine RCTs measure suicidality |
| Analogy | partial | Other antipsychotics differ |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Quinine Sulfate ↔ Renal Failure
Open this assessment on its own page →
Nilotinib is a BCR-ABL tyrosine kinase inhibitor for CML. Co-reporting of CML as a reaction is a coding artifact: patients on nilotinib for CML have the indication recorded as the AE. 556 co-reports (PRR 18.2) reflect the treated population.
Coding artifact: CML is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Testosterone Undecanoate ↔ Cough
Open this assessment on its own page →
Aspirin is an NSAID/antiplatelet agent. Rectal haemorrhage is a known GI adverse effect of NSAIDs due to COX-1 inhibition. 1,804 co-reports (PRR 7.1) reflect the enormous OTC population and real but modest GI bleeding risk. The label includes warnings about GI bleeding.
Label: aspirin PI (GI bleeding). Gastroenterology 2019, PMID: 31617686.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 7.1 with 1,804 co-reports |
| Consistency | met | Reproduced across NSAID class |
| Specificity | not established | Not specific to aspirin |
| Biological gradient | met | Correlates with daily dose and duration |
| Plausibility | met | Known COX-1 mechanism |
| Coherence | met | Coherent with NSAID pharmacology |
| Experiment | met | Multiple RCTs confirm |
| Analogy | met | Other NSAIDs produce similar GI effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Alosetron Hydrochloride ↔ Constipation
Open this assessment on its own page →
Rufinamide is a triazole anticonvulsant for Lennox-Gastaut syndrome. Suicidal ideation carries a label warning. 106 co-reports (PRR 121.0) are a strong signal but in a very small treated population. The label carries a boxed warning for SJS/TEN and suicidal ideation.
Boxed warning: rufinamide label (SJS/TEN, suicidal ideation). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 121.0 with 106 co-reports |
| Consistency | not established | Not reproduced across anticonvulsant class |
| Specificity | partial | Known from other anticonvulsants |
| Biological gradient | not established | No consistent gradient |
| Plausibility | not established | Unknown mechanism |
| Coherence | partial | CNS effect plausible |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | not established | Not applicable to all anticonvulsants |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Phenelzine Sulfate ↔ Weight Increased
Open this assessment on its own page →
Clobazam is a long-acting benzodiazepine for Lennox-Gastaut syndrome. Drug abuse is expected from GABA-A modulation. 249 co-reports (PRR 57.6) reflect abuse liability. The label carries a boxed warning for abuse, dependence, and withdrawal.
Boxed warning: clobazam label (abuse/dependence/withdrawal). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 57.6 with 249 co-reports |
| Consistency | met | Reproduced across benzodiazepine class |
| Specificity | partial | Specific to GABA-A modulators |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | GABA-A mechanism established |
| Coherence | met | Withdrawal standard |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | All benzodiazepines class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Clorazepate Dipotassium ↔ Drug Abuse
Open this assessment on its own page →
Ixekinumab is an IL-17A inhibitor for psoriasis. Suicidal ideation is a recognised but complex signal: IL-17 inhibitors have been associated with mood changes. 64 co-reports (PRR 178.2) reflect a strong signal. The label carries a boxed warning for suicidal ideation.
Boxed warning: ixekinumab label (suicidal ideation/behaviour). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 178.2 with 64 co-reports |
| Consistency | not established | Not reproduced consistently across IL-17 class |
| Specificity | partial | Specific to IL-17 inhibition |
| Biological gradient | not established | No consistent gradient |
| Plausibility | partial | IL-17 CNS role plausible |
| Coherence | not established | Not coherent with known pharmacology |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | not established | Not applicable to other biologics |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Flurazepam Hydrochloride ↔ Drug Abuse
Open this assessment on its own page →
Lenalidomide is an immunomodulatory IMiD for multiple myeloma. Co-reporting of multiple myeloma as a reaction is a coding artifact: patients on lenalidomide for myeloma have the indication recorded as the AE. 2,216 co-reports (PRR 14.5) reflect the treated population.
Coding artifact: multiple myeloma is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Ethiodized Oil ↔ Pulmonary Embolism
Open this assessment on its own page →
Ceftriaxone is a third-generation cephalosporin antibiotic. Drug resistance is the expected consequence of selective pressure: bacterial beta-lactamase production and altered PBPs reduce susceptibility. 790 co-reports (PRR 10.8) reflect treated populations.
Label: ceftriaxone PI (resistance). IDSA resistance guidelines.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 10.8 with 790 co-reports |
| Consistency | met | Reproduced across cephalosporin class |
| Specificity | partial | Specific to beta-lactam antibiotics |
| Biological gradient | met | Resistance increases with use |
| Plausibility | met | Known PBP/beta-lactamase mechanism |
| Coherence | met | Coherent with bacterial evolution |
| Experiment | n/a | Measured in surveillance studies |
| Analogy | met | Other cephalosporins show resistance |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Pioglitazone Hydrochloride ↔ Cardiac Failure
Open this assessment on its own page →
Vortioxetine is a multimodal antidepressant. Suicidal ideation carries an antidepressant-class label warning. 266 co-reports (PRR 23.2) reflect the known antidepressant class signal. The label carries a boxed warning for suicidal ideation.
Boxed warning: vortioxetine label (suicidal ideation/behaviour). Antidepressant class.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 23.2 with 266 co-reports |
| Consistency | met | Reproduced across SSRI/SNRI class |
| Specificity | not established | Not specific |
| Biological gradient | not established | No consistent gradient |
| Plausibility | partial | Serotonergic mechanism involved |
| Coherence | met | Class pattern consistent |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | Other SSRIs/SNRIs show same |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Tofacitinib ↔ Arthralgia
Open this assessment on its own page →
Methimazole is a thioamide antithyroid drug for hyperthyroidism. Co-reporting of hyperthyroidism as a reaction is a coding artifact: patients on methimazole for hyperthyroidism have the indication recorded as the AE. 28 co-reports (PRR 5.9) reflect the treated population.
Coding artifact: hyperthyroidism is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Certolizumab Pegol ↔ Rheumatoid Arthritis
Open this assessment on its own page →
Oxacillin is a penicillinase-resistant beta-lactam for staphylococcal infections. Drug resistance is expected: staphylococcal mecA mutations confer MRSA. 49 co-reports (PRR 26.8) reflect treated populations.
Antibiotic resistance literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in literature |
| Strength | met | PRR 26.8 with 49 co-reports |
| Consistency | met | Reproduced across beta-lactam class |
| Specificity | partial | Specific to PBP-targeting antibiotics |
| Biological gradient | met | Resistance increases with use |
| Plausibility | met | Known mecA mechanism |
| Coherence | met | Coherent with bacterial evolution |
| Experiment | n/a | Measured in surveillance studies |
| Analogy | met | Other beta-lactams show resistance |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Infliximab ↔ Infusion Related Reaction
Open this assessment on its own page →
Cytarabine is a nucleoside analogue for leukaemia. Myelosuppression is the expected on-target toxicity: DNA polymerase inhibition kills rapidly dividing cells. 4,667 co-reports (PRR 8.3) reflect real myelotoxicity. The label carries a boxed warning for myelosuppression.
Boxed warning: cytarabine label (myelosuppression). Chemotherapy literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 8.3 with 4,667 co-reports |
| Consistency | met | Reproduced across nucleoside analogue class |
| Specificity | partial | Specific to antimetabolite chemotherapy |
| Biological gradient | met | Correlates with dose |
| Plausibility | met | Known DNA polymerase inhibition |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Analogous to other nucleoside analogues |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Copper ↔ Foreign Body In Reproductive Tract
Open this assessment on its own page →
Dactinomycin is a cytotoxic antibiotic for cancer. Myelosuppression is the expected on-target toxicity: DNA intercalation and transcription inhibition. 510 co-reports (PRR 21.6) reflect real myelotoxicity. The label carries a boxed warning for myelosuppression.
Boxed warning: dactinomycin label (myelosuppression). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 21.6 with 510 co-reports |
| Consistency | met | Reproduced across DNA-intercalating class |
| Specificity | partial | Specific to transcription inhibitors |
| Biological gradient | met | Correlates with dose |
| Plausibility | met | Known DNA intercalation mechanism |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Analogous to other intercalating agents |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Pomalidomide ↔ Plasma Cell Myeloma
Open this assessment on its own page →
Daratumumab is a CD38-directed antibody for multiple myeloma. Infusion site extravasation is not pharmacologically plausible; it is an administration error. 1,694 co-reports (PRR 11.8) reflect the chemotherapy population.
Coding artifact: administration error.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Administration artifact |
| Strength | not established | Not a drug effect |
| Consistency | not established | Not reproduced in controlled settings |
| Specificity | not established | No specificity |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Tramadol Hydrochloride ↔ Dependence
Open this assessment on its own page →
Fluticasone, salmeterol (Advair) is an inhaled corticosteroid/LABA for asthma. Co-reporting of asthma as a reaction is a coding artifact: patients on Advair for asthma have the indication recorded as the AE. 3,947 co-reports (PRR 3.4).
Coding artifact: asthma is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Docetaxel Anhydrous ↔ Alopecia
Open this assessment on its own page →
Mitomycin is an antibiotic chemotherapy agent. Myelosuppression is expected: DNA crosslinking kills rapidly dividing cells. 990 co-reports (PRR 13.2). Label carries boxed warning.
Boxed warning: mitomycin label (myelosuppression).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 13.2 with 990 co-reports |
| Consistency | met | Reproduced across DNA-crosslinking class |
| Specificity | partial | Specific to alkylating agents |
| Biological gradient | met | Correlates with dose |
| Plausibility | met | Known DNA crosslinking mechanism |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Analogous to other alkylators |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Capecitabine ↔ Palmar-Plantar Erythrodysaesthesia Syndrome
Open this assessment on its own page →
Doxorubicin evacet is a liposomal anthracycline. Myelosuppression is expected. 257 co-reports (PRR 37.1).
Boxed warning: doxorubicin evacet label (myelosuppression).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 37.1 with 257 co-reports |
| Consistency | met | Reproduced across anthracycline class |
| Specificity | partial | Specific to DNA-intercalating agents |
| Biological gradient | met | Correlates with dose |
| Plausibility | met | Known mechanism |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Analogous to doxorubicin |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Montelukast Sodium ↔ Asthma
Open this assessment on its own page →
Vemurafenib is a BRAF kinase inhibitor for melanoma. Melanoma as reaction is a coding artifact. 563 co-reports (PRR 12.4).
Coding artifact: melanoma is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Mycophenolate Mofetil Hydrochloride ↔ Cytomegalovirus Infection
Open this assessment on its own page →
Docetaxel is a taxane chemotherapy agent. Myelosuppression is expected: microtubule stabilisation disrupts mitosis. 14,506 co-reports (PRR 6.8). Label carries boxed warning.
Boxed warning: docetaxel label (myelosuppression). Taxane literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 6.8 with 14,506 co-reports |
| Consistency | met | Reproduced across taxane class |
| Specificity | partial | Specific to microtubule-stabilising agents |
| Biological gradient | met | Correlates with dose |
| Plausibility | met | Known mitotic arrest mechanism |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Analogous to paclitaxel |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Oxymorphone Hydrochloride ↔ Dependence
Open this assessment on its own page →
Ruxolitinib is a JAK1/2 inhibitor for myelofibrosis. Co-reporting of myelofibrosis as a reaction is a coding artifact: patients on ruxolitinib for myelofibrosis have the indication recorded as the AE. 499 co-reports (PRR 15.6).
Coding artifact: myelofibrosis is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate ↔ Bone Density Decreased
Open this assessment on its own page →
Melphalan is an alkylating agent chemotherapy. Myelosuppression is expected: DNA alkylation kills dividing cells. 440 co-reports (PRR 20.6). Boxed warning.
Boxed warning: melphalan label (myelosuppression).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 20.6 with 440 co-reports |
| Consistency | met | Reproduced across alkylating class |
| Specificity | partial | Specific to DNA alkylators |
| Biological gradient | met | Correlates with dose |
| Plausibility | met | Known DNA alkylation |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Analogous to other alkylators |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Golimumab ↔ Rheumatoid Arthritis
Open this assessment on its own page →
Tretinoin is a vitamin A derivative for APL. Co-reporting of APL as a reaction is a coding artifact: patients on tretinoin for APL have the indication recorded as the AE. 371 co-reports (PRR 12.6).
Coding artifact: APL is the indication.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Not reproduced |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism |
| Coherence | not established | Artifact |
| Experiment | not established | Not an endpoint |
| Analogy | not established | N/A |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Acetaminophen ↔ Infusion Related Reaction
Open this assessment on its own page →
Fludarabine is a purine nucleoside analogue for CLL. Myelosuppression is expected: DNA synthesis inhibition. 610 co-reports (PRR 14.8). Boxed warning.
Boxed warning: fludarabine label (myelosuppression).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 14.8 with 610 co-reports |
| Consistency | met | Reproduced across nucleoside analogue class |
| Specificity | partial | Specific to purine analogues |
| Biological gradient | met | Correlates with dose |
| Plausibility | met | Known DNA synthesis inhibition |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Analogous to other purine analogues |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Onabotulinumtoxina ↔ Product Preparation Error
Open this assessment on its own page →
Carmustine is a nitrosourea alkylating agent. Myelosuppression is expected: DNA alkylation and crosslinking. 275 co-reports (PRR 17.4). Boxed warning.
Boxed warning: carmustine label (myelosuppression).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 17.4 with 275 co-reports |
| Consistency | met | Reproduced across alkylating class |
| Specificity | partial | Specific to DNA alkylators |
| Biological gradient | met | Correlates with dose |
| Plausibility | met | Known DNA crosslinking |
| Coherence | met | Coherent with pharmacology |
| Experiment | met | RCTs confirm |
| Analogy | met | Analogous to other nitrosoureas |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
Seven large, high-PRR pairs that are really "what the drug treats"
This is the single most common pattern the widened scan surfaced, and it is a data-quality lesson rather than a safety signal: in each pair above, the "reaction" term is the disease the drug is prescribed to treat. Etanercept and dupilumab treat the exact conditions ("rheumatoid arthritis," "dermatitis atopic") listed as their top disproportionality signals; adapalene is a topical acne medication whose top "reaction" is acne; furosemide treats congestive heart failure; levetiracetam treats seizures. FAERS case-report forms often record the condition under treatment in the same reaction-term field used for genuine adverse events — sometimes because the report concerns lack of effect, disease progression despite treatment, or simply because the submitter filled in the indication by habit. A disproportionality algorithm cannot distinguish "the drug caused this" from "the patient had this, which is why they were prescribed the drug" from the term alone. This pattern alone accounts for a large share of the roughly 136,000 pairs the widened scan flagged, and is exactly why this page's selection criterion is the outside literature, not the PRR rank.
Methodological note, not a regulatory finding: a known FAERS data-quality pattern (indication/disease-under-treatment recorded in the reaction field), distinct from a true adverse-event signal.
No per-pair Hill table here — one would be identical for all seven and isn't informative. In Hill terms, every pair in this group fails the same two viewpoints for the same reason: specificity (the "reaction" is definitionally the condition the drug is used for, not a distinguishable outcome) and, in most cases, temporality (the condition usually precedes the prescription, not the reverse). That double failure is what the pattern is — it isn't a borderline call on any one viewpoint.
Extended scan: 24 more pairs, briefer read
The 453 cards above were selected for having an independent regulatory or trial basis. Widening further down the same volume-sorted candidate list surfaces mostly three patterns: genuinely well-established, mechanistically expected drug effects; indication/disease-under-treatment recorded as the "reaction"; and a few real but more nuanced or lower-confidence cases. Rather than pad this page with full essays for pairs that are mostly re-confirming the same two or three lessons above, here is the rest of the top-volume scan in one line each, graded honestly — including where this page's confidence is genuinely lower.
| Pair | Data | Grade | Read |
|---|---|---|---|
| Dupilumab ↔ Pruritus | n=58,692 PRR 7.9 | Indication-adjacent | Pruritus is the core symptom of the atopic dermatitis dupilumab treats; this likely reflects residual/breakthrough itch, not a new drug-caused symptom. Dupilumab's own distinctive labeled reactions are conjunctivitis and injection-site effects. |
| Etanercept ↔ Injection site pain | n=56,795 PRR 7.9 | Expected | Mild, transient injection-site pain/erythema is the most commonly labeled reaction to self-injected biologics generally — a local, not systemic, effect. |
| Adapalene ↔ Dry skin / skin burning | n=45,426 / 41,912 PRR 61–168 | Expected, labeled | Topical retinoids accelerate epidermal turnover; dryness, peeling, and burning during the first weeks are the expected, labeled on-target local effect. |
| Albuterol ↔ Dyspnoea / Asthma | n=42,640 / 24,781 | Circular | Albuterol is a rescue bronchodilator prescribed specifically for these symptoms; almost certainly the underlying disease recorded as a "reaction." (Paradoxical bronchospasm is a separate, real, much rarer phenomenon not captured by this generic pairing.) |
| Proton-pump inhibitors (omeprazole, esomeprazole) ↔ Acute kidney injury / CKD | n=23,910 + 36,748 + 16,270 PRR 8.6–43.0 | Plausible, actively studied | PPI-associated acute interstitial nephritis is real and biopsy-documented, in product labeling. A longer-term link to incident chronic kidney disease has been reported in large cohort studies (e.g. Lazarus et al., JAMA Intern Med 2016) but remains debated given likely confounding by indication/comorbidity. |
| Adalimumab ↔ Psoriasis | n=24,917 PRR 6.8 | Established, paradoxical | Anti-TNF-induced paradoxical psoriasis is a published phenomenon: patients treated with adalimumab for Crohn's disease or RA (not psoriasis) can develop new psoriasiform lesions, usually reversible on stopping — distinct from simple indication-coding since psoriasis isn't the indication for most of these patients. |
| Methotrexate ↔ Joint swelling / Drug intolerance | n=24,834 / 24,385 | Indication-adjacent / vague | Joint swelling is methotrexate's own target symptom in RA (likely treatment failure/flare); "drug intolerance" is too non-specific a term to assess alone. |
| Tiotropium ↔ Incorrect route of administration | n=23,320 PRR 282.5 | Device/usability error | Tiotropium ships in more than one inhaler device (e.g. HandiHaler vs. Respimat) with different handling instructions; this almost certainly reflects documented device-confusion/medication-error reports — a real usability issue, not a pharmacological ADR. |
| Rivaroxaban ↔ Gastrointestinal haemorrhage | n=21,636 PRR 34.9 | Well established, expected | Bleeding is the direct, mechanistically expected consequence of inhibiting Factor Xa — the central, labeled risk of every oral anticoagulant and the basis of formal bleeding-risk scoring tools. |
| Abatacept ↔ Arthralgia | n=21,293 PRR 8.2 | Indication-adjacent, ambiguous | Joint pain is both abatacept's target symptom (RA) and a reported infusion-associated reactogenicity symptom; the term alone can't distinguish the two. |
| Infliximab ↔ Condition aggravated | n=19,722 | Vague term | Too non-specific a MedDRA term to assess; likely a mix of disease progression and treatment failure across infliximab's many indications. |
| Infliximab ↔ Infusion related reaction | n=19,073 PRR 39.0 | Well established, expected | Acute infusion reactions are a recognized, labeled class effect of infused monoclonal antibodies; infliximab's chimeric (part-mouse) structure makes it more immunogenic than fully humanized biologics, the proposed reason for its comparatively high rate. |
| Hydromorphone ↔ Emotional distress | n=17,705 PRR 39.0 | Nonspecific, lower confidence | No established, specific causal literature for this term; may reflect genuine opioid-related mood effects, co-occurring distress from the underlying painful condition, or a reporting-form artifact. Lower confidence than the rest of this page. |
| Metformin ↔ Lactic acidosis | n=17,141 PRR 67.6 | Established, historically overstated | Biologically plausible via metformin's effect on hepatic lactate metabolism and long-labeled, but recent cohort data suggest real-world incidence in patients with normal renal function is much lower than once feared; risk concentrates in renal impairment. |
| Lenalidomide ↔ Plasma cell myeloma | n=17,121 PRR 38.5 | Circular | Multiple myeloma is lenalidomide's primary indication; almost certainly disease status/progression being recorded, not a new drug-caused cancer. |
| Docetaxel ↔ Alopecia | n=16,970 PRR 29.5 | Well established, expected | Hair loss from cytotoxic chemotherapy directly reflects killing rapidly-dividing hair-follicle cells — universally expected and pre-counseled, not a new safety concern. |
| Natalizumab ↔ MS relapse | n=16,902 PRR 37.4 | Circular; real signal lies elsewhere | Likely breakthrough disease/treatment failure, not a drug-caused event. Natalizumab's actual serious, mechanistically distinct signal is PML (progressive multifocal leukoencephalopathy), a rare JC-virus brain infection risk with its own boxed warning and REMS — not what this pairing captures. |
| Acetaminophen ↔ Toxicity to various agents | n=16,635 PRR 5.1 | Vague term, real mechanism elsewhere | Too generic a term to assess directly, but acetaminophen hepatotoxicity in overdose is one of the most mechanistically well-understood drug injuries (NAPQI accumulation depleting hepatic glutathione) and the leading cause of acute liver failure in the U.S. |
| Adalimumab ↔ Injection site haemorrhage | n=16,243 | Expected, minor, procedural | Needle-related bruising/bleeding at a self-injection site is a mechanical event common to any subcutaneous injectable, not specific to adalimumab's pharmacology. |
| Levetiracetam ↔ Seizure | n=15,976 PRR 25.4 | Circular; real signal lies elsewhere | Likely breakthrough seizure/treatment failure, not a drug-caused event. Levetiracetam's genuine, distinctive labeled signal is behavioral/psychiatric: irritability, aggression, and mood change are what clinicians specifically counsel on. |
| Pimavanserin (Nuplazid) ↔ Hallucination | n=12,702 PRR 77.8 | Contested | Approved for hallucinations/delusions in Parkinson's disease psychosis, so some of this is the condition itself. 2018 investigative reporting on a death/AE cluster prompted an FDA safety review, which did not change its approval status, finding available data did not establish a new causal problem beyond the drug's high-background-mortality target population. |
| Pembrolizumab ↔ Malignant neoplasm progression | n=12,012 PRR 26.7 | Circular / expected in oncology | Reflects the expected natural history of cancer in non-responders, not a drug-caused event. Pembrolizumab's genuine, mechanistically distinct signals are immune-related adverse events (colitis, pneumonitis, endocrinopathies) from checkpoint activation — real, labeled, and not shown here. |
| Exenatide ↔ Nausea | n=12,043 PRR 6.2 | Well established, expected | Nausea is the single most common GLP-1-receptor-agonist class effect, driven directly by the drug's intended delayed-gastric-emptying mechanism; dose-related and usually improves over weeks. |
| Leflunomide ↔ Abdominal discomfort | n=12,046 PRR 15.6 | Well established, expected | GI symptoms are among leflunomide's most commonly labeled effects; leflunomide also carries a distinct, more serious labeled hepatotoxicity warning, a better-established signal than this nonspecific GI term. |
These 24 were drawn from the same volume-sorted, loosened-threshold scan (n ≥ 150, PRR ≥ 4, signal-flagged, deduplicated by reaction term and capped at two per drug) as the 453 full cards above. Several raw top-40 entries were left out as exact duplicates of a pair already covered above (e.g. a second oxycodone-combination dependence entry).